----- Comparison Report -----

The files compared: 
QA: C:\Users\gyu\source\marcreader\qa_bkshlf.20241204.mrc
Prod: C:\Users\gyu\source\marcreader\pr_bkshlf.20241202.mrc

The two file have the same number of records and every record matches based on the control number. 
QA records: 57; Prod records: 57

The comparison details are below.
Control Number: 9918935430806676

Leader:
| File       | Leader                   | Equal  |
| QA         | 01623naa a2200457 i 4500 | True   |
| PROD       | 01623naa a2200457 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918935430806676                                                                | True   |
| 001   | PROD       |              | 9918935430806676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241104162331.0                                                                | True   |
| 005   | PROD       |              | 20241104162331.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240802s2023    enk     ob    000|0 eng                                          | True   |
| 008   | PROD       |              | 240802s2023    enk     ob    000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918935430806676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK605307                                                      | True   |
| 035   | PROD       |              | $9: 9918935430806676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK605307                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: England                                                                     | True   |
| 044   | PROD       |              | $9: England                                                                     | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WZ 330                                                                      | True   |
| 060   | PROD       | 00           | $a: WZ 330                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Saunders, Corinne J., $d: 1963- $e: author.                                 | True   |
| 100   | PROD       | 1            | $a: Saunders, Corinne J., $d: 1963- $e: author.                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 13           | $a: 'A lowde voys clepyng' : $b: voice-hearing, revelation, and imagination / $c: Corinne Saunders. | True   |
| 245   | PROD       | 13           | $a: 'A lowde voys clepyng' : $b: voice-hearing, revelation, and imagination / $c: Corinne Saunders. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Oxford, UK : $b: Oxford University Press, $c: [2023]                        | True   |
| 264   | PROD       |  1           | $a: Oxford, UK : $b: Oxford University Press, $c: [2023]                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (pages 107-124))                              | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (pages 107-124))                              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 500   | QA         |              | $a: Chapter 5 of the book: Literature and the senses. Oxford, UK : Oxford University Press, 2023. | True   |
| 500   | PROD       |              | $a: Chapter 5 of the book: Literature and the senses. Oxford, UK : Oxford University Press, 2023. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 530   | QA         |              | $a: Issued also in print.                                                       | True   |
| 530   | PROD       |              | $a: Issued also in print.                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed Nov. 4, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed Nov. 4, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Sensation                                                                   | True   |
| 650   | QA         | 12           | $a: Medicine in Literature $x: history                                          | True   |
| 650   | QA         | 22           | $a: History, Medieval                                                           | True   |
| 650   | QA         | 22           | $a: Hearing                                                                     | True   |
| 650   | PROD       | 12           | $a: Sensation                                                                   | True   |
| 650   | PROD       | 12           | $a: Medicine in Literature $x: history                                          | True   |
| 650   | PROD       | 22           | $a: History, Medieval                                                           | True   |
| 650   | PROD       | 22           | $a: Hearing                                                                     | True   |
--------------------------------------------------------------------------------------------------------------------------
| 730   | QA         | 0            | $i: Contained in (work): $a: Literature and the senses.                         | True   |
| 730   | PROD       | 0            | $i: Contained in (work): $a: Literature and the senses.                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 773   | QA         | 0            | $t: Literature and the senses $z: 9780192843777 $w: (DNLM)9918879462006676      | True   |
| 773   | PROD       | 0            | $t: Literature and the senses $z: 9780192843777 $w: (DNLM)9918879462006676      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK605307/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK605307/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: YYC $b: 20241030                                                            | True   |
| 993   | PROD       |              | $a: YYC $b: 20241030                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241104                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241104                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241104                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241104                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240802                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240802                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9917354213406676

Leader:
| File       | Leader                   | Equal  |
| QA         | 03998cam a2200541 i 4500 | True   |
| PROD       | 03998cam a2200541 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9917354213406676                                                                | True   |
| 001   | PROD       |              | 9917354213406676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20240610005002.0                                                                | True   |
| 005   | PROD       |              | 20240610005002.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 181002s2015    mdu     ob   f000 0 eng                                          | True   |
| 008   | PROD       |              | 181002s2015    mdu     ob   f000 0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 101735421                                                                   | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK519744                                                      | True   |
| 035   | QA         |              | $a: (OCoLC)1061059765                                                           | True   |
| 035   | PROD       |              | $9: 101735421                                                                   | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK519744                                                      | True   |
| 035   | PROD       |              | $a: (OCoLC)1061059765                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WA 900 AA1                                                                  | True   |
| 060   | PROD       | 00           | $a: WA 900 AA1                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Kott, Phillip S., $e: author.                                               | True   |
| 100   | PROD       | 1            | $a: Kott, Phillip S., $e: author.                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: 2012 National Survey on Drug Use and Health : $b: estimating mental illness among adults in the United States: revisions to 2008 estimation procedures / $c: authors, Phillip Kott [and six others] ; Substance Abuse and Mental Health Services Administration. | True   |
| 245   | PROD       | 10           | $a: 2012 National Survey on Drug Use and Health : $b: estimating mental illness among adults in the United States: revisions to 2008 estimation procedures / $c: authors, Phillip Kott [and six others] ; Substance Abuse and Mental Health Services Administration. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Rockville, Maryland : $b: Substance Abuse and Mental Health Services Administration, $c: September 2015. | True   |
| 264   | PROD       |  1           | $a: Rockville, Maryland : $b: Substance Abuse and Mental Health Services Administration, $c: September 2015. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (various pagings))                            | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (various pagings))                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: CBHSQ methodology report                                                    | True   |
| 490   | PROD       | 1            | $a: CBHSQ methodology report                                                    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: BACKGROUND: The National Survey on Drug Use and Health (NSDUH) estimates serious mental illness (SMI) and any mental illness (AMI) among adults aged 18 or older. These estimates are based on a prediction model of SMI developed from a subsample of NSDUH respondents who answered the NSDUH short scales of psychological distress and functional impairment and who also participated in the Mental Health Surveillance Study (MHSS), which included a clinical diagnostic interview to assess the presence of mental disorders and functional impairment. The initial model was developed using the 2008 MHSS subsample of approximately 750 respondents. The MHSS data collection continued from 2009 to 2012, and this larger pool of data was used to reevaluate the model. This report discusses improvements to the methods used to produce SMI and AMI estimates. METHOD: Using 5,000 clinical interviews collected in the 2008 to 2012 MHSS, this analysis assessed the original 2008 statistical model and the weights applied to the clinical interview sample, while also examining additional predictors that would improve the model. Estimates of SMI using the initial 2008 method and estimates based on an improved method were compared with estimates from the clinical interview sample. RESULTS: This report demonstrates that the improved methods produce model-based estimates that are more accurate because they are more consistent with the direct estimates from the clinical interview. For example, estimates of SMI and AMI by age groups produced using the improved methods were closer to the estimates produced using the clinical data. CONCLUSION: Revising the weights and adding new predictors to the model produced more accurate estimations of SMI and AMI. | True   |
| 520   | PROD       | 3            | $a: BACKGROUND: The National Survey on Drug Use and Health (NSDUH) estimates serious mental illness (SMI) and any mental illness (AMI) among adults aged 18 or older. These estimates are based on a prediction model of SMI developed from a subsample of NSDUH respondents who answered the NSDUH short scales of psychological distress and functional impairment and who also participated in the Mental Health Surveillance Study (MHSS), which included a clinical diagnostic interview to assess the presence of mental disorders and functional impairment. The initial model was developed using the 2008 MHSS subsample of approximately 750 respondents. The MHSS data collection continued from 2009 to 2012, and this larger pool of data was used to reevaluate the model. This report discusses improvements to the methods used to produce SMI and AMI estimates. METHOD: Using 5,000 clinical interviews collected in the 2008 to 2012 MHSS, this analysis assessed the original 2008 statistical model and the weights applied to the clinical interview sample, while also examining additional predictors that would improve the model. Estimates of SMI using the initial 2008 method and estimates based on an improved method were compared with estimates from the clinical interview sample. RESULTS: This report demonstrates that the improved methods produce model-based estimates that are more accurate because they are more consistent with the direct estimates from the clinical interview. For example, estimates of SMI and AMI by age groups produced using the improved methods were closer to the estimates produced using the clinical data. CONCLUSION: Revising the weights and adding new predictors to the model produced more accurate estimations of SMI and AMI. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: This report was prepared for the Substance Abuse and Mental Health Services Administration (SAMHSA) under Contract No. HHSS283201000003C with SAMHSA, U.S. Department of Health and Human Services (HHS). | True   |
| 536   | PROD       |              | $a: This report was prepared for the Substance Abuse and Mental Health Services Administration (SAMHSA) under Contract No. HHSS283201000003C with SAMHSA, U.S. Department of Health and Human Services (HHS). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed October 31, 2018). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed October 31, 2018). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 610   | QA         | 22           | $a: National Survey on Drug Use and Health (U.S.)                               | True   |
| 610   | PROD       | 22           | $a: National Survey on Drug Use and Health (U.S.)                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Health Surveys                                                              | True   |
| 650   | QA         | 22           | $a: Mental Disorders $x: epidemiology                                           | True   |
| 650   | QA         | 22           | $a: Models, Statistical                                                         | True   |
| 650   | QA         | 22           | $a: Statistics as Topic                                                         | True   |
| 650   | PROD       | 12           | $a: Health Surveys                                                              | True   |
| 650   | PROD       | 22           | $a: Mental Disorders $x: epidemiology                                           | True   |
| 650   | PROD       | 22           | $a: Models, Statistical                                                         | True   |
| 650   | PROD       | 22           | $a: Statistics as Topic                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 651   | QA         |  2           | $a: United States $x: epidemiology                                              | True   |
| 651   | PROD       |  2           | $a: United States $x: epidemiology                                              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 655   | QA         |  2           | $a: Tables                                                                      | True   |
| 655   | PROD       |  2           | $a: Tables                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 1            | $a: United States. $b: Substance Abuse and Mental Health Services Administration, $e: sponsoring body. | True   |
| 710   | QA         | 2            | $a: Research Triangle Institute, $e: issuing body.                              | True   |
| 710   | PROD       | 1            | $a: United States. $b: Substance Abuse and Mental Health Services Administration, $e: sponsoring body. | True   |
| 710   | PROD       | 2            | $a: Research Triangle Institute, $e: issuing body.                              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: CBHSQ methodology report                                                    | True   |
| 830   | PROD       |  0           | $a: CBHSQ methodology report                                                    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK519744/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK519744/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 935   | QA         |              | $a: (DNLM)1735421-nlmdb                                                         | True   |
| 935   | PROD       |              | $a: (DNLM)1735421-nlmdb                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20181002                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20181002                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: ARS $b: 20181009                                                            | True   |
| 993   | PROD       |              | $a: ARS $b: 20181009                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20181031                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20181031                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20181102 $c: REV $d: 20200110                                      | True   |
| 995   | PROD       |              | $a: AUTH $b: 20181102 $c: REV $d: 20200110                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20181002                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20181002                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9911573093406676

Leader:
| File       | Leader                   | Equal  |
| QA         | 02904cas a2200697 a 4500 | True   |
| PROD       | 02904cas a2200697 a 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9911573093406676                                                                | True   |
| 001   | PROD       |              | 9911573093406676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241118103905.0                                                                | True   |
| 005   | PROD       |              | 20241118103905.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 011221c20009999ncugr        f0    0eng d                                        | True   |
| 008   | PROD       |              | 011221c20009999ncugr        f0    0eng d                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 010   | QA         |              | $a:   2002208427                                                                | True   |
| 010   | PROD       |              | $a:   2002208427                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 022   | QA         |              | $a: 1551-8272 $l: 1551-8272 $9: PY $7: (Print)                                  | True   |
| 022   | QA         |              | $a: 1551-8280 $9: EN $7: (Electronic)                                           | True   |
| 022   | PROD       |              | $a: 1551-8272 $l: 1551-8272 $9: PY $7: (Print)                                  | True   |
| 022   | PROD       |              | $a: 1551-8280 $9: EN $7: (Electronic)                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 101157309                                                                   | True   |
| 035   | QA         |              | $a: (OCoLC)48729167                                                             | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK592055                                                      | True   |
| 035   | PROD       |              | $9: 101157309                                                                   | True   |
| 035   | PROD       |              | $a: (OCoLC)48729167                                                             | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK592055                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: CUY $c: CUY $d: DLC $d: MYG                                                 | True   |
| 040   | PROD       |              | $a: CUY $c: CUY $d: DLC $d: MYG                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: lc $a: nlmcopyc                                                             | True   |
| 042   | PROD       |              | $a: lc $a: nlmcopyc                                                             | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 050   | QA         | 00           | $a: RC268.6 $b: .R475                                                           | True   |
| 050   | PROD       | 00           | $a: RC268.6 $b: .R475                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: W1 $b: AN78MK                                                               | True   |
| 060   | PROD       | 00           | $a: W1 $b: AN78MK                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 074   | QA         |              | $a: 0507-P-05 (online)                                                          | True   |
| 074   | PROD       |              | $a: 0507-P-05 (online)                                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 086   | QA         | 0            | $a: HE 20.3562:                                                                 | True   |
| 086   | PROD       | 0            | $a: HE 20.3562:                                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 210   | QA         | 10           | $a: Rep Carcinog $2: DNLM                                                       | True   |
| 210   | PROD       | 10           | $a: Rep Carcinog $2: DNLM                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 00           | $a: Report on carcinogens : $b: carcinogen profiles / $c: U.S. Dept. of Health and Human Services, Public Health Service, National Toxicology Program. | True   |
| 245   | PROD       | 00           | $a: Report on carcinogens : $b: carcinogen profiles / $c: U.S. Dept. of Health and Human Services, Public Health Service, National Toxicology Program. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 246   | QA         | 30           | $a: Carcinogen profiles                                                         | True   |
| 246   | PROD       | 30           | $a: Carcinogen profiles                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 260   | QA         |              | $a: Durham, N.C. : $b: National Institute of Environmental Health Sciences, [2000- | True   |
| 260   | PROD       |              | $a: Durham, N.C. : $b: National Institute of Environmental Health Sciences, [2000- | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: v. ; $c: 28 cm.                                                             | True   |
| 300   | PROD       |              | $a: v. ; $c: 28 cm.                                                             | True   |
--------------------------------------------------------------------------------------------------------------------------
| 310   | QA         |              | $a: Biennial                                                                    | True   |
| 310   | PROD       |              | $a: Biennial                                                                    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: unmediated $b: n $2: rdamedia                                               | True   |
| 337   | PROD       |              | $a: unmediated $b: n $2: rdamedia                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: volume $b: nc $2: rdacarrier                                                | True   |
| 338   | PROD       |              | $a: volume $b: nc $2: rdacarrier                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 362   | QA         | 0            | $a: 9th (2000)-                                                                 | True   |
| 362   | PROD       | 0            | $a: 9th (2000)-                                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 500   | QA         |              | $a: "Pursuant to Section 301(b)(4) of the Public Health Service Act as amended by Section 262, PL 95-622." | True   |
| 500   | QA         |              | $a: Vol. for 2000 accompanied by CD-ROM version.                                | True   |
| 500   | QA         |              | $a: Prepared for the National Institute of Environmental Health Sciences by Technology Planning and Management Corp. | True   |
| 500   | QA         |              | $a: Print issues ceased with v.12 (2011).                                       | True   |
| 500   | PROD       |              | $a: "Pursuant to Section 301(b)(4) of the Public Health Service Act as amended by Section 262, PL 95-622." | True   |
| 500   | PROD       |              | $a: Vol. for 2000 accompanied by CD-ROM version.                                | True   |
| 500   | PROD       |              | $a: Prepared for the National Institute of Environmental Health Sciences by Technology Planning and Management Corp. | True   |
| 500   | PROD       |              | $a: Print issues ceased with v.12 (2011).                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 510   | QA         | 1            | $9: 3 $a: MEDLINE $b: 10th, 2002-15th, 2021                                     | True   |
| 510   | QA         | 0            | $9: 3 $a: PubMed $b: 10th, 2002-15th, 2021                                      | True   |
| 510   | QA         | 1            | $a: Index medicus                                                               | True   |
| 510   | PROD       | 1            | $9: 3 $a: MEDLINE $b: 10th, 2002-15th, 2021                                     | True   |
| 510   | PROD       | 0            | $9: 3 $a: PubMed $b: 10th, 2002-15th, 2021                                      | True   |
| 510   | PROD       | 1            | $a: Index medicus                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 515   | QA         |              | $a: An addendum dated: Jan. 2001 revised, accompanies the 2000 ed.; 2000 ed. issued also in revised form as: 9th rev. (Jan. 2001). | True   |
| 515   | PROD       |              | $a: An addendum dated: Jan. 2001 revised, accompanies the 2000 ed.; 2000 ed. issued also in revised form as: 9th rev. (Jan. 2001). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 530   | QA         |              | $a: Also issued online.                                                         | True   |
| 530   | PROD       |              | $a: Also issued online.                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 580   | QA         |              | $a: Merger of: Report on carcinogens. Summary, and: National Toxicology Program (U.S.). Report on carcinogens. Full report. | True   |
| 580   | PROD       |              | $a: Merger of: Report on carcinogens. Summary, and: National Toxicology Program (U.S.). Report on carcinogens. Full report. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Carcinogens                                                                 | True   |
| 650   | PROD       | 12           | $a: Carcinogens                                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: National Institute of Environmental Health Sciences.                        | True   |
| 710   | PROD       | 2            | $a: National Institute of Environmental Health Sciences.                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 780   | QA         | 14           | $t: Report on carcinogens. Summary $w: (OCoLC)40778512                          | True   |
| 780   | QA         | 14           | $a: National Toxicology Program (U.S.). $t: Report on carcinogens. Full report $w: (OCoLC)42656579 | True   |
| 780   | PROD       | 14           | $t: Report on carcinogens. Summary $w: (OCoLC)40778512                          | True   |
| 780   | PROD       | 14           | $a: National Toxicology Program (U.S.). $t: Report on carcinogens. Full report $w: (OCoLC)42656579 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 787   | QA         | 1            | $t: Report on carcinogens background document for ... $x: 2151-7746 $w: (DLC)   2009203971 $w: (OCoLC)463648835 | True   |
| 787   | QA         | 1            | $t: Report on carcinogens. Monograph on ... $x: 2331-267X $w: (DLC)   2013273323 $w: (OCoLC)858799835 | True   |
| 787   | PROD       | 1            | $t: Report on carcinogens background document for ... $x: 2151-7746 $w: (DLC)   2009203971 $w: (OCoLC)463648835 | True   |
| 787   | PROD       | 1            | $t: Report on carcinogens. Monograph on ... $x: 2331-267X $w: (DLC)   2013273323 $w: (OCoLC)858799835 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 4            | $u: http://ntp.niehs.nih.gov/go/roc                                             | True   |
| 856   | QA         | 1            | $u: https://www.ncbi.nlm.nih.gov/books/NBK592055/                               | True   |
| 856   | PROD       | 4            | $u: http://ntp.niehs.nih.gov/go/roc                                             | True   |
| 856   | PROD       | 1            | $u: https://www.ncbi.nlm.nih.gov/books/NBK592055/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 911   | QA         |              | $a: Electronic only, print ceased 2011. Confirmed 20150330                      | True   |
| 911   | PROD       |              | $a: Electronic only, print ceased 2011. Confirmed 20150330                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 935   | QA         |              | $a: (DNLM)1157309-nlmdb                                                         | True   |
| 935   | PROD       |              | $a: (DNLM)1157309-nlmdb                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20021011                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20021011                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: SYM $b: 20021021                                                            | True   |
| 993   | PROD       |              | $a: SYM $b: 20021021                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20021021                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20021021                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20021021 $c: REV $d: 20241118                                      | True   |
| 995   | PROD       |              | $a: AUTH $b: 20021021 $c: REV $d: 20241118                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 996   | QA         |              | $a: CONSER $b: 20000101                                                         | True   |
| 996   | PROD       |              | $a: CONSER $b: 20000101                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: FER $b: 20130712                                                            | True   |
| 998   | QA         |              | $a: BKSHLF $b: 20230622                                                         | True   |
| 998   | PROD       |              | $a: FER $b: 20130712                                                            | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20230622                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9917376853406676

Leader:
| File       | Leader                   | Equal  |
| QA         | 03890cam a2200553 i 4500 | True   |
| PROD       | 03890cam a2200553 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9917376853406676                                                                | True   |
| 001   | PROD       |              | 9917376853406676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20240610015008.0                                                                | True   |
| 005   | PROD       |              | 20240610015008.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 181102s2013    mdu     ob   f000 0 eng                                          | True   |
| 008   | PROD       |              | 181102s2013    mdu     ob   f000 0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 101737685                                                                   | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK531551                                                      | True   |
| 035   | QA         |              | $a: (OCoLC)1081337541                                                           | True   |
| 035   | PROD       |              | $9: 101737685                                                                   | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK531551                                                      | True   |
| 035   | PROD       |              | $a: (OCoLC)1081337541                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WA 900 AA1                                                                  | True   |
| 060   | PROD       | 00           | $a: WA 900 AA1                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Kott, Phillip S., $e: author.                                               | True   |
| 100   | PROD       | 1            | $a: Kott, Phillip S., $e: author.                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: 2012 National Survey on Drug Use and Health : $b: a revised strategy for estimating the prevalence of mental illness / $c: authors, Phillip Kott, Sarra Hedden, Jeremy Aldworth, Jonaki Bose, James Chromy, Joseph Gfroerer, Dan Liao, Thomas G Virag. | True   |
| 245   | PROD       | 10           | $a: 2012 National Survey on Drug Use and Health : $b: a revised strategy for estimating the prevalence of mental illness / $c: authors, Phillip Kott, Sarra Hedden, Jeremy Aldworth, Jonaki Bose, James Chromy, Joseph Gfroerer, Dan Liao, Thomas G Virag. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Rockville, Maryland : $b: Substance Abuse and Mental Health Services Administration, $c: October 2013. | True   |
| 264   | PROD       |  1           | $a: Rockville, Maryland : $b: Substance Abuse and Mental Health Services Administration, $c: October 2013. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (vi, 13 pages))                               | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (vi, 13 pages))                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: CBHSQ methodology report                                                    | True   |
| 490   | PROD       | 1            | $a: CBHSQ methodology report                                                    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: BACKGROUND: One of the goals of the National Survey on Drug Use and Health (NSDUH) is to estimate serious mental illness (SMI) among adults aged 18 or older. Starting in 2001, NSDUH mental health estimates used a cut point methodology based on Kessler-6 (K6) developed by Kessler and colleagues, using a sample of 155 respondents from the Boston area. Subsequent Substance Abuse and Mental Health Services Administration (SAMHSA) research concluded that K6 alone was not adequate for the model-based estimation of SMI. SAMHSA undertook the Mental Health Surveillance Study (MHSS), which included a clinical diagnostic interview to assess the presence of mental disorders and functional impairment, and was a follow-up to NSDUH. SAMHSA developed a prediction model to estimate SMI using the 2008 MHSS data, and the model was reevaluated in 2012 based on 2008 to 2012 MHSS data. The purpose of this report is to summarize current and prior approaches and to document the research conducted to revise the 2012 strategy for estimating the prevalence of mental illness. METHOD: This report compares the estimates of SMI based on the direct MHSS data, the 2008 prediction model, and the 2012 prediction model. There were 750 clinical interviews in 2008 and a combined 5,000 clinical interviews in the 2008 to 2012 MHSS. RESULTS: This report demonstrates that the revised 2012 prediction model produces SMI estimates that are more accurate because they are more consistent with the direct estimates from the clinical interview. CONCLUSION: SAMHSA has made improvements to produce more accurate estimations of SMI. | True   |
| 520   | PROD       | 3            | $a: BACKGROUND: One of the goals of the National Survey on Drug Use and Health (NSDUH) is to estimate serious mental illness (SMI) among adults aged 18 or older. Starting in 2001, NSDUH mental health estimates used a cut point methodology based on Kessler-6 (K6) developed by Kessler and colleagues, using a sample of 155 respondents from the Boston area. Subsequent Substance Abuse and Mental Health Services Administration (SAMHSA) research concluded that K6 alone was not adequate for the model-based estimation of SMI. SAMHSA undertook the Mental Health Surveillance Study (MHSS), which included a clinical diagnostic interview to assess the presence of mental disorders and functional impairment, and was a follow-up to NSDUH. SAMHSA developed a prediction model to estimate SMI using the 2008 MHSS data, and the model was reevaluated in 2012 based on 2008 to 2012 MHSS data. The purpose of this report is to summarize current and prior approaches and to document the research conducted to revise the 2012 strategy for estimating the prevalence of mental illness. METHOD: This report compares the estimates of SMI based on the direct MHSS data, the 2008 prediction model, and the 2012 prediction model. There were 750 clinical interviews in 2008 and a combined 5,000 clinical interviews in the 2008 to 2012 MHSS. RESULTS: This report demonstrates that the revised 2012 prediction model produces SMI estimates that are more accurate because they are more consistent with the direct estimates from the clinical interview. CONCLUSION: SAMHSA has made improvements to produce more accurate estimations of SMI. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: This report was prepared for the Substance Abuse and Mental Health Services Administration (SAMHSA) under Contract No. HHSS283201000003C with SAMHSA, U.S. Department of Health and Human Services (HHS). | True   |
| 536   | PROD       |              | $a: This report was prepared for the Substance Abuse and Mental Health Services Administration (SAMHSA) under Contract No. HHSS283201000003C with SAMHSA, U.S. Department of Health and Human Services (HHS). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed December 17, 2018). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed December 17, 2018). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 610   | QA         | 22           | $a: National Survey on Drug Use and Health (U.S.)                               | True   |
| 610   | PROD       | 22           | $a: National Survey on Drug Use and Health (U.S.)                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Health Surveys $x: methods                                                  | True   |
| 650   | QA         | 22           | $a: Data Collection $x: methods                                                 | True   |
| 650   | QA         | 22           | $a: Mental Disorders $x: epidemiology                                           | True   |
| 650   | QA         | 22           | $a: Models, Statistical                                                         | True   |
| 650   | QA         | 22           | $a: Statistics as Topic                                                         | True   |
| 650   | PROD       | 12           | $a: Health Surveys $x: methods                                                  | True   |
| 650   | PROD       | 22           | $a: Data Collection $x: methods                                                 | True   |
| 650   | PROD       | 22           | $a: Mental Disorders $x: epidemiology                                           | True   |
| 650   | PROD       | 22           | $a: Models, Statistical                                                         | True   |
| 650   | PROD       | 22           | $a: Statistics as Topic                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 651   | QA         |  2           | $a: United States $x: epidemiology                                              | True   |
| 651   | PROD       |  2           | $a: United States $x: epidemiology                                              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 655   | QA         |  2           | $a: Tables                                                                      | True   |
| 655   | PROD       |  2           | $a: Tables                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 1            | $a: United States. $b: Substance Abuse and Mental Health Services Administration, $e: sponsoring body. | True   |
| 710   | QA         | 2            | $a: RTI International, $e: issuing body.                                        | True   |
| 710   | PROD       | 1            | $a: United States. $b: Substance Abuse and Mental Health Services Administration, $e: sponsoring body. | True   |
| 710   | PROD       | 2            | $a: RTI International, $e: issuing body.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: CBHSQ methodology report                                                    | True   |
| 830   | PROD       |  0           | $a: CBHSQ methodology report                                                    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK531551/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK531551/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 935   | QA         |              | $a: (DNLM)1737685-nlmdb                                                         | True   |
| 935   | PROD       |              | $a: (DNLM)1737685-nlmdb                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20181102                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20181102                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: CJM $b: 20181120                                                            | True   |
| 993   | PROD       |              | $a: CJM $b: 20181120                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20181217                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20181217                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20190103 $c: REV $d: 20200110                                      | True   |
| 995   | PROD       |              | $a: AUTH $b: 20190103 $c: REV $d: 20200110                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20181102                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20181102                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918521664706676

Leader:
| File       | Leader                   | Equal  |
| QA         | 01551aam a2200457 i 4500 | True   |
| PROD       | 01551aam a2200457 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918521664706676                                                                | True   |
| 001   | PROD       |              | 9918521664706676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241121095218.0                                                                | True   |
| 005   | PROD       |              | 20241121095218.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 221202s2022    sz a     b    000|0 eng                                          | True   |
| 008   | PROD       |              | 221202s2022    sz a     b    000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 020   | QA         |              | $a: 9783030833985                                                               | True   |
| 020   | QA         |              | $z: 9783030833992 $q: eBook                                                     | True   |
| 020   | PROD       |              | $a: 9783030833985                                                               | True   |
| 020   | PROD       |              | $z: 9783030833992 $q: eBook                                                     | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918521664706676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK586010                                                      | True   |
| 035   | QA         |              | $a: (OCoLC)1258779989                                                           | True   |
| 035   | PROD       |              | $9: 9918521664706676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK586010                                                      | True   |
| 035   | PROD       |              | $a: (OCoLC)1258779989                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: YDX $b: eng $e: rda $c: YDX $d: BDX $d: UKMGB $d: OCLCF $d: OHX             | True   |
| 040   | PROD       |              | $a: YDX $b: eng $e: rda $c: YDX $d: BDX $d: UKMGB $d: OCLCF $d: OHX             | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: Switzerland                                                                 | True   |
| 044   | PROD       |              | $9: Switzerland                                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WI 980                                                                      | True   |
| 060   | PROD       | 00           | $a: WI 980                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 00           | $a: Bariatric surgery in clinical practice / $c: David Haslam, Aseem Malhotra, Matthew S. Capehorn, editors. | True   |
| 245   | PROD       | 00           | $a: Bariatric surgery in clinical practice / $c: David Haslam, Aseem Malhotra, Matthew S. Capehorn, editors. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Cham, Switzerland : $b: Springer, $c: [2022]                                | True   |
| 264   | PROD       |  1           | $a: Cham, Switzerland : $b: Springer, $c: [2022]                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: xiii, 182 pages : $b: illustrations ; $c: 24 cm.                            | True   |
| 300   | PROD       |              | $a: xiii, 182 pages : $b: illustrations ; $c: 24 cm.                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: unmediated $b: n $2: rdamedia                                               | True   |
| 337   | PROD       |              | $a: unmediated $b: n $2: rdamedia                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: volume $b: nc $2: rdacarrier                                                | True   |
| 338   | PROD       |              | $a: volume $b: nc $2: rdacarrier                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: In clinical practice, $x: 2199-6652                                         | True   |
| 490   | PROD       | 1            | $a: In clinical practice, $x: 2199-6652                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 530   | QA         |              | $a: Also issued online.                                                         | True   |
| 530   | PROD       |              | $a: Also issued online.                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Bariatric Surgery                                                           | True   |
| 650   | QA         | 22           | $a: Obesity Management                                                          | True   |
| 650   | QA         | 22           | $a: Obesity $x: surgery                                                         | True   |
| 650   | PROD       | 12           | $a: Bariatric Surgery                                                           | True   |
| 650   | PROD       | 22           | $a: Obesity Management                                                          | True   |
| 650   | PROD       | 22           | $a: Obesity $x: surgery                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 700   | QA         | 1            | $a: Haslam, David W., $e: editor.                                               | True   |
| 700   | QA         | 1            | $a: Malhotra, Aseem, $e: editor.                                                | True   |
| 700   | QA         | 1            | $a: Capehorn, Matthew S., $e: editor.                                           | True   |
| 700   | PROD       | 1            | $a: Haslam, David W., $e: editor.                                               | True   |
| 700   | PROD       | 1            | $a: Malhotra, Aseem, $e: editor.                                                | True   |
| 700   | PROD       | 1            | $a: Capehorn, Matthew S., $e: editor.                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: In clinical practice (Springer (Firm)) $x: 2199-6652                        | True   |
| 830   | PROD       |  0           | $a: In clinical practice (Springer (Firm)) $x: 2199-6652                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $3: Selected chapters $u: https://www.ncbi.nlm.nih.gov/books/NBK586010/         | True   |
| 856   | PROD       | 40           | $3: Selected chapters $u: https://www.ncbi.nlm.nih.gov/books/NBK586010/         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20221206                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20221206                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: KXP $b: 20230105                                                            | True   |
| 993   | PROD       |              | $a: KXP $b: 20230105                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20230612                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20230612                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20230612 $c: REV $d: 20241121                                      | True   |
| 995   | PROD       |              | $a: AUTH $b: 20230612 $c: REV $d: 20241121                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 997   | QA         |              | $a: Collection link Wellcome Trust-Funded Monographs and Book Chapters          | True   |
| 997   | PROD       |              | $a: Collection link Wellcome Trust-Funded Monographs and Book Chapters          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20221202                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20221202                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9917376873406676

Leader:
| File       | Leader                   | Equal  |
| QA         | 04883cam a2200601 i 4500 | True   |
| PROD       | 04883cam a2200601 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9917376873406676                                                                | True   |
| 001   | PROD       |              | 9917376873406676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20240610015003.0                                                                | True   |
| 005   | PROD       |              | 20240610015003.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 181102s2013    mdua    ob   f000 0 eng                                          | True   |
| 008   | PROD       |              | 181102s2013    mdua    ob   f000 0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 101737687                                                                   | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK531567                                                      | True   |
| 035   | QA         |              | $a: (OCoLC)1081346743                                                           | True   |
| 035   | PROD       |              | $9: 101737687                                                                   | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK531567                                                      | True   |
| 035   | PROD       |              | $a: (OCoLC)1081346743                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WA 900 AA1                                                                  | True   |
| 060   | PROD       | 00           | $a: WA 900 AA1                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Wang, Kevin $c: (Survey methodologist) $e: author.                          | True   |
| 100   | PROD       | 1            | $a: Wang, Kevin $c: (Survey methodologist) $e: author.                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Assessing the relationship between interviewer effects and NSDUH data quality / $c: authors, Kevin Wang, Phil Kott, Andrew Moore. | True   |
| 245   | PROD       | 10           | $a: Assessing the relationship between interviewer effects and NSDUH data quality / $c: authors, Kevin Wang, Phil Kott, Andrew Moore. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Rockville, Maryland : $b: Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality, $c: October 24, 2013. | True   |
| 264   | PROD       |  1           | $a: Rockville, Maryland : $b: Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality, $c: October 24, 2013. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (various pagings)) : $b: illustrations.       | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (various pagings)) : $b: illustrations.       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: CBHSQ methodology report                                                    | True   |
| 490   | PROD       | 1            | $a: CBHSQ methodology report                                                    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: BACKGROUND: For interviewer-administered surveys, interviewers can have a major effect on various measures of survey data quality, including unit response rates, item missing rates, estimates of uncertainty (variances), and the accuracy of survey estimates. As applicable to the National Survey on Drug Use and Health (NSDUH), this report summarizes research on the relationships between interviewer characteristics and survey participation, data quality, and survey outcomes. METHOD: This report used NSDUH data before 2002 to run logistic regression models that examine the relationship between interviewer characteristics and the likelihood of obtaining screener contact, screener cooperation, and interview cooperation. To assess the effects of various interviewer characteristics on the reporting of substance use and mental health items, single regression models used pooled 2002 to 2007 NSDUH data. To assess the impact of interviewer experience, two cohort analyses were conducted using 2002 and 2007 NSDUH data. RESULTS: The analyses of the relationships between several interviewer characteristics and various survey outcomes, including response rates and respondent self-reports on substance use and mental health indicators, have for the most part provided additional evidence in support of prior work in this area. Interviewer experience remains positively correlated with response rates and negatively associated with self-reported substance use. However, evidence suggests that the association between experience and substance use reporting has declined over time. Not much evidence was found that other interviewer characteristics (e.g., demographics) and characteristics of their work (e.g., hours worked, miles traveled) were related to substance use and mental health outcomes in ways that suggest that changes in the distribution of these characteristics among interviewers would affect resulting survey estimates. CONCLUSION: The results of this study can be used to produce predictions of self-reported prevalence rates if a change in the sample design can be expressed in terms of the change in the distribution of a characteristic of interviewers. At the most basic level, one can assume that a design change, such as a reduction in the overall NSDUH sample size, will result in a change in the distribution of interviewer experience. | True   |
| 520   | PROD       | 3            | $a: BACKGROUND: For interviewer-administered surveys, interviewers can have a major effect on various measures of survey data quality, including unit response rates, item missing rates, estimates of uncertainty (variances), and the accuracy of survey estimates. As applicable to the National Survey on Drug Use and Health (NSDUH), this report summarizes research on the relationships between interviewer characteristics and survey participation, data quality, and survey outcomes. METHOD: This report used NSDUH data before 2002 to run logistic regression models that examine the relationship between interviewer characteristics and the likelihood of obtaining screener contact, screener cooperation, and interview cooperation. To assess the effects of various interviewer characteristics on the reporting of substance use and mental health items, single regression models used pooled 2002 to 2007 NSDUH data. To assess the impact of interviewer experience, two cohort analyses were conducted using 2002 and 2007 NSDUH data. RESULTS: The analyses of the relationships between several interviewer characteristics and various survey outcomes, including response rates and respondent self-reports on substance use and mental health indicators, have for the most part provided additional evidence in support of prior work in this area. Interviewer experience remains positively correlated with response rates and negatively associated with self-reported substance use. However, evidence suggests that the association between experience and substance use reporting has declined over time. Not much evidence was found that other interviewer characteristics (e.g., demographics) and characteristics of their work (e.g., hours worked, miles traveled) were related to substance use and mental health outcomes in ways that suggest that changes in the distribution of these characteristics among interviewers would affect resulting survey estimates. CONCLUSION: The results of this study can be used to produce predictions of self-reported prevalence rates if a change in the sample design can be expressed in terms of the change in the distribution of a characteristic of interviewers. At the most basic level, one can assume that a design change, such as a reduction in the overall NSDUH sample size, will result in a change in the distribution of interviewer experience. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: This report was prepared for the Substance Abuse and Mental Health Services Administration (SAMHSA) under Contract Nos. HHSS283200800004C and HHSS283201000003C with SAMHSA, U.S. Department of Health and Human Services (HHS). | True   |
| 536   | PROD       |              | $a: This report was prepared for the Substance Abuse and Mental Health Services Administration (SAMHSA) under Contract Nos. HHSS283200800004C and HHSS283201000003C with SAMHSA, U.S. Department of Health and Human Services (HHS). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed December 15, 2018). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed December 15, 2018). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 610   | QA         | 22           | $a: National Survey on Drug Use and Health (U.S.)                               | True   |
| 610   | PROD       | 22           | $a: National Survey on Drug Use and Health (U.S.)                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Health Surveys                                                              | True   |
| 650   | QA         | 22           | $a: Cohort Studies                                                              | True   |
| 650   | QA         | 22           | $a: Data Accuracy                                                               | True   |
| 650   | QA         | 22           | $a: Interview, Psychological                                                    | True   |
| 650   | QA         | 22           | $a: Researcher-Subject Relations                                                | True   |
| 650   | QA         | 22           | $a: Substance-Related Disorders $x: epidemiology                                | True   |
| 650   | PROD       | 12           | $a: Health Surveys                                                              | True   |
| 650   | PROD       | 22           | $a: Cohort Studies                                                              | True   |
| 650   | PROD       | 22           | $a: Data Accuracy                                                               | True   |
| 650   | PROD       | 22           | $a: Interview, Psychological                                                    | True   |
| 650   | PROD       | 22           | $a: Researcher-Subject Relations                                                | True   |
| 650   | PROD       | 22           | $a: Substance-Related Disorders $x: epidemiology                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 651   | QA         |  2           | $a: United States $x: epidemiology                                              | True   |
| 651   | PROD       |  2           | $a: United States $x: epidemiology                                              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 655   | QA         |  2           | $a: Tables                                                                      | True   |
| 655   | PROD       |  2           | $a: Tables                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 700   | QA         | 1            | $a: Kott, Phillip S., $e: author.                                               | True   |
| 700   | QA         | 1            | $a: Moore, Andrew $c: (Of RTI International) $e: author.                        | True   |
| 700   | PROD       | 1            | $a: Kott, Phillip S., $e: author.                                               | True   |
| 700   | PROD       | 1            | $a: Moore, Andrew $c: (Of RTI International) $e: author.                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 1            | $a: United States. $b: Substance Abuse and Mental Health Services Administration, $e: sponsoring body. | True   |
| 710   | QA         | 2            | $a: Center for Behavioral Health Statistics and Quality (U.S.), $e: sponsoring body. | True   |
| 710   | QA         | 2            | $a: RTI International, $e: issuing body.                                        | True   |
| 710   | PROD       | 1            | $a: United States. $b: Substance Abuse and Mental Health Services Administration, $e: sponsoring body. | True   |
| 710   | PROD       | 2            | $a: Center for Behavioral Health Statistics and Quality (U.S.), $e: sponsoring body. | True   |
| 710   | PROD       | 2            | $a: RTI International, $e: issuing body.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: CBHSQ methodology report                                                    | True   |
| 830   | PROD       |  0           | $a: CBHSQ methodology report                                                    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK531567/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK531567/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 935   | QA         |              | $a: (DNLM)1737687-nlmdb                                                         | True   |
| 935   | PROD       |              | $a: (DNLM)1737687-nlmdb                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20181102                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20181102                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: CJM $b: 20181120                                                            | True   |
| 993   | PROD       |              | $a: CJM $b: 20181120                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20181215                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20181215                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20190103 $c: REV $d: 20200110                                      | True   |
| 995   | PROD       |              | $a: AUTH $b: 20190103 $c: REV $d: 20200110                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20181102                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20181102                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918861355006676

Leader:
| File       | Leader                   | Equal  |
| QA         | 02919nam a2200469 i 4500 | True   |
| PROD       | 02919nam a2200469 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918861355006676                                                                | True   |
| 001   | PROD       |              | 9918861355006676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241101165935.0                                                                | True   |
| 005   | PROD       |              | 20241101165935.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240702s2022    mduac   ob   f000|0 eng                                          | True   |
| 008   | PROD       |              | 240702s2022    mduac   ob   f000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918861355006676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK604149                                                      | True   |
| 035   | PROD       |              | $9: 9918861355006676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK604149                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: W 20.5                                                                      | True   |
| 060   | PROD       | 00           | $a: W 20.5                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 00           | $a: How do diversity supplements impact careers in biomedical and behavioral research? / $c: National Institutes of Health, Office of the Director, Chief Officer for Scientific Workforce Diversity. | True   |
| 245   | PROD       | 00           | $a: How do diversity supplements impact careers in biomedical and behavioral research? / $c: National Institutes of Health, Office of the Director, Chief Officer for Scientific Workforce Diversity. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: [Bethesda, Md.] : $b: National Institutes of Health, $c: [2022]             | True   |
| 264   | PROD       |  1           | $a: [Bethesda, Md.] : $b: National Institutes of Health, $c: [2022]             | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (10 pages)) : $b: illustrations, portraits    | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (10 pages)) : $b: illustrations, portraits    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Scientific workforce diversity seminar series                               | True   |
| 490   | PROD       | 1            | $a: Scientific workforce diversity seminar series                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: This document encapsulates the proceedings of "How Do Diversity Supplements Impact Careers in Biomedical and Behavioral Research?"--the second seminar of the 2022-2023 Scientific Workforce Diversity Seminar Series (SWDSS). The National Institutes of Health (NIH) Chief Officer for Scientific Workforce Diversity (COSWD) hosted the seminar on November 17, 2022. Marie A. Bernard, M.D., COSWD, moderated a panel discussion on how diversity supplements can influence the career pathways of individuals from diverse backgrounds in biomedical and behavioral science. A panel of six invited experts from academic institutions and NIH Institutes and Centers (ICs) shared perspectives and discussed current research on the evaluation, implementation, and effective communication of diversity supplements. A question-and-answer session, moderated by Dr. Bernard, followed the panel presentations. This document delineates the main points from the speakers' presentations and the subsequent discussion on how diversity supplements impact careers in biomedical and behavioral research. The seminar recording and panelists' presentation materials are available on the COSWD website. | True   |
| 520   | PROD       | 3            | $a: This document encapsulates the proceedings of "How Do Diversity Supplements Impact Careers in Biomedical and Behavioral Research?"--the second seminar of the 2022-2023 Scientific Workforce Diversity Seminar Series (SWDSS). The National Institutes of Health (NIH) Chief Officer for Scientific Workforce Diversity (COSWD) hosted the seminar on November 17, 2022. Marie A. Bernard, M.D., COSWD, moderated a panel discussion on how diversity supplements can influence the career pathways of individuals from diverse backgrounds in biomedical and behavioral science. A panel of six invited experts from academic institutions and NIH Institutes and Centers (ICs) shared perspectives and discussed current research on the evaluation, implementation, and effective communication of diversity supplements. A question-and-answer session, moderated by Dr. Bernard, followed the panel presentations. This document delineates the main points from the speakers' presentations and the subsequent discussion on how diversity supplements impact careers in biomedical and behavioral research. The seminar recording and panelists' presentation materials are available on the COSWD website. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 530   | QA         |              | $a: Issued also in print.                                                       | True   |
| 530   | PROD       |              | $a: Issued also in print.                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed Nov. 1, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed Nov. 1, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Workforce Diversity                                                         | True   |
| 650   | QA         | 12           | $a: Biomedical Research $x: economics                                           | True   |
| 650   | QA         | 22           | $a: Behavioral Research $x: economics                                           | True   |
| 650   | QA         | 22           | $a: Research Personnel $x: economics                                            | True   |
| 650   | QA         | 22           | $a: Financing, Government                                                       | True   |
| 650   | PROD       | 12           | $a: Workforce Diversity                                                         | True   |
| 650   | PROD       | 12           | $a: Biomedical Research $x: economics                                           | True   |
| 650   | PROD       | 22           | $a: Behavioral Research $x: economics                                           | True   |
| 650   | PROD       | 22           | $a: Research Personnel $x: economics                                            | True   |
| 650   | PROD       | 22           | $a: Financing, Government                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: National Institutes of Health (U.S.), $e: sponsoring body.                  | True   |
| 710   | PROD       | 2            | $a: National Institutes of Health (U.S.), $e: sponsoring body.                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: Scientific workforce diversity seminar series                               | True   |
| 830   | PROD       |  0           | $a: Scientific workforce diversity seminar series                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604149/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604149/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240702                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240702                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: YYC $b: 20241030                                                            | True   |
| 993   | PROD       |              | $a: YYC $b: 20241030                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241031                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241031                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241101                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241101                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240702                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240702                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918628884306676

Leader:
| File       | Leader                   | Equal  |
| QA         | 01959nam a2200505 i 4500 | True   |
| PROD       | 01959nam a2200505 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918628884306676                                                                | True   |
| 001   | PROD       |              | 9918628884306676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241115152511.0                                                                | True   |
| 005   | PROD       |              | 20241115152511.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 230622s2022    sz a||||ob    000|0 eng                                          | True   |
| 008   | PROD       |              | 230622s2022    sz a||||ob    000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 020   | QA         |              | $a: 9783030998110                                                               | True   |
| 020   | QA         |              | $a: 9783030998103                                                               | True   |
| 020   | PROD       |              | $a: 9783030998110                                                               | True   |
| 020   | PROD       |              | $a: 9783030998103                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918628884306676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK589333                                                      | True   |
| 035   | QA         |              | $a: (OCoLC)1341845957                                                           | True   |
| 035   | PROD       |              | $9: 9918628884306676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK589333                                                      | True   |
| 035   | PROD       |              | $a: (OCoLC)1341845957                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: Switzerland                                                                 | True   |
| 044   | PROD       |              | $9: Switzerland                                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: SB 731                                                                      | True   |
| 060   | PROD       | 00           | $a: SB 731                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 00           | $a: Critical points for the organisation of test performance studies in microbiology : $b: plant pathogens as a case study / $c: Ana Vučurović, Nataša Mehle, Geraldine Anthoine, Tanja Dreo, Maja Ravnikar [editors]. | True   |
| 245   | PROD       | 00           | $a: Critical points for the organisation of test performance studies in microbiology : $b: plant pathogens as a case study / $c: Ana Vučurović, Nataša Mehle, Geraldine Anthoine, Tanja Dreo, Maja Ravnikar [editors]. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Cham (CH) : $b: Springer, $c: 2022.                                         | True   |
| 264   | PROD       |  1           | $a: Cham (CH) : $b: Springer, $c: 2022.                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource : $b: illustrations                                       | True   |
| 300   | PROD       |              | $a: 1 online resource : $b: illustrations                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Plant pathology in the 21st century                                         | True   |
| 490   | PROD       | 1            | $a: Plant pathology in the 21st century                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 530   | QA         |              | $a: Also issued in print.                                                       | True   |
| 530   | PROD       |              | $a: Also issued in print.                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: European Union's Horizon 2020 research and innovation programmeFunded in the frame of Valitest project (grant agreement n°773139.) | True   |
| 536   | PROD       |              | $a: European Union's Horizon 2020 research and innovation programmeFunded in the frame of Valitest project (grant agreement n°773139.) | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from HTML page(viewed October 11, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from HTML page(viewed October 11, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Plant Diseases                                                              | True   |
| 650   | PROD       | 12           | $a: Plant Diseases                                                              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 700   | QA         | 1            | $a: Vučurović, Ana, $e: editor.                                               | True   |
| 700   | QA         | 1            | $a: Mehle, Nataša, $e: editor.                                                 | True   |
| 700   | QA         | 1            | $a: Anthoine, Géraldine, $e: editor.                                           | True   |
| 700   | QA         | 1            | $a: Dreo, Tanja, $e: editor.                                                    | True   |
| 700   | QA         | 1            | $a: Ravnikar, Maja, $d: 1960- $e: editor.                                       | True   |
| 700   | PROD       | 1            | $a: Vučurović, Ana, $e: editor.                                               | True   |
| 700   | PROD       | 1            | $a: Mehle, Nataša, $e: editor.                                                 | True   |
| 700   | PROD       | 1            | $a: Anthoine, Géraldine, $e: editor.                                           | True   |
| 700   | PROD       | 1            | $a: Dreo, Tanja, $e: editor.                                                    | True   |
| 700   | PROD       | 1            | $a: Ravnikar, Maja, $d: 1960- $e: editor.                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 811   | QA         | 1            | $a: International Congress of Plant Pathology $n: (9th : $d: 2008 : Turin, Italy). $t: Plant pathology in the 21st century | True   |
| 811   | PROD       | 1            | $a: International Congress of Plant Pathology $n: (9th : $d: 2008 : Turin, Italy). $t: Plant pathology in the 21st century | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK589333/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK589333/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20230626                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20230626                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: KJD $b: 20240130                                                            | True   |
| 993   | PROD       |              | $a: KJD $b: 20240130                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241011                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241011                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241011 $c: REV $d: 20241115                                      | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241011 $c: REV $d: 20241115                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20230622                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20230622                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918802921206676

Leader:
| File       | Leader                   | Equal  |
| QA         | 03090nam a2200493 i 4500 | True   |
| PROD       | 03090nam a2200493 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918802921206676                                                                | True   |
| 001   | PROD       |              | 9918802921206676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241107105512.0                                                                | True   |
| 005   | PROD       |              | 20241107105512.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240402s2024    ncu     ob    000|0 eng                                          | True   |
| 008   | PROD       |              | 240402s2024    ncu     ob    000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918802921206676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK602204                                                      | True   |
| 035   | QA         |              | $a: (OCoLC)1437827748                                                           | True   |
| 035   | PROD       |              | $9: 9918802921206676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK602204                                                      | True   |
| 035   | PROD       |              | $a: (OCoLC)1437827748                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: QZ 185                                                                      | True   |
| 060   | PROD       | 00           | $a: QZ 185                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Yeika, Eugene, $e: author.                                                  | True   |
| 100   | PROD       | 1            | $a: Yeika, Eugene, $e: author.                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Integrating noncommunicable diseases into antenatal care in Cameroon : $b: a triangulated qualitative analysis / $c: Eugene Yeika, Erica L. Kocher, and Carrie Ngongo. | True   |
| 245   | PROD       | 10           | $a: Integrating noncommunicable diseases into antenatal care in Cameroon : $b: a triangulated qualitative analysis / $c: Eugene Yeika, Erica L. Kocher, and Carrie Ngongo. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Research Triangle Park, NC : $b: RTI Press, $c: January 2024.               | True   |
| 264   | PROD       |  1           | $a: Research Triangle Park, NC : $b: RTI Press, $c: January 2024.               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (11 pages))                                   | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (11 pages))                                   | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Research report, $x: 2378-7902                                              | True   |
| 490   | PROD       | 1            | $a: Research report, $x: 2378-7902                                              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 500   | QA         |              | $a: "RTI Press publication RR-0051-2401"--T.p. verso.                           | True   |
| 500   | PROD       |              | $a: "RTI Press publication RR-0051-2401"--T.p. verso.                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: Noncommunicable diseases (NCDs) have important implications for pregnancy outcomes and the subsequent health of women and their children. The aim of this study is to determine the status of NCD and maternal health program integration, identify barriers to integration, and explore what would be required to deepen integration of NCD care into antenatal care in Cameroon. We used two methods of data collection and synthesis: a desk review of policy documents and protocols and a series of key informant interviews with health system experts and managers working in public, private, and faith-based health facilities at central, regional, and district levels. Although screening for blood glucose and blood pressure occurs during antenatal care, post-diagnosis management is not well-integrated and often requires referral to specialists in higher-level health facilities. Key barriers to integration include lack of guidelines for the management of NCDs, financial constraints for facilities and patients, and shortages of health workers, medications, and supplies for laboratory investigations. Further integration of services for NCDs during pregnancy will require national guidelines backed up by system-wide strengthening of health information systems, insurance coverage, supply chain management, and human resource capacity, particularly in remote areas. | True   |
| 520   | PROD       | 3            | $a: Noncommunicable diseases (NCDs) have important implications for pregnancy outcomes and the subsequent health of women and their children. The aim of this study is to determine the status of NCD and maternal health program integration, identify barriers to integration, and explore what would be required to deepen integration of NCD care into antenatal care in Cameroon. We used two methods of data collection and synthesis: a desk review of policy documents and protocols and a series of key informant interviews with health system experts and managers working in public, private, and faith-based health facilities at central, regional, and district levels. Although screening for blood glucose and blood pressure occurs during antenatal care, post-diagnosis management is not well-integrated and often requires referral to specialists in higher-level health facilities. Key barriers to integration include lack of guidelines for the management of NCDs, financial constraints for facilities and patients, and shortages of health workers, medications, and supplies for laboratory investigations. Further integration of services for NCDs during pregnancy will require national guidelines backed up by system-wide strengthening of health information systems, insurance coverage, supply chain management, and human resource capacity, particularly in remote areas. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed June 4, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed June 4, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Noncommunicable Diseases                                                    | True   |
| 650   | QA         | 22           | $a: Prenatal Care                                                               | True   |
| 650   | PROD       | 12           | $a: Noncommunicable Diseases                                                    | True   |
| 650   | PROD       | 22           | $a: Prenatal Care                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 651   | QA         |  2           | $a: Cameroon                                                                    | True   |
| 651   | PROD       |  2           | $a: Cameroon                                                                    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 700   | QA         | 1            | $a: Kocher, Erica L., $e: author.                                               | True   |
| 700   | QA         | 1            | $a: Ngongo, Carrie, $e: author.                                                 | True   |
| 700   | PROD       | 1            | $a: Kocher, Erica L., $e: author.                                               | True   |
| 700   | PROD       | 1            | $a: Ngongo, Carrie, $e: author.                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: RTI International, $e: issuing body.                                        | True   |
| 710   | PROD       | 2            | $a: RTI International, $e: issuing body.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: RTI Press research report series $x: 2378-7902                              | True   |
| 830   | PROD       |  0           | $a: RTI Press research report series $x: 2378-7902                              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK602204/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK602204/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240402                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240402                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: KXP $b: 20240603                                                            | True   |
| 993   | PROD       |              | $a: KXP $b: 20240603                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20240604                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20240604                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20240605 $c: REV $d: 20241107                                      | True   |
| 995   | PROD       |              | $a: AUTH $b: 20240605 $c: REV $d: 20241107                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240402                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240402                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918802920706676

Leader:
| File       | Leader                   | Equal  |
| QA         | 07825nam a2200541 i 4500 | True   |
| PROD       | 07825nam a2200541 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918802920706676                                                                | True   |
| 001   | PROD       |              | 9918802920706676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241106163255.0                                                                | True   |
| 005   | PROD       |              | 20241106163255.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240402s2024    enka    on   i000|0 eng                                          | True   |
| 008   | PROD       |              | 240402s2024    enka    on   i000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918802920706676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK602233                                                      | True   |
| 035   | QA         |              | $a: (OCoLC)1456538860                                                           | True   |
| 035   | PROD       |              | $9: 9918802920706676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK602233                                                      | True   |
| 035   | PROD       |              | $a: (OCoLC)1456538860                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: England                                                                     | True   |
| 044   | PROD       |              | $9: England                                                                     | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WM 171.5                                                                    | True   |
| 060   | PROD       | 00           | $a: WM 171.5                                                                    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Nava-Ruelas, Rocio, $e: author.                                             | True   |
| 100   | PROD       | 1            | $a: Nava-Ruelas, Rocio, $e: author.                                             | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Approaches to deliver depression care and understanding barriers and facilitators to implementation in people with tuberculosis in LMICs : $b: a systematic review / $c: Rocio Nava-Ruelas, Olamide Todowede, Najma Siddiqi, Helen Elsey. | True   |
| 245   | PROD       | 10           | $a: Approaches to deliver depression care and understanding barriers and facilitators to implementation in people with tuberculosis in LMICs : $b: a systematic review / $c: Rocio Nava-Ruelas, Olamide Todowede, Najma Siddiqi, Helen Elsey. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Southampton (UK) : $b: National Institute for Health and Care Research, $c: February 2024. | True   |
| 264   | PROD       |  1           | $a: Southampton (UK) : $b: National Institute for Health and Care Research, $c: February 2024. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (37 pages)) : $b: illustrations, tables.      | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (37 pages)) : $b: illustrations, tables.      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Global health research                                                      | True   |
| 490   | PROD       | 1            | $a: Global health research                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: BACKGROUND: Depression is a common comorbidity in people with tuberculosis. Various approaches to delivering depression care for people with tuberculosis have been implemented in low- and middle-income countries. To date, there are no comprehensive reviews that summarise and explore the implementation of these approaches to delivering depression care for people with tuberculosis. OBJECTIVES: To identify the various interventions and approaches to delivering depression care as part of routine tuberculosis care in low- and middle-income countries, and to summarise the barriers and facilitators to their implementation. REVIEW METHODS: We conducted a systematic review to identify the relevant evidence. We conducted searches in June and July 2020 in the following databases, from inception: MEDLINE, Scopus, PsycINFO, Web of Science, PubMed, EMBASE, Cochrane Library, SciELO and LILACS, Health Management Information Consortium. We also hand-searched the reference lists of the included studies. Two reviewers independently screened the titles and abstracts of all records. Two reviewers independently screened the full texts. We used the Mixed Methods Appraisal Tool for quality appraisal. We coded and synthesised the findings using the constructs of the Consolidated Framework for Implementation Research as an a priori guide to analyse the barriers and facilitators. RESULTS: The search retrieved 10,982 records, 39 studies were selected for full-text screening and 10 studies were included in the analysis. We categorised the interventions as psychological, combined (pharmacological and psychological), combined with socioeconomic support and screening-only approaches. The most commonly implemented types of intervention were psychological interventions, on their own or combined with pharmacological interventions or socioeconomic support. The most common barrier to implementation was the costs associated with the intervention and its implementation. There were multiple facilitators for implementation for all types of interventions in different Consolidated Framework for Implementation Research domains. Facilitators were related to the characteristics of the intervention (relative advantage), the inner setting (compatibility of the intervention with existing workflows) and the process of implementation (the positive attitudes of innovation participants). LIMITATIONS: This study relied on published information; thus, it is possible that important barriers and facilitators were not reported in the published studies and were, therefore, absent from this evidence synthesis. CONCLUSION: We identified psychological interventions as the most commonly implemented approach to the delivery of depression care for people with tuberculosis, alone or in combination with other approaches. We identified the increase in costs as a barrier experienced for all intervention types. We identified the relative advantage of the intervention, its compatibility and the beliefs and attitudes of people with tuberculosis, their families and communities as facilitators that were reported in all intervention types. The integration of depression care for people with tuberculosis in existing tuberculosis services is possible but will require the barrier of the costs associated with delivery and implementation to be addressed. This review was carried out during the COVID-19 pandemic, when the effects of the pandemic on tuberculosis and mental health services were yet to be seen. Future research should focus on the impact of the pandemic on tuberculosis and mental health services, and on people with tuberculosis and their mental health. FUNDING: This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Global Health Research programme as award number 17/63/130. A plain language summary of this article is available on the NIHR Journals Library website https://doi.org/10.3310/GRWH1425. | True   |
| 520   | QA         | 3            | $a: We wanted to find out how to treat depression in people with tuberculosis living in low- and middle-income countries and how to deliver depression care for this population. Depression, or depressive symptoms, are common in people with tuberculosis. It is possible to treat depression in people with tuberculosis, but we do not know the best way to treat it or to deliver depression care. Tuberculosis is a common condition in low-income and middle-income countries. We explored what was done in these countries to provide depression care for people with tuberculosis. We also explored what facilitated or made difficult the delivery of depression care. We conducted a systematic review study which aimed to find all the published information to answer our question. We searched academic and grey literature to gather as much information as possible from different sources. We identified over 10,000 relevant records related to our question. We selected 10 studies that described how depression care had been delivered to people with tuberculosis living in low- and middle-income countries. We found that psychological treatment is the most common depression treatment offered to people with tuberculosis. We found that mental health training for health-care workers and more health-care human resources were necessary to deliver depression care. We found that the costs associated with delivering depression care made it difficult to include this as part of routine tuberculosis services. We found that people with tuberculosis and health-care workers believed in the beneficial impact of delivering depression care which made it easier to deliver it. We found that what makes it hard or easy to deliver depression care can vary across different treatments or interventions for depression. We found that we need more information on how to best deliver depression care. | True   |
| 520   | PROD       | 3            | $a: BACKGROUND: Depression is a common comorbidity in people with tuberculosis. Various approaches to delivering depression care for people with tuberculosis have been implemented in low- and middle-income countries. To date, there are no comprehensive reviews that summarise and explore the implementation of these approaches to delivering depression care for people with tuberculosis. OBJECTIVES: To identify the various interventions and approaches to delivering depression care as part of routine tuberculosis care in low- and middle-income countries, and to summarise the barriers and facilitators to their implementation. REVIEW METHODS: We conducted a systematic review to identify the relevant evidence. We conducted searches in June and July 2020 in the following databases, from inception: MEDLINE, Scopus, PsycINFO, Web of Science, PubMed, EMBASE, Cochrane Library, SciELO and LILACS, Health Management Information Consortium. We also hand-searched the reference lists of the included studies. Two reviewers independently screened the titles and abstracts of all records. Two reviewers independently screened the full texts. We used the Mixed Methods Appraisal Tool for quality appraisal. We coded and synthesised the findings using the constructs of the Consolidated Framework for Implementation Research as an a priori guide to analyse the barriers and facilitators. RESULTS: The search retrieved 10,982 records, 39 studies were selected for full-text screening and 10 studies were included in the analysis. We categorised the interventions as psychological, combined (pharmacological and psychological), combined with socioeconomic support and screening-only approaches. The most commonly implemented types of intervention were psychological interventions, on their own or combined with pharmacological interventions or socioeconomic support. The most common barrier to implementation was the costs associated with the intervention and its implementation. There were multiple facilitators for implementation for all types of interventions in different Consolidated Framework for Implementation Research domains. Facilitators were related to the characteristics of the intervention (relative advantage), the inner setting (compatibility of the intervention with existing workflows) and the process of implementation (the positive attitudes of innovation participants). LIMITATIONS: This study relied on published information; thus, it is possible that important barriers and facilitators were not reported in the published studies and were, therefore, absent from this evidence synthesis. CONCLUSION: We identified psychological interventions as the most commonly implemented approach to the delivery of depression care for people with tuberculosis, alone or in combination with other approaches. We identified the increase in costs as a barrier experienced for all intervention types. We identified the relative advantage of the intervention, its compatibility and the beliefs and attitudes of people with tuberculosis, their families and communities as facilitators that were reported in all intervention types. The integration of depression care for people with tuberculosis in existing tuberculosis services is possible but will require the barrier of the costs associated with delivery and implementation to be addressed. This review was carried out during the COVID-19 pandemic, when the effects of the pandemic on tuberculosis and mental health services were yet to be seen. Future research should focus on the impact of the pandemic on tuberculosis and mental health services, and on people with tuberculosis and their mental health. FUNDING: This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Global Health Research programme as award number 17/63/130. A plain language summary of this article is available on the NIHR Journals Library website https://doi.org/10.3310/GRWH1425. | True   |
| 520   | PROD       | 3            | $a: We wanted to find out how to treat depression in people with tuberculosis living in low- and middle-income countries and how to deliver depression care for this population. Depression, or depressive symptoms, are common in people with tuberculosis. It is possible to treat depression in people with tuberculosis, but we do not know the best way to treat it or to deliver depression care. Tuberculosis is a common condition in low-income and middle-income countries. We explored what was done in these countries to provide depression care for people with tuberculosis. We also explored what facilitated or made difficult the delivery of depression care. We conducted a systematic review study which aimed to find all the published information to answer our question. We searched academic and grey literature to gather as much information as possible from different sources. We identified over 10,000 relevant records related to our question. We selected 10 studies that described how depression care had been delivered to people with tuberculosis living in low- and middle-income countries. We found that psychological treatment is the most common depression treatment offered to people with tuberculosis. We found that mental health training for health-care workers and more health-care human resources were necessary to deliver depression care. We found that the costs associated with delivering depression care made it difficult to include this as part of routine tuberculosis services. We found that people with tuberculosis and health-care workers believed in the beneficial impact of delivering depression care which made it easier to deliver it. We found that what makes it hard or easy to deliver depression care can vary across different treatments or interventions for depression. We found that we need more information on how to best deliver depression care. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed August 16, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed August 16, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Depression $x: complications                                                | True   |
| 650   | QA         | 22           | $a: Tuberculosis $x: complications                                              | True   |
| 650   | QA         | 22           | $a: Mental Health Services                                                      | True   |
| 650   | QA         | 22           | $a: Developing Countries                                                        | True   |
| 650   | PROD       | 12           | $a: Depression $x: complications                                                | True   |
| 650   | PROD       | 22           | $a: Tuberculosis $x: complications                                              | True   |
| 650   | PROD       | 22           | $a: Mental Health Services                                                      | True   |
| 650   | PROD       | 22           | $a: Developing Countries                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 655   | QA         |  2           | $a: Systematic Review                                                           | True   |
| 655   | QA         |  2           | $a: Tables                                                                      | True   |
| 655   | PROD       |  2           | $a: Systematic Review                                                           | True   |
| 655   | PROD       |  2           | $a: Tables                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 700   | QA         | 1            | $a: Todowede, Olamide, $e: author.                                              | True   |
| 700   | QA         | 1            | $a: Siddiqi, Najma, $e: author.                                                 | True   |
| 700   | QA         | 1            | $a: Elsey, Helen, $e: author.                                                   | True   |
| 700   | PROD       | 1            | $a: Todowede, Olamide, $e: author.                                              | True   |
| 700   | PROD       | 1            | $a: Siddiqi, Najma, $e: author.                                                 | True   |
| 700   | PROD       | 1            | $a: Elsey, Helen, $e: author.                                                   | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: National Institute for Health and Care Research (Great Britain), $e: issuing body. | True   |
| 710   | PROD       | 2            | $a: National Institute for Health and Care Research (Great Britain), $e: issuing body. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: Global health research $x: 2631-7613                                        | True   |
| 830   | PROD       |  0           | $a: Global health research $x: 2631-7613                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK602233/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK602233/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240402                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240402                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: CJM $b: 20240709                                                            | True   |
| 993   | PROD       |              | $a: CJM $b: 20240709                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20240816                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20240816                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20240912 $c: REV $d: 20241106                                      | True   |
| 995   | PROD       |              | $a: AUTH $b: 20240912 $c: REV $d: 20241106                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240402                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240402                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918802920606676

Leader:
| File       | Leader                   | Equal  |
| QA         | 06620nam a2200493 i 4500 | True   |
| PROD       | 06620nam a2200493 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918802920606676                                                                | True   |
| 001   | PROD       |              | 9918802920606676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241107130848.0                                                                | True   |
| 005   | PROD       |              | 20241107130848.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240402s2024    enka    ob   f000|0 eng                                          | True   |
| 008   | PROD       |              | 240402s2024    enka    ob   f000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918802920606676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK602234                                                      | True   |
| 035   | QA         |              | $a: (OCoLC)1446471958                                                           | True   |
| 035   | PROD       |              | $9: 9918802920606676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK602234                                                      | True   |
| 035   | PROD       |              | $a: (OCoLC)1446471958                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: England                                                                     | True   |
| 044   | PROD       |              | $9: England                                                                     | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WM 167                                                                      | True   |
| 060   | PROD       | 00           | $a: WM 167                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Daruwalla, Nayreen, $e: author.                                             | True   |
| 100   | PROD       | 1            | $a: Daruwalla, Nayreen, $e: author.                                             | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Support needs of survivors of violence against women in urban India : $b: a prospective analysis of client records / $c: Nayreen Daruwalla, Tanushree Das, Sangeeta Punekar, Sonali Patil, Shreya Manjrekar, Shanti Pantvaidya, Vanessa D'Souza and David Osrin. | True   |
| 245   | PROD       | 10           | $a: Support needs of survivors of violence against women in urban India : $b: a prospective analysis of client records / $c: Nayreen Daruwalla, Tanushree Das, Sangeeta Punekar, Sonali Patil, Shreya Manjrekar, Shanti Pantvaidya, Vanessa D'Souza and David Osrin. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Southampton, UK : $b: National Institute for Health and Care Research, $c: January 2024. | True   |
| 264   | PROD       |  1           | $a: Southampton, UK : $b: National Institute for Health and Care Research, $c: January 2024. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (14 pages)) : $b: illustrations.              | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (14 pages)) : $b: illustrations.              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Global health research                                                      | True   |
| 490   | PROD       | 1            | $a: Global health research                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: BACKGROUND: Violence against women harms individuals, communities, and society. Supporting survivors requires a combination of skills and resources and involvement of multiple institutions. We aimed to document the range of responses that a counselling service should be able to provide, based on direct experience of working with survivors predominantly from urban informal settlements. METHODS: At non-government counselling centres in Mumbai, we analysed unlinked electronic records collected by counsellors supporting survivors of violence. We examined how women knew of the services, how they described their concerns, what they said they expected, and what was provided. We quantified the proportions of clients who required crisis intervention, police action, legal input, and medical, psychological and psychiatric support. RESULTS: Counsellors met with 2278 women clients in 2019, almost half of whom had been encouraged to attend through community outreach. Clients described intimate partner violence (37%), domestic violence by a family member other than their partner (22%), or both (27%). Common forms of violence reported were emotional (88%), economic (73%), and physical (71%); 68% of clients reported episodes of neglect, 59% of coercive control, and 36% of sexual violence, while 77% had survived three or more forms of violence. Over a median seven consultations, 32% required crisis intervention, 31% home visits from counsellors, and 17% legal support; 13% saw a clinical psychologist, 7% were assisted in consulting the police, and 5% required medical care. DISCUSSION: Demand for services was substantial at 200 new clients each month. Key concerns for counsellors were coping with this heavy workload, skills in responding to women's experience of multiple forms of violence and their desire to stay in relationships, skills in emotional support, ability to undertake and act on risk and mental health assessment, and effective engagement with health, police, and legal services. FUTURE WORK: Counsellors need to take a systematic approach to interacting with survivors of violence that covers all the considerations and activities needed in order of priority. We have developed a package of guidelines to meet this requirement, including trauma-informed counselling and mental health assessment and support (https://garima.snehamumbai.org/). LIMITATIONS: The record system may have been subject to errors in data entry or systematic differences between counsellor choices, with the possibility of over- or under-identification of need and different counsellors' propensities for and choices of referral. The spectrum of concerns relates to women residents of urban informal settlements, and we should be cautious about their application to other populations. FUNDING: This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Global Health Research programme as award number 17/63/47. A plain language summary of this research article is available on the NIHR Journals Library Website https://doi.org/10.3310/LKNH2423. | True   |
| 520   | QA         | 3            | $a: Violence against women harms individuals, community, and society. Supporting survivors requires a combination of skills and resources and involvement of multiple institutions. We aimed to document the range of responses that a counselling service should be able to provide, based on direct experience of working with survivors predominantly from urban informal settlements. At non-government counselling centres in Mumbai, we analysed records collected by counsellors supporting survivors of violence. We examined how women knew of the services, how they described their concerns, what they said they expected, and what was provided. We looked at the numbers of clients who required crisis intervention, police action, legal input, and medical, psychological and psychiatric support. Almost half the clients had been encouraged to attend through community outreach. Clients described intimate partner violence, domestic violence by a family member other than their partner, or both. Common forms of violence reported were emotional, economic, and physical. Many reported episodes of neglect, coercive control, and sexual violence, and most had survived three or more forms of violence. One-third required crisis intervention and home visits from counsellors, and one-fifth needed legal support. Demand for services was substantial. Key concerns for counsellors were coping with their heavy workload, skills in responding to women's experience of multiple forms of violence and their desire to stay in relationships, skills in emotional support, ability to undertake and act on risk and mental health assessment, and effective engagement with health, police, and legal services. | True   |
| 520   | PROD       | 3            | $a: BACKGROUND: Violence against women harms individuals, communities, and society. Supporting survivors requires a combination of skills and resources and involvement of multiple institutions. We aimed to document the range of responses that a counselling service should be able to provide, based on direct experience of working with survivors predominantly from urban informal settlements. METHODS: At non-government counselling centres in Mumbai, we analysed unlinked electronic records collected by counsellors supporting survivors of violence. We examined how women knew of the services, how they described their concerns, what they said they expected, and what was provided. We quantified the proportions of clients who required crisis intervention, police action, legal input, and medical, psychological and psychiatric support. RESULTS: Counsellors met with 2278 women clients in 2019, almost half of whom had been encouraged to attend through community outreach. Clients described intimate partner violence (37%), domestic violence by a family member other than their partner (22%), or both (27%). Common forms of violence reported were emotional (88%), economic (73%), and physical (71%); 68% of clients reported episodes of neglect, 59% of coercive control, and 36% of sexual violence, while 77% had survived three or more forms of violence. Over a median seven consultations, 32% required crisis intervention, 31% home visits from counsellors, and 17% legal support; 13% saw a clinical psychologist, 7% were assisted in consulting the police, and 5% required medical care. DISCUSSION: Demand for services was substantial at 200 new clients each month. Key concerns for counsellors were coping with this heavy workload, skills in responding to women's experience of multiple forms of violence and their desire to stay in relationships, skills in emotional support, ability to undertake and act on risk and mental health assessment, and effective engagement with health, police, and legal services. FUTURE WORK: Counsellors need to take a systematic approach to interacting with survivors of violence that covers all the considerations and activities needed in order of priority. We have developed a package of guidelines to meet this requirement, including trauma-informed counselling and mental health assessment and support (https://garima.snehamumbai.org/). LIMITATIONS: The record system may have been subject to errors in data entry or systematic differences between counsellor choices, with the possibility of over- or under-identification of need and different counsellors' propensities for and choices of referral. The spectrum of concerns relates to women residents of urban informal settlements, and we should be cautious about their application to other populations. FUNDING: This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Global Health Research programme as award number 17/63/47. A plain language summary of this research article is available on the NIHR Journals Library Website https://doi.org/10.3310/LKNH2423. | True   |
| 520   | PROD       | 3            | $a: Violence against women harms individuals, community, and society. Supporting survivors requires a combination of skills and resources and involvement of multiple institutions. We aimed to document the range of responses that a counselling service should be able to provide, based on direct experience of working with survivors predominantly from urban informal settlements. At non-government counselling centres in Mumbai, we analysed records collected by counsellors supporting survivors of violence. We examined how women knew of the services, how they described their concerns, what they said they expected, and what was provided. We looked at the numbers of clients who required crisis intervention, police action, legal input, and medical, psychological and psychiatric support. Almost half the clients had been encouraged to attend through community outreach. Clients described intimate partner violence, domestic violence by a family member other than their partner, or both. Common forms of violence reported were emotional, economic, and physical. Many reported episodes of neglect, coercive control, and sexual violence, and most had survived three or more forms of violence. One-third required crisis intervention and home visits from counsellors, and one-fifth needed legal support. Demand for services was substantial. Key concerns for counsellors were coping with their heavy workload, skills in responding to women's experience of multiple forms of violence and their desire to stay in relationships, skills in emotional support, ability to undertake and act on risk and mental health assessment, and effective engagement with health, police, and legal services. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed July 11, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed July 11, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Intimate Partner Violence                                                   | True   |
| 650   | QA         | 12           | $a: Gender-Based Violence                                                       | True   |
| 650   | QA         | 22           | $a: Battered Women                                                              | True   |
| 650   | QA         | 22           | $a: Psychosocial Support Systems                                                | True   |
| 650   | PROD       | 12           | $a: Intimate Partner Violence                                                   | True   |
| 650   | PROD       | 12           | $a: Gender-Based Violence                                                       | True   |
| 650   | PROD       | 22           | $a: Battered Women                                                              | True   |
| 650   | PROD       | 22           | $a: Psychosocial Support Systems                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 651   | QA         |  2           | $a: India                                                                       | True   |
| 651   | PROD       |  2           | $a: India                                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: National Institute for Health and Care Research (Great Britain), $e: issuing body. | True   |
| 710   | PROD       | 2            | $a: National Institute for Health and Care Research (Great Britain), $e: issuing body. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: Global health research $x: 2631-7613                                        | True   |
| 830   | PROD       |  0           | $a: Global health research $x: 2631-7613                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK602234/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK602234/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240402                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240402                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: YYC $b: 20240617                                                            | True   |
| 993   | PROD       |              | $a: YYC $b: 20240617                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20240711                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20240711                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20240714 $c: REV $d: 20241107                                      | True   |
| 995   | PROD       |              | $a: AUTH $b: 20240714 $c: REV $d: 20241107                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240402                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240402                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918802825106676

Leader:
| File       | Leader                   | Equal  |
| QA         | 05942nam a2200517 i 4500 | True   |
| PROD       | 05942nam a2200517 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918802825106676                                                                | True   |
| 001   | PROD       |              | 9918802825106676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241106170527.0                                                                | True   |
| 005   | PROD       |              | 20241106170527.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240402s2021    dcua    ob    000|0 eng                                          | True   |
| 008   | PROD       |              | 240402s2021    dcua    ob    000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918802825106676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK601516                                                      | True   |
| 035   | QA         |              | $a: (OCoLC)1436450624                                                           | True   |
| 035   | PROD       |              | $9: 9918802825106676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK601516                                                      | True   |
| 035   | PROD       |              | $a: (OCoLC)1436450624                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WS 342                                                                      | True   |
| 060   | PROD       | 00           | $a: WS 342                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Heathcock, Jill C., $e: author.                                             | True   |
| 100   | PROD       | 1            | $a: Heathcock, Jill C., $e: author.                                             | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Comparing two physical therapy schedules for children with cerebral palsy : $b: the ACHIEVE study / $c: Jill C. Heathcock, Xueliang (Jeff) Pan, Rachel Ferrante, Petra Sternberg, Kelly Tanner. | True   |
| 245   | PROD       | 10           | $a: Comparing two physical therapy schedules for children with cerebral palsy : $b: the ACHIEVE study / $c: Jill C. Heathcock, Xueliang (Jeff) Pan, Rachel Ferrante, Petra Sternberg, Kelly Tanner. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington, DC : $b: Patient-Centered Outcomes Research Institute, $c: [2021] | True   |
| 264   | PROD       |  1           | $a: Washington, DC : $b: Patient-Centered Outcomes Research Institute, $c: [2021] | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (88 pages)) : $b: illustrations.              | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (88 pages)) : $b: illustrations.              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Final research report                                                       | True   |
| 490   | PROD       | 1            | $a: Final research report                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: BACKGROUND: Children with cerebral palsy (CP) often receive outpatient physical therapy (PT) services, although the dosing schedule can vary widely depending on the child and the setting. Parents could make more informed choices about their child's therapy schedule if they knew whether a high-intensity (HIP) schedule of therapy was better than or equivalent to a usual model of weekly therapy. OBJECTIVES: The main objective of the ACHIEVE study was to (1) compare the short-term and long-term effects of 2 treatment service delivery models: 1 hour per day, 1× per week for 40 weeks (weekly); and 2 hours every weekday for 2 periods of 10 consecutive weekdays (total of 4 weeks) of a repeated periodic (HIP) bout of outpatient PT. We hypothesized that HIP therapy would result in comparatively greater improvements than would weekly therapy. In addition, we aimed to (2) determine individual differences in (a) children's response to treatment and (b) parent preferences; (3) monitor the progress and variability of motor function; (4) explore patient and family factors associated with treatment response; and (5) identify relationships between the assessment of the child's function by parents and the child's gross motor function as evaluated by professionals. METHODS: We enrolled 100 children aged 2 to 8 years with CP in our study, which took place over a 9-month period. Forty-six participants were randomly assigned to either the weekly or HIP treatment group. Fifty-four participants self-selected their treatment group; this option was added to the study for families that could not commit to accepting either of the schedules. Trained therapists assigned each child a Gross Motor Function Classification System (GMFCS) level and completed baseline and 9-month testing. Testing included the Gross Motor Function Measure-66 (GMFM-66) score (primary outcome measure), as well as secondary measures, including Goal Attainment Scale (GAS) and Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III) scores. Parents also completed questionnaires on their children's skills, such as the Pediatric Evaluation of Disability Inventory-Computer Adaptive Test (PEDI-CAT). We analyzed the participants' scores using a linear mixed model, comparing the weekly and HIP groups in both the randomized and self-selected groups. RESULTS: Both the weekly and HIP groups improved from baseline to 9 months in both the randomized and self-selected cohorts. At the time of this report, there was a 76% follow-up rate for the primary outcome measure at 9 months. There were no significant differences between the HIP and weekly groups for either cohort on the GMFM-66 (−0.92; 95% CI, −2.83 to 0.98; P = .34). There were also no significant differences between groups on the GAS, Bayley-III, or PEDI-CAT, although all groups improved on these measures over time, with significant main effects for time and clinically meaningful differences. Children with lower GMFCS levels (better function) and higher parent satisfaction with treatment made greater gains in motor function. CONCLUSIONS: HIP and weekly outpatient PT treatments, when provided using the same total number of hours, are likely to produce similar motor outcomes for children aged 2 to 8 years with CP. Parents and therapists can decide which schedule will be more beneficial for an individual child based on their unique personal and family needs. LIMITATIONS: A limitation of this study was a possible lack of power due to attrition during follow-up, which might have limited our ability to detect differences between groups and generalize the results. We may not be able to tell which changes may be due to normal development rather than the interventions, because the interventions were only 9 months long. | True   |
| 520   | PROD       | 3            | $a: BACKGROUND: Children with cerebral palsy (CP) often receive outpatient physical therapy (PT) services, although the dosing schedule can vary widely depending on the child and the setting. Parents could make more informed choices about their child's therapy schedule if they knew whether a high-intensity (HIP) schedule of therapy was better than or equivalent to a usual model of weekly therapy. OBJECTIVES: The main objective of the ACHIEVE study was to (1) compare the short-term and long-term effects of 2 treatment service delivery models: 1 hour per day, 1× per week for 40 weeks (weekly); and 2 hours every weekday for 2 periods of 10 consecutive weekdays (total of 4 weeks) of a repeated periodic (HIP) bout of outpatient PT. We hypothesized that HIP therapy would result in comparatively greater improvements than would weekly therapy. In addition, we aimed to (2) determine individual differences in (a) children's response to treatment and (b) parent preferences; (3) monitor the progress and variability of motor function; (4) explore patient and family factors associated with treatment response; and (5) identify relationships between the assessment of the child's function by parents and the child's gross motor function as evaluated by professionals. METHODS: We enrolled 100 children aged 2 to 8 years with CP in our study, which took place over a 9-month period. Forty-six participants were randomly assigned to either the weekly or HIP treatment group. Fifty-four participants self-selected their treatment group; this option was added to the study for families that could not commit to accepting either of the schedules. Trained therapists assigned each child a Gross Motor Function Classification System (GMFCS) level and completed baseline and 9-month testing. Testing included the Gross Motor Function Measure-66 (GMFM-66) score (primary outcome measure), as well as secondary measures, including Goal Attainment Scale (GAS) and Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III) scores. Parents also completed questionnaires on their children's skills, such as the Pediatric Evaluation of Disability Inventory-Computer Adaptive Test (PEDI-CAT). We analyzed the participants' scores using a linear mixed model, comparing the weekly and HIP groups in both the randomized and self-selected groups. RESULTS: Both the weekly and HIP groups improved from baseline to 9 months in both the randomized and self-selected cohorts. At the time of this report, there was a 76% follow-up rate for the primary outcome measure at 9 months. There were no significant differences between the HIP and weekly groups for either cohort on the GMFM-66 (−0.92; 95% CI, −2.83 to 0.98; P = .34). There were also no significant differences between groups on the GAS, Bayley-III, or PEDI-CAT, although all groups improved on these measures over time, with significant main effects for time and clinically meaningful differences. Children with lower GMFCS levels (better function) and higher parent satisfaction with treatment made greater gains in motor function. CONCLUSIONS: HIP and weekly outpatient PT treatments, when provided using the same total number of hours, are likely to produce similar motor outcomes for children aged 2 to 8 years with CP. Parents and therapists can decide which schedule will be more beneficial for an individual child based on their unique personal and family needs. LIMITATIONS: A limitation of this study was a possible lack of power due to attrition during follow-up, which might have limited our ability to detect differences between groups and generalize the results. We may not be able to tell which changes may be due to normal development rather than the interventions, because the interventions were only 9 months long. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: Institution Receiving Award: Ohio State University Original Project Title: Comparing Two Schedules of Physical Therapy for Children with Cerebral Palsy PCORI: CER-1507-31899 ClinicalTrials.gov ID: NCT02897024 | True   |
| 536   | PROD       |              | $a: Institution Receiving Award: Ohio State University Original Project Title: Comparing Two Schedules of Physical Therapy for Children with Cerebral Palsy PCORI: CER-1507-31899 ClinicalTrials.gov ID: NCT02897024 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed May 22, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed May 22, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Cerebral Palsy $x: therapy                                                  | True   |
| 650   | QA         | 22           | $a: Physical Therapy Modalities                                                 | True   |
| 650   | QA         | 22           | $a: Comparative Effectiveness Research $x: methods                              | True   |
| 650   | PROD       | 12           | $a: Cerebral Palsy $x: therapy                                                  | True   |
| 650   | PROD       | 22           | $a: Physical Therapy Modalities                                                 | True   |
| 650   | PROD       | 22           | $a: Comparative Effectiveness Research $x: methods                              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 700   | QA         | 1            | $a: Pan, Xueliang, $e: author.                                                  | True   |
| 700   | QA         | 1            | $a: Ferrante, Rachel, $e: author.                                               | True   |
| 700   | QA         | 1            | $a: Sternberg, Petra, $e: author.                                               | True   |
| 700   | QA         | 1            | $a: Tanner, Kelly $q: (Kelly J.), $e: author.                                   | True   |
| 700   | PROD       | 1            | $a: Pan, Xueliang, $e: author.                                                  | True   |
| 700   | PROD       | 1            | $a: Ferrante, Rachel, $e: author.                                               | True   |
| 700   | PROD       | 1            | $a: Sternberg, Petra, $e: author.                                               | True   |
| 700   | PROD       | 1            | $a: Tanner, Kelly $q: (Kelly J.), $e: author.                                   | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: Patient-Centered Outcomes Research Institute (U.S.), $e: issuing body.      | True   |
| 710   | PROD       | 2            | $a: Patient-Centered Outcomes Research Institute (U.S.), $e: issuing body.      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: Final research report (Patient-Centered Outcomes Research Institute (U.S.)) | True   |
| 830   | PROD       |  0           | $a: Final research report (Patient-Centered Outcomes Research Institute (U.S.)) | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK601516/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK601516/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240402                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240402                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: YYC $b: 20240521                                                            | True   |
| 993   | PROD       |              | $a: YYC $b: 20240521                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20240522                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20240522                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20240523 $c: REV $d: 20241106                                      | True   |
| 995   | PROD       |              | $a: AUTH $b: 20240523 $c: REV $d: 20241106                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240402                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240402                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918840078706676

Leader:
| File       | Leader                   | Equal  |
| QA         | 02987nam a2200517 i 4500 | True   |
| PROD       | 02987nam a2200517 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918840078706676                                                                | True   |
| 001   | PROD       |              | 9918840078706676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241011154929.0                                                                | True   |
| 005   | PROD       |              | 20241011154929.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240602s2023    dcua    ob   f000|0 eng                                          | True   |
| 008   | PROD       |              | 240602s2023    dcua    ob   f000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918840078706676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK603243                                                      | True   |
| 035   | QA         |              | $a: (OCoLC)1461734771                                                           | True   |
| 035   | PROD       |              | $9: 9918840078706676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK603243                                                      | True   |
| 035   | PROD       |              | $a: (OCoLC)1461734771                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: W 26                                                                        | True   |
| 060   | PROD       | 00           | $a: W 26                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Parasrampuria, Sonal, $e: author.                                           | True   |
| 100   | PROD       | 1            | $a: Parasrampuria, Sonal, $e: author.                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: FDA user fees : $b: examining changes in medical product development and economic benefits  / $c: Sonal Parasrampuria, Trinidad Beleche. | True   |
| 245   | PROD       | 10           | $a: FDA user fees : $b: examining changes in medical product development and economic benefits  / $c: Sonal Parasrampuria, Trinidad Beleche. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 246   | QA         | 1            | $a: Food and Drug Administration user fees                                      | True   |
| 246   | PROD       | 1            | $a: Food and Drug Administration user fees                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington, D.C. : $b: ASPE, Office of the Assistant Secretary for Planning and Evaluation, $c: March 2023. | True   |
| 264   | PROD       |  1           | $a: Washington, D.C. : $b: ASPE, Office of the Assistant Secretary for Planning and Evaluation, $c: March 2023. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (13 pages)) : $b: illustrations.              | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (13 pages)) : $b: illustrations.              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Issue brief                                                                 | True   |
| 490   | PROD       | 1            | $a: Issue brief                                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: The Food and Drug Administration (FDA) assesses and collects user fees to supplement Congressional appropriations. In fiscal year (FY) 2022, user fees represented 46% ($2.9 billion) of FDA's total budget of $6.2 billion. User fees vary substantially across FDA programs. In FY2022, across FDA's medical product centers, user fees accounted for $1.4 billion (66%) of the human drugs program budget, $197 million (43%) of the biologics program budget, and $228 million (35%) of the medical device program budget. Research evidence suggests that user fees have contributed to increased access to new medical products for patients and reduced review timelines for industry. The benefits of user fees can be substantial for industry and patients. Using public and proprietary data from 2000 to 2018, we estimate that between 0.5% and 2.0% of the total cost of developing a new drug, complex medical device, or preventive vaccine went towards user fees. Using data from 2013 to 2021, we estimate that 1.7% of the total cost to develop a generic drug went towards user fees. | True   |
| 520   | PROD       | 3            | $a: The Food and Drug Administration (FDA) assesses and collects user fees to supplement Congressional appropriations. In fiscal year (FY) 2022, user fees represented 46% ($2.9 billion) of FDA's total budget of $6.2 billion. User fees vary substantially across FDA programs. In FY2022, across FDA's medical product centers, user fees accounted for $1.4 billion (66%) of the human drugs program budget, $197 million (43%) of the biologics program budget, and $228 million (35%) of the medical device program budget. Research evidence suggests that user fees have contributed to increased access to new medical products for patients and reduced review timelines for industry. The benefits of user fees can be substantial for industry and patients. Using public and proprietary data from 2000 to 2018, we estimate that between 0.5% and 2.0% of the total cost of developing a new drug, complex medical device, or preventive vaccine went towards user fees. Using data from 2013 to 2021, we estimate that 1.7% of the total cost to develop a generic drug went towards user fees. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed October 11, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed October 11, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 610   | QA         | 12           | $a: United States. $b: Food and Drug Administration                             | True   |
| 610   | PROD       | 12           | $a: United States. $b: Food and Drug Administration                             | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Fees and Charges                                                            | True   |
| 650   | QA         | 12           | $a: Equipment and Supplies $x: economics                                        | True   |
| 650   | QA         | 22           | $a: Inventions $x: economics                                                    | True   |
| 650   | QA         | 22           | $a: Cost-Benefit Analysis                                                       | True   |
| 650   | PROD       | 12           | $a: Fees and Charges                                                            | True   |
| 650   | PROD       | 12           | $a: Equipment and Supplies $x: economics                                        | True   |
| 650   | PROD       | 22           | $a: Inventions $x: economics                                                    | True   |
| 650   | PROD       | 22           | $a: Cost-Benefit Analysis                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 651   | QA         |  2           | $a: United States                                                               | True   |
| 651   | PROD       |  2           | $a: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 700   | QA         | 1            | $a: Beleche, Trinidad, $e: author.                                              | True   |
| 700   | PROD       | 1            | $a: Beleche, Trinidad, $e: author.                                              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 1            | $a: United States. $b: Department of Health and Human Services. $b: Office of the Assistant Secretary for Planning and Evaluation, $e: issuing body. | True   |
| 710   | PROD       | 1            | $a: United States. $b: Department of Health and Human Services. $b: Office of the Assistant Secretary for Planning and Evaluation, $e: issuing body. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: ASPE issue brief                                                            | True   |
| 830   | PROD       |  0           | $a: ASPE issue brief                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK603243/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK603243/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240603                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240603                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: CAD $b: 20240821                                                            | True   |
| 993   | PROD       |              | $a: CAD $b: 20240821                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241011                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241011                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241011                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241011                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240602                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240602                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918840077906676

Leader:
| File       | Leader                   | Equal  |
| QA         | 03575nam a2200541 i 4500 | True   |
| PROD       | 03575nam a2200541 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918840077906676                                                                | True   |
| 001   | PROD       |              | 9918840077906676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241120090913.0                                                                | True   |
| 005   | PROD       |              | 20241120090913.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240602s2024    dcua    ob    100|0 eng                                          | True   |
| 008   | PROD       |              | 240602s2024    dcua    ob    100|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 020   | QA         |              | $z: 9780309715171                                                               | True   |
| 020   | QA         |              | $z: 0309715172                                                                  | True   |
| 020   | PROD       |              | $z: 9780309715171                                                               | True   |
| 020   | PROD       |              | $z: 0309715172                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918840077906676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK603310                                                      | True   |
| 035   | PROD       |              | $9: 9918840077906676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK603310                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: QU 248.1                                                                    | True   |
| 060   | PROD       | 00           | $a: QU 248.1                                                                    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Berhaupt, Amanda, $e: rapporteur.                                           | True   |
| 100   | PROD       | 1            | $a: Berhaupt, Amanda, $e: rapporteur.                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Exploring the science on measures of body composition, body fat distribution, and obesity / $c: Amanda Berhaupt, rapporteur ; Roundtable on Obesity Solutions, Food and Nutrition Board, Health and Medicine Division. | True   |
| 245   | PROD       | 10           | $a: Exploring the science on measures of body composition, body fat distribution, and obesity / $c: Amanda Berhaupt, rapporteur ; Roundtable on Obesity Solutions, Food and Nutrition Board, Health and Medicine Division. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington, DC : $b: National Academies Press, $c: [2024]                   | True   |
| 264   | PROD       |  1           | $a: Washington, DC : $b: National Academies Press, $c: [2024]                   | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (xx, 122 pages)) : $b: illustrations          | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (xx, 122 pages)) : $b: illustrations          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 500   | QA         |              | $a: "Proceedings of a workshop series."                                         | True   |
| 500   | PROD       |              | $a: "Proceedings of a workshop series."                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: The National Academies Roundtable on Obesity Solutions hosted a public workshop series in April and June 2023 that explored the current science on measures of body composition and body fat distribution. Discussions focused on the strengths and limitations, and clinical and anthropological perspectives of body mass index (BMI) as a measure of adiposity and health. Presentations also shed light on the connection between misinformation and bias and stigma, as well as challenged current communication strategies to improve messaging about obesity. | True   |
| 520   | PROD       | 3            | $a: The National Academies Roundtable on Obesity Solutions hosted a public workshop series in April and June 2023 that explored the current science on measures of body composition and body fat distribution. Discussions focused on the strengths and limitations, and clinical and anthropological perspectives of body mass index (BMI) as a measure of adiposity and health. Presentations also shed light on the connection between misinformation and bias and stigma, as well as challenged current communication strategies to improve messaging about obesity. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 530   | QA         |              | $a: Issued also in print.                                                       | True   |
| 530   | PROD       |              | $a: Issued also in print.                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: This activity was supported by the Academy of Nutrition and Dietetics; Alliance for a Healthier Generation; American Academy of Pediatrics; American Cancer Society; American Council on Exercise; American Society for Nutrition; Blue Shield of California Foundation; Bipartisan Policy Center; Eli Lilly and Company; Found Health Inc.; General Mills, Inc.; The JPB Foundation; Kresge Foundation; Mars, Inc.; Nemours Children's Health System; Novo Nordisk; Obesity Action Coalition; Partnership for a Healthier America; Reinvestment Fund; Rudd Center for Food Policy and Health; Robert Wood Johnson Foundation; SHAPE America; Society of Behavioral Medicine; The Obesity Society; Trust for America's Health; Wake Forest Baptist Medical Center; and Walmart. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. | True   |
| 536   | PROD       |              | $a: This activity was supported by the Academy of Nutrition and Dietetics; Alliance for a Healthier Generation; American Academy of Pediatrics; American Cancer Society; American Council on Exercise; American Society for Nutrition; Blue Shield of California Foundation; Bipartisan Policy Center; Eli Lilly and Company; Found Health Inc.; General Mills, Inc.; The JPB Foundation; Kresge Foundation; Mars, Inc.; Nemours Children's Health System; Novo Nordisk; Obesity Action Coalition; Partnership for a Healthier America; Reinvestment Fund; Rudd Center for Food Policy and Health; Robert Wood Johnson Foundation; SHAPE America; Society of Behavioral Medicine; The Obesity Society; Trust for America's Health; Wake Forest Baptist Medical Center; and Walmart. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed Sept. 30, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed Sept. 30, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Obesity                                                                     | True   |
| 650   | QA         | 22           | $a: Body Mass Index                                                             | True   |
| 650   | QA         | 22           | $a: Body Weight                                                                 | True   |
| 650   | QA         | 22           | $a: Body Fat Distribution                                                       | True   |
| 650   | QA         | 22           | $a: Health Communication                                                        | True   |
| 650   | PROD       | 12           | $a: Obesity                                                                     | True   |
| 650   | PROD       | 22           | $a: Body Mass Index                                                             | True   |
| 650   | PROD       | 22           | $a: Body Weight                                                                 | True   |
| 650   | PROD       | 22           | $a: Body Fat Distribution                                                       | True   |
| 650   | PROD       | 22           | $a: Health Communication                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 655   | QA         |  2           | $a: Congress                                                                    | True   |
| 655   | PROD       |  2           | $a: Congress                                                                    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Roundtable on Obesity Solutions, $e: host institution. | True   |
| 710   | PROD       | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Roundtable on Obesity Solutions, $e: host institution. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 711   | QA         | 2            | $a: BMI and Beyond: Considering Context in Measuring Obesity and Its Applications (Workshop) $d: (2023 : $d: Washington, D.C.). | True   |
| 711   | QA         | 2            | $a: Going Beyond BMI: Communicating About Body Weight (Workshop) $d: (2023 : $d: Washington, D.C.). | True   |
| 711   | PROD       | 2            | $a: BMI and Beyond: Considering Context in Measuring Obesity and Its Applications (Workshop) $d: (2023 : $d: Washington, D.C.). | True   |
| 711   | PROD       | 2            | $a: Going Beyond BMI: Communicating About Body Weight (Workshop) $d: (2023 : $d: Washington, D.C.). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK603310/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK603310/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240603                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240603                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: YYC $b: 20240926                                                            | True   |
| 993   | PROD       |              | $a: YYC $b: 20240926                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20240930                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20240930                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241120                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241120                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240602                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240602                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918840181906676

Leader:
| File       | Leader                   | Equal  |
| QA         | 03199nam a2200541 i 4500 | True   |
| PROD       | 03199nam a2200541 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918840181906676                                                                | True   |
| 001   | PROD       |              | 9918840181906676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241010103345.0                                                                | True   |
| 005   | PROD       |              | 20241010103345.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240602s2024    dcua    ob    100|0 eng                                          | True   |
| 008   | PROD       |              | 240602s2024    dcua    ob    100|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 020   | QA         |              | $z: 9780309715799                                                               | True   |
| 020   | QA         |              | $z: 0309715792                                                                  | True   |
| 020   | PROD       |              | $z: 9780309715799                                                               | True   |
| 020   | PROD       |              | $z: 0309715792                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918840181906676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK603582                                                      | True   |
| 035   | QA         |              | $a: (OCoLC)1432148101                                                           | True   |
| 035   | PROD       |              | $9: 9918840181906676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK603582                                                      | True   |
| 035   | PROD       |              | $a: (OCoLC)1432148101                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: QU 145                                                                      | True   |
| 060   | PROD       | 00           | $a: QU 145                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Maitin-Shepard, Melissa, $e: rapporteur.                                    | True   |
| 100   | PROD       | 1            | $a: Maitin-Shepard, Melissa, $e: rapporteur.                                    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Use of meta-analyses in nutrition research and policy : $b: proceedings of a workshop series / $c: Melissa Maitin-Shepard and Marian Flaxman, rapporteurs ; Food and Nutrition Board, Health and Medicine Division. | True   |
| 245   | PROD       | 10           | $a: Use of meta-analyses in nutrition research and policy : $b: proceedings of a workshop series / $c: Melissa Maitin-Shepard and Marian Flaxman, rapporteurs ; Food and Nutrition Board, Health and Medicine Division. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington, DC : $b: National Academies Press, $c: [2024]                   | True   |
| 264   | PROD       |  1           | $a: Washington, DC : $b: National Academies Press, $c: [2024]                   | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (xiv, 86 pages)) : $b: illustrations          | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (xiv, 86 pages)) : $b: illustrations          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 505   | QA         | 0            | $a: Workshop 1: Use of Meta-Analyses in Nutrition Research and Policy: Planning of Meta-Analysis, September 19, 2023 -- Workshop 2: Use of Meta-Analyses in Nutrition Research and Policy: Best Practices of Conducting Meta-Analysis, September 25, 2023 -- Workshop 3: Use of Meta-Analyses in Nutrition Research and Policy: Interpretation and Application of Meta-Analysis to Evaluate the Totality of Evidence, October 3, 2023. | True   |
| 505   | PROD       | 0            | $a: Workshop 1: Use of Meta-Analyses in Nutrition Research and Policy: Planning of Meta-Analysis, September 19, 2023 -- Workshop 2: Use of Meta-Analyses in Nutrition Research and Policy: Best Practices of Conducting Meta-Analysis, September 25, 2023 -- Workshop 3: Use of Meta-Analyses in Nutrition Research and Policy: Interpretation and Application of Meta-Analysis to Evaluate the Totality of Evidence, October 3, 2023. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: The Food and Nutrition Board of the National Academies of Sciences, Engineering, and Medicine convened a virtual workshop series that gathered researchers, government officials, and other global leaders in nutrition research and policy. The event, sponsored by the U.S. Food and Drug Administration (FDA), carefully considered meta-analysis methodologies that could in turn be used to advance nutrition research, develop policy, and inform regulatory decision-making. | True   |
| 520   | PROD       | 3            | $a: The Food and Nutrition Board of the National Academies of Sciences, Engineering, and Medicine convened a virtual workshop series that gathered researchers, government officials, and other global leaders in nutrition research and policy. The event, sponsored by the U.S. Food and Drug Administration (FDA), carefully considered meta-analysis methodologies that could in turn be used to advance nutrition research, develop policy, and inform regulatory decision-making. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 530   | QA         |              | $a: Issued also in print.                                                       | True   |
| 530   | PROD       |              | $a: Issued also in print.                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: This activity was supported by a contract between the National Academy of Sciences and the U.S. Food and Drug Administration. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. | True   |
| 536   | PROD       |              | $a: This activity was supported by a contract between the National Academy of Sciences and the U.S. Food and Drug Administration. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed October 7, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed October 7, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Nutritional Physiological Phenomena                                         | True   |
| 650   | QA         | 22           | $a: Nutrition Policy                                                            | True   |
| 650   | QA         | 22           | $a: Meta-Analysis as Topic                                                      | True   |
| 650   | QA         | 22           | $a: Systematic Reviews as Topic                                                 | True   |
| 650   | PROD       | 12           | $a: Nutritional Physiological Phenomena                                         | True   |
| 650   | PROD       | 22           | $a: Nutrition Policy                                                            | True   |
| 650   | PROD       | 22           | $a: Meta-Analysis as Topic                                                      | True   |
| 650   | PROD       | 22           | $a: Systematic Reviews as Topic                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 655   | QA         |  2           | $a: Congress                                                                    | True   |
| 655   | PROD       |  2           | $a: Congress                                                                    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 700   | QA         | 1            | $a: Flaxman, Marian, $e: rapporteur.                                            | True   |
| 700   | PROD       | 1            | $a: Flaxman, Marian, $e: rapporteur.                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Food and Nutrition Board, $e: host institution. | True   |
| 710   | PROD       | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Food and Nutrition Board, $e: host institution. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 711   | QA         | 2            | $a: Use of Meta-Analyses in Nutrition Research and Policy (Workshop series) $d: (2023 : $c: online) | True   |
| 711   | PROD       | 2            | $a: Use of Meta-Analyses in Nutrition Research and Policy (Workshop series) $d: (2023 : $c: online) | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK603582/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK603582/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240603                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240603                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: YYC $b: 20240926                                                            | True   |
| 993   | PROD       |              | $a: YYC $b: 20240926                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241007                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241007                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241010                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241010                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240602                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240602                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918861355806676

Leader:
| File       | Leader                   | Equal  |
| QA         | 02979nam a2200505 i 4500 | True   |
| PROD       | 02979nam a2200505 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918861355806676                                                                | True   |
| 001   | PROD       |              | 9918861355806676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241104092431.0                                                                | True   |
| 005   | PROD       |              | 20241104092431.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240702s2024    dcua    o     100|0 eng                                          | True   |
| 008   | PROD       |              | 240702s2024    dcua    o     100|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 020   | QA         |              | $a: 9780309719742                                                               | True   |
| 020   | QA         |              | $a: 0309719747                                                                  | True   |
| 020   | PROD       |              | $a: 9780309719742                                                               | True   |
| 020   | PROD       |              | $a: 0309719747                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918861355806676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK604121                                                      | True   |
| 035   | PROD       |              | $9: 9918861355806676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK604121                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: Q 334                                                                       | True   |
| 060   | PROD       | 00           | $a: Q 334                                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Whitacre, Paula, $e: rapporteur.                                            | True   |
| 100   | PROD       | 1            | $a: Whitacre, Paula, $e: rapporteur.                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Artificial intelligence at the nexus of collaboration, competition, and change : $b: proceedings of a workshop--in brief / $c: prepared by Paula Whitacre [rapporteur] ; [Government-University-Industry Research Roundtable, Policy and Global Affairs, National Academies of Sciences, Engineering, and Medicine]. | True   |
| 245   | PROD       | 10           | $a: Artificial intelligence at the nexus of collaboration, competition, and change : $b: proceedings of a workshop--in brief / $c: prepared by Paula Whitacre [rapporteur] ; [Government-University-Industry Research Roundtable, Policy and Global Affairs, National Academies of Sciences, Engineering, and Medicine]. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington, DC : $b: National Academies Press, $c: May 2024.                | True   |
| 264   | PROD       |  1           | $a: Washington, DC : $b: National Academies Press, $c: May 2024.                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (11 pages)) : $b: illustrations               | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (11 pages)) : $b: illustrations               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Proceedings of a workshop--in brief                                         | True   |
| 490   | PROD       | 1            | $a: Proceedings of a workshop--in brief                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: The rapid evolution of artificial intelligence (AI) technology underscores the need for public and private institutions to understand the impact of AI on research and development (R&D), workforce development, and policies and practices in every sector of society. AI offers tremendous benefits and opportunities, but also hazards and challenges, many of which remain unknown. In recognition of the rapidly changing AI landscape, the Government-University-Industry Research Roundtable (GUIRR) of the National Academies of Sciences, Engineering, and Medicine convened its membership at a workshop on October 10-11, 2023, in Washington, DC. Guests were invited to discuss the effects of the AI revolution on policy, organizational governance, and strategic cooperation among sectors in the research landscape and workforce development. | True   |
| 520   | PROD       | 3            | $a: The rapid evolution of artificial intelligence (AI) technology underscores the need for public and private institutions to understand the impact of AI on research and development (R&D), workforce development, and policies and practices in every sector of society. AI offers tremendous benefits and opportunities, but also hazards and challenges, many of which remain unknown. In recognition of the rapidly changing AI landscape, the Government-University-Industry Research Roundtable (GUIRR) of the National Academies of Sciences, Engineering, and Medicine convened its membership at a workshop on October 10-11, 2023, in Washington, DC. Guests were invited to discuss the effects of the AI revolution on policy, organizational governance, and strategic cooperation among sectors in the research landscape and workforce development. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 530   | QA         |              | $a: Issued also in print.                                                       | True   |
| 530   | PROD       |              | $a: Issued also in print.                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: SPONSOR This workshop was supported by the National Institutes of Health (HHSN263201800029I/75N98021F00017). For additional information regarding the workshop, visit: www.nas.edu/guirr. | True   |
| 536   | PROD       |              | $a: SPONSOR This workshop was supported by the National Institutes of Health (HHSN263201800029I/75N98021F00017). For additional information regarding the workshop, visit: www.nas.edu/guirr. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed Nov. 1, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed Nov. 1, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Artificial Intelligence                                                     | True   |
| 650   | QA         | 22           | $a: Intersectoral Collaboration                                                 | True   |
| 650   | QA         | 22           | $a: Digital Technology $x: trends                                               | True   |
| 650   | PROD       | 12           | $a: Artificial Intelligence                                                     | True   |
| 650   | PROD       | 22           | $a: Intersectoral Collaboration                                                 | True   |
| 650   | PROD       | 22           | $a: Digital Technology $x: trends                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 655   | QA         |  2           | $a: Congress                                                                    | True   |
| 655   | PROD       |  2           | $a: Congress                                                                    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: Government-University-Industry Research Roundtable, $e: host institution.   | True   |
| 710   | PROD       | 2            | $a: Government-University-Industry Research Roundtable, $e: host institution.   | True   |
--------------------------------------------------------------------------------------------------------------------------
| 711   | QA         | 2            | $a: Artificial Intelligence at the Nexus of Collaboration, Competition, and Change (Workshop) $d: (2023 : $c: Washington, D.C.) | True   |
| 711   | PROD       | 2            | $a: Artificial Intelligence at the Nexus of Collaboration, Competition, and Change (Workshop) $d: (2023 : $c: Washington, D.C.) | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: Workshop in brief                                                           | True   |
| 830   | PROD       |  0           | $a: Workshop in brief                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604121/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604121/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240702                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240702                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: YYC $b: 20241030                                                            | True   |
| 993   | PROD       |              | $a: YYC $b: 20241030                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241031                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241031                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241104                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241104                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240702                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240702                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918861355306676

Leader:
| File       | Leader                   | Equal  |
| QA         | 03040nam a2200469 i 4500 | True   |
| PROD       | 03040nam a2200469 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918861355306676                                                                | True   |
| 001   | PROD       |              | 9918861355306676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241103153400.0                                                                | True   |
| 005   | PROD       |              | 20241103153400.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240702s2023    mduac   ob   f000|0 eng                                          | True   |
| 008   | PROD       |              | 240702s2023    mduac   ob   f000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918861355306676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK604146                                                      | True   |
| 035   | PROD       |              | $9: 9918861355306676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK604146                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: W 20.5                                                                      | True   |
| 060   | PROD       | 00           | $a: W 20.5                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 00           | $a: How do research-active institutions impact the diversity of the scientific workforce? / $c: National Institutes of Health, Office of the Director, Chief Officer for Scientific Workforce Diversity. | True   |
| 245   | PROD       | 00           | $a: How do research-active institutions impact the diversity of the scientific workforce? / $c: National Institutes of Health, Office of the Director, Chief Officer for Scientific Workforce Diversity. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: [Bethesda, Md. : $b: National Institutes of Health, $c: 2023.               | True   |
| 264   | PROD       |  1           | $a: [Bethesda, Md. : $b: National Institutes of Health, $c: 2023.               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (12 pages)) : $b: illustrations, portraits.   | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (12 pages)) : $b: illustrations, portraits.   | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Scientific workforce diversity seminar series proceedings                   | True   |
| 490   | PROD       | 1            | $a: Scientific workforce diversity seminar series proceedings                   | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: This document summarizes the proceedings of "How Do Research-Active Institutions Impact the Diversity of the Scientific Workforce?," a Scientific Workforce Diversity Seminar Series (SWDSS) event. The National Institutes of Health (NIH) Chief Officer for Scientific Workforce Diversity (COSWD) office hosted the seminar on November 30, 2023. Marie A. Bernard, M.D., COSWD, moderated a panel discussion on the critical role Research-Active Institutions (RAIs) have in enhancing scientific workforce diversity. The discussion examined the strategies RAIs employ to achieve student and faculty success in science, technology, engineering, mathematics, and medicine (STEMM) and how NIH and other funders might better partner with and support RAIs to expand their impact. Darryl Monteau, Ed.D., Associate Director of Mission Programs Native Initiatives, Society for Advancement of Chicanos/Hispanics and Native Americans in Science, was invited but unable to participate in the seminar at the last moment. Dr. Monteau was to represent viewpoints from Tribal Colleges and Universities (TCUs). This document details the main points from the speakers' presentations and the subsequent question-and-answer session. The seminar recording and panelists' presentation materials are on the COSWD website. | True   |
| 520   | PROD       | 3            | $a: This document summarizes the proceedings of "How Do Research-Active Institutions Impact the Diversity of the Scientific Workforce?," a Scientific Workforce Diversity Seminar Series (SWDSS) event. The National Institutes of Health (NIH) Chief Officer for Scientific Workforce Diversity (COSWD) office hosted the seminar on November 30, 2023. Marie A. Bernard, M.D., COSWD, moderated a panel discussion on the critical role Research-Active Institutions (RAIs) have in enhancing scientific workforce diversity. The discussion examined the strategies RAIs employ to achieve student and faculty success in science, technology, engineering, mathematics, and medicine (STEMM) and how NIH and other funders might better partner with and support RAIs to expand their impact. Darryl Monteau, Ed.D., Associate Director of Mission Programs Native Initiatives, Society for Advancement of Chicanos/Hispanics and Native Americans in Science, was invited but unable to participate in the seminar at the last moment. Dr. Monteau was to represent viewpoints from Tribal Colleges and Universities (TCUs). This document details the main points from the speakers' presentations and the subsequent question-and-answer session. The seminar recording and panelists' presentation materials are on the COSWD website. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 530   | QA         |              | $a: Issued also in print.                                                       | True   |
| 530   | PROD       |              | $a: Issued also in print.                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed Oct. 31, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed Oct. 31, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Workforce Diversity                                                         | True   |
| 650   | QA         | 12           | $a: Research Personnel                                                          | True   |
| 650   | QA         | 22           | $a: Science $x: organization & administration                                   | True   |
| 650   | PROD       | 12           | $a: Workforce Diversity                                                         | True   |
| 650   | PROD       | 12           | $a: Research Personnel                                                          | True   |
| 650   | PROD       | 22           | $a: Science $x: organization & administration                                   | True   |
--------------------------------------------------------------------------------------------------------------------------
| 651   | QA         |  2           | $a: United States                                                               | True   |
| 651   | PROD       |  2           | $a: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 700   | QA         | 1            | $a: Bernard, Marie A., $e: moderator.                                           | True   |
| 700   | PROD       | 1            | $a: Bernard, Marie A., $e: moderator.                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: National Institutes of Health (U.S.), $e: issuing body.                     | True   |
| 710   | PROD       | 2            | $a: National Institutes of Health (U.S.), $e: issuing body.                     | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: Scientific workforce diversity seminar series                               | True   |
| 830   | PROD       |  0           | $a: Scientific workforce diversity seminar series                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604146/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604146/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240702                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240702                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: YYC $b: 20241030                                                            | True   |
| 993   | PROD       |              | $a: YYC $b: 20241030                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241031                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241031                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241103                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241103                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240702                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240702                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918861359806676

Leader:
| File       | Leader                   | Equal  |
| QA         | 02610nam a2200541 i 4500 | True   |
| PROD       | 02610nam a2200541 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918861359806676                                                                | True   |
| 001   | PROD       |              | 9918861359806676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241104150711.0                                                                | True   |
| 005   | PROD       |              | 20241104150711.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240702s2023    dcua    obs  f000|0 eng                                          | True   |
| 008   | PROD       |              | 240702s2023    dcua    obs  f000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918861359806676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK604394                                                      | True   |
| 035   | PROD       |              | $9: 9918861359806676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK604394                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: W 250 AA1                                                                   | True   |
| 060   | PROD       | 00           | $a: W 250 AA1                                                                   | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Lee, Aiden, $e: author.                                                     | True   |
| 100   | PROD       | 1            | $a: Lee, Aiden, $e: author.                                                     | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Medicaid enrollees who are employed : $b: implications for unwinding the medicaid continuous enrollment provision / $c: Aiden Lee, Joel Ruhter, Christie Peters, Nancy De Lew, Benjamin D. Sommers. | True   |
| 245   | PROD       | 10           | $a: Medicaid enrollees who are employed : $b: implications for unwinding the medicaid continuous enrollment provision / $c: Aiden Lee, Joel Ruhter, Christie Peters, Nancy De Lew, Benjamin D. Sommers. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington, D.C. : $b: U.S. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, $c: April 2023. | True   |
| 264   | PROD       |  1           | $a: Washington, D.C. : $b: U.S. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, $c: April 2023. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (18 pages)) : $b: illustrations.              | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (18 pages)) : $b: illustrations.              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Issue brief                                                                 | True   |
| 490   | PROD       | 1            | $a: Issue brief                                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 500   | QA         |              | $a: "HP-2023-11."                                                               | True   |
| 500   | PROD       |              | $a: "HP-2023-11."                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: Many Medicaid enrollees are employed, and in 2021, 15 percent of working enrollees reported having both Medicaid and employer sponsored health coverage. The intersection between Medicaid and employment has implications for employers and others as the pandemic-related Medicaid continuous enrollment ends. For additional information on demographic characteristics of Medicaid enrollees who are employed by state, see the table available on ASPE's website at: https://aspe.hhs.gov/reports/state-estimates-employed-medicaid-enrollees. | True   |
| 520   | PROD       | 3            | $a: Many Medicaid enrollees are employed, and in 2021, 15 percent of working enrollees reported having both Medicaid and employer sponsored health coverage. The intersection between Medicaid and employment has implications for employers and others as the pandemic-related Medicaid continuous enrollment ends. For additional information on demographic characteristics of Medicaid enrollees who are employed by state, see the table available on ASPE's website at: https://aspe.hhs.gov/reports/state-estimates-employed-medicaid-enrollees. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed October 8, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed October 8, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Medicaid $x: statistics & numerical data                                    | True   |
| 650   | QA         | 22           | $a: Medical Assistance $x: economics                                            | True   |
| 650   | QA         | 22           | $a: Health Benefit Plans, Employee $x: economics                                | True   |
| 650   | QA         | 22           | $a: Employment                                                                  | True   |
| 650   | PROD       | 12           | $a: Medicaid $x: statistics & numerical data                                    | True   |
| 650   | PROD       | 22           | $a: Medical Assistance $x: economics                                            | True   |
| 650   | PROD       | 22           | $a: Health Benefit Plans, Employee $x: economics                                | True   |
| 650   | PROD       | 22           | $a: Employment                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 651   | QA         |  2           | $a: United States                                                               | True   |
| 651   | PROD       |  2           | $a: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 655   | QA         |  2           | $a: Statistics                                                                  | True   |
| 655   | PROD       |  2           | $a: Statistics                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 700   | QA         | 1            | $a: Ruhter, Joel, $e: author.                                                   | True   |
| 700   | QA         | 1            | $a: Peters, Christie Provost, $e: author.                                       | True   |
| 700   | QA         | 1            | $a: De Lew, Nancy, $e: author.                                                  | True   |
| 700   | QA         | 1            | $a: Sommers, Benjamin D., $e: author.                                           | True   |
| 700   | PROD       | 1            | $a: Ruhter, Joel, $e: author.                                                   | True   |
| 700   | PROD       | 1            | $a: Peters, Christie Provost, $e: author.                                       | True   |
| 700   | PROD       | 1            | $a: De Lew, Nancy, $e: author.                                                  | True   |
| 700   | PROD       | 1            | $a: Sommers, Benjamin D., $e: author.                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 1            | $a: United States. $b: Department of Health and Human Services. $b: Office of the Assistant Secretary for Planning and Evaluation, $e: issuing body. | True   |
| 710   | PROD       | 1            | $a: United States. $b: Department of Health and Human Services. $b: Office of the Assistant Secretary for Planning and Evaluation, $e: issuing body. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: ASPE issue brief                                                            | True   |
| 830   | PROD       |  0           | $a: ASPE issue brief                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604394/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604394/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240702                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240702                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: YYC $b: 20240926                                                            | True   |
| 993   | PROD       |              | $a: YYC $b: 20240926                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241008                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241008                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241104                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241104                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240702                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240702                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918861354806676

Leader:
| File       | Leader                   | Equal  |
| QA         | 03464nam a2200481 i 4500 | True   |
| PROD       | 03464nam a2200481 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918861354806676                                                                | True   |
| 001   | PROD       |              | 9918861354806676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241030171750.0                                                                | True   |
| 005   | PROD       |              | 20241030171750.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240702s2024    dcuab   ob   f000|0 eng                                          | True   |
| 008   | PROD       |              | 240702s2024    dcuab   ob   f000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918861354806676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK604165                                                      | True   |
| 035   | QA         |              | $a: (OCoLC)1464579055                                                           | True   |
| 035   | PROD       |              | $9: 9918861354806676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK604165                                                      | True   |
| 035   | PROD       |              | $a: (OCoLC)1464579055                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WM 31.5                                                                     | True   |
| 060   | PROD       | 00           | $a: WM 31.5                                                                     | True   |
--------------------------------------------------------------------------------------------------------------------------
| 130   | QA         | 0            | $a: National strategy for suicide prevention (2024)                             | True   |
| 130   | PROD       | 0            | $a: National strategy for suicide prevention (2024)                             | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: National strategy for suicide prevention.                                   | True   |
| 245   | PROD       | 10           | $a: National strategy for suicide prevention.                                   | True   |
--------------------------------------------------------------------------------------------------------------------------
| 246   | QA         | 1            | $a: 2024 National strategy for suicide prevention                               | True   |
| 246   | PROD       | 1            | $a: 2024 National strategy for suicide prevention                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington, DC : $b: U.S. Department of Health and Human Services, $c: 2024. | True   |
| 264   | PROD       |  1           | $a: Washington, DC : $b: U.S. Department of Health and Human Services, $c: 2024. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (xiii, 177 pages)) : $b: illustrations, maps  | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (xiii, 177 pages)) : $b: illustrations, maps  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: For the first time, in 2024, the National Strategy takes a "whole of government" approach. It was developed in collaboration with a federal Interagency Work Group, consisting of over 20 agencies and offices in 10 departments across the federal government. Support came from the Suicide Prevention Resource Center (SPRC) and the National Action Alliance for Suicide Prevention (Action Alliance), guided by a project management team co-led by officials at the Substance Abuse and Mental Health Services Administration (SAMHSA) and the Centers for Disease Control and Prevention (CDC), alongside the National Institute of Mental Health (NIMH) and the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Planning and Evaluation (ASPE/HHS). Input and feedback from outside of the federal government came from a national needs assessment reaching more than 2,000 respondents and multiple listening sessions with people with lived experience, populations disproportionately affected by suicide, community members, practitioners, and suicide prevention experts. The 2024 National Strategy builds upon the previous 2012 National Strategy. It addresses gaps and incorporates advances in the field. It specifically addresses health equity, youth and social media, and the intersection of suicide and substance use. Other examples of new content include the 988 Suicide and Crisis Lifeline, expanded workplace suicide prevention, and an increased focus on social determinants of health. These topics are addressed within the National Strategy's four Strategic Directions-Community-Based Suicide Prevention; Treatment and Crisis Services; Surveillance, Quality Improvement, and Research; and Health Equity in Suicide Prevention--and related Goals. | True   |
| 520   | PROD       | 3            | $a: For the first time, in 2024, the National Strategy takes a "whole of government" approach. It was developed in collaboration with a federal Interagency Work Group, consisting of over 20 agencies and offices in 10 departments across the federal government. Support came from the Suicide Prevention Resource Center (SPRC) and the National Action Alliance for Suicide Prevention (Action Alliance), guided by a project management team co-led by officials at the Substance Abuse and Mental Health Services Administration (SAMHSA) and the Centers for Disease Control and Prevention (CDC), alongside the National Institute of Mental Health (NIMH) and the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Planning and Evaluation (ASPE/HHS). Input and feedback from outside of the federal government came from a national needs assessment reaching more than 2,000 respondents and multiple listening sessions with people with lived experience, populations disproportionately affected by suicide, community members, practitioners, and suicide prevention experts. The 2024 National Strategy builds upon the previous 2012 National Strategy. It addresses gaps and incorporates advances in the field. It specifically addresses health equity, youth and social media, and the intersection of suicide and substance use. Other examples of new content include the 988 Suicide and Crisis Lifeline, expanded workplace suicide prevention, and an increased focus on social determinants of health. These topics are addressed within the National Strategy's four Strategic Directions-Community-Based Suicide Prevention; Treatment and Crisis Services; Surveillance, Quality Improvement, and Research; and Health Equity in Suicide Prevention--and related Goals. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed October 30, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed October 30, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Suicide Prevention $x: methods                                              | True   |
| 650   | QA         | 22           | $a: Crisis Intervention $x: methods                                             | True   |
| 650   | QA         | 22           | $a: Community Mental Health Services                                            | True   |
| 650   | QA         | 22           | $a: Health Equity                                                               | True   |
| 650   | PROD       | 12           | $a: Suicide Prevention $x: methods                                              | True   |
| 650   | PROD       | 22           | $a: Crisis Intervention $x: methods                                             | True   |
| 650   | PROD       | 22           | $a: Community Mental Health Services                                            | True   |
| 650   | PROD       | 22           | $a: Health Equity                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 651   | QA         |  2           | $a: United States                                                               | True   |
| 651   | PROD       |  2           | $a: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 1            | $a: United States. $b: Department of Health and Human Services, $e: issuing body. | True   |
| 710   | PROD       | 1            | $a: United States. $b: Department of Health and Human Services, $e: issuing body. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604165/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604165/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240702                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240702                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: YYC $b: 20241030                                                            | True   |
| 993   | PROD       |              | $a: YYC $b: 20241030                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241030                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241030                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241030                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241030                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 997   | QA         |              | $a: Collection link Publications and Reports of the Surgeon General             | True   |
| 997   | PROD       |              | $a: Collection link Publications and Reports of the Surgeon General             | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240702                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240702                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918879461706676

Leader:
| File       | Leader                   | Equal  |
| QA         | 03396nam a2200577 i 4500 | True   |
| PROD       | 03396nam a2200577 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918879461706676                                                                | True   |
| 001   | PROD       |              | 9918879461706676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241105115127.0                                                                | True   |
| 005   | PROD       |              | 20241105115127.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240802t20242024dcua    ob    000|0 eng                                          | True   |
| 008   | PROD       |              | 240802t20242024dcua    ob    000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 010   | QA         |              | $a:   2024937873                                                                | True   |
| 010   | PROD       |              | $a:   2024937873                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 020   | QA         |              | $z: 9780309717373                                                               | True   |
| 020   | QA         |              | $z: 030971737X                                                                  | True   |
| 020   | PROD       |              | $z: 9780309717373                                                               | True   |
| 020   | PROD       |              | $z: 030971737X                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918879461706676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK605458                                                      | True   |
| 035   | PROD       |              | $9: 9918879461706676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK605458                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WC 588                                                                      | True   |
| 060   | PROD       | 00           | $a: WC 588                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 110   | QA         | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Committee on the Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures, $e: author, $e: issuing body. | True   |
| 110   | PROD       | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Committee on the Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures, $e: author, $e: issuing body. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Future state of smallpox medical countermeasures / $c: Lawrence O. Gostin, Lisa Brown, Shalini Singaravelu, and Matthew Masiello, editors ; Committee on the Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures, Board on Health Sciences Policy, Board on Global Health, Health and Medicine Division, Board on Life Sciences, Division on Earth and Life Studies, the National Academies of Sciences, Engneering, Medicine. | True   |
| 245   | PROD       | 10           | $a: Future state of smallpox medical countermeasures / $c: Lawrence O. Gostin, Lisa Brown, Shalini Singaravelu, and Matthew Masiello, editors ; Committee on the Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures, Board on Health Sciences Policy, Board on Global Health, Health and Medicine Division, Board on Life Sciences, Division on Earth and Life Studies, the National Academies of Sciences, Engneering, Medicine. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington, DC : $b: National Academies Press, $c: [2024]                   | True   |
| 264   | QA         |  4           | $c: ©2024                                                                       | True   |
| 264   | PROD       |  1           | $a: Washington, DC : $b: National Academies Press, $c: [2024]                   | True   |
| 264   | PROD       |  4           | $c: ©2024                                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (xxi, 172 pages)) : $b: illustrations.        | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (xxi, 172 pages)) : $b: illustrations.        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Consensus study report                                                      | True   |
| 490   | PROD       | 1            | $a: Consensus study report                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: At the request of the Administration for Strategic Preparedness and Response, the National Academies convened a committee to examine lessons learned from the COVID-19 pandemic and mpox multi-country outbreak to inform an evaluation of the state of smallpox research, development, and stockpiling of medical countermeasures (MCM). In the resulting report, the committee presents findings and conclusions that may inform U.S. Government investment decisions in smallpox MCM readiness, as well as the official U.S. position on the disposition of live viral collections at future World Health Assembly meetings. | True   |
| 520   | PROD       | 3            | $a: At the request of the Administration for Strategic Preparedness and Response, the National Academies convened a committee to examine lessons learned from the COVID-19 pandemic and mpox multi-country outbreak to inform an evaluation of the state of smallpox research, development, and stockpiling of medical countermeasures (MCM). In the resulting report, the committee presents findings and conclusions that may inform U.S. Government investment decisions in smallpox MCM readiness, as well as the official U.S. position on the disposition of live viral collections at future World Health Assembly meetings. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 530   | QA         |              | $a: Issued also in print.                                                       | True   |
| 530   | PROD       |              | $a: Issued also in print.                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: This activity was supported by contracts between the National Academy of Sciences and the Administration for Strategic Preparedness and Response (75A50121C00061). Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. | True   |
| 536   | PROD       |              | $a: This activity was supported by contracts between the National Academy of Sciences and the Administration for Strategic Preparedness and Response (75A50121C00061). Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed November 1, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed November 1, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Smallpox $x: prevention & control                                           | True   |
| 650   | QA         | 12           | $a: Smallpox Vaccine $x: supply & distribution                                  | True   |
| 650   | QA         | 22           | $a: Medical Countermeasures                                                     | True   |
| 650   | QA         | 22           | $a: Pandemic Preparedness                                                       | True   |
| 650   | PROD       | 12           | $a: Smallpox $x: prevention & control                                           | True   |
| 650   | PROD       | 12           | $a: Smallpox Vaccine $x: supply & distribution                                  | True   |
| 650   | PROD       | 22           | $a: Medical Countermeasures                                                     | True   |
| 650   | PROD       | 22           | $a: Pandemic Preparedness                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 651   | QA         |  2           | $a: United States                                                               | True   |
| 651   | PROD       |  2           | $a: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 700   | QA         | 1            | $a: Gostin, Lawrence O. $q: (Lawrence Ogalthorpe), $e: editor.                  | True   |
| 700   | QA         | 1            | $a: Brown, Lisa $q: (Lisa M.), $e: editor.                                      | True   |
| 700   | QA         | 1            | $a: Singaravelu, Shalini, $e: editor.                                           | True   |
| 700   | QA         | 1            | $a: Masiello, Matthew, $e: editor.                                              | True   |
| 700   | PROD       | 1            | $a: Gostin, Lawrence O. $q: (Lawrence Ogalthorpe), $e: editor.                  | True   |
| 700   | PROD       | 1            | $a: Brown, Lisa $q: (Lisa M.), $e: editor.                                      | True   |
| 700   | PROD       | 1            | $a: Singaravelu, Shalini, $e: editor.                                           | True   |
| 700   | PROD       | 1            | $a: Masiello, Matthew, $e: editor.                                              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: Consensus study report                                                      | True   |
| 830   | PROD       |  0           | $a: Consensus study report                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK605458/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK605458/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: CAD $b: 20241017                                                            | True   |
| 993   | PROD       |              | $a: CAD $b: 20241017                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241101                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241101                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241105                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241105                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240802                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240802                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918879464106676

Leader:
| File       | Leader                   | Equal  |
| QA         | 06034nam a2200565 i 4500 | True   |
| PROD       | 06034nam a2200565 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918879464106676                                                                | True   |
| 001   | PROD       |              | 9918879464106676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241127133322.0                                                                | True   |
| 005   | PROD       |              | 20241127133322.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240802s2019    dcua    obs   000|0 eng                                          | True   |
| 008   | PROD       |              | 240802s2019    dcua    obs   000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918879464106676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK604768                                                      | True   |
| 035   | PROD       |              | $9: 9918879464106676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK604768                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: W 16 AA1                                                                    | True   |
| 060   | PROD       | 00           | $a: W 16 AA1                                                                    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Turner, Barbara J. $q: (Barbara Jean), $d: 1950- $e: author.                | True   |
| 100   | PROD       | 1            | $a: Turner, Barbara J. $q: (Barbara Jean), $d: 1950- $e: author.                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Comparing sampling methods to engage residents of underrepresented communities to identify research priorities / $c: Barbara J. Turner, Paula Winkler, Melissa A. Valerio, Yuanyuan Liang, Natalia D. Rodriguez. | True   |
| 245   | PROD       | 10           | $a: Comparing sampling methods to engage residents of underrepresented communities to identify research priorities / $c: Barbara J. Turner, Paula Winkler, Melissa A. Valerio, Yuanyuan Liang, Natalia D. Rodriguez. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: [Washington, DC] : $b: PCORI, Patient-Centered Outcomes Research Institute, $c: 2019. | True   |
| 264   | PROD       |  1           | $a: [Washington, DC] : $b: PCORI, Patient-Centered Outcomes Research Institute, $c: 2019. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (121 pages)) : $b: illustrations.             | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (121 pages)) : $b: illustrations.             | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Final research report                                                       | True   |
| 490   | PROD       | 1            | $a: Final research report                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: BACKGROUND: For patient-centered outcomes research to improve health care decision-making and ultimately health status, patients and caregivers need to serve as research partners. Yet evidence-based community engagement methods are lacking, especially with hard-to-reach populations. This study evaluated sampling methods to recruit and engage residents of rural, Hispanic-majority communities to identify research priorities. OBJECTIVES: (Aim 1) To compare purposive sampling (PS) and respondent-driven sampling (RDS) to recruit patients and caregivers to serve as research participants (RPs) who then brainstormed and prioritized ideas about services, programs, and research to improve outcomes for persons with chronic noncancer pain (CNCP); and (Aim 2) to publish a practical guide to start and sustain hard-to-reach community partnerships. METHODS: Two county-based community advisory boards (cCABs) in 2 similar rural, Hispanic-majority counties with poor health outcomes directed implementation of PS and RDS. We predicted that PS would yield greater recruitment and retention and more research ideas. However, low recruitment using PS led the cCAB in 1 county to add purposive sampling plus convenience sampling (P + C) using a local recruiter. In the other county, the cCAB preferred a different chain-referral method--snowball sampling (SS)--to RDS because it was less complex and demanding for participants. In each county, 3 groups of consenting RPs, both caregivers and people with CNCP, attended 3 structured meetings to generate and rate ideas for research (total 12 meetings). Thematic analysis was used to categorize ideas. In a mixed methods analysis, RPs recruited by P + C vs SS were compared on demographics; participation (number consenting, number attending); number of ideas; and Likert scale ratings of ideas on importance to improve living with chronic pain and feasibility to implement. For external validity, a representative sample of Hispanic adults from 5 southwestern states was surveyed online to evaluate the RPs' ideas. RESULTS: Using P + C, 62 RPs were recruited; 36 (58%) attended the first meeting and 26 (42%) attended all 3 meetings. XXXX RPs were recruited using SS; 52 (95%) attended the first meeting and 36 (65%) attended all 3. SS yielded more Hispanic RPs than P + C (87% vs 73%; P = .049) and more recruits who were disabled (47% vs 10%; P < .001). SS RPs generated 115 ideas vs 101 ideas for P + C RPs. For 7 of 8 categories of ideas, ratings on importance and feasibility did not differ between SS and P + C RPs (P > .05). The 5-state online sample represented 10.5 million primarily urban Hispanics. Ratings on importance to improve living with chronic pain by this sample were all lower than the RPs' ratings (P < .002), but the order of relative ranking on the Likert scale and in a MaxDiff preference analysis was similar to that of the RPs. To fulfill Aim 2, the UP AHEAD Research Handbook was produced as a guide for investigators seeking to partner with hard-to-reach communities. CONCLUSIONS: Snowball sampling yielded greater and more sustained study participation--especially by Hispanics--than P + C sampling, but the SS method recruited more RPs who were disabled. RPs from both groups had similar ideas and ratings. A largely urban 5-state online Hispanic sample rated the rural RPs' ideas lower but, again, the highest priority ideas were similar. The advisory boards from hard-to-reach communities served a vital role in directing engagement. LIMITATIONS AND SUBPOPULATIONS: The project's methods were adjusted to align with real-world circumstances. Lessons learned may be most relevant to rural, Hispanic-majority communities. | True   |
| 520   | PROD       | 3            | $a: BACKGROUND: For patient-centered outcomes research to improve health care decision-making and ultimately health status, patients and caregivers need to serve as research partners. Yet evidence-based community engagement methods are lacking, especially with hard-to-reach populations. This study evaluated sampling methods to recruit and engage residents of rural, Hispanic-majority communities to identify research priorities. OBJECTIVES: (Aim 1) To compare purposive sampling (PS) and respondent-driven sampling (RDS) to recruit patients and caregivers to serve as research participants (RPs) who then brainstormed and prioritized ideas about services, programs, and research to improve outcomes for persons with chronic noncancer pain (CNCP); and (Aim 2) to publish a practical guide to start and sustain hard-to-reach community partnerships. METHODS: Two county-based community advisory boards (cCABs) in 2 similar rural, Hispanic-majority counties with poor health outcomes directed implementation of PS and RDS. We predicted that PS would yield greater recruitment and retention and more research ideas. However, low recruitment using PS led the cCAB in 1 county to add purposive sampling plus convenience sampling (P + C) using a local recruiter. In the other county, the cCAB preferred a different chain-referral method--snowball sampling (SS)--to RDS because it was less complex and demanding for participants. In each county, 3 groups of consenting RPs, both caregivers and people with CNCP, attended 3 structured meetings to generate and rate ideas for research (total 12 meetings). Thematic analysis was used to categorize ideas. In a mixed methods analysis, RPs recruited by P + C vs SS were compared on demographics; participation (number consenting, number attending); number of ideas; and Likert scale ratings of ideas on importance to improve living with chronic pain and feasibility to implement. For external validity, a representative sample of Hispanic adults from 5 southwestern states was surveyed online to evaluate the RPs' ideas. RESULTS: Using P + C, 62 RPs were recruited; 36 (58%) attended the first meeting and 26 (42%) attended all 3 meetings. XXXX RPs were recruited using SS; 52 (95%) attended the first meeting and 36 (65%) attended all 3. SS yielded more Hispanic RPs than P + C (87% vs 73%; P = .049) and more recruits who were disabled (47% vs 10%; P < .001). SS RPs generated 115 ideas vs 101 ideas for P + C RPs. For 7 of 8 categories of ideas, ratings on importance and feasibility did not differ between SS and P + C RPs (P > .05). The 5-state online sample represented 10.5 million primarily urban Hispanics. Ratings on importance to improve living with chronic pain by this sample were all lower than the RPs' ratings (P < .002), but the order of relative ranking on the Likert scale and in a MaxDiff preference analysis was similar to that of the RPs. To fulfill Aim 2, the UP AHEAD Research Handbook was produced as a guide for investigators seeking to partner with hard-to-reach communities. CONCLUSIONS: Snowball sampling yielded greater and more sustained study participation--especially by Hispanics--than P + C sampling, but the SS method recruited more RPs who were disabled. RPs from both groups had similar ideas and ratings. A largely urban 5-state online Hispanic sample rated the rural RPs' ideas lower but, again, the highest priority ideas were similar. The advisory boards from hard-to-reach communities served a vital role in directing engagement. LIMITATIONS AND SUBPOPULATIONS: The project's methods were adjusted to align with real-world circumstances. Lessons learned may be most relevant to rural, Hispanic-majority communities. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: Original Project Title: Evaluating Methods to Engage Minority Patients and Caregivers as Stakeholders PCORI ID: ME-1303-5729 | True   |
| 536   | PROD       |              | $a: Original Project Title: Evaluating Methods to Engage Minority Patients and Caregivers as Stakeholders PCORI ID: ME-1303-5729 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed November 26, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed November 26, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Patient Outcome Assessment                                                  | True   |
| 650   | QA         | 22           | $a: Research Design                                                             | True   |
| 650   | QA         | 22           | $a: Community Participation                                                     | True   |
| 650   | QA         | 22           | $a: Medically Underserved Area.                                                 | True   |
| 650   | QA         | 22           | $a: Sampling Studies                                                            | True   |
| 650   | QA         | 22           | $a: Comparative Effectiveness Research                                          | True   |
| 650   | PROD       | 12           | $a: Patient Outcome Assessment                                                  | True   |
| 650   | PROD       | 22           | $a: Research Design                                                             | True   |
| 650   | PROD       | 22           | $a: Community Participation                                                     | True   |
| 650   | PROD       | 22           | $a: Medically Underserved Area.                                                 | True   |
| 650   | PROD       | 22           | $a: Sampling Studies                                                            | True   |
| 650   | PROD       | 22           | $a: Comparative Effectiveness Research                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 651   | QA         |  2           | $a: United States                                                               | True   |
| 651   | PROD       |  2           | $a: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 655   | QA         |  2           | $a: Statistics                                                                  | True   |
| 655   | PROD       |  2           | $a: Statistics                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 700   | QA         | 1            | $a: Winkler, Paula $c: (Of University of Texas Health Science Center at San Antonio) $e: author. | True   |
| 700   | QA         | 1            | $a: Valerio, Melissa A., $e: author.                                            | True   |
| 700   | QA         | 1            | $a: Liang, Yuanyuan $c: (Professor of epidemiology & public health) $e: author. | True   |
| 700   | QA         | 1            | $a: Rodriguez, Natalia D., $e: author.                                          | True   |
| 700   | PROD       | 1            | $a: Winkler, Paula $c: (Of University of Texas Health Science Center at San Antonio) $e: author. | True   |
| 700   | PROD       | 1            | $a: Valerio, Melissa A., $e: author.                                            | True   |
| 700   | PROD       | 1            | $a: Liang, Yuanyuan $c: (Professor of epidemiology & public health) $e: author. | True   |
| 700   | PROD       | 1            | $a: Rodriguez, Natalia D., $e: author.                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: Patient-Centered Outcomes Research Institute (U.S.), $e: issuing body.      | True   |
| 710   | PROD       | 2            | $a: Patient-Centered Outcomes Research Institute (U.S.), $e: issuing body.      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: Final research report (Patient-Centered Outcomes Research Institute (U.S.)) | True   |
| 830   | PROD       |  0           | $a: Final research report (Patient-Centered Outcomes Research Institute (U.S.)) | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604768/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604768/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: CAD $b: 20241017                                                            | True   |
| 993   | PROD       |              | $a: CAD $b: 20241017                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241126                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241126                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241127                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241127                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240802                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240802                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918879459006676

Leader:
| File       | Leader                   | Equal  |
| QA         | 08702nam a2200493 i 4500 | True   |
| PROD       | 08702nam a2200493 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918879459006676                                                                | True   |
| 001   | PROD       |              | 9918879459006676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241115090955.0                                                                | True   |
| 005   | PROD       |              | 20241115090955.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240802s2021    dcua    obs   000|0 eng                                          | True   |
| 008   | PROD       |              | 240802s2021    dcua    obs   000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918879459006676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK604851                                                      | True   |
| 035   | PROD       |              | $9: 9918879459006676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK604851                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: QZ 16.1                                                                     | True   |
| 060   | PROD       | 00           | $a: QZ 16.1                                                                     | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Holm, Ingrid A., $e: author.                                                | True   |
| 100   | PROD       | 1            | $a: Holm, Ingrid A., $e: author.                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Testing two patient surveys for diagnosing rare genetic conditions / $c: Ingrid A. Holm, Melissa Haendel. | True   |
| 245   | PROD       | 10           | $a: Testing two patient surveys for diagnosing rare genetic conditions / $c: Ingrid A. Holm, Melissa Haendel. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington (DC) : $b: PCORI, Patient-Centered Outcomes Research Institute, $c: [2021] | True   |
| 264   | PROD       |  1           | $a: Washington (DC) : $b: PCORI, Patient-Centered Outcomes Research Institute, $c: [2021] | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (108 pages)) : $b: illustrations.             | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (108 pages)) : $b: illustrations.             | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Final research report                                                       | True   |
| 490   | PROD       | 1            | $a: Final research report                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: BACKGROUND: Patients with rare diseases may be the best source of information on their phenotypes (their physical features). The premise of our study is that "self-phenotyping" will be an accurate source of patient data and will empower patients, which may be particularly beneficial to the rare disease population. ClinGen, an NIH-funded resource, developed a patient self-phenotyping survey, GenomeConnect (https://www.genomeconnect.org/), which asks patient-friendly questions that are mapped to a small subset of Human Phenotype Ontology (HPO) terms (https://hpo.jax.org/app/). An alternative method for self-phenotyping is for patients to generate HPO terms for their condition directly. Because most HPO terms are medical and often unfamiliar to patients, the Monarch Initiative translated approximately a third of the HPO terms into layperson language (the other terms were too clinical to have a lay-friendly translation). This layperson version of HPO is a much larger set of HPO terms than those mapped to the GenomeConnect survey. However, the layperson HPO has not yet been incorporated into patient-centered applications, and neither the GenomeConnect survey nor the layperson HPO has been validated to effectively inform diagnosis in patients with rare diseases. OBJECTIVES: The overall objective was to understand how best to support patients providing descriptions of their own phenotypes. The specific objectives were to (1) develop a layperson HPO-based tool for patients to use for self-phenotyping (Phenotypr); (2) validate the GenomeConnect-mapped HPO profiles and layperson HPO profiles computationally through the Monarch Initiative's algorithms (https://monarchinitiative.org/) to determine their diagnostic utility relative to gold-standard clinical profiles; and (3) test the GenomeConnect survey and Phenotypr tool in participants with diagnosed genetic diseases to determine which was better at identifying the clinical diagnosis and which survey participants preferred. METHODS: To evaluate the diagnostic utility of the layperson HPO and GenomeConnect survey, we created derived disease profiles for every known Mendelian disease in the Monarch corpus (∼7600 diseases, encoded using the Mondo disease terminology). These disease profiles were subsets of the gold-standard Monarch profiles and were based on the GenomeConnect survey mappings to HPO and the layperson HPO subset of HPO. We compared each of the derived profiles against the corpus of Monarch gold-standard profiles and determined the degree to which the given disease was detected as the closest match. We offered enrollment to participants aged ≥18 years, or the parent/guardian of a child aged <18 years, who were diagnosed with a genetic disease. We enrolled participants from the Boston Children's Hospital (BCH) genetics clinic, the BCH Down syndrome program, GenomeConnect, a 16p research registry, and the BCH Manton Center for Orphan Diseases Research. Participants were randomly assigned to the GenomeConnect survey, Phenotypr survey (the layperson HPO-based tool that we developed), or both. We compared the derived HPO phenotypic profile from each patient with the corresponding Phenotypr survey HPO profile and/or the GenomeConnect survey HPO profile (depending on which survey they completed, or if they completed both), as well as against the clinical-grade, gold-standard HPO profiles developed by Monarch. Multiple semantic similarity methods were used to determine which survey generated HPO terms that best matched the derived HPO profile and clinical gold-standard profiles. Our primary end point was a comparison of the similarity scores between the patient-derived HPO profiles from the GenomeConnect or Phenotypr survey and the simulated HPO profiles overall to see which survey, GenomeConnect or Phenotypr, yielded higher similarity scores on average and a tighter distribution compared with the simulated HPO profiles. We conducted qualitative interviews with a subset of participants to determine which survey participants preferred. RESULTS: 1. Objective A (aim 1). We developed Phenotypr, a layperson HPO-based software application, which uses an autocompletion format (the user starts typing and a menu of options appears starting with the typed letters). We adapted the preexisting GenomeConnect survey, which uses a multiple-choice format, for the study.2. Objective B (aim 1). For 7344 known Mendelian diseases in the Monarch corpus, the diagnostic power (ie, the capability of returning the correct diagnosis) of layperson HPO profiles was greater than that of the GenomeConnect HPO profiles. This was measured by simulating patient responses for each disease, running them through a disease classifier, and plotting a receiving operating characteristic (ROC) curve (eg, the true-positive rate vs the false-positive rate). The layperson subset had an area under the ROC curve (AUROC) of 0.95, and the GenomeConnect subset had an AUROC of 0.91, suggesting that the layperson subset can better distinguish the correct disease.3. Objective C (aim 2). We offered enrollment to 1061 individuals and enrolled 282 (26.5%). Participants completing the GenomeConnect survey generally had a higher median similarity score to their derived disease profile than did those completing the Phenotypr survey; therefore, the GenomeConnect survey was more accurate. However, the Phenotypr survey had a tighter distribution of scores for respondents who completed both surveys and was therefore more precise. We conducted 17 qualitative interviews, and participants generally preferred the GenomeConnect multiple-choice format over the autocomplete Phenotypr format. CONCLUSIONS: Both the GenomeConnect and Phenotypr surveys were useful in obtaining phenotype data directly from patients. The GenomeConnect survey was more accurate, and the Phenotypr survey was more precise. The use of the layperson HPO, developed as Phenotypr (objective A), could effectively inform diagnosis if performed accurately by patients (objective B). Phenotypr has a large vocabulary of layperson HPO terms and uses an autocomplete method. GenomeConnect maps to tenfold-fewer HPO terms and uses a multiple-choice format. Future work will involve taking the strengths of each mode of survey to develop a combined approach to patient self-phenotyping (objective C). LIMITATIONS: The number of individuals with any given diagnosis was small, making comparisons between the 2 surveys for any given diagnosis challenging. In addition, the overall variety of types of diseases (eg, the heterogeneity of phenotypic profiles) was limited. These tools should be tested in larger and more-diverse populations and with patients with unknown diagnoses. | True   |
| 520   | PROD       | 3            | $a: BACKGROUND: Patients with rare diseases may be the best source of information on their phenotypes (their physical features). The premise of our study is that "self-phenotyping" will be an accurate source of patient data and will empower patients, which may be particularly beneficial to the rare disease population. ClinGen, an NIH-funded resource, developed a patient self-phenotyping survey, GenomeConnect (https://www.genomeconnect.org/), which asks patient-friendly questions that are mapped to a small subset of Human Phenotype Ontology (HPO) terms (https://hpo.jax.org/app/). An alternative method for self-phenotyping is for patients to generate HPO terms for their condition directly. Because most HPO terms are medical and often unfamiliar to patients, the Monarch Initiative translated approximately a third of the HPO terms into layperson language (the other terms were too clinical to have a lay-friendly translation). This layperson version of HPO is a much larger set of HPO terms than those mapped to the GenomeConnect survey. However, the layperson HPO has not yet been incorporated into patient-centered applications, and neither the GenomeConnect survey nor the layperson HPO has been validated to effectively inform diagnosis in patients with rare diseases. OBJECTIVES: The overall objective was to understand how best to support patients providing descriptions of their own phenotypes. The specific objectives were to (1) develop a layperson HPO-based tool for patients to use for self-phenotyping (Phenotypr); (2) validate the GenomeConnect-mapped HPO profiles and layperson HPO profiles computationally through the Monarch Initiative's algorithms (https://monarchinitiative.org/) to determine their diagnostic utility relative to gold-standard clinical profiles; and (3) test the GenomeConnect survey and Phenotypr tool in participants with diagnosed genetic diseases to determine which was better at identifying the clinical diagnosis and which survey participants preferred. METHODS: To evaluate the diagnostic utility of the layperson HPO and GenomeConnect survey, we created derived disease profiles for every known Mendelian disease in the Monarch corpus (∼7600 diseases, encoded using the Mondo disease terminology). These disease profiles were subsets of the gold-standard Monarch profiles and were based on the GenomeConnect survey mappings to HPO and the layperson HPO subset of HPO. We compared each of the derived profiles against the corpus of Monarch gold-standard profiles and determined the degree to which the given disease was detected as the closest match. We offered enrollment to participants aged ≥18 years, or the parent/guardian of a child aged <18 years, who were diagnosed with a genetic disease. We enrolled participants from the Boston Children's Hospital (BCH) genetics clinic, the BCH Down syndrome program, GenomeConnect, a 16p research registry, and the BCH Manton Center for Orphan Diseases Research. Participants were randomly assigned to the GenomeConnect survey, Phenotypr survey (the layperson HPO-based tool that we developed), or both. We compared the derived HPO phenotypic profile from each patient with the corresponding Phenotypr survey HPO profile and/or the GenomeConnect survey HPO profile (depending on which survey they completed, or if they completed both), as well as against the clinical-grade, gold-standard HPO profiles developed by Monarch. Multiple semantic similarity methods were used to determine which survey generated HPO terms that best matched the derived HPO profile and clinical gold-standard profiles. Our primary end point was a comparison of the similarity scores between the patient-derived HPO profiles from the GenomeConnect or Phenotypr survey and the simulated HPO profiles overall to see which survey, GenomeConnect or Phenotypr, yielded higher similarity scores on average and a tighter distribution compared with the simulated HPO profiles. We conducted qualitative interviews with a subset of participants to determine which survey participants preferred. RESULTS: 1. Objective A (aim 1). We developed Phenotypr, a layperson HPO-based software application, which uses an autocompletion format (the user starts typing and a menu of options appears starting with the typed letters). We adapted the preexisting GenomeConnect survey, which uses a multiple-choice format, for the study.2. Objective B (aim 1). For 7344 known Mendelian diseases in the Monarch corpus, the diagnostic power (ie, the capability of returning the correct diagnosis) of layperson HPO profiles was greater than that of the GenomeConnect HPO profiles. This was measured by simulating patient responses for each disease, running them through a disease classifier, and plotting a receiving operating characteristic (ROC) curve (eg, the true-positive rate vs the false-positive rate). The layperson subset had an area under the ROC curve (AUROC) of 0.95, and the GenomeConnect subset had an AUROC of 0.91, suggesting that the layperson subset can better distinguish the correct disease.3. Objective C (aim 2). We offered enrollment to 1061 individuals and enrolled 282 (26.5%). Participants completing the GenomeConnect survey generally had a higher median similarity score to their derived disease profile than did those completing the Phenotypr survey; therefore, the GenomeConnect survey was more accurate. However, the Phenotypr survey had a tighter distribution of scores for respondents who completed both surveys and was therefore more precise. We conducted 17 qualitative interviews, and participants generally preferred the GenomeConnect multiple-choice format over the autocomplete Phenotypr format. CONCLUSIONS: Both the GenomeConnect and Phenotypr surveys were useful in obtaining phenotype data directly from patients. The GenomeConnect survey was more accurate, and the Phenotypr survey was more precise. The use of the layperson HPO, developed as Phenotypr (objective A), could effectively inform diagnosis if performed accurately by patients (objective B). Phenotypr has a large vocabulary of layperson HPO terms and uses an autocomplete method. GenomeConnect maps to tenfold-fewer HPO terms and uses a multiple-choice format. Future work will involve taking the strengths of each mode of survey to develop a combined approach to patient self-phenotyping (objective C). LIMITATIONS: The number of individuals with any given diagnosis was small, making comparisons between the 2 surveys for any given diagnosis challenging. In addition, the overall variety of types of diseases (eg, the heterogeneity of phenotypic profiles) was limited. These tools should be tested in larger and more-diverse populations and with patients with unknown diagnoses. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: Institution Receiving Award: Boston Children's Hospital Original Project Title: Realization of a Standard of Care for Rare Diseases Using Patient-Engaged Phenotyping PCORI ID: ME-1511-33184; HSRProj ID: HSRP20181624. | True   |
| 536   | PROD       |              | $a: Institution Receiving Award: Boston Children's Hospital Original Project Title: Realization of a Standard of Care for Rare Diseases Using Patient-Engaged Phenotyping PCORI ID: ME-1511-33184; HSRProj ID: HSRP20181624. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed November 7, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed November 7, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Genetic Diseases, Inborn $x: diagnosis                                      | True   |
| 650   | QA         | 12           | $a: Rare Diseases $x: diagnosis                                                 | True   |
| 650   | QA         | 22           | $a: Patient Reported Outcome Measures                                           | True   |
| 650   | QA         | 22           | $a: Health Care Surveys                                                         | True   |
| 650   | PROD       | 12           | $a: Genetic Diseases, Inborn $x: diagnosis                                      | True   |
| 650   | PROD       | 12           | $a: Rare Diseases $x: diagnosis                                                 | True   |
| 650   | PROD       | 22           | $a: Patient Reported Outcome Measures                                           | True   |
| 650   | PROD       | 22           | $a: Health Care Surveys                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 655   | QA         |  2           | $a: Statistics                                                                  | True   |
| 655   | PROD       |  2           | $a: Statistics                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 700   | QA         | 1            | $a: Haendel, Melissa A., $e: author.                                            | True   |
| 700   | PROD       | 1            | $a: Haendel, Melissa A., $e: author.                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: Patient-Centered Outcomes Research Institute (U.S.), $e: issuing body.      | True   |
| 710   | PROD       | 2            | $a: Patient-Centered Outcomes Research Institute (U.S.), $e: issuing body.      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: Final research report (Patient-Centered Outcomes Research Institute (U.S.)) | True   |
| 830   | PROD       |  0           | $a: Final research report (Patient-Centered Outcomes Research Institute (U.S.)) | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604851/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604851/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: CAD $b: 20241017                                                            | True   |
| 993   | PROD       |              | $a: CAD $b: 20241017                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241114                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241114                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241115                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241115                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240802                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240802                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918879464806676

Leader:
| File       | Leader                   | Equal  |
| QA         | 05539nam a2200481 i 4500 | True   |
| PROD       | 05539nam a2200481 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918879464806676                                                                | True   |
| 001   | PROD       |              | 9918879464806676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241101145201.0                                                                | True   |
| 005   | PROD       |              | 20241101145201.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240802s2020    dcua    ob    000|0 eng                                          | True   |
| 008   | PROD       |              | 240802s2020    dcua    ob    000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918879464806676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK604722                                                      | True   |
| 035   | PROD       |              | $9: 9918879464806676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK604722                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WP 946                                                                      | True   |
| 060   | PROD       | 00           | $a: WP 946                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Penson, David F., $e: author.                                               | True   |
| 100   | PROD       | 1            | $a: Penson, David F., $e: author.                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Comparing the effects of surgery, radiation therapy, and active surveillance on men with localized prostate cancer : $b: the CEASAR study / $c: David F. Penson, Daniel A. Barocas ; the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) investigators. | True   |
| 245   | PROD       | 10           | $a: Comparing the effects of surgery, radiation therapy, and active surveillance on men with localized prostate cancer : $b: the CEASAR study / $c: David F. Penson, Daniel A. Barocas ; the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) investigators. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington (DC) : $b: Patient-Centered Outcomes Research Institute (PCORI), $c: [2020] | True   |
| 264   | PROD       |  1           | $a: Washington (DC) : $b: Patient-Centered Outcomes Research Institute (PCORI), $c: [2020] | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (71 pages)) : $b: illustrations.              | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (71 pages)) : $b: illustrations.              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Final research report                                                       | True   |
| 490   | PROD       | 1            | $a: Final research report                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: BACKGROUND: The 2008 evidence report of the Agency for Healthcare Research and Quality (AHRQ) called for high-quality, prospective cohort studies that identified men at the time of diagnosis of localized prostate cancer (PCa) and collected comprehensive patient, tumor, and treatment selection characteristics to generate critical patient-centered information to aid in decision-making for localized disease. Although new evidence has been generated since 2008 that has advanced the understanding of outcomes following treatment for PCa, the knowledge gap identified in the AHRQ report remains unfilled. OBJECTIVES: (1) Compare the effectiveness of contemporary surgical and radiation techniques for localized PCa; (2) identify patient-level characteristics that may influence comparative effectiveness; and (3) assess how the comparative effectiveness of the different therapies varies by the quality of care received. METHODS: The Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study is a prospective, population-based observational cohort study of 3269 men younger than age 80 with clinically localized PCa diagnosed in 2011-2012 and enrolled in the study within 6 months of diagnosis. We followed the cohort longitudinally, collecting clinical and key patient-reported outcome data at baseline and at 6, 12, and 36 months after enrollment. In addition, we performed a full medical record review for each participant within a year of enrollment. We used multivariate statistical methods to achieve the proposed specific objectives and standard imputation methods to address missing data. RESULTS: To achieve our first objective, we compared baseline, 6-month, 1-year, and 3-year health-related quality-of-life outcomes in men undergoing surgery, radiotherapy (RT), or active surveillance (AS). The analytic cohort for this analysis contained 2550 men: 1523 (59.9%) radical prostatectomy (RP); 598 (23.6%) external beam radiotherapy (EBRT); and 429 (16.6%) AS. At 3 years, sexual function for men undergoing RP was significantly worse than for those undergoing EBRT (−17.1 points; P < .001). The difference in sexual function between EBRT and AS at 3 years, while statistically significant, was not clinically significant (−5.9 points; P = .023). RP was associated with worse urinary continence scores than EBRT (−18 points; P < .001) or AS (−13.4 points; P < .001). No clinically significant differences in bowel or hormone function were noted. We explored the independent relationship of race on patient-reported outcomes at 1 year and found no significant associations. Similarly, we explored the relationship between commonly used quality of care metrics in PCa and patient-reported outcomes at 1 year and failed to find an association. CONCLUSIONS: Significant differences exist in patient-reported outcomes following modern treatments for localized PCa, and these differences may vary in certain subgroups of patients. Future research should focus on exploring these potential associations and detecting longer-term differences in cancer control between treatments. LIMITATIONS AND SUBPOPULATION CONSIDERATIONS: All observational studies face considerable risk for confounding by indication. We have attempted to control for this risk by using appropriate methods of statistical adjustment and by trying to capture previously unmeasured potential confounders at baseline. Our results may still contain some bias, although probably less than previous studies. | True   |
| 520   | PROD       | 3            | $a: BACKGROUND: The 2008 evidence report of the Agency for Healthcare Research and Quality (AHRQ) called for high-quality, prospective cohort studies that identified men at the time of diagnosis of localized prostate cancer (PCa) and collected comprehensive patient, tumor, and treatment selection characteristics to generate critical patient-centered information to aid in decision-making for localized disease. Although new evidence has been generated since 2008 that has advanced the understanding of outcomes following treatment for PCa, the knowledge gap identified in the AHRQ report remains unfilled. OBJECTIVES: (1) Compare the effectiveness of contemporary surgical and radiation techniques for localized PCa; (2) identify patient-level characteristics that may influence comparative effectiveness; and (3) assess how the comparative effectiveness of the different therapies varies by the quality of care received. METHODS: The Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study is a prospective, population-based observational cohort study of 3269 men younger than age 80 with clinically localized PCa diagnosed in 2011-2012 and enrolled in the study within 6 months of diagnosis. We followed the cohort longitudinally, collecting clinical and key patient-reported outcome data at baseline and at 6, 12, and 36 months after enrollment. In addition, we performed a full medical record review for each participant within a year of enrollment. We used multivariate statistical methods to achieve the proposed specific objectives and standard imputation methods to address missing data. RESULTS: To achieve our first objective, we compared baseline, 6-month, 1-year, and 3-year health-related quality-of-life outcomes in men undergoing surgery, radiotherapy (RT), or active surveillance (AS). The analytic cohort for this analysis contained 2550 men: 1523 (59.9%) radical prostatectomy (RP); 598 (23.6%) external beam radiotherapy (EBRT); and 429 (16.6%) AS. At 3 years, sexual function for men undergoing RP was significantly worse than for those undergoing EBRT (−17.1 points; P < .001). The difference in sexual function between EBRT and AS at 3 years, while statistically significant, was not clinically significant (−5.9 points; P = .023). RP was associated with worse urinary continence scores than EBRT (−18 points; P < .001) or AS (−13.4 points; P < .001). No clinically significant differences in bowel or hormone function were noted. We explored the independent relationship of race on patient-reported outcomes at 1 year and found no significant associations. Similarly, we explored the relationship between commonly used quality of care metrics in PCa and patient-reported outcomes at 1 year and failed to find an association. CONCLUSIONS: Significant differences exist in patient-reported outcomes following modern treatments for localized PCa, and these differences may vary in certain subgroups of patients. Future research should focus on exploring these potential associations and detecting longer-term differences in cancer control between treatments. LIMITATIONS AND SUBPOPULATION CONSIDERATIONS: All observational studies face considerable risk for confounding by indication. We have attempted to control for this risk by using appropriate methods of statistical adjustment and by trying to capture previously unmeasured potential confounders at baseline. Our results may still contain some bias, although probably less than previous studies. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: Original Project Title: Generating Critical Patient-Centered Information for Decision Making in Localized Prostate Cancer PCORI ID: CE-12-11-4667 ClinicalTrials.gov ID: NCT01326286 | True   |
| 536   | PROD       |              | $a: Original Project Title: Generating Critical Patient-Centered Information for Decision Making in Localized Prostate Cancer PCORI ID: CE-12-11-4667 ClinicalTrials.gov ID: NCT01326286 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed Nov. 1, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed Nov. 1, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Prostatic Neoplasms $x: therapy                                             | True   |
| 650   | QA         | 22           | $a: Treatment Outcome                                                           | True   |
| 650   | QA         | 22           | $a: Self Report                                                                 | True   |
| 650   | QA         | 22           | $a: Comparative Effectiveness Research                                          | True   |
| 650   | PROD       | 12           | $a: Prostatic Neoplasms $x: therapy                                             | True   |
| 650   | PROD       | 22           | $a: Treatment Outcome                                                           | True   |
| 650   | PROD       | 22           | $a: Self Report                                                                 | True   |
| 650   | PROD       | 22           | $a: Comparative Effectiveness Research                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 700   | QA         | 1            | $a: Barocas, Daniel A., $e: author.                                             | True   |
| 700   | PROD       | 1            | $a: Barocas, Daniel A., $e: author.                                             | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: Patient-Centered Outcomes Research Institute (U.S.), $e: issuing body.      | True   |
| 710   | PROD       | 2            | $a: Patient-Centered Outcomes Research Institute (U.S.), $e: issuing body.      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: Final research report (Patient-Centered Outcomes Research Institute (U.S.)) | True   |
| 830   | PROD       |  0           | $a: Final research report (Patient-Centered Outcomes Research Institute (U.S.)) | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604722/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604722/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: IHH $b: 20241101                                                            | True   |
| 993   | PROD       |              | $a: IHH $b: 20241101                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241101                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241101                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241101                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241101                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240802                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240802                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918879458206676

Leader:
| File       | Leader                   | Equal  |
| QA         | 05835nam a2200457 i 4500 | True   |
| PROD       | 05835nam a2200457 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918879458206676                                                                | True   |
| 001   | PROD       |              | 9918879458206676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241101114537.0                                                                | True   |
| 005   | PROD       |              | 20241101114537.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240802s2020    dcua    ob    000|0 eng                                          | True   |
| 008   | PROD       |              | 240802s2020    dcua    ob    000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918879458206676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK605031                                                      | True   |
| 035   | PROD       |              | $9: 9918879458206676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK605031                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WP 870                                                                      | True   |
| 060   | PROD       | 00           | $a: WP 870                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Punglia, Rinaa, $e: author.                                                 | True   |
| 100   | PROD       | 1            | $a: Punglia, Rinaa, $e: author.                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Predicting the impact of treatment options on survival and breast conservation in patients with ductal carcinoma in situ (DCIS) / $c: Rinaa Punglia, Natasha Stout, Angel Cronin, Hajime Uno, Elissa Ozanne, Michael Hassett, Elizabeth Frank, Deborah Schrag, Caprice Greenberg, Djora Soeteman. | True   |
| 245   | PROD       | 10           | $a: Predicting the impact of treatment options on survival and breast conservation in patients with ductal carcinoma in situ (DCIS) / $c: Rinaa Punglia, Natasha Stout, Angel Cronin, Hajime Uno, Elissa Ozanne, Michael Hassett, Elizabeth Frank, Deborah Schrag, Caprice Greenberg, Djora Soeteman. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington (DC) : $b: Patient-Centered Outcomes Research Institute (PCORI), $c: [2020] | True   |
| 264   | PROD       |  1           | $a: Washington (DC) : $b: Patient-Centered Outcomes Research Institute (PCORI), $c: [2020] | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (84 pages)) : $b: illustrations.              | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (84 pages)) : $b: illustrations.              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Final research report                                                       | True   |
| 490   | PROD       | 1            | $a: Final research report                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: BACKGROUND: Currently, more than 70% of women with ductal carcinoma in situ (DCIS) receive breast-conserving surgery (BCS) but then are at risk of a second cancer diagnosis in the same breast. Radiation therapy (RT) after BCS decreases recurrence in the 10 years after diagnosis by half but does not improve survival. Women with DCIS are also at elevated risk for cancer in the contralateral breast. Radiation after BCS for DCIS limits therapy choice to mastectomy if a woman has a second cancer in the treated breast because radiation can be given only once due to limits of normal tissue tolerance. If radiation was not received initially, a patient may be able to avoid mastectomy after a second ipsilateral breast cancer. For these reasons, the choice of treatment for DCIS is complex. A web-based decision aid would help a patient quantify the tradeoffs between her long-term survival and breast preservation. OBJECTIVES: 1. Determine the risk of and risk factors for new breast cancer after DCIS.2. Determine the likelihood of mastectomy at time of recurrence or new diagnosis after DCIS in a previously unirradiated breast and the association of regional use of RT on this likelihood.3. Determine the tradeoffs associated with RT for DCIS in terms of breast conservation for an individual patient in a web-based decision aid. METHODS: 1. To examine predictors of contralateral breast cancer following DCIS, we identified women diagnosed with DCIS in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program. We used multivariable Cox proportional hazards models to examine risks and predictors of contralateral second breast cancer.2. We performed a retrospective analysis of population-based databases SEER and SEER-Medicare. We also measured mastectomy vs BCS at a second breast event (DCIS recurrence or new invasive cancer).3. We developed a discrete event simulation model integrating data from the published literature to simulate the clinical events after 6 treatments for women with newly diagnosed DCIS. RESULTS: 1. In multivariable analysis, age and year of diagnosis, race, size, and estrogen receptor (ER) status were all significant predictors of contralateral breast cancer.2. Residence in a health service area (HSA) with greater radiotherapy use for DCIS was associated with an increased likelihood of receiving mastectomy vs BCS at a subsequent breast event, even among women who had not previously received radiotherapy for DCIS.3. A total of 1 million women of a given age at diagnosis were simulated for each treatment strategy. The model outcomes were disease-free survival, invasive disease- free survival, overall survival, and likelihood of breast preservation over a 10-year and lifetime horizon. The simulation process was automated to create the model output tables for the decision tool. CONCLUSIONS: 1. We demonstrate that DCIS that expresses the ER is associated with a statistically increased risk of having a contralateral breast cancer diagnosis.2. Geographic areas with more radiotherapy use for DCIS had more use of mastectomy at the time of a second breast event even among patients eligible for breast conservation.3. This work culminates in a decision aid that will enable patients and their physicians to choose the treatment most consonant with the patient's history, characteristics, and preferences; it has the potential to improve both quality of life and decision-making for patients diagnosed with DCIS. LIMITATIONS: 1. There may be underascertainment of contralateral breast cancer diagnosis in SEER.2. The SEER database does not capture radiation use and second breast events.3. Although the decision aid aims to help patients and their physicians choose a treatment path based on potential outcomes, it does not consider every possible outcome patients can experience. | True   |
| 520   | PROD       | 3            | $a: BACKGROUND: Currently, more than 70% of women with ductal carcinoma in situ (DCIS) receive breast-conserving surgery (BCS) but then are at risk of a second cancer diagnosis in the same breast. Radiation therapy (RT) after BCS decreases recurrence in the 10 years after diagnosis by half but does not improve survival. Women with DCIS are also at elevated risk for cancer in the contralateral breast. Radiation after BCS for DCIS limits therapy choice to mastectomy if a woman has a second cancer in the treated breast because radiation can be given only once due to limits of normal tissue tolerance. If radiation was not received initially, a patient may be able to avoid mastectomy after a second ipsilateral breast cancer. For these reasons, the choice of treatment for DCIS is complex. A web-based decision aid would help a patient quantify the tradeoffs between her long-term survival and breast preservation. OBJECTIVES: 1. Determine the risk of and risk factors for new breast cancer after DCIS.2. Determine the likelihood of mastectomy at time of recurrence or new diagnosis after DCIS in a previously unirradiated breast and the association of regional use of RT on this likelihood.3. Determine the tradeoffs associated with RT for DCIS in terms of breast conservation for an individual patient in a web-based decision aid. METHODS: 1. To examine predictors of contralateral breast cancer following DCIS, we identified women diagnosed with DCIS in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program. We used multivariable Cox proportional hazards models to examine risks and predictors of contralateral second breast cancer.2. We performed a retrospective analysis of population-based databases SEER and SEER-Medicare. We also measured mastectomy vs BCS at a second breast event (DCIS recurrence or new invasive cancer).3. We developed a discrete event simulation model integrating data from the published literature to simulate the clinical events after 6 treatments for women with newly diagnosed DCIS. RESULTS: 1. In multivariable analysis, age and year of diagnosis, race, size, and estrogen receptor (ER) status were all significant predictors of contralateral breast cancer.2. Residence in a health service area (HSA) with greater radiotherapy use for DCIS was associated with an increased likelihood of receiving mastectomy vs BCS at a subsequent breast event, even among women who had not previously received radiotherapy for DCIS.3. A total of 1 million women of a given age at diagnosis were simulated for each treatment strategy. The model outcomes were disease-free survival, invasive disease- free survival, overall survival, and likelihood of breast preservation over a 10-year and lifetime horizon. The simulation process was automated to create the model output tables for the decision tool. CONCLUSIONS: 1. We demonstrate that DCIS that expresses the ER is associated with a statistically increased risk of having a contralateral breast cancer diagnosis.2. Geographic areas with more radiotherapy use for DCIS had more use of mastectomy at the time of a second breast event even among patients eligible for breast conservation.3. This work culminates in a decision aid that will enable patients and their physicians to choose the treatment most consonant with the patient's history, characteristics, and preferences; it has the potential to improve both quality of life and decision-making for patients diagnosed with DCIS. LIMITATIONS: 1. There may be underascertainment of contralateral breast cancer diagnosis in SEER.2. The SEER database does not capture radiation use and second breast events.3. Although the decision aid aims to help patients and their physicians choose a treatment path based on potential outcomes, it does not consider every possible outcome patients can experience. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: Original Title: Impact of Radiation Therapy on Breast Conservation in DCIS PCORI ID: CE-12-11-4173 ClinicalTrials.gov ID: NCT02248662Includes bibliographical references. | True   |
| 536   | PROD       |              | $a: Original Title: Impact of Radiation Therapy on Breast Conservation in DCIS PCORI ID: CE-12-11-4173 ClinicalTrials.gov ID: NCT02248662Includes bibliographical references. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed Oct. 31, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed Oct. 31, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Carcinoma, Intraductal, Noninfiltrating $x: therapy                         | True   |
| 650   | QA         | 22           | $a: Breast $x: surgery                                                          | True   |
| 650   | QA         | 22           | $a: Radiotherapy                                                                | True   |
| 650   | PROD       | 12           | $a: Carcinoma, Intraductal, Noninfiltrating $x: therapy                         | True   |
| 650   | PROD       | 22           | $a: Breast $x: surgery                                                          | True   |
| 650   | PROD       | 22           | $a: Radiotherapy                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 1            | $a: Patient-Centered Outcomes Research Institute (U.S.), $e: issuing body.      | True   |
| 710   | PROD       | 1            | $a: Patient-Centered Outcomes Research Institute (U.S.), $e: issuing body.      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: Final research report (Patient-Centered Outcomes Research Institute (U.S.)) | True   |
| 830   | PROD       |  0           | $a: Final research report (Patient-Centered Outcomes Research Institute (U.S.)) | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK605031/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK605031/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: IHH $b: 20241031                                                            | True   |
| 993   | PROD       |              | $a: IHH $b: 20241031                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241031                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241031                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241101                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241101                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240802                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240802                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918879459106676

Leader:
| File       | Leader                   | Equal  |
| QA         | 09183nam a2200505 i 4500 | True   |
| PROD       | 09183nam a2200505 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918879459106676                                                                | True   |
| 001   | PROD       |              | 9918879459106676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241104082909.0                                                                | True   |
| 005   | PROD       |              | 20241104082909.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240802s2020    dcua    ob    000|0 eng                                          | True   |
| 008   | PROD       |              | 240802s2020    dcua    ob    000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918879459106676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK604850                                                      | True   |
| 035   | PROD       |              | $9: 9918879459106676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK604850                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WS 130                                                                      | True   |
| 060   | PROD       | 00           | $a: WS 130                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Block, Jason, $e: author.                                                   | True   |
| 100   | PROD       | 1            | $a: Block, Jason, $e: author.                                                   | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Looking at the effects of antibiotic use on childhood obesity and growth : $b: the PCORnet(r) antibiotics study / $c: Jason Block, Christopher Forrest, Douglas Lunsford, Juliane Reynolds, Bridget Nolan. | True   |
| 245   | PROD       | 10           | $a: Looking at the effects of antibiotic use on childhood obesity and growth : $b: the PCORnet(r) antibiotics study / $c: Jason Block, Christopher Forrest, Douglas Lunsford, Juliane Reynolds, Bridget Nolan. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington (DC) : $b: Patient-Centered Outcomes Research Institute (PCORI), $c: [2020] | True   |
| 264   | PROD       |  1           | $a: Washington (DC) : $b: Patient-Centered Outcomes Research Institute (PCORI), $c: [2020] | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (211 pages)) : $b: illustrations.             | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (211 pages)) : $b: illustrations.             | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Final research report                                                       | True   |
| 490   | PROD       | 1            | $a: Final research report                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: BACKGROUND: Research has demonstrated associations between antibiotic use in early life and higher weight in later childhood. Lingering questions regarding this association include potential heterogeneity of treatment effects: the timing, type, and number of antibiotic exposures in early life; and differential effects of antibiotics in subgroups, such as by sex and medical comorbidities. With electronic health record (EHR) and other health care data available for large populations, the National Patient-Centered Clinical Research Network (PCORnet) provided a unique opportunity to investigate these questions and help build the research capacity of this new network. The study was led by 3 principal investigators, and the study results include data from 36 PCORnet institutions in 10 clinical data research networks (CDRNs). OBJECTIVES: The study aims were to examine the association between antibiotic use before 24 months of age and weight outcomes at ages 48 to <72 months (ie, approximately 5 years) and at 108 to 132 months (ie, approximately 10 years) and weight trajectories from early- to mid-childhood. To explore the association of maternal antibiotic use during pregnancy, we also incorporated maternal variables from the data of 7 participating institutions. The study had a qualitative aim to gauge opinions from parents and providers about their impressions of the potential relationship between antibiotics and childhood obesity, as well as an evaluation aim intended to identify accomplishments and needed improvements in the development of PCORnet. METHODS: For all analytic aims, the study used PCORnet's infrastructure and common data model (CDM) to capture all relevant data from 2009 to 2016. The CDM allows each participating institution to store its data in a standardized manner, facilitating the combination of data across sites. Study cohort inclusion criteria were the availability of same-day height and weight measurements at 0 to <a12, 12 to <30, and >24 months of age. Using deidentified individual-level data, we determined the association between antibiotic use at <24 months of age with the primary outcomes of (1) body mass index (BMI) z-score and overweight or obesity prevalence at 48 to <72 months (5 years) and 108 to 132 months (10 years) of age; and (2) weight trajectories from 24 months of age on. In 7 institutions, we were able to link data from mothers and children. For these sites, we assessed whether maternal antibiotics during pregnancy were associated with child BMI z-score and overweight or obesity prevalence at 48 to <72 months of age. For analyses of BMI z-score and overweight or obesity prevalence, we used mixed-effects regression models stratified by complex chronic condition status, accounting for clustering by network partner and adjusting for demographic and clinical factors, including sex, race, ethnicity, preterm birth, asthma, infections, corticosteroid episodes, encounters at <24 months of age, and age at outcome. We also conducted several secondary analyses, including examining differential effects on BMI z-score by antibiotic spectrum (narrow and broad spectrum, with further analyses of specific classes of medications within the broad-spectrum category) and age period (<6 months, 6 to <12 months, and 12 to <24 months) of exposures. We incorporated data on maternal characteristics from the subset of institutions for which we had data available linking mothers to children. For the trajectory analyses, we used longitudinal rate regression to assess differences in the rates of weight change across exposure groups. The study's qualitative aim used parent focus groups at 4 participating institutions and telephone provider interviews using scripts developed by the study team and stakeholder advisory group. We audio-recorded and transcribed focus groups and interviews, coded themes identified during the review of transcripts, and analyzed the code lists using a content analysis approach.1,2 Because this study was one of the first observational epidemiologic studies to be conducted across PCORnet, an external evaluator completed an extensive review of it, along with the PCORnet Bariatric Study; we report some of the findings from that evaluation. RESULTS: Among 1 792 849 children with a same-day height and weight measurement at <12 months of age, 362 550 children were eligible for the cohort for 5-year outcomes; 430 376 children were eligible for the trajectory analysis; 56 727 children were eligible for 10-year outcomes; and 53 320 mother-child pairs were eligible for the analysis of maternal antibiotics during pregnancy. Among children who received antibiotics at <24 months of age, we found that BMI z-score was slightly higher at 5 years by 0.04 (95% CI, 0.03-0.05) with slightly higher odds of overweight or obesity (odds ratio, 1.05; 95% CI, 1.03-1.07) than among children who had not received antibiotics. We found modest evidence of a dose response, with more antibiotic exposure translating to higher weight; the BMI z-score differences were 0.07 higher [0.06-0.08] for children exposed to ≥4 antibiotics vs children who had no antibiotics. For 5-year-old boys and girls who were at average height in this study, this difference amounted to 0.11 kg more weight if exposed to ≥4 antibiotic courses (vs 0) before 24 months of age. Broad-spectrum antibiotics were associated with slightly higher BMI z-scores than were narrow-spectrum antibiotics. We did not identify substantive differences by timing of exposure, sociodemographics, and whether children had chronic diseases. Effects were similar when we examined weight trajectories after 24 months and for weight outcomes at 10 years. We found no association between maternal antibiotic use during pregnancy and child weight outcomes. In the qualitative aim, we discovered that both parents and clinicians generally prioritized providing acute relief to children with an infection over the modest concern about long-term risks of weight gain. CONCLUSIONS: Antibiotic use at <24 months was associated with a slightly higher weight in later childhood. Maternal antibiotic use during pregnancy was not associated with weight in children. These findings likely should not affect clinical decision-making regarding whether to give children antibiotics, but they may be important at the population level considering the widespread use of antibiotics. While completing this project, the study team helped create a process for the curation and use of EHR prescribing data in PCORnet. LIMITATIONS: The PCORnet CDM focuses largely on EHR data, which includes prescribing data rather than dispensing data. In a limited number of participating institutions, our own analyses found missing data in PCORnet prescribing data compared with insurance claims and pharmacy dispensing data. In addition, at the time of this study, PCORnet did not have the ability to link patients across institutions. Thus, there was a possibility of duplicate patients in our study data set. | True   |
| 520   | PROD       | 3            | $a: BACKGROUND: Research has demonstrated associations between antibiotic use in early life and higher weight in later childhood. Lingering questions regarding this association include potential heterogeneity of treatment effects: the timing, type, and number of antibiotic exposures in early life; and differential effects of antibiotics in subgroups, such as by sex and medical comorbidities. With electronic health record (EHR) and other health care data available for large populations, the National Patient-Centered Clinical Research Network (PCORnet) provided a unique opportunity to investigate these questions and help build the research capacity of this new network. The study was led by 3 principal investigators, and the study results include data from 36 PCORnet institutions in 10 clinical data research networks (CDRNs). OBJECTIVES: The study aims were to examine the association between antibiotic use before 24 months of age and weight outcomes at ages 48 to <72 months (ie, approximately 5 years) and at 108 to 132 months (ie, approximately 10 years) and weight trajectories from early- to mid-childhood. To explore the association of maternal antibiotic use during pregnancy, we also incorporated maternal variables from the data of 7 participating institutions. The study had a qualitative aim to gauge opinions from parents and providers about their impressions of the potential relationship between antibiotics and childhood obesity, as well as an evaluation aim intended to identify accomplishments and needed improvements in the development of PCORnet. METHODS: For all analytic aims, the study used PCORnet's infrastructure and common data model (CDM) to capture all relevant data from 2009 to 2016. The CDM allows each participating institution to store its data in a standardized manner, facilitating the combination of data across sites. Study cohort inclusion criteria were the availability of same-day height and weight measurements at 0 to <a12, 12 to <30, and >24 months of age. Using deidentified individual-level data, we determined the association between antibiotic use at <24 months of age with the primary outcomes of (1) body mass index (BMI) z-score and overweight or obesity prevalence at 48 to <72 months (5 years) and 108 to 132 months (10 years) of age; and (2) weight trajectories from 24 months of age on. In 7 institutions, we were able to link data from mothers and children. For these sites, we assessed whether maternal antibiotics during pregnancy were associated with child BMI z-score and overweight or obesity prevalence at 48 to <72 months of age. For analyses of BMI z-score and overweight or obesity prevalence, we used mixed-effects regression models stratified by complex chronic condition status, accounting for clustering by network partner and adjusting for demographic and clinical factors, including sex, race, ethnicity, preterm birth, asthma, infections, corticosteroid episodes, encounters at <24 months of age, and age at outcome. We also conducted several secondary analyses, including examining differential effects on BMI z-score by antibiotic spectrum (narrow and broad spectrum, with further analyses of specific classes of medications within the broad-spectrum category) and age period (<6 months, 6 to <12 months, and 12 to <24 months) of exposures. We incorporated data on maternal characteristics from the subset of institutions for which we had data available linking mothers to children. For the trajectory analyses, we used longitudinal rate regression to assess differences in the rates of weight change across exposure groups. The study's qualitative aim used parent focus groups at 4 participating institutions and telephone provider interviews using scripts developed by the study team and stakeholder advisory group. We audio-recorded and transcribed focus groups and interviews, coded themes identified during the review of transcripts, and analyzed the code lists using a content analysis approach.1,2 Because this study was one of the first observational epidemiologic studies to be conducted across PCORnet, an external evaluator completed an extensive review of it, along with the PCORnet Bariatric Study; we report some of the findings from that evaluation. RESULTS: Among 1 792 849 children with a same-day height and weight measurement at <12 months of age, 362 550 children were eligible for the cohort for 5-year outcomes; 430 376 children were eligible for the trajectory analysis; 56 727 children were eligible for 10-year outcomes; and 53 320 mother-child pairs were eligible for the analysis of maternal antibiotics during pregnancy. Among children who received antibiotics at <24 months of age, we found that BMI z-score was slightly higher at 5 years by 0.04 (95% CI, 0.03-0.05) with slightly higher odds of overweight or obesity (odds ratio, 1.05; 95% CI, 1.03-1.07) than among children who had not received antibiotics. We found modest evidence of a dose response, with more antibiotic exposure translating to higher weight; the BMI z-score differences were 0.07 higher [0.06-0.08] for children exposed to ≥4 antibiotics vs children who had no antibiotics. For 5-year-old boys and girls who were at average height in this study, this difference amounted to 0.11 kg more weight if exposed to ≥4 antibiotic courses (vs 0) before 24 months of age. Broad-spectrum antibiotics were associated with slightly higher BMI z-scores than were narrow-spectrum antibiotics. We did not identify substantive differences by timing of exposure, sociodemographics, and whether children had chronic diseases. Effects were similar when we examined weight trajectories after 24 months and for weight outcomes at 10 years. We found no association between maternal antibiotic use during pregnancy and child weight outcomes. In the qualitative aim, we discovered that both parents and clinicians generally prioritized providing acute relief to children with an infection over the modest concern about long-term risks of weight gain. CONCLUSIONS: Antibiotic use at <24 months was associated with a slightly higher weight in later childhood. Maternal antibiotic use during pregnancy was not associated with weight in children. These findings likely should not affect clinical decision-making regarding whether to give children antibiotics, but they may be important at the population level considering the widespread use of antibiotics. While completing this project, the study team helped create a process for the curation and use of EHR prescribing data in PCORnet. LIMITATIONS: The PCORnet CDM focuses largely on EHR data, which includes prescribing data rather than dispensing data. In a limited number of participating institutions, our own analyses found missing data in PCORnet prescribing data compared with insurance claims and pharmacy dispensing data. In addition, at the time of this study, PCORnet did not have the ability to link patients across institutions. Thus, there was a possibility of duplicate patients in our study data set. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: Institution Receiving the Award: Harvard Pilgrim Health Care Institute Original Project Title: Understanding How Antibiotic Use Affects Childhood Obesity and Growth PCORI ID: OBS-1505-30699 ClinicalTrials.gov ID: NCT02744846 | True   |
| 536   | PROD       |              | $a: Institution Receiving the Award: Harvard Pilgrim Health Care Institute Original Project Title: Understanding How Antibiotic Use Affects Childhood Obesity and Growth PCORI ID: OBS-1505-30699 ClinicalTrials.gov ID: NCT02744846 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed Nov. 1, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed Nov. 1, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Pediatric Obesity $x: etiology                                              | True   |
| 650   | QA         | 22           | $a: Child Development $x: drug effects                                          | True   |
| 650   | QA         | 22           | $a: Anti-Bacterial Agents $x: adverse effects                                   | True   |
| 650   | PROD       | 12           | $a: Pediatric Obesity $x: etiology                                              | True   |
| 650   | PROD       | 22           | $a: Child Development $x: drug effects                                          | True   |
| 650   | PROD       | 22           | $a: Anti-Bacterial Agents $x: adverse effects                                   | True   |
--------------------------------------------------------------------------------------------------------------------------
| 700   | QA         | 1            | $a: Forrest, Christopher B., $e: author.                                        | True   |
| 700   | QA         | 1            | $a: Lunsford, Douglas, $e: author.                                              | True   |
| 700   | QA         | 1            | $a: Reynolds, Juliane, $e: author.                                              | True   |
| 700   | QA         | 1            | $a: Nolan, Bridget $c: (Project manager) $e: author.                            | True   |
| 700   | PROD       | 1            | $a: Forrest, Christopher B., $e: author.                                        | True   |
| 700   | PROD       | 1            | $a: Lunsford, Douglas, $e: author.                                              | True   |
| 700   | PROD       | 1            | $a: Reynolds, Juliane, $e: author.                                              | True   |
| 700   | PROD       | 1            | $a: Nolan, Bridget $c: (Project manager) $e: author.                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: Patient-Centered Outcomes Research Institute (U.S.), $e: issuing body.      | True   |
| 710   | PROD       | 2            | $a: Patient-Centered Outcomes Research Institute (U.S.), $e: issuing body.      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: Final research report (Patient-Centered Outcomes Research Institute (U.S.)) | True   |
| 830   | PROD       |  0           | $a: Final research report (Patient-Centered Outcomes Research Institute (U.S.)) | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604850/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604850/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: IHH $b: 20241101                                                            | True   |
| 993   | PROD       |              | $a: IHH $b: 20241101                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241101                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241101                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241104                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241104                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240802                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240802                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918879466606676

Leader:
| File       | Leader                   | Equal  |
| QA         | 02873nam a2200493 i 4500 | True   |
| PROD       | 02873nam a2200493 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918879466606676                                                                | True   |
| 001   | PROD       |              | 9918879466606676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241105143926.0                                                                | True   |
| 005   | PROD       |              | 20241105143926.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240802s2022    dcua    o     000|0 eng                                          | True   |
| 008   | PROD       |              | 240802s2022    dcua    o     000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 020   | QA         |              | $a: 0309689422                                                                  | True   |
| 020   | PROD       |              | $a: 0309689422                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918879466606676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK581381                                                      | True   |
| 035   | PROD       |              | $9: 9918879466606676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK581381                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WC 506.7                                                                    | True   |
| 060   | PROD       | 00           | $a: WC 506.7                                                                    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Whitacre, Paula, $e: rapporteur.                                            | True   |
| 100   | PROD       | 1            | $a: Whitacre, Paula, $e: rapporteur.                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Addressing supply chain and manufacturing challenges and opportunities / $c: prepared by Paula Whitacre. | True   |
| 245   | PROD       | 10           | $a: Addressing supply chain and manufacturing challenges and opportunities / $c: prepared by Paula Whitacre. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington, D.C. : $b: National Academies Press, $c: June 2022.             | True   |
| 264   | PROD       |  1           | $a: Washington, D.C. : $b: National Academies Press, $c: June 2022.             | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (11 pages)) : $b: illustrations.              | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (11 pages)) : $b: illustrations.              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Proceedings of a workshop--in brief                                         | True   |
| 490   | PROD       | 1            | $a: Proceedings of a workshop--in brief                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: The COVID-19 pandemic escalated supply chain vulnerabilities that affect almost every sector of the economy. Identifying key vulnerabilities and developing responses to them will require the mobilization of diverse actors across the U.S. research enterprise. In October and November 2021, the Government-University-Industry Research Roundtable (GUIRR) of the National Academies of Sciences, Engineering, and Medicine convened a number of virtual workshops for its membership and invited guests to discuss opportunities for enhancing U.S. approaches to addressing manufacturing and supply chain resilience, security, and sustainability challenges through partnerships and cross-sector collaboration. In convening experts and leaders from across sectors and disciplines, GUIRR provided a forum for dialogue on policy priorities for consideration by leaders across the research enterprise. This publication summarizes the presentation and discussion of the workshop series. | True   |
| 520   | PROD       | 3            | $a: The COVID-19 pandemic escalated supply chain vulnerabilities that affect almost every sector of the economy. Identifying key vulnerabilities and developing responses to them will require the mobilization of diverse actors across the U.S. research enterprise. In October and November 2021, the Government-University-Industry Research Roundtable (GUIRR) of the National Academies of Sciences, Engineering, and Medicine convened a number of virtual workshops for its membership and invited guests to discuss opportunities for enhancing U.S. approaches to addressing manufacturing and supply chain resilience, security, and sustainability challenges through partnerships and cross-sector collaboration. In convening experts and leaders from across sectors and disciplines, GUIRR provided a forum for dialogue on policy priorities for consideration by leaders across the research enterprise. This publication summarizes the presentation and discussion of the workshop series. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 530   | QA         |              | $a: Issued also in print.                                                       | True   |
| 530   | PROD       |              | $a: Issued also in print.                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: SPONSORS: This workshop was supported by the Government-University-Industry Research Roundtable membership, National Institutes of Health, Office of Naval Research, and the United States Department of Agriculture. | True   |
| 536   | PROD       |              | $a: SPONSORS: This workshop was supported by the Government-University-Industry Research Roundtable membership, National Institutes of Health, Office of Naval Research, and the United States Department of Agriculture. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed Nov. 5, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed Nov. 5, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: COVID-19 $x: economics.                                                     | True   |
| 650   | QA         | 22           | $a: Manufacturing Industry                                                      | True   |
| 650   | QA         | 22           | $a: Congresses as Topic                                                         | True   |
| 650   | PROD       | 12           | $a: COVID-19 $x: economics.                                                     | True   |
| 650   | PROD       | 22           | $a: Manufacturing Industry                                                      | True   |
| 650   | PROD       | 22           | $a: Congresses as Topic                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 651   | QA         |  2           | $a: United States                                                               | True   |
| 651   | PROD       |  2           | $a: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: Government-University-Industry Research Roundtable, $e: sponsoring body.    | True   |
| 710   | QA         | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.), $e: issuing body. | True   |
| 710   | PROD       | 2            | $a: Government-University-Industry Research Roundtable, $e: sponsoring body.    | True   |
| 710   | PROD       | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.), $e: issuing body. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: Workshop in brief                                                           | True   |
| 830   | PROD       |  0           | $a: Workshop in brief                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK581381/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK581381/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: IHH $b: 20241105                                                            | True   |
| 993   | PROD       |              | $a: IHH $b: 20241105                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241105                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241105                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241105                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241105                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240802                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240802                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918879465906676

Leader:
| File       | Leader                   | Equal  |
| QA         | 05389cam  2200637 i 4500 | True   |
| PROD       | 05389cam  2200637 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918879465906676                                                                | True   |
| 001   | PROD       |              | 9918879465906676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241101080802.0                                                                | True   |
| 005   | PROD       |              | 20241101080802.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240805s2024    dcu     ob    100 0 eng d                                        | True   |
| 008   | PROD       |              | 240805s2024    dcu     ob    100 0 eng d                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 020   | QA         |              | $a: 9780309717458 $q: electronic book                                           | True   |
| 020   | QA         |              | $a: 0309717450 $q: electronic book                                              | True   |
| 020   | QA         |              | $z: 9780309717441                                                               | True   |
| 020   | QA         |              | $z: 0309717442                                                                  | True   |
| 020   | PROD       |              | $a: 9780309717458 $q: electronic book                                           | True   |
| 020   | PROD       |              | $a: 0309717450 $q: electronic book                                              | True   |
| 020   | PROD       |              | $z: 9780309717441                                                               | True   |
| 020   | PROD       |              | $z: 0309717442                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918879465906676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK602537                                                      | True   |
| 035   | QA         |              | $a: (OCoLC)1451073769                                                           | True   |
| 035   | PROD       |              | $9: 9918879465906676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK602537                                                      | True   |
| 035   | PROD       |              | $a: (OCoLC)1451073769                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: OCLKB $b: eng $e: rda $e: pn $c: OCLKB $d: EBLCP $d: OCLCQ $d: YDX $d: OCLCO | True   |
| 040   | PROD       |              | $a: OCLKB $b: eng $e: rda $e: pn $c: OCLKB $d: EBLCP $d: OCLCQ $d: YDX $d: OCLCO | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 050   | QA         |  4           | $a: RC387.5 $b: .N38 2024                                                       | True   |
| 050   | PROD       |  4           | $a: RC387.5 $b: .N38 2024                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WL 354                                                                      | True   |
| 060   | PROD       | 00           | $a: WL 354                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 082   | QA         | 04           | $a: 617.481 $2: 23/eng/20241021                                                 | True   |
| 082   | PROD       | 04           | $a: 617.481 $2: 23/eng/20241021                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Haag, Tamara, $e: rapporteur.                                               | True   |
| 100   | PROD       | 1            | $a: Haag, Tamara, $e: rapporteur.                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Data integration in learning health care systems for traumatic brain injury : $b: proceedings of a workshop / $c: Tamara Haag, Chanel Matney, Katherine Bowman, rapporteurs ; Forum on Traumatic Brain Injury, Board on Health Sciences Policy, Health and Medicine Division. | True   |
| 245   | PROD       | 10           | $a: Data integration in learning health care systems for traumatic brain injury : $b: proceedings of a workshop / $c: Tamara Haag, Chanel Matney, Katherine Bowman, rapporteurs ; Forum on Traumatic Brain Injury, Board on Health Sciences Policy, Health and Medicine Division. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington, DC : $b: National Academies Press, $c: [2024]                   | True   |
| 264   | PROD       |  1           | $a: Washington, DC : $b: National Academies Press, $c: [2024]                   | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (xvii, 102 pages)) : $b: illustrations        | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (xvii, 102 pages)) : $b: illustrations        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 505   | QA         | 0            | $a: Intro -- FrontMatter -- Reviewers -- Contents -- Box and Figures -- Acronyms and Abbreviations -- 1 Introduction -- 2 Lived Experiences -- 3 The Learning Health System -- 4 Use of Learning Health Care Systems to Improve Care for Traumatic Brain Injury -- 5 Examples of Learning Health Care Systems in Traumatic Brain Injury -- 6 Data Capture, Surveillance, and Supporting Long-Term Care Needs -- 7 Using Learning Health Care Systems to Combat Inequitable Outcomes in Traumatic Brain Injury -- Appendix A: References -- Appendix B: Workshop Statement of Task -- Appendix C: Workshop Agenda | True   |
| 505   | PROD       | 0            | $a: Intro -- FrontMatter -- Reviewers -- Contents -- Box and Figures -- Acronyms and Abbreviations -- 1 Introduction -- 2 Lived Experiences -- 3 The Learning Health System -- 4 Use of Learning Health Care Systems to Improve Care for Traumatic Brain Injury -- 5 Examples of Learning Health Care Systems in Traumatic Brain Injury -- 6 Data Capture, Surveillance, and Supporting Long-Term Care Needs -- 7 Using Learning Health Care Systems to Combat Inequitable Outcomes in Traumatic Brain Injury -- Appendix A: References -- Appendix B: Workshop Statement of Task -- Appendix C: Workshop Agenda | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: Traumatic brain injuries (TBI) affect millions of Americans each year, causing symptoms that can be debilitating and long-lasting and resulting in physical, cognitive, emotional, and financial ramifications. The complexity and heterogeneity of TBI make it challenging to target the right interventions to the right patient at the right time. For those who do receive care, unlinked health records, fragmented care delivery, and gaps in medical surveillance means many questions remain unanswered about TBI prevalence, comorbidities, adverse outcome risk factors, and long-term outcomes. To help address this challenge, learning health care systems that bidirectionally exchange data and insights across clinical research, care services, and public health have been identified as key to improving patient outcomes. To help move the field forward, the National Academies Forum on Traumatic Brain Injury hosted a public workshop to explore the role of learning health systems in advancing TBI research and care. This Proceedings of a Workshop summarizes discussions and key messages from the workshop. | True   |
| 520   | PROD       | 3            | $a: Traumatic brain injuries (TBI) affect millions of Americans each year, causing symptoms that can be debilitating and long-lasting and resulting in physical, cognitive, emotional, and financial ramifications. The complexity and heterogeneity of TBI make it challenging to target the right interventions to the right patient at the right time. For those who do receive care, unlinked health records, fragmented care delivery, and gaps in medical surveillance means many questions remain unanswered about TBI prevalence, comorbidities, adverse outcome risk factors, and long-term outcomes. To help address this challenge, learning health care systems that bidirectionally exchange data and insights across clinical research, care services, and public health have been identified as key to improving patient outcomes. To help move the field forward, the National Academies Forum on Traumatic Brain Injury hosted a public workshop to explore the role of learning health systems in advancing TBI research and care. This Proceedings of a Workshop summarizes discussions and key messages from the workshop. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 530   | QA         |              | $a: Issued also in print.                                                       | True   |
| 530   | PROD       |              | $a: Issued also in print.                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: This activity was supported by contracts and grants between the National Academy of Sciences and Abbott Laboratories; AARP; Brain Scope, Inc.; Department of Defense (contract W81XWH22C0033); Department of Veterans Affairs (contract 36C24E22P0005); National Highway Traffic Safety Administration; National Institute on Disability, Independent Living, and Rehabilitation Research (contract 140D0423C0099 through the Department of the Interior); National Institutes of Health (contract HHSN263201800029I, task order 75N98022F00001); Neurotrauma Sciences; American Academy of Nursing; American Academy of Physical Medicine and Rehabilitation; American Association of Neurological Surgeons; American College of Surgeons; American Physical Therapy Association; Brain Injury Association of America; Concussion Legacy Foundation;; Emergency Nurses Association; National Association of Emergency Medical Technicians; National Association of State Head Injury Administrators; and National College Athletic Association. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. | True   |
| 536   | PROD       |              | $a: This activity was supported by contracts and grants between the National Academy of Sciences and Abbott Laboratories; AARP; Brain Scope, Inc.; Department of Defense (contract W81XWH22C0033); Department of Veterans Affairs (contract 36C24E22P0005); National Highway Traffic Safety Administration; National Institute on Disability, Independent Living, and Rehabilitation Research (contract 140D0423C0099 through the Department of the Interior); National Institutes of Health (contract HHSN263201800029I, task order 75N98022F00001); Neurotrauma Sciences; American Academy of Nursing; American Academy of Physical Medicine and Rehabilitation; American Association of Neurological Surgeons; American College of Surgeons; American Physical Therapy Association; Brain Injury Association of America; Concussion Legacy Foundation;; Emergency Nurses Association; National Association of Emergency Medical Technicians; National Association of State Head Injury Administrators; and National College Athletic Association. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed on October 31, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed on October 31, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Brain Injuries, Traumatic $x: rehabilitation                                | True   |
| 650   | QA         | 22           | $a: Delivery of Health Care, Integrated $x: organization & administration       | True   |
| 650   | QA         | 22           | $a: Electronic Health Records $x: organization & administration                 | True   |
| 650   | QA         | 22           | $a: Precision Medicine                                                          | True   |
| 650   | QA         | 22           | $a: Data Management                                                             | True   |
| 650   | QA         | 22           | $a: Systems Integration                                                         | True   |
| 650   | PROD       | 12           | $a: Brain Injuries, Traumatic $x: rehabilitation                                | True   |
| 650   | PROD       | 22           | $a: Delivery of Health Care, Integrated $x: organization & administration       | True   |
| 650   | PROD       | 22           | $a: Electronic Health Records $x: organization & administration                 | True   |
| 650   | PROD       | 22           | $a: Precision Medicine                                                          | True   |
| 650   | PROD       | 22           | $a: Data Management                                                             | True   |
| 650   | PROD       | 22           | $a: Systems Integration                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 651   | QA         |  2           | $a: United States                                                               | True   |
| 651   | PROD       |  2           | $a: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 655   | QA         |  2           | $a: Congress                                                                    | True   |
| 655   | PROD       |  2           | $a: Congress                                                                    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 700   | QA         | 1            | $a: Matney, Chanel, $e: rapporteur.                                             | True   |
| 700   | QA         | 1            | $a: Bowman, Katherine, $e: rapporteur.                                          | True   |
| 700   | PROD       | 1            | $a: Matney, Chanel, $e: rapporteur.                                             | True   |
| 700   | PROD       | 1            | $a: Bowman, Katherine, $e: rapporteur.                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Forum on Traumatic Brain Injury, $e: issuing body. | True   |
| 710   | PROD       | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Forum on Traumatic Brain Injury, $e: issuing body. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 711   | QA         | 2            | $a: Data Integration in Learning Health Care Systems for Traumatic Brain Injury (Workshop) $d: (2024 : $c: Washington, D.C.) | True   |
| 711   | PROD       | 2            | $a: Data Integration in Learning Health Care Systems for Traumatic Brain Injury (Workshop) $d: (2024 : $c: Washington, D.C.) | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK602537/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK602537/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: CAD $b: 20241017                                                            | True   |
| 993   | PROD       |              | $a: CAD $b: 20241017                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241031                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241031                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241101                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241101                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240802                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240802                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918879461306676

Leader:
| File       | Leader                   | Equal  |
| QA         | 08593nam a2200457 i 4500 | True   |
| PROD       | 08593nam a2200457 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918879461306676                                                                | True   |
| 001   | PROD       |              | 9918879461306676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241101142429.0                                                                | True   |
| 005   | PROD       |              | 20241101142429.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240802s2022    dcua    ob    000|0 eng                                          | True   |
| 008   | PROD       |              | 240802s2022    dcua    ob    000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918879461306676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK605480                                                      | True   |
| 035   | PROD       |              | $9: 9918879461306676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK605480                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WG 340                                                                      | True   |
| 060   | PROD       | 00           | $a: WG 340                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Green, Beverly B. $q: (Beverly Beth), $e: author.                           | True   |
| 100   | PROD       | 1            | $a: Green, Beverly B. $q: (Beverly Beth), $e: author.                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Comparing the effectiveness of home, clinic, and kiosk blood pressure checks for diagnosing high blood pressure : $b: the BP-CHECK study / $c: Beverly B. Green, Melissa L. Anderson, Andrea J. Cook, Kelly Ehrlich, Yoshio N. Hall, Laurel D. Hansell, Clarissa Hsu, Dwayne Joseph, Karen L. Margolis, Jennifer B. McClure, Sean A. Munson, Matthew J. Thompson. | True   |
| 245   | PROD       | 10           | $a: Comparing the effectiveness of home, clinic, and kiosk blood pressure checks for diagnosing high blood pressure : $b: the BP-CHECK study / $c: Beverly B. Green, Melissa L. Anderson, Andrea J. Cook, Kelly Ehrlich, Yoshio N. Hall, Laurel D. Hansell, Clarissa Hsu, Dwayne Joseph, Karen L. Margolis, Jennifer B. McClure, Sean A. Munson, Matthew J. Thompson. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington (DC) : $b: Patient-Centered Outcomes Research Institute (PCORI), $c: [2022] | True   |
| 264   | PROD       |  1           | $a: Washington (DC) : $b: Patient-Centered Outcomes Research Institute (PCORI), $c: [2022] | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (93 pages)) : $b: illustrations.              | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (93 pages)) : $b: illustrations.              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Final research report                                                       | True   |
| 490   | PROD       | 1            | $a: Final research report                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: BACKGROUND: Uncontrolled hypertension is the largest single contributor to all-cause and cardiovascular mortality. Although most adults with hypertension are treated, more than 1 in 3 may be unaware they have high blood pressure (BP). The US Preventive Services Task Force strongly recommends screening all adults aged ≥18 years for hypertension, with follow-up testing using 24-hour ambulatory BP monitoring (ABPM) or home BP monitoring (HBPM) before a new hypertension diagnosis. Clinicians rarely order ABPM, however; they sometimes suggest HBPM but not according to recommended protocols. Whether BP kiosks (often in pharmacies) could be used to diagnose hypertension is unknown. OBJECTIVES: BP Checks for Diagnosing Hypertension (BP-CHECK) was a randomized controlled study to evaluate performance, patient acceptability, and patient attitudes about clinic, HBPM, and kiosk hypertension diagnostic testing compared with ABPM (reference or gold standard) and longer-term outcomes after hypertension diagnostic testing. We also assessed provider knowledge, beliefs, and preferences about hypertension diagnostic tests. METHODS: We enrolled individuals aged 18 to 85 years who had no hypertension diagnosis, were taking no antihypertensive medications, and had a systolic BP (SBP) ≥138 mm Hg or a diastolic BP (DBP) ≥88 mm Hg in the electronic health record (EHR) and an SBP ≥140 mm Hg or DBP ≥90 mm Hg at a screening visit. Participants were randomly assigned to 1 of 3 regimens for diagnosing hypertension: (1) clinic BP (follow-up clinic appointment), (2) HBPM (duplicate measurements twice daily for 5 days), or (3) kiosk BP in clinic or at a nearby pharmacy (triplicate measurements over 3 days). Participants were asked to complete their assigned regimen within 3 weeks of randomization. Participants returned for ABPM (the reference standard for diagnosing hypertension) at 3 weeks, with a final research visit 6 months after study enrollment. The primary outcome was the mean difference in SBP between the clinic, HBPM, and kiosk diagnostic regimens and the reference test (daytime ABPM). Secondary outcomes included mean differences in DBP and sensitivity and specificity (as well as positive and negative likelihood ratios) of the diagnostic regimens relative to the reference test. Additional secondary outcomes included adherence to diagnostic regimens, patient-reported outcomes after diagnostic testing and at 6 months, and BP outcomes at 6 months by randomization group. Qualitative interviews with patients and providers assessed their views on the BP measurement regimens as well as their interpretations of BP measurement and hypertension diagnostic testing. RESULTS: Of 510 individuals randomly assigned, the mean age was 59 years; 48% were female, 80% were White, 7% were African American, 13% were other races, and 4% were Hispanic White. Mean baseline BP was similar across groups: 150/88 mm Hg. Among the 510 participants, 76 (14.9%) were excluded from primary analyses because of fewer than 14 daytime ABPM measurements and/or no clinic, HBPM, or kiosk BP measurements. Among those randomly assigned, 85.1% (434/510) had sufficient data for primary analyses (clinic, 82.6%; HBPM, 89.4%; kiosk, 83.3%). Using a diagnostic threshold of ABPM daytime mean SBP ≥135 mm Hg or DBP ≥85 mmHg as the reference standard, 71.7% of participants tested positive for hypertension. Compared with the reference standard, clinic, HBPM, and kiosk mean differences in SBP were 4.7 mm Hg lower, 0.1 mm Hg lower, and 9.5 mm Hg higher, respectively (P < .001 clinic and kiosk). Mean differences in DBP were 7.2 mm Hg lower, 0.4 mm Hg lower, and 5.0 mm Hg higher than mean daytime ABPM, respectively (P < .001 clinic and kiosk). The sensitivities of clinic, HBPM, and kiosk for detecting hypertension were 31.1%, 82.2%, and 96.0%, respectively. Specificities were 79.5% (clinic), 53.3% (HBPM), and 28.2% (kiosk); false positives were 5.6%, 13.8%, and 20.0%; and false negatives 50.0%, 12.5%, and 2.9%, respectively. Positive likelihood ratios of clinic, HBPM, and kiosk were 1.51, 1.76, and 1.34 respectively. Negative likelihood ratios were 0.87, 0.33, and 0.14, respectively. Adherence to BP data collection, defined as completing the minimum number of required BP checks, was 87.2% for clinic, 90.6% for HBPM, and 67.9% for kiosk, with 91.6% of all participants completing ABPM. HBPM was preferred. ABPM was more likely to disturb sleep and be uncomfortable, but participants perceived it as accurate. Six months after randomization, all groups had lower BP levels, with no significant differences in BP reduction, lifestyle behavior, or quality of life by randomization group. The proportion who were treated, defined as 1 or more prescription fills for an antihypertensive medication between randomization and 6-month follow-up, was similar across randomization groups (clinic, 25.6%; HBPM, 24.7%; and kiosk, 24.4%). Among individuals with hypertension based on ABPM testing, 40.1% (125/312) had a hypertension diagnosis recorded in the EHR by their provider between baseline and 6-month follow-up. Individuals with high BP measurements on ABPM and an EHR hypertension diagnosis had significantly greater declines from baseline to 6 months for both SBP and DBP compared with individuals with high BP measurements on ABPM and no EHR hypertension diagnosis (mean difference in SBP, −4.9 mm Hg [range, −7.8 to −2.1], P < .001; mean difference in DBP, −2.3 mm Hg [range, −4.3 to −0.4], P = .02). Providers believed that measuring BP manually using a stethoscope was more accurate than using automated, home, or kiosk BP monitors. Most physicians did not know standard protocols or out-of-office BP thresholds for diagnosing hypertension. CONCLUSIONS: HBPM had better diagnostic performance, adherence, and acceptability than clinic or kiosk methods for making a new hypertension diagnosis. Most participants with high BP measurements on screening and ABPM diagnostic testing did not receive a hypertension diagnosis. New strategies are needed to improve hypertension diagnosis. LIMITATIONS: Participants had to have high BP measurements in the EHR and at a baseline visit to be eligible, and most were confirmed to have hypertension on ABPM. Thus, our population may not be generalizable to those with lower BP measurements (and lower hypertension prevalence). Diverse racial and ethnic groups were underrepresented. | True   |
| 520   | PROD       | 3            | $a: BACKGROUND: Uncontrolled hypertension is the largest single contributor to all-cause and cardiovascular mortality. Although most adults with hypertension are treated, more than 1 in 3 may be unaware they have high blood pressure (BP). The US Preventive Services Task Force strongly recommends screening all adults aged ≥18 years for hypertension, with follow-up testing using 24-hour ambulatory BP monitoring (ABPM) or home BP monitoring (HBPM) before a new hypertension diagnosis. Clinicians rarely order ABPM, however; they sometimes suggest HBPM but not according to recommended protocols. Whether BP kiosks (often in pharmacies) could be used to diagnose hypertension is unknown. OBJECTIVES: BP Checks for Diagnosing Hypertension (BP-CHECK) was a randomized controlled study to evaluate performance, patient acceptability, and patient attitudes about clinic, HBPM, and kiosk hypertension diagnostic testing compared with ABPM (reference or gold standard) and longer-term outcomes after hypertension diagnostic testing. We also assessed provider knowledge, beliefs, and preferences about hypertension diagnostic tests. METHODS: We enrolled individuals aged 18 to 85 years who had no hypertension diagnosis, were taking no antihypertensive medications, and had a systolic BP (SBP) ≥138 mm Hg or a diastolic BP (DBP) ≥88 mm Hg in the electronic health record (EHR) and an SBP ≥140 mm Hg or DBP ≥90 mm Hg at a screening visit. Participants were randomly assigned to 1 of 3 regimens for diagnosing hypertension: (1) clinic BP (follow-up clinic appointment), (2) HBPM (duplicate measurements twice daily for 5 days), or (3) kiosk BP in clinic or at a nearby pharmacy (triplicate measurements over 3 days). Participants were asked to complete their assigned regimen within 3 weeks of randomization. Participants returned for ABPM (the reference standard for diagnosing hypertension) at 3 weeks, with a final research visit 6 months after study enrollment. The primary outcome was the mean difference in SBP between the clinic, HBPM, and kiosk diagnostic regimens and the reference test (daytime ABPM). Secondary outcomes included mean differences in DBP and sensitivity and specificity (as well as positive and negative likelihood ratios) of the diagnostic regimens relative to the reference test. Additional secondary outcomes included adherence to diagnostic regimens, patient-reported outcomes after diagnostic testing and at 6 months, and BP outcomes at 6 months by randomization group. Qualitative interviews with patients and providers assessed their views on the BP measurement regimens as well as their interpretations of BP measurement and hypertension diagnostic testing. RESULTS: Of 510 individuals randomly assigned, the mean age was 59 years; 48% were female, 80% were White, 7% were African American, 13% were other races, and 4% were Hispanic White. Mean baseline BP was similar across groups: 150/88 mm Hg. Among the 510 participants, 76 (14.9%) were excluded from primary analyses because of fewer than 14 daytime ABPM measurements and/or no clinic, HBPM, or kiosk BP measurements. Among those randomly assigned, 85.1% (434/510) had sufficient data for primary analyses (clinic, 82.6%; HBPM, 89.4%; kiosk, 83.3%). Using a diagnostic threshold of ABPM daytime mean SBP ≥135 mm Hg or DBP ≥85 mmHg as the reference standard, 71.7% of participants tested positive for hypertension. Compared with the reference standard, clinic, HBPM, and kiosk mean differences in SBP were 4.7 mm Hg lower, 0.1 mm Hg lower, and 9.5 mm Hg higher, respectively (P < .001 clinic and kiosk). Mean differences in DBP were 7.2 mm Hg lower, 0.4 mm Hg lower, and 5.0 mm Hg higher than mean daytime ABPM, respectively (P < .001 clinic and kiosk). The sensitivities of clinic, HBPM, and kiosk for detecting hypertension were 31.1%, 82.2%, and 96.0%, respectively. Specificities were 79.5% (clinic), 53.3% (HBPM), and 28.2% (kiosk); false positives were 5.6%, 13.8%, and 20.0%; and false negatives 50.0%, 12.5%, and 2.9%, respectively. Positive likelihood ratios of clinic, HBPM, and kiosk were 1.51, 1.76, and 1.34 respectively. Negative likelihood ratios were 0.87, 0.33, and 0.14, respectively. Adherence to BP data collection, defined as completing the minimum number of required BP checks, was 87.2% for clinic, 90.6% for HBPM, and 67.9% for kiosk, with 91.6% of all participants completing ABPM. HBPM was preferred. ABPM was more likely to disturb sleep and be uncomfortable, but participants perceived it as accurate. Six months after randomization, all groups had lower BP levels, with no significant differences in BP reduction, lifestyle behavior, or quality of life by randomization group. The proportion who were treated, defined as 1 or more prescription fills for an antihypertensive medication between randomization and 6-month follow-up, was similar across randomization groups (clinic, 25.6%; HBPM, 24.7%; and kiosk, 24.4%). Among individuals with hypertension based on ABPM testing, 40.1% (125/312) had a hypertension diagnosis recorded in the EHR by their provider between baseline and 6-month follow-up. Individuals with high BP measurements on ABPM and an EHR hypertension diagnosis had significantly greater declines from baseline to 6 months for both SBP and DBP compared with individuals with high BP measurements on ABPM and no EHR hypertension diagnosis (mean difference in SBP, −4.9 mm Hg [range, −7.8 to −2.1], P < .001; mean difference in DBP, −2.3 mm Hg [range, −4.3 to −0.4], P = .02). Providers believed that measuring BP manually using a stethoscope was more accurate than using automated, home, or kiosk BP monitors. Most physicians did not know standard protocols or out-of-office BP thresholds for diagnosing hypertension. CONCLUSIONS: HBPM had better diagnostic performance, adherence, and acceptability than clinic or kiosk methods for making a new hypertension diagnosis. Most participants with high BP measurements on screening and ABPM diagnostic testing did not receive a hypertension diagnosis. New strategies are needed to improve hypertension diagnosis. LIMITATIONS: Participants had to have high BP measurements in the EHR and at a baseline visit to be eligible, and most were confirmed to have hypertension on ABPM. Thus, our population may not be generalizable to those with lower BP measurements (and lower hypertension prevalence). Diverse racial and ethnic groups were underrepresented. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: Original Project Title: Blood Pressure Checks for Diagnosing Hypertension (BP-CHECK) Organization Receiving the Award: Kaiser Permanente Washington Health Research Institute PCORI ID: CER-1511-32979 ClinicalTrials.gov ID: NCT03130257 | True   |
| 536   | PROD       |              | $a: Original Project Title: Blood Pressure Checks for Diagnosing Hypertension (BP-CHECK) Organization Receiving the Award: Kaiser Permanente Washington Health Research Institute PCORI ID: CER-1511-32979 ClinicalTrials.gov ID: NCT03130257 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed Nov. 1, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed Nov. 1, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Hypertension $x: diagnosis                                                  | True   |
| 650   | QA         | 22           | $a: Blood Pressure Determination $x: instrumentation                            | True   |
| 650   | QA         | 22           | $a: Comparative Effectiveness Research                                          | True   |
| 650   | PROD       | 12           | $a: Hypertension $x: diagnosis                                                  | True   |
| 650   | PROD       | 22           | $a: Blood Pressure Determination $x: instrumentation                            | True   |
| 650   | PROD       | 22           | $a: Comparative Effectiveness Research                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: Patient-Centered Outcomes Research Institute (U.S.), $e: issuing body.      | True   |
| 710   | PROD       | 2            | $a: Patient-Centered Outcomes Research Institute (U.S.), $e: issuing body.      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: Final research report (Patient-Centered Outcomes Research Institute (U.S.)) | True   |
| 830   | PROD       |  0           | $a: Final research report (Patient-Centered Outcomes Research Institute (U.S.)) | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK605480/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK605480/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: IHH $b: 20241101                                                            | True   |
| 993   | PROD       |              | $a: IHH $b: 20241101                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241101                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241101                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241101                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241101                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240802                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240802                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918916898506676

Leader:
| File       | Leader                   | Equal  |
| QA         | 03845nam a2200529 i 4500 | True   |
| PROD       | 03845nam a2200529 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918916898506676                                                                | True   |
| 001   | PROD       |              | 9918916898506676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241108111811.0                                                                | True   |
| 005   | PROD       |              | 20241108111811.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 241002s2024    dcua    ob    100|0 eng                                          | True   |
| 008   | PROD       |              | 241002s2024    dcua    ob    100|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 020   | QA         |              | $z: 9780309717939                                                               | True   |
| 020   | QA         |              | $z: 0309717930                                                                  | True   |
| 020   | PROD       |              | $z: 9780309717939                                                               | True   |
| 020   | PROD       |              | $z: 0309717930                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918916898506676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK605857                                                      | True   |
| 035   | PROD       |              | $9: 9918916898506676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK605857                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: W 20.55.A5                                                                  | True   |
| 060   | PROD       | 00           | $a: W 20.55.A5                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Johnson, Anne Frances, $e: rapporteur.                                      | True   |
| 100   | PROD       | 1            | $a: Johnson, Anne Frances, $e: rapporteur.                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Effective communication with the general public about scientific research that requires the care and use of animals : $b: proceedings of a workshop / $c: Anne Frances Johnson and  Nia D. Johnson,, rapporteurs ; Roundtable on Science and Welfare of Animals Involved in Research,  Board on Animal Health Sciences, Conservation, and Research, Division on Earth and Life Studies. | True   |
| 245   | PROD       | 10           | $a: Effective communication with the general public about scientific research that requires the care and use of animals : $b: proceedings of a workshop / $c: Anne Frances Johnson and  Nia D. Johnson,, rapporteurs ; Roundtable on Science and Welfare of Animals Involved in Research,  Board on Animal Health Sciences, Conservation, and Research, Division on Earth and Life Studies. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington, DC : $b: National Academies Press, $c: [2024]                   | True   |
| 264   | PROD       |  1           | $a: Washington, DC : $b: National Academies Press, $c: [2024]                   | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (ix, 35 pages)) : $b: illustration            | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (ix, 35 pages)) : $b: illustration            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: Involvement of animals in scientific research can elicit strong emotions and responses from some members of the public, in part because the information they receive is inadequate. There is therefore an urgent need for scientists who conduct research involving animals to communicate more effectively about their work. To identify strategies for effective communication, the National Academies of Sciences, Engineering, and Medicine convened a workshop in December 19-20, 2023, entitled Effective Communication with the General Public About Scientific Research That Requires the Care and Use of Animals. The workshop focused on enhancing public understanding of scientific research with animals, how research animals are cared for and treated, the ethical considerations that are involved in these activities, and how research with animals has contributed to improvements in animal and human health. Participants explored characteristics of effective communication, ways to integrate information from scientists into media for diverse public audiences, and opportunities to address challenges in understanding research with animals. | True   |
| 520   | PROD       | 3            | $a: Involvement of animals in scientific research can elicit strong emotions and responses from some members of the public, in part because the information they receive is inadequate. There is therefore an urgent need for scientists who conduct research involving animals to communicate more effectively about their work. To identify strategies for effective communication, the National Academies of Sciences, Engineering, and Medicine convened a workshop in December 19-20, 2023, entitled Effective Communication with the General Public About Scientific Research That Requires the Care and Use of Animals. The workshop focused on enhancing public understanding of scientific research with animals, how research animals are cared for and treated, the ethical considerations that are involved in these activities, and how research with animals has contributed to improvements in animal and human health. Participants explored characteristics of effective communication, ways to integrate information from scientists into media for diverse public audiences, and opportunities to address challenges in understanding research with animals. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 530   | QA         |              | $a: Issued also in print.                                                       | True   |
| 530   | PROD       |              | $a: Issued also in print.                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: This activity was supported by contracts between the National Academy of Sciences and U.S. National Institutes of Health (Contract No. HHSN263201800029I); U.S. Department of Agriculture; U.S. Department of Veterans Affairs; U.S. Food and Drug Administration; and the National Science Foundation. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. | True   |
| 536   | PROD       |              | $a: This activity was supported by contracts between the National Academy of Sciences and U.S. National Institutes of Health (Contract No. HHSN263201800029I); U.S. Department of Agriculture; U.S. Department of Veterans Affairs; U.S. Food and Drug Administration; and the National Science Foundation. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed November 7, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed November 7, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Animal Experimentation                                                      | True   |
| 650   | QA         | 12           | $a: Public Opinion                                                              | True   |
| 650   | QA         | 22           | $a: Animal Welfare                                                              | True   |
| 650   | QA         | 22           | $a: Communication                                                               | True   |
| 650   | QA         | 22           | $a: Information Dissemination $x: methods                                       | True   |
| 650   | PROD       | 12           | $a: Animal Experimentation                                                      | True   |
| 650   | PROD       | 12           | $a: Public Opinion                                                              | True   |
| 650   | PROD       | 22           | $a: Animal Welfare                                                              | True   |
| 650   | PROD       | 22           | $a: Communication                                                               | True   |
| 650   | PROD       | 22           | $a: Information Dissemination $x: methods                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 655   | QA         |  2           | $a: Congress                                                                    | True   |
| 655   | PROD       |  2           | $a: Congress                                                                    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 700   | QA         | 1            | $a: Johnson, Nia D., $e: rapporteur.                                            | True   |
| 700   | PROD       | 1            | $a: Johnson, Nia D., $e: rapporteur.                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Roundtable on Science and Welfare of Animals Involved in Research, $e: issuing body. | True   |
| 710   | PROD       | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Roundtable on Science and Welfare of Animals Involved in Research, $e: issuing body. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 711   | QA         | 2            | $a: Effective Communication with the General Public About Scientific Research That Requires the Care and Use of Animals (Workshop) $d: (2023 : $c: Washington, D.C.) | True   |
| 711   | PROD       | 2            | $a: Effective Communication with the General Public About Scientific Research That Requires the Care and Use of Animals (Workshop) $d: (2023 : $c: Washington, D.C.) | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK605857/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK605857/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20241002                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20241002                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: EJP $b: 20241107                                                            | True   |
| 993   | PROD       |              | $a: EJP $b: 20241107                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241107                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241107                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241108                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241108                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20241002                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20241002                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918879461906676

Leader:
| File       | Leader                   | Equal  |
| QA         | 05427aam  2200757 i 4500 | True   |
| PROD       | 05427aam  2200757 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918879461906676                                                                | True   |
| 001   | PROD       |              | 9918879461906676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241031143539.0                                                                | True   |
| 005   | PROD       |              | 20241031143539.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240730t20242024dcua    ob    000 0 eng d                                        | True   |
| 008   | PROD       |              | 240730t20242024dcua    ob    000 0 eng d                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 019   | QA         |              | $a: 1437647937 $a: 1437992930 $a: 1455116404 $a: 1458756746                     | True   |
| 019   | PROD       |              | $a: 1437647937 $a: 1437992930 $a: 1455116404 $a: 1458756746                     | True   |
--------------------------------------------------------------------------------------------------------------------------
| 020   | QA         |              | $a: 9780309716994 $q: (electronic bk.)                                          | True   |
| 020   | QA         |              | $a: 0309716993 $q: (electronic bk.)                                             | True   |
| 020   | QA         |              | $z: 0309716985                                                                  | True   |
| 020   | QA         |              | $z: 9780309716987                                                               | True   |
| 020   | PROD       |              | $a: 9780309716994 $q: (electronic bk.)                                          | True   |
| 020   | PROD       |              | $a: 0309716993 $q: (electronic bk.)                                             | True   |
| 020   | PROD       |              | $z: 0309716985                                                                  | True   |
| 020   | PROD       |              | $z: 9780309716987                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 024   | QA         | 7            | $a: 10.17226/27623 $2: doi                                                      | True   |
| 024   | PROD       | 7            | $a: 10.17226/27623 $2: doi                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918879461906676                                                            | True   |
| 035   | QA         |              | $a: (OCoLC)1450510645                                                           | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK605437                                                      | True   |
| 035   | PROD       |              | $9: 9918879461906676                                                            | True   |
| 035   | PROD       |              | $a: (OCoLC)1450510645                                                           | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK605437                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: YDX $b: eng $e: rda $e: pn $c: YDX $d: OCLCO $d: OCLKB $d: EBLCP $d: N$T $d: OCLCQ | True   |
| 040   | PROD       |              | $a: YDX $b: eng $e: rda $e: pn $c: YDX $d: OCLCO $d: OCLKB $d: EBLCP $d: N$T $d: OCLCQ | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 043   | QA         |              | $a: n-us---                                                                     | True   |
| 043   | PROD       |              | $a: n-us---                                                                     | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 050   | QA         |  4           | $a: QP144.F56 $b: R65 2024                                                      | True   |
| 050   | QA         |  4           | $a: QP144 $b: .R654 2024                                                        | True   |
| 050   | PROD       |  4           | $a: QP144.F56 $b: R65 2024                                                      | True   |
| 050   | PROD       |  4           | $a: QP144 $b: .R654 2024                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WA 707                                                                      | True   |
| 060   | PROD       | 00           | $a: WA 707                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 072   | QA         |  7           | $a: MED069000 $2: bisacsh                                                       | True   |
| 072   | QA         |  7           | $a: MJW $2: bicssc                                                              | True   |
| 072   | QA         |  7           | $a: MED060000 $2: bisacsh                                                       | True   |
| 072   | QA         |  7           | $a: MBNH3 $2: bicssc                                                            | True   |
| 072   | QA         |  7           | $a: MED036000 $2: bisacsh                                                       | True   |
| 072   | QA         |  7           | $a: M $2: bicssc                                                                | True   |
| 072   | PROD       |  7           | $a: MED069000 $2: bisacsh                                                       | True   |
| 072   | PROD       |  7           | $a: MJW $2: bicssc                                                              | True   |
| 072   | PROD       |  7           | $a: MED060000 $2: bisacsh                                                       | True   |
| 072   | PROD       |  7           | $a: MBNH3 $2: bicssc                                                            | True   |
| 072   | PROD       |  7           | $a: MED036000 $2: bisacsh                                                       | True   |
| 072   | PROD       |  7           | $a: M $2: bicssc                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 082   | QA         | 04           | $a: 613.2/6 $2: 23/eng/20240814                                                 | True   |
| 082   | PROD       | 04           | $a: 613.2/6 $2: 23/eng/20240814                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 04           | $a: The role of seafood consumption in child growth and development / $c: Committee on the Role of Seafood Consumption on Child Growth and Development, Food and Nutrition Board, Health and Medicine Division, National Academies, Sciences, Engineering, Medicine. | True   |
| 245   | PROD       | 04           | $a: The role of seafood consumption in child growth and development / $c: Committee on the Role of Seafood Consumption on Child Growth and Development, Food and Nutrition Board, Health and Medicine Division, National Academies, Sciences, Engineering, Medicine. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington, DC : $b: National Academies Press, $c: [2024]                   | True   |
| 264   | QA         |  4           | $c: ©2024                                                                       | True   |
| 264   | PROD       |  1           | $a: Washington, DC : $b: National Academies Press, $c: [2024]                   | True   |
| 264   | PROD       |  4           | $c: ©2024                                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (xvi, 187 pages)) : $b: illustrations (chiefly color). | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (xvi, 187 pages)) : $b: illustrations (chiefly color). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Consensus study report                                                      | True   |
| 490   | PROD       | 1            | $a: Consensus study report                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 505   | QA         | 0            | $a: Intro -- FrontMatter -- Reviewers -- Contents -- Acronyms and Abbreviations -- Preface -- Summary -- 1 Introduction -- 2 Methodological Approach to the Task -- 3 Seafood Consumption Patterns in the United States and Canada -- 4 Dietary Intake and Nutrient Composition of Seafood -- 5 Exposure to Contaminants Associated with Consumption of Seafood -- 6 Health Outcomes Associated with Seafood Consumption -- 7 Risk-Benefit Analysis -- Appendix A: Committee Member Biosketches -- Appendix B: Open Session Agendas -- Appendix C: Commissioned Systematic Reviews | True   |
| 505   | QA         | 8            | $a: Appendix D: Supplemental Review of Systematic Reviews -- Appendix E: NHANES Data Analysis Methodology. | True   |
| 505   | PROD       | 0            | $a: Intro -- FrontMatter -- Reviewers -- Contents -- Acronyms and Abbreviations -- Preface -- Summary -- 1 Introduction -- 2 Methodological Approach to the Task -- 3 Seafood Consumption Patterns in the United States and Canada -- 4 Dietary Intake and Nutrient Composition of Seafood -- 5 Exposure to Contaminants Associated with Consumption of Seafood -- 6 Health Outcomes Associated with Seafood Consumption -- 7 Risk-Benefit Analysis -- Appendix A: Committee Member Biosketches -- Appendix B: Open Session Agendas -- Appendix C: Commissioned Systematic Reviews | True   |
| 505   | PROD       | 8            | $a: Appendix D: Supplemental Review of Systematic Reviews -- Appendix E: NHANES Data Analysis Methodology. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         |              | $a: 1 Introduction -- 2 Methodological Approach to the Task -- 3 Seafood Consumption Patterns in the United States and Canada -- 4 Dietary Intake and Nutrient Composition of Seafood -- 5 Exposure to Contaminants Associated with Consumption of Seafood -- 6 Health Outcomes Associated with Seafood Consumption -- 7 Risk-Benefit Analysis -- Appendixes. [Appendix] A: Committee Member Biosketches -- [Appendix] B: Open Session Agendas -- [Appendix] C: Commissioned Systematic Reviews -- [Appendix] D: Supplemental Review of Systematic Reviews -- [Appendix] E: NHANES Data Analysis Methodology. | True   |
| 520   | QA         |              | $a: "Seafood--including marine and freshwater fish, mollusks, and crustaceans--is a healthy food choice, but it can also contain contaminants. It is currently unclear how much seafood children or pregnant and lactating women are consuming, and what impact seafood consumption is having on children's growth and development.The U.S. Department of Health and Human Services, the U.S. Department of Agriculture, the U.S. Environmental Protection Agency, and the National Oceanic and Atmospheric Administration tasked the National Academies of Sciences, Engineering, and Medicine with convening an expert committee to examine associations between seafood intake for children, adolescents, and pregnant and lactating women and child growth and development. The committee also evaluated when to conduct risk-benefit analyses (RBAs), while considering contextual factors such as equity, diversity, inclusion, and access to health care, and explored how these factors might impact RBAs."--Publisher's website. | True   |
| 520   | PROD       |              | $a: 1 Introduction -- 2 Methodological Approach to the Task -- 3 Seafood Consumption Patterns in the United States and Canada -- 4 Dietary Intake and Nutrient Composition of Seafood -- 5 Exposure to Contaminants Associated with Consumption of Seafood -- 6 Health Outcomes Associated with Seafood Consumption -- 7 Risk-Benefit Analysis -- Appendixes. [Appendix] A: Committee Member Biosketches -- [Appendix] B: Open Session Agendas -- [Appendix] C: Commissioned Systematic Reviews -- [Appendix] D: Supplemental Review of Systematic Reviews -- [Appendix] E: NHANES Data Analysis Methodology. | True   |
| 520   | PROD       |              | $a: "Seafood--including marine and freshwater fish, mollusks, and crustaceans--is a healthy food choice, but it can also contain contaminants. It is currently unclear how much seafood children or pregnant and lactating women are consuming, and what impact seafood consumption is having on children's growth and development.The U.S. Department of Health and Human Services, the U.S. Department of Agriculture, the U.S. Environmental Protection Agency, and the National Oceanic and Atmospheric Administration tasked the National Academies of Sciences, Engineering, and Medicine with convening an expert committee to examine associations between seafood intake for children, adolescents, and pregnant and lactating women and child growth and development. The committee also evaluated when to conduct risk-benefit analyses (RBAs), while considering contextual factors such as equity, diversity, inclusion, and access to health care, and explored how these factors might impact RBAs."--Publisher's website. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 530   | QA         |              | $a: Issued also in print.                                                       | True   |
| 530   | PROD       |              | $a: Issued also in print.                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: This activity was supported by a contract between the National Academy of Sciences and the U.S. Department of Health and Human Services, U.S. Food and Drug Administration Grant No. 75F40122F19001, which includes funds from the National Oceanic and Atmospheric Administration, the U.S. Department of Agriculture, and the U.S. Environmental Protection Agency. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. | True   |
| 536   | PROD       |              | $a: This activity was supported by a contract between the National Academy of Sciences and the U.S. Department of Health and Human Services, U.S. Food and Drug Administration Grant No. 75F40122F19001, which includes funds from the National Oceanic and Atmospheric Administration, the U.S. Department of Agriculture, and the U.S. Environmental Protection Agency. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed October 31, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed October 31, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Seafood                                                                     | True   |
| 650   | QA         | 12           | $a: Nutritive Value                                                             | True   |
| 650   | QA         | 22           | $a: Child Development                                                           | True   |
| 650   | QA         | 22           | $a: Pregnant Women                                                              | True   |
| 650   | QA         | 22           | $a: Child Nutritional Physiological Phenomena                                   | True   |
| 650   | QA         | 22           | $a: Food Safety                                                                 | True   |
| 650   | PROD       | 12           | $a: Seafood                                                                     | True   |
| 650   | PROD       | 12           | $a: Nutritive Value                                                             | True   |
| 650   | PROD       | 22           | $a: Child Development                                                           | True   |
| 650   | PROD       | 22           | $a: Pregnant Women                                                              | True   |
| 650   | PROD       | 22           | $a: Child Nutritional Physiological Phenomena                                   | True   |
| 650   | PROD       | 22           | $a: Food Safety                                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 651   | QA         |  2           | $a: United States                                                               | True   |
| 651   | PROD       |  2           | $a: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Committee on the Role of Seafood Consumption on Child Growth and Development, $e: issuing body. | True   |
| 710   | PROD       | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Committee on the Role of Seafood Consumption on Child Growth and Development, $e: issuing body. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: Consensus study report                                                      | True   |
| 830   | PROD       |  0           | $a: Consensus study report                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK605437/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK605437/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: CAD $b: 20241017                                                            | True   |
| 993   | PROD       |              | $a: CAD $b: 20241017                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241031                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241031                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241031                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241031                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240802                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240802                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918879462006676

Leader:
| File       | Leader                   | Equal  |
| QA         | 01291nam a22003615i 4500 | True   |
| PROD       | 01291nam a22003615i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918879462006676                                                                | True   |
| 001   | PROD       |              | 9918879462006676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241104161025.0                                                                | True   |
| 005   | PROD       |              | 20241104161025.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240802s2023    enk     ob    000|0 eng                                          | True   |
| 008   | PROD       |              | 240802s2023    enk     ob    000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 010   | QA         |              | $a:   2023936138                                                                | True   |
| 010   | PROD       |              | $a:   2023936138                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 020   | QA         |              | $z: 9780192843777                                                               | True   |
| 020   | PROD       |              | $z: 9780192843777                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918879462006676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK605308                                                      | True   |
| 035   | PROD       |              | $9: 9918879462006676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK605308                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: England                                                                     | True   |
| 044   | PROD       |              | $9: England                                                                     | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 00           | $a: Literature and the senses / $c: edited by Annette Kern-Stähler and Elizabeth Robertson. | True   |
| 245   | PROD       | 00           | $a: Literature and the senses / $c: edited by Annette Kern-Stähler and Elizabeth Robertson. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Oxford, UK : $b: Oxford University Press, $c: 2023.                         | True   |
| 264   | PROD       |  1           | $a: Oxford, UK : $b: Oxford University Press, $c: 2023.                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file)                                              | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file)                                              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Oxford twenty-first century approaches to literature                        | True   |
| 490   | PROD       | 1            | $a: Oxford twenty-first century approaches to literature                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 530   | QA         |              | $a: Issued also in print.                                                       | True   |
| 530   | PROD       |              | $a: Issued also in print.                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 700   | QA         | 1            | $a: Kern-Stähler, Annette, $d: 1971- $e: editor.                               | True   |
| 700   | QA         | 1            | $a: Robertson, Elizabeth, $e: editor.                                           | True   |
| 700   | PROD       | 1            | $a: Kern-Stähler, Annette, $d: 1971- $e: editor.                               | True   |
| 700   | PROD       | 1            | $a: Robertson, Elizabeth, $e: editor.                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: Oxford twenty-first century approaches to literature                        | True   |
| 830   | PROD       |  0           | $a: Oxford twenty-first century approaches to literature                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $3: Selected chapter $u: https://www.ncbi.nlm.nih.gov/books/NBK605308/          | True   |
| 856   | PROD       | 40           | $3: Selected chapter $u: https://www.ncbi.nlm.nih.gov/books/NBK605308/          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 997   | QA         |              | $a: Collection link Wellcome Trust-Funded Monographs and Book Chapters          | True   |
| 997   | PROD       |              | $a: Collection link Wellcome Trust-Funded Monographs and Book Chapters          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240802                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240802                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: BRF                                                                         | True   |
| 999   | PROD       |              | $a: BRF                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918879464606676

Leader:
| File       | Leader                   | Equal  |
| QA         | 01941nam a2200409 i 4500 | True   |
| PROD       | 01941nam a2200409 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918879464606676                                                                | True   |
| 001   | PROD       |              | 9918879464606676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241105150235.0                                                                | True   |
| 005   | PROD       |              | 20241105150235.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240802s2022    dcu     ob   f000|0 eng                                          | True   |
| 008   | PROD       |              | 240802s2022    dcu     ob   f000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918879464606676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK605137                                                      | True   |
| 035   | PROD       |              | $9: 9918879464606676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK605137                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WM 284                                                                      | True   |
| 060   | PROD       | 00           | $a: WM 284                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 00           | $a: Addressing the opioid overdose crisis through better data.                  | True   |
| 245   | PROD       | 00           | $a: Addressing the opioid overdose crisis through better data.                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington, D.C. : $b: Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, Office of Health Policy, $c: October 2022 | True   |
| 264   | PROD       |  1           | $a: Washington, D.C. : $b: Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, Office of Health Policy, $c: October 2022 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (6 pages))                                    | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (6 pages))                                    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: This updated 2022 vignette provides examples of how a range of Office of the Secretary Patient-Centered Outcomes Research Trust Fund (OS-PCORTF) cross-agency projects are working to address the opioid overdose crisis by 1) Improving Timeliness and Quality of Outcomes Data 2) Building Capacity for Collection of Patient-Reported Outcomes 3) Building Linkages to Address Co-Morbidities. | True   |
| 520   | PROD       | 3            | $a: This updated 2022 vignette provides examples of how a range of Office of the Secretary Patient-Centered Outcomes Research Trust Fund (OS-PCORTF) cross-agency projects are working to address the opioid overdose crisis by 1) Improving Timeliness and Quality of Outcomes Data 2) Building Capacity for Collection of Patient-Reported Outcomes 3) Building Linkages to Address Co-Morbidities. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed Nov. 5, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed Nov. 5, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Opiate Overdose $x: epidemiology                                            | True   |
| 650   | QA         | 22           | $a: Patient Outcome Assessment                                                  | True   |
| 650   | PROD       | 12           | $a: Opiate Overdose $x: epidemiology                                            | True   |
| 650   | PROD       | 22           | $a: Patient Outcome Assessment                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 651   | QA         |  2           | $a: United States $x: epidemiology                                              | True   |
| 651   | PROD       |  2           | $a: United States $x: epidemiology                                              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 1            | $a: United States. $b: Department of Health and Human Services. $b: Office of the Assistant Secretary for Planning and Evaluation. $b: Office of Health Policy, $e: issuing body. | True   |
| 710   | PROD       | 1            | $a: United States. $b: Department of Health and Human Services. $b: Office of the Assistant Secretary for Planning and Evaluation. $b: Office of Health Policy, $e: issuing body. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK605137/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK605137/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: IHH $b: 20241105                                                            | True   |
| 993   | PROD       |              | $a: IHH $b: 20241105                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241105                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241105                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241105                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241105                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240802                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240802                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918879461106676

Leader:
| File       | Leader                   | Equal  |
| QA         | 03077nam a2200517 i 4500 | True   |
| PROD       | 03077nam a2200517 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918879461106676                                                                | True   |
| 001   | PROD       |              | 9918879461106676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241101152427.0                                                                | True   |
| 005   | PROD       |              | 20241101152427.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240802s2023    dcua    obs  f000|0 eng                                          | True   |
| 008   | PROD       |              | 240802s2023    dcua    obs  f000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918879461106676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK604796                                                      | True   |
| 035   | PROD       |              | $9: 9918879461106676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK604796                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WT 31.5                                                                     | True   |
| 060   | PROD       | 00           | $a: WT 31.5                                                                     | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Xu, Lanlan, $e: author.                                                     | True   |
| 100   | PROD       | 1            | $a: Xu, Lanlan, $e: author.                                                     | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Medicare Advantage overview : $b: primer on enrollment and spending / $c: Lanlan Xu, W. Pete Welch, Joel Ruhter, Nguyen X. Nguyen, Steven Sheingold, Nancy De Lew, Benjamin D. Sommers. | True   |
| 245   | PROD       | 10           | $a: Medicare Advantage overview : $b: primer on enrollment and spending / $c: Lanlan Xu, W. Pete Welch, Joel Ruhter, Nguyen X. Nguyen, Steven Sheingold, Nancy De Lew, Benjamin D. Sommers. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington (DC) : $b: ASPE, Assistant Secretary for Planning and Evaluation, Office of Health Policy, $c: May 25, 2023. | True   |
| 264   | PROD       |  1           | $a: Washington (DC) : $b: ASPE, Assistant Secretary for Planning and Evaluation, Office of Health Policy, $c: May 25, 2023. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (17 pages)) : $b: illustrations.              | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (17 pages)) : $b: illustrations.              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Issue brief                                                                 | True   |
| 490   | PROD       | 1            | $a: Issue brief                                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 500   | QA         |              | $a: Caption title.                                                              | True   |
| 500   | PROD       |              | $a: Caption title.                                                              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: Enrollment in Medicare Advantage plans has increased rapidly in recent years. The share of eligible Medicare beneficiaries enrolled in MA rose from 25% in 2010 to 47% in 2021 (27.6 million enrollees). Payments to MA plans more than doubled between 2015 and 2021 (from $175 to $361 billion), taking the share of total Medicare Parts A & B spending on MA from 38% to 54%. Over the next 10 years, CMS is expected to pay MA health insurance companies over $7 trillion. Evidence suggests that federal spending per person in MA exceeds spending for comparable FFS Medicare beneficiaries, with estimates ranging from 4 to 10 percent higher spending in MA in 2021. This differential is projected to grow over time, in large part from differences in diagnostic coding intensity - the number and type of diagnosis codes submitted by plans, which can increase federal payment due to MA risk adjustment practices. In recent years, margins are higher in MA than other markets, while enrollment in MA has continued to increase and the number of MA plans available to Medicare beneficiaries has grown significantly. | True   |
| 520   | PROD       | 3            | $a: Enrollment in Medicare Advantage plans has increased rapidly in recent years. The share of eligible Medicare beneficiaries enrolled in MA rose from 25% in 2010 to 47% in 2021 (27.6 million enrollees). Payments to MA plans more than doubled between 2015 and 2021 (from $175 to $361 billion), taking the share of total Medicare Parts A & B spending on MA from 38% to 54%. Over the next 10 years, CMS is expected to pay MA health insurance companies over $7 trillion. Evidence suggests that federal spending per person in MA exceeds spending for comparable FFS Medicare beneficiaries, with estimates ranging from 4 to 10 percent higher spending in MA in 2021. This differential is projected to grow over time, in large part from differences in diagnostic coding intensity - the number and type of diagnosis codes submitted by plans, which can increase federal payment due to MA risk adjustment practices. In recent years, margins are higher in MA than other markets, while enrollment in MA has continued to increase and the number of MA plans available to Medicare beneficiaries has grown significantly. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 530   | QA         |              | $a: Issued also in print.                                                       | True   |
| 530   | PROD       |              | $a: Issued also in print.                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed November 1, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed November 1, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Medicare Part C $x: economics                                               | True   |
| 650   | QA         | 22           | $a: Medicare Part C $x: statistics & numerical data                             | True   |
| 650   | QA         | 22           | $a: Insurance Coverage $x: economics                                            | True   |
| 650   | QA         | 22           | $a: Insurance Benefits $x: economics                                            | True   |
| 650   | QA         | 22           | $a: Costs and Cost Analysis                                                     | True   |
| 650   | PROD       | 12           | $a: Medicare Part C $x: economics                                               | True   |
| 650   | PROD       | 22           | $a: Medicare Part C $x: statistics & numerical data                             | True   |
| 650   | PROD       | 22           | $a: Insurance Coverage $x: economics                                            | True   |
| 650   | PROD       | 22           | $a: Insurance Benefits $x: economics                                            | True   |
| 650   | PROD       | 22           | $a: Costs and Cost Analysis                                                     | True   |
--------------------------------------------------------------------------------------------------------------------------
| 651   | QA         |  2           | $a: United States                                                               | True   |
| 651   | PROD       |  2           | $a: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 655   | QA         |  2           | $a: Statistics                                                                  | True   |
| 655   | PROD       |  2           | $a: Statistics                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 1            | $a: United States. $b: Department of Health and Human Services. $b: Office of the Assistant Secretary for Planning and Evaluation. $b: Office of Health Policy, $e: issuing body. | True   |
| 710   | PROD       | 1            | $a: United States. $b: Department of Health and Human Services. $b: Office of the Assistant Secretary for Planning and Evaluation. $b: Office of Health Policy, $e: issuing body. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: ASPE issue brief                                                            | True   |
| 830   | PROD       |  0           | $a: ASPE issue brief                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604796/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604796/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: CAD $b: 20241017                                                            | True   |
| 993   | PROD       |              | $a: CAD $b: 20241017                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241101                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241101                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241101                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241101                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240802                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240802                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918879458906676

Leader:
| File       | Leader                   | Equal  |
| QA         | 06112nam a2200517 i 4500 | True   |
| PROD       | 06112nam a2200517 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918879458906676                                                                | True   |
| 001   | PROD       |              | 9918879458906676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241115090515.0                                                                | True   |
| 005   | PROD       |              | 20241115090515.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240802s2020    dcua    obs   000|0 eng                                          | True   |
| 008   | PROD       |              | 240802s2020    dcua    obs   000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918879458906676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK604852                                                      | True   |
| 035   | PROD       |              | $9: 9918879458906676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK604852                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WO 16.1                                                                     | True   |
| 060   | PROD       | 00           | $a: WO 16.1                                                                     | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Hubbard, Alan $q: (Alan E.), $e: author.                                    | True   |
| 100   | PROD       | 1            | $a: Hubbard, Alan $q: (Alan E.), $e: author.                                    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Developing methods to predict health outcomes in trauma patients / $c: Alan Hubbard, Mark van der Laan. | True   |
| 245   | PROD       | 10           | $a: Developing methods to predict health outcomes in trauma patients / $c: Alan Hubbard, Mark van der Laan. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: [Washington, DC] : $b: PCORI, Patient-Centered Outcomes Research Institute, $c: [2020] | True   |
| 264   | PROD       |  1           | $a: [Washington, DC] : $b: PCORI, Patient-Centered Outcomes Research Institute, $c: [2020] | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (56 pages)) : $b: illustrations.              | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (56 pages)) : $b: illustrations.              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Final research report                                                       | True   |
| 490   | PROD       | 1            | $a: Final research report                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: BACKGROUND: The revolution in digitizing medical data, along with high throughput biology, has resulted in unprecedented numbers of potential prognostic variables for health outcomes. Recent research suggests that clinical data can be used for continually updated accurate prognostics to optimize medical interventions. We address gaps in methodology available for estimating causal impacts in acute trauma settings using machine learning, and tailor this methodological research to the goals of using complex clinical data to analyze potential outcomes in acute trauma patients. OBJECTIVE: Our primary aims were the following: 1. Develop diagnostic (prediction) scores via SuperLearner for each of the trauma studies. Estimate the relative prediction accuracy of competing algorithms via cross-validation tools, such as cross-validated area under the curve.2. Develop and evaluate variable importance estimators, which can potentially quantify the differentiable impact of treatments within covariate groups.3. Develop and evaluate algorithms and software for deriving optimal patient rules using machine learning methods.We had several supplemental aims:1. Create new R packages for analysis functions developed for the above-listed aims.2. Develop data-adaptive parameter theoretical statistical framework, providing estimators and methods for deriving inference for a very general category of estimators that rely on data-derived parameters.3. Develop a data-adaptive parameter for variable importance measures.4. Derive method for estimating the variance in treatment effects across covariate groups. METHODS: Our statistical methodology is based on 3 developments: (1) SuperLearning for optimizing prediction, (2) causal structural models to define targeted parameters, and (3) targeted maximum likelihood estimation (TMLE). Research in statistical methodology might be ordered as the following process: parameter (question) Þ theory Þ estimator Þ evaluation in finite samples (simulations) Þ software Þ applied in empirical analyses. For some of our approaches, we started at the end (empirical analysis of existing data) and for others we had to start with a new theoretical framework (eg, data-adaptive parameter estimation). We used the Targeted Learning framework in the methods development and performed limited simulations to examine where the finite sample performance departs from the asymptotic behavior of the estimators. We also employed the estimators on several data sets (Activation of Coagulation and Inflammation in Trauma program, n = 467; Prospective Observational Multicenter Major Trauma Transfusion study, n = 977; Pragmatic, Randomized Optimal Platelet and Plasma Ratios trial, n = 660) as another check for their performance and modifications necessary to handle messy data. RESULTS: Software for each of the goals has been created with corresponding open source R packages available for download. We developed general and parallelizable software for cross-validation (origami) procedures, implementation of data-adaptive development of treatment rules with relevant intervention parameters (opttx), and data-adaptive variable importance measures (varImpact). In addition to using the data analyses to demonstrate the practical performance of these new methods, we also used them to demonstrate the potential for existing, but not widely used, tools for prediction (SuperLearning) and variable importance (TMLE). Finally, we developed and estimated a new parameter related to treatment impact heterogeneity, creating a statistic summarizing the potential for improved health with more precisely tuned treatment regimens. CONCLUSIONS: The results show great promise for incorporating health record data into individualized trauma patient care as well as well as into more generalized trauma care settings. LIMITATIONS: Given that the data collection in the studies used for this research was somewhat incomplete, these algorithms will require modifications in the future to handle densely sampled time-structured data (eg, streaming vital sign data). | True   |
| 520   | PROD       | 3            | $a: BACKGROUND: The revolution in digitizing medical data, along with high throughput biology, has resulted in unprecedented numbers of potential prognostic variables for health outcomes. Recent research suggests that clinical data can be used for continually updated accurate prognostics to optimize medical interventions. We address gaps in methodology available for estimating causal impacts in acute trauma settings using machine learning, and tailor this methodological research to the goals of using complex clinical data to analyze potential outcomes in acute trauma patients. OBJECTIVE: Our primary aims were the following: 1. Develop diagnostic (prediction) scores via SuperLearner for each of the trauma studies. Estimate the relative prediction accuracy of competing algorithms via cross-validation tools, such as cross-validated area under the curve.2. Develop and evaluate variable importance estimators, which can potentially quantify the differentiable impact of treatments within covariate groups.3. Develop and evaluate algorithms and software for deriving optimal patient rules using machine learning methods.We had several supplemental aims:1. Create new R packages for analysis functions developed for the above-listed aims.2. Develop data-adaptive parameter theoretical statistical framework, providing estimators and methods for deriving inference for a very general category of estimators that rely on data-derived parameters.3. Develop a data-adaptive parameter for variable importance measures.4. Derive method for estimating the variance in treatment effects across covariate groups. METHODS: Our statistical methodology is based on 3 developments: (1) SuperLearning for optimizing prediction, (2) causal structural models to define targeted parameters, and (3) targeted maximum likelihood estimation (TMLE). Research in statistical methodology might be ordered as the following process: parameter (question) Þ theory Þ estimator Þ evaluation in finite samples (simulations) Þ software Þ applied in empirical analyses. For some of our approaches, we started at the end (empirical analysis of existing data) and for others we had to start with a new theoretical framework (eg, data-adaptive parameter estimation). We used the Targeted Learning framework in the methods development and performed limited simulations to examine where the finite sample performance departs from the asymptotic behavior of the estimators. We also employed the estimators on several data sets (Activation of Coagulation and Inflammation in Trauma program, n = 467; Prospective Observational Multicenter Major Trauma Transfusion study, n = 977; Pragmatic, Randomized Optimal Platelet and Plasma Ratios trial, n = 660) as another check for their performance and modifications necessary to handle messy data. RESULTS: Software for each of the goals has been created with corresponding open source R packages available for download. We developed general and parallelizable software for cross-validation (origami) procedures, implementation of data-adaptive development of treatment rules with relevant intervention parameters (opttx), and data-adaptive variable importance measures (varImpact). In addition to using the data analyses to demonstrate the practical performance of these new methods, we also used them to demonstrate the potential for existing, but not widely used, tools for prediction (SuperLearning) and variable importance (TMLE). Finally, we developed and estimated a new parameter related to treatment impact heterogeneity, creating a statistic summarizing the potential for improved health with more precisely tuned treatment regimens. CONCLUSIONS: The results show great promise for incorporating health record data into individualized trauma patient care as well as well as into more generalized trauma care settings. LIMITATIONS: Given that the data collection in the studies used for this research was somewhat incomplete, these algorithms will require modifications in the future to handle densely sampled time-structured data (eg, streaming vital sign data). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: Original Project Title: Semiparametric Causal Inference Methods for Adaptive Statistical Learning in Trauma Patient-Centered Outcomes Research PCORI ID: ME-1306-02735; HSRProj ID: 20143598. | True   |
| 536   | PROD       |              | $a: Original Project Title: Semiparametric Causal Inference Methods for Adaptive Statistical Learning in Trauma Patient-Centered Outcomes Research PCORI ID: ME-1306-02735; HSRProj ID: 20143598. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed November 7, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed November 7, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Wounds and Injuries $x: therapy                                             | True   |
| 650   | QA         | 22           | $a: Trauma Centers                                                              | True   |
| 650   | QA         | 22           | $a: Treatment Outcome                                                           | True   |
| 650   | QA         | 22           | $a: Outcome Assessment, Health Care $x: methods                                 | True   |
| 650   | QA         | 22           | $a: Multivariate Analysis                                                       | True   |
| 650   | QA         | 22           | $a: Patient Reported Outcome Measures                                           | True   |
| 650   | PROD       | 12           | $a: Wounds and Injuries $x: therapy                                             | True   |
| 650   | PROD       | 22           | $a: Trauma Centers                                                              | True   |
| 650   | PROD       | 22           | $a: Treatment Outcome                                                           | True   |
| 650   | PROD       | 22           | $a: Outcome Assessment, Health Care $x: methods                                 | True   |
| 650   | PROD       | 22           | $a: Multivariate Analysis                                                       | True   |
| 650   | PROD       | 22           | $a: Patient Reported Outcome Measures                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 655   | QA         |  2           | $a: Statistics                                                                  | True   |
| 655   | PROD       |  2           | $a: Statistics                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 700   | QA         | 1            | $a: Laan, M. J. van der, $e: author.                                            | True   |
| 700   | PROD       | 1            | $a: Laan, M. J. van der, $e: author.                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: Patient-Centered Outcomes Research Institute (U.S.), $e: issuing body.      | True   |
| 710   | PROD       | 2            | $a: Patient-Centered Outcomes Research Institute (U.S.), $e: issuing body.      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: Final research report (Patient-Centered Outcomes Research Institute (U.S.)) | True   |
| 830   | PROD       |  0           | $a: Final research report (Patient-Centered Outcomes Research Institute (U.S.)) | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604852/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604852/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: CAD $b: 20241017                                                            | True   |
| 993   | PROD       |              | $a: CAD $b: 20241017                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241114                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241114                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241115                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241115                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240802                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240802                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918879461006676

Leader:
| File       | Leader                   | Equal  |
| QA         | 03412nam a2200517 i 4500 | True   |
| PROD       | 03412nam a2200517 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918879461006676                                                                | True   |
| 001   | PROD       |              | 9918879461006676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241108101918.0                                                                | True   |
| 005   | PROD       |              | 20241108101918.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240802s2023    dcuab   ob   f000|0 eng                                          | True   |
| 008   | PROD       |              | 240802s2023    dcuab   ob   f000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918879461006676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK604809                                                      | True   |
| 035   | PROD       |              | $9: 9918879461006676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK604809                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WA 546 AA1                                                                  | True   |
| 060   | PROD       | 00           | $a: WA 546 AA1                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Breslau, Joshua, $e: author.                                                | True   |
| 100   | PROD       | 1            | $a: Breslau, Joshua, $e: author.                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Community care hubs : $b: a promising model for health and social care coordination / $c: Joshua Breslau, Petra W. Rasmussen, Nabeel Qureshi and Evan D. Peet. | True   |
| 245   | PROD       | 10           | $a: Community care hubs : $b: a promising model for health and social care coordination / $c: Joshua Breslau, Petra W. Rasmussen, Nabeel Qureshi and Evan D. Peet. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 246   | QA         | 1            | $a: Approaches to coordination of health and social care : $b: an overview of backbone organizations and key takeaways from case studies of community care hubs | True   |
| 246   | PROD       | 1            | $a: Approaches to coordination of health and social care : $b: an overview of backbone organizations and key takeaways from case studies of community care hubs | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington (DC) : $b: The Office of the Assistant Secretary for Planning and Evaluation (ASPE) and the Administration for Community Living (ACL) at the U.S. Department of Health & Human Services, $c: November 2023. | True   |
| 264   | PROD       |  1           | $a: Washington (DC) : $b: The Office of the Assistant Secretary for Planning and Evaluation (ASPE) and the Administration for Community Living (ACL) at the U.S. Department of Health & Human Services, $c: November 2023. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (xiv, 76 pages)) : $b: illustrations, map     | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (xiv, 76 pages)) : $b: illustrations, map     | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 500   | QA         |              | $a: At head of title: HHS strategic approach to addressing social determinants of health to advance health equity. | True   |
| 500   | PROD       |              | $a: At head of title: HHS strategic approach to addressing social determinants of health to advance health equity. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: ASPE, in partnership with the Administration for Community Living, commissioned the RAND Corporation to better understand existing approaches to coordinating health and social care services through backbone organizations, with a focus on one particular model, community care hubs (Hubs). This project sought to gain insights into the various forms of backbone organizations that exist in the field, and to gain a deeper understanding of Hubs, including their structures, approaches to community input, partners, information technology infrastructure, and financing sources, as well as any policy changes identified by specific Hubs included in the report that would enhance their ability to operate successfully. As community-focused entities that support a network of community-based organizations in contracting with health care entities to provide services to address social needs that can affect health outcomes, Hubs can serve as the connective tissue within a community to ensure individuals' social needs are met, which can also contribute to improved health outcomes. | True   |
| 520   | PROD       | 3            | $a: ASPE, in partnership with the Administration for Community Living, commissioned the RAND Corporation to better understand existing approaches to coordinating health and social care services through backbone organizations, with a focus on one particular model, community care hubs (Hubs). This project sought to gain insights into the various forms of backbone organizations that exist in the field, and to gain a deeper understanding of Hubs, including their structures, approaches to community input, partners, information technology infrastructure, and financing sources, as well as any policy changes identified by specific Hubs included in the report that would enhance their ability to operate successfully. As community-focused entities that support a network of community-based organizations in contracting with health care entities to provide services to address social needs that can affect health outcomes, Hubs can serve as the connective tissue within a community to ensure individuals' social needs are met, which can also contribute to improved health outcomes. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed November 7, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed November 7, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Community Health Centers                                                    | True   |
| 650   | QA         | 22           | $a: Community Health Services                                                   | True   |
| 650   | QA         | 22           | $a: Models, Organizational                                                      | True   |
| 650   | PROD       | 12           | $a: Community Health Centers                                                    | True   |
| 650   | PROD       | 22           | $a: Community Health Services                                                   | True   |
| 650   | PROD       | 22           | $a: Models, Organizational                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 651   | QA         |  2           | $a: United States                                                               | True   |
| 651   | PROD       |  2           | $a: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 700   | QA         | 1            | $a: Rasmussen, Petra W., $e: author.                                            | True   |
| 700   | QA         | 1            | $a: Qureshi, Nabeel Shariq, $e: author.                                         | True   |
| 700   | QA         | 1            | $a: Peet, Evan D., $e: author.                                                  | True   |
| 700   | PROD       | 1            | $a: Rasmussen, Petra W., $e: author.                                            | True   |
| 700   | PROD       | 1            | $a: Qureshi, Nabeel Shariq, $e: author.                                         | True   |
| 700   | PROD       | 1            | $a: Peet, Evan D., $e: author.                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: RAND Health Care, $e: issuing body.                                         | True   |
| 710   | QA         | 1            | $a: United States. $b: Department of Health and Human Services. $b: Office of the Assistant Secretary for Planning and Evaluation, $e: sponsoring body. | True   |
| 710   | QA         | 1            | $a: United States. $b: Administration for Community Living, $e: sponsoring body. | True   |
| 710   | PROD       | 2            | $a: RAND Health Care, $e: issuing body.                                         | True   |
| 710   | PROD       | 1            | $a: United States. $b: Department of Health and Human Services. $b: Office of the Assistant Secretary for Planning and Evaluation, $e: sponsoring body. | True   |
| 710   | PROD       | 1            | $a: United States. $b: Administration for Community Living, $e: sponsoring body. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604809/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604809/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: IHH $b: 20241107                                                            | True   |
| 993   | PROD       |              | $a: IHH $b: 20241107                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241107                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241107                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241108                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241108                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240802                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240802                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918879465206676

Leader:
| File       | Leader                   | Equal  |
| QA         | 04951nam a2200577 i 4500 | True   |
| PROD       | 04951nam a2200577 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918879465206676                                                                | True   |
| 001   | PROD       |              | 9918879465206676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241105114924.0                                                                | True   |
| 005   | PROD       |              | 20241105114924.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240802s2024    dcua    ob    100|0 eng                                          | True   |
| 008   | PROD       |              | 240802s2024    dcua    ob    100|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 020   | QA         |              | $z: 9780309718561                                                               | True   |
| 020   | QA         |              | $z: 0309718562                                                                  | True   |
| 020   | PROD       |              | $z: 9780309718561                                                               | True   |
| 020   | PROD       |              | $z: 0309718562                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918879465206676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK603777                                                      | True   |
| 035   | PROD       |              | $9: 9918879465206676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK603777                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: QV 21                                                                       | True   |
| 060   | PROD       | 00           | $a: QV 21                                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Forstag, Erin Hammers, $e: rapporteur.                                      | True   |
| 100   | PROD       | 1            | $a: Forstag, Erin Hammers, $e: rapporteur.                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Preparing the future workforce in drug research and development : $b: proceedings of a workshop / $c: Erin Hammers Forstag, Noah Ontjes, Carolyn Shore, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Board on Population Health and Public Health Practice, Health and Medicine Division, Roundtable on Black Men and Black Women in Science, Engineering and Medicine, U.S. Science and Innovation Policy, Policy and Global Affairs. | True   |
| 245   | PROD       | 10           | $a: Preparing the future workforce in drug research and development : $b: proceedings of a workshop / $c: Erin Hammers Forstag, Noah Ontjes, Carolyn Shore, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Board on Population Health and Public Health Practice, Health and Medicine Division, Roundtable on Black Men and Black Women in Science, Engineering and Medicine, U.S. Science and Innovation Policy, Policy and Global Affairs. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington, DC : $b: National Academies Press, $c: [2024]                   | True   |
| 264   | PROD       |  1           | $a: Washington, DC : $b: National Academies Press, $c: [2024]                   | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (xx, 119 pages)) : $b: illustrations          | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (xx, 119 pages)) : $b: illustrations          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: Despite advances over the past several decades, the clinical trials enterprise has struggled to meet the needs of an increasingly diverse U.S. population. To help address this issue, a 2023 National Academies workshop sought to identify the expertise and disciplines needed to achieve the aspirations for a transformed clinical trials enterprise by 2030 and enable a workforce that can better support the evolving needs of drug R&D - one that is resilient, culturally aware, anti-racist, and interdisciplinary. The workshop, hosted by the Forum on Drug Discovery, Development, and Translation and Roundtable on Black Men and Black Women in Science, Engineering, and Medicine explored strategies to bolster workforce capacity and challenges and opportunities associated with supporting the next-generation drug R&D workforce. | True   |
| 520   | PROD       | 3            | $a: Despite advances over the past several decades, the clinical trials enterprise has struggled to meet the needs of an increasingly diverse U.S. population. To help address this issue, a 2023 National Academies workshop sought to identify the expertise and disciplines needed to achieve the aspirations for a transformed clinical trials enterprise by 2030 and enable a workforce that can better support the evolving needs of drug R&D - one that is resilient, culturally aware, anti-racist, and interdisciplinary. The workshop, hosted by the Forum on Drug Discovery, Development, and Translation and Roundtable on Black Men and Black Women in Science, Engineering, and Medicine explored strategies to bolster workforce capacity and challenges and opportunities associated with supporting the next-generation drug R&D workforce. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 530   | QA         |              | $a: Issued also in print.                                                       | True   |
| 530   | PROD       |              | $a: Issued also in print.                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: This activity was supported by contracts between the National Academy of Sciences and Aetna Foundation (Contract No. 18-8876); Amgen Inc.; Association of American Medical Colleges; AstraZeneca; Biogen; Burroughs Wellcome Fund (Contract No. 1023129); Chan Zuckerberg Initiative; Critical Path Institute; Eli Lilly and Company; FasterCures, Milken Institute; Foundation for the National Institutes of Health; Friends of Cancer Research; Johnson & Johnson; Medable Inc.; Merck & Co., Inc. (Award No. MRLCPO-23-166623); National Research Council President's Circle Fund; National Institutes of Health (Contract No. HHSN263201800029I; Task Order No. HHSN26300007, 75N98021F00006): National Cancer Institute, National Center for Advancing Translational Sciences, National Institute of Allergy and Infectious Diseases, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, Office of the Director; New England Journal of Medicine; Robert Woods Johnson Foundation; Sanofi (Contract No. 77646387); Takeda; The University of Pittsburgh; U.S. Food and Drug Administration (Contract No. 1R13FD007302-01); W.K. Kellogg Foundation. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. | True   |
| 536   | PROD       |              | $a: This activity was supported by contracts between the National Academy of Sciences and Aetna Foundation (Contract No. 18-8876); Amgen Inc.; Association of American Medical Colleges; AstraZeneca; Biogen; Burroughs Wellcome Fund (Contract No. 1023129); Chan Zuckerberg Initiative; Critical Path Institute; Eli Lilly and Company; FasterCures, Milken Institute; Foundation for the National Institutes of Health; Friends of Cancer Research; Johnson & Johnson; Medable Inc.; Merck & Co., Inc. (Award No. MRLCPO-23-166623); National Research Council President's Circle Fund; National Institutes of Health (Contract No. HHSN263201800029I; Task Order No. HHSN26300007, 75N98021F00006): National Cancer Institute, National Center for Advancing Translational Sciences, National Institute of Allergy and Infectious Diseases, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, Office of the Director; New England Journal of Medicine; Robert Woods Johnson Foundation; Sanofi (Contract No. 77646387); Takeda; The University of Pittsburgh; U.S. Food and Drug Administration (Contract No. 1R13FD007302-01); W.K. Kellogg Foundation. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed November 1, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed November 1, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Pharmaceutical Research                                                     | True   |
| 650   | QA         | 12           | $a: Drug Development                                                            | True   |
| 650   | QA         | 22           | $a: Research Personnel                                                          | True   |
| 650   | QA         | 22           | $a: Workforce Diversity                                                         | True   |
| 650   | PROD       | 12           | $a: Pharmaceutical Research                                                     | True   |
| 650   | PROD       | 12           | $a: Drug Development                                                            | True   |
| 650   | PROD       | 22           | $a: Research Personnel                                                          | True   |
| 650   | PROD       | 22           | $a: Workforce Diversity                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 651   | QA         |  2           | $a: United States                                                               | True   |
| 651   | PROD       |  2           | $a: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 655   | QA         |  2           | $a: Congress                                                                    | True   |
| 655   | PROD       |  2           | $a: Congress                                                                    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 700   | QA         | 1            | $a: Ontjes, Noah, $e: rapporteur.                                               | True   |
| 700   | QA         | 1            | $a: Shore, Carolyn, $e: rapporteur.                                             | True   |
| 700   | PROD       | 1            | $a: Ontjes, Noah, $e: rapporteur.                                               | True   |
| 700   | PROD       | 1            | $a: Shore, Carolyn, $e: rapporteur.                                             | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Forum on Drug Discovery, Development, and Translation, $e: issuing body, $e: host institution. | True   |
| 710   | QA         | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Board on Population Health and Public Health Practice, $e: issuing body. | True   |
| 710   | QA         | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Roundtable on Black Men and Black Women in Science, Engineering, and Medicine, $e: issuing body. | True   |
| 710   | QA         | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: U.S. Science and Innovation Policy, $e: issuing body. | True   |
| 710   | PROD       | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Forum on Drug Discovery, Development, and Translation, $e: issuing body, $e: host institution. | True   |
| 710   | PROD       | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Board on Population Health and Public Health Practice, $e: issuing body. | True   |
| 710   | PROD       | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Roundtable on Black Men and Black Women in Science, Engineering, and Medicine, $e: issuing body. | True   |
| 710   | PROD       | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: U.S. Science and Innovation Policy, $e: issuing body. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 711   | QA         | 2            | $a: Preparing the Future Workforce in Drug Research & Development (Workshop) $d: (2023 : $c: Washington, D.C.) | True   |
| 711   | PROD       | 2            | $a: Preparing the Future Workforce in Drug Research & Development (Workshop) $d: (2023 : $c: Washington, D.C.) | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK603777/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK603777/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: CAD $b: 20241017                                                            | True   |
| 993   | PROD       |              | $a: CAD $b: 20241017                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241101                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241101                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241105                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241105                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240802                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240802                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918879458006676

Leader:
| File       | Leader                   | Equal  |
| QA         | 05929nam a2200517 i 4500 | True   |
| PROD       | 05929nam a2200517 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918879458006676                                                                | True   |
| 001   | PROD       |              | 9918879458006676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241118162854.0                                                                | True   |
| 005   | PROD       |              | 20241118162854.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240802s2019    dcua    obs   000|0 eng                                          | True   |
| 008   | PROD       |              | 240802s2019    dcua    obs   000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918879458006676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK605033                                                      | True   |
| 035   | PROD       |              | $9: 9918879458006676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK605033                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WG 16.1                                                                     | True   |
| 060   | PROD       | 00           | $a: WG 16.1                                                                     | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Pekmezaris, Renee, $e: author.                                              | True   |
| 100   | PROD       | 1            | $a: Pekmezaris, Renee, $e: author.                                              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Comparing two methods of caring for Black and Hispanic adults with heart failure after they leave the hospital / $c: Renee Pekmezaris, Christian N. Nouryan, Rebecca Schwartz, Stacy Castillo, Amgad N. Makaryus, Deborah Ahern, Meredith B. Akerman, Martin L. Lesser, Lorinda Bauer, Lawrence Murray, Kathleen Pecinka, Roman Zeltser, Paola DiMarzio. | True   |
| 245   | PROD       | 10           | $a: Comparing two methods of caring for Black and Hispanic adults with heart failure after they leave the hospital / $c: Renee Pekmezaris, Christian N. Nouryan, Rebecca Schwartz, Stacy Castillo, Amgad N. Makaryus, Deborah Ahern, Meredith B. Akerman, Martin L. Lesser, Lorinda Bauer, Lawrence Murray, Kathleen Pecinka, Roman Zeltser, Paola DiMarzio. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: [Washington, DC] : $b: PCORI, Patient-Centered Outcomes Research Institute, $c: [2019] | True   |
| 264   | PROD       |  1           | $a: [Washington, DC] : $b: PCORI, Patient-Centered Outcomes Research Institute, $c: [2019] | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (55 pages)) : $b: illustrations.              | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (55 pages)) : $b: illustrations.              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Final research report                                                       | True   |
| 490   | PROD       | 1            | $a: Final research report                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: BACKGROUND: In the United States, Black and Hispanic populations experience a high prevalence of heart failure (HF). To address this disparity, we sought to compare health care utilization and quality of life (QOL) for Black and Hispanic patients admitted to a "safety net" hospital for HF. Patients were randomly assigned to receive a telehealth self-monitoring (TSM) intervention or comprehensive outpatient management (COM). OBJECTIVES: 1. Aim 1: To assess usability and adapt TSM to facilitate acceptability and feasibility in a population of underserved Black and Hispanic patients.2. Aim 2: To compare inpatient and emergency department (ED) utilization and QOL of underserved patients with HF randomized at discharge to TSM or COM. METHODS: We used a mixed-methods approach, including a randomized controlled trial (RCT), to assess TSM usability and effectiveness. Medical history, hospital utilization, demographics, depression, anxiety, and QOL were recorded at days 1 and 90. TSM patients transmitted their vital signs daily and attended a weekly video visit. We analyzed binary outcomes for ED visits and hospitalizations using the standard chi-square or Fisher exact test. We also used Poisson or negative binomial regression, repeated-measures analysis of variance, or generalized estimating equations (GEEs) as appropriate. We based the choice of Poisson, overdispersed Poisson, or negative binomial on standard goodness-of-fit statistics (the deviance statistic). We computed associated 95% CIs for these proportions and their differences using exact methods. RESULTS: 1. Aim 1: We used the ADAPT-ITT framework (Assessment, Decisions, Administration, Production, Topical experts, Integration, Training staff, and Testing) to tailor the TSM intervention. The adaptation, based on data from 3 focus groups, theater testing, and a small pilot study, resulted in an acceptable and feasible intervention for the target patient population.2. Aim 2: Of the 104 patients randomized, 31% were Hispanic, 69% Black, and 41% female. Overall, 72% of patients reported incomes of <$10 000/year. Intention-to-treat (ITT) analyses revealed no significant utilization differences between TSM and COM groups for (1 or more) all-cause ED visits (relative risk [RR], 1.37; 95% CI, 0.83-2.27) or hospitalizations (RR, 0.92; 95% CI, 0.57-1.48) and mean length of stay (TSM: 5.2 vs COM: 3.6 days) within 90 days of discharge. The average number of all-cause hospitalizations greater than 90 days was significantly lower for COM patients (TSM = 0.78 vs COM = 0.55; P = .03). Finally, while QOL improved for both groups over time (TSM baseline = 62.7; 90-day = 36.3; COM baseline = 59.2; 90-day = 27.8; P = .5), COM patients reported a greater reduction of anxiety (TSM baseline = 50%; 90-day = 28%; COM baseline = 57%; 90-day = 13%; P = .05). TSM adherence was low: 50% of participants provided <10 transmittals of vital signs during the 90-day period. CONCLUSIONS: While the ADAPT-ITT framework was successfully utilized to tailor a TSM intervention for patients with HF from Black and Hispanic low-income communities, TSM was not associated with reduced all-cause 90-day ED and inpatient utilization. The mean number of all-cause hospitalizations was significantly lower for the COM group. QOL and depression did not differ between the 2 groups, while COM patients reported a greater reduction of anxiety over time. LIMITATIONS AND SUBPOPULATION CONSIDERATIONS: This single-center study may not be generalizable to other underserved patients with HF. Future studies should address methods to improve compliance to improve TSM treatment effect size on all-cause- and HF-related utilization outcomes. | True   |
| 520   | PROD       | 3            | $a: BACKGROUND: In the United States, Black and Hispanic populations experience a high prevalence of heart failure (HF). To address this disparity, we sought to compare health care utilization and quality of life (QOL) for Black and Hispanic patients admitted to a "safety net" hospital for HF. Patients were randomly assigned to receive a telehealth self-monitoring (TSM) intervention or comprehensive outpatient management (COM). OBJECTIVES: 1. Aim 1: To assess usability and adapt TSM to facilitate acceptability and feasibility in a population of underserved Black and Hispanic patients.2. Aim 2: To compare inpatient and emergency department (ED) utilization and QOL of underserved patients with HF randomized at discharge to TSM or COM. METHODS: We used a mixed-methods approach, including a randomized controlled trial (RCT), to assess TSM usability and effectiveness. Medical history, hospital utilization, demographics, depression, anxiety, and QOL were recorded at days 1 and 90. TSM patients transmitted their vital signs daily and attended a weekly video visit. We analyzed binary outcomes for ED visits and hospitalizations using the standard chi-square or Fisher exact test. We also used Poisson or negative binomial regression, repeated-measures analysis of variance, or generalized estimating equations (GEEs) as appropriate. We based the choice of Poisson, overdispersed Poisson, or negative binomial on standard goodness-of-fit statistics (the deviance statistic). We computed associated 95% CIs for these proportions and their differences using exact methods. RESULTS: 1. Aim 1: We used the ADAPT-ITT framework (Assessment, Decisions, Administration, Production, Topical experts, Integration, Training staff, and Testing) to tailor the TSM intervention. The adaptation, based on data from 3 focus groups, theater testing, and a small pilot study, resulted in an acceptable and feasible intervention for the target patient population.2. Aim 2: Of the 104 patients randomized, 31% were Hispanic, 69% Black, and 41% female. Overall, 72% of patients reported incomes of <$10 000/year. Intention-to-treat (ITT) analyses revealed no significant utilization differences between TSM and COM groups for (1 or more) all-cause ED visits (relative risk [RR], 1.37; 95% CI, 0.83-2.27) or hospitalizations (RR, 0.92; 95% CI, 0.57-1.48) and mean length of stay (TSM: 5.2 vs COM: 3.6 days) within 90 days of discharge. The average number of all-cause hospitalizations greater than 90 days was significantly lower for COM patients (TSM = 0.78 vs COM = 0.55; P = .03). Finally, while QOL improved for both groups over time (TSM baseline = 62.7; 90-day = 36.3; COM baseline = 59.2; 90-day = 27.8; P = .5), COM patients reported a greater reduction of anxiety (TSM baseline = 50%; 90-day = 28%; COM baseline = 57%; 90-day = 13%; P = .05). TSM adherence was low: 50% of participants provided <10 transmittals of vital signs during the 90-day period. CONCLUSIONS: While the ADAPT-ITT framework was successfully utilized to tailor a TSM intervention for patients with HF from Black and Hispanic low-income communities, TSM was not associated with reduced all-cause 90-day ED and inpatient utilization. The mean number of all-cause hospitalizations was significantly lower for the COM group. QOL and depression did not differ between the 2 groups, while COM patients reported a greater reduction of anxiety over time. LIMITATIONS AND SUBPOPULATION CONSIDERATIONS: This single-center study may not be generalizable to other underserved patients with HF. Future studies should address methods to improve compliance to improve TSM treatment effect size on all-cause- and HF-related utilization outcomes. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: Original Project Title: Telehealth Self-management Program in Older Adults Living With Heart Failure in Health Disparity Communities PCORI ID: AD-1304-6294 ClinicalTrials.gov ID: NCT02196922 | True   |
| 536   | PROD       |              | $a: Original Project Title: Telehealth Self-management Program in Older Adults Living With Heart Failure in Health Disparity Communities PCORI ID: AD-1304-6294 ClinicalTrials.gov ID: NCT02196922 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed November 7, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed November 7, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Heart Failure $x: therapy                                                   | True   |
| 650   | QA         | 22           | $a: Black or African American                                                   | True   |
| 650   | QA         | 22           | $a: Hispanics or Latino                                                         | True   |
| 650   | QA         | 22           | $a: Ambulatory Care $x: methods                                                 | True   |
| 650   | QA         | 22           | $a: Network Meta-Analysis                                                       | True   |
| 650   | QA         | 22           | $a: Patient Reported Outcome Measures                                           | True   |
| 650   | PROD       | 12           | $a: Heart Failure $x: therapy                                                   | True   |
| 650   | PROD       | 22           | $a: Black or African American                                                   | True   |
| 650   | PROD       | 22           | $a: Hispanics or Latino                                                         | True   |
| 650   | PROD       | 22           | $a: Ambulatory Care $x: methods                                                 | True   |
| 650   | PROD       | 22           | $a: Network Meta-Analysis                                                       | True   |
| 650   | PROD       | 22           | $a: Patient Reported Outcome Measures                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 651   | QA         |  2           | $a: United States                                                               | True   |
| 651   | PROD       |  2           | $a: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 655   | QA         |  2           | $a: Statistics                                                                  | True   |
| 655   | PROD       |  2           | $a: Statistics                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: Patient-Centered Outcomes Research Institute (U.S.), $e: issuing body.      | True   |
| 710   | PROD       | 2            | $a: Patient-Centered Outcomes Research Institute (U.S.), $e: issuing body.      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: Final research report (Patient-Centered Outcomes Research Institute (U.S.)) | True   |
| 830   | PROD       |  0           | $a: Final research report (Patient-Centered Outcomes Research Institute (U.S.)) | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK605033/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK605033/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: CAD $b: 20241017                                                            | True   |
| 993   | PROD       |              | $a: CAD $b: 20241017                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241118                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241118                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241118                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241118                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240802                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240802                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918879465106676

Leader:
| File       | Leader                   | Equal  |
| QA         | 03263nam a2200529 i 4500 | True   |
| PROD       | 03263nam a2200529 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918879465106676                                                                | True   |
| 001   | PROD       |              | 9918879465106676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241113094314.0                                                                | True   |
| 005   | PROD       |              | 20241113094314.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240802s2023    dcua    ob   f000|0 eng                                          | True   |
| 008   | PROD       |              | 240802s2023    dcua    ob   f000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918879465106676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK605135                                                      | True   |
| 035   | PROD       |              | $9: 9918879465106676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK605135                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: W 84.4 AA1                                                                  | True   |
| 060   | PROD       | 00           | $a: W 84.4 AA1                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Evans, Emily $c: (Health scientist administrator), $e: author.              | True   |
| 100   | PROD       | 1            | $a: Evans, Emily $c: (Health scientist administrator), $e: author.              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Understanding the impacts of OS-PCORTF projects on data capacity : $b: an interim qualitative assessment / $c: prepared for The Office of the Assistant Secretary for Planning and Evaluation (ASPE) at the U.S. Department of Health and Human Services ; by NORC at the University of Chicago ; contributing authors, Emily Evans, Mithuna Srinivasan, Correa Kiran, Sofia Ryan, Mikaela Harmsen, Susan Lumsden, Prashila Dullabh. | True   |
| 245   | PROD       | 10           | $a: Understanding the impacts of OS-PCORTF projects on data capacity : $b: an interim qualitative assessment / $c: prepared for The Office of the Assistant Secretary for Planning and Evaluation (ASPE) at the U.S. Department of Health and Human Services ; by NORC at the University of Chicago ; contributing authors, Emily Evans, Mithuna Srinivasan, Correa Kiran, Sofia Ryan, Mikaela Harmsen, Susan Lumsden, Prashila Dullabh. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: [Washington, D.C.] : $b: Office of the Assistant Secretary for Planning and Evaluation, $c: September 2023. | True   |
| 264   | PROD       |  1           | $a: [Washington, D.C.] : $b: Office of the Assistant Secretary for Planning and Evaluation, $c: September 2023. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (iii, 21 pages)) : $b: illustration           | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (iii, 21 pages)) : $b: illustration           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 500   | QA         |              | $a: At head of title: Report.                                                   | True   |
| 500   | PROD       |              | $a: At head of title: Report.                                                   | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: This report presents findings from an interim qualitative assessment that examined the ways in which OS-PCORTF projects collectively advanced the ability of researchers to conduct patient-centered outcomes research (PCOR) by (1) improving the quality of data; (2) providing more relevant, comprehensive data; (3) enhancing analytical resources; and (4) reducing barriers to data access and use. | True   |
| 520   | PROD       | 3            | $a: This report presents findings from an interim qualitative assessment that examined the ways in which OS-PCORTF projects collectively advanced the ability of researchers to conduct patient-centered outcomes research (PCOR) by (1) improving the quality of data; (2) providing more relevant, comprehensive data; (3) enhancing analytical resources; and (4) reducing barriers to data access and use. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: This report was funded by the Office of the Secretary Patient-Centered Outcomes Research Trust Fund (OS-PCORTF) under Contract Number HHSP233201500048II of the HHS Office of the Assistant Secretary for Planning and Evaluation (ASPE). The work was carried out by NORC at the University of Chicago and ASPE. The authors are solely responsible for this document's contents, findings, and conclusions, which do not necessarily represent the views of HHS, ASPE, or NORC. Readers should not interpret any statement in this product as an official position of ASPE or of HHS. | True   |
| 536   | PROD       |              | $a: This report was funded by the Office of the Secretary Patient-Centered Outcomes Research Trust Fund (OS-PCORTF) under Contract Number HHSP233201500048II of the HHS Office of the Assistant Secretary for Planning and Evaluation (ASPE). The work was carried out by NORC at the University of Chicago and ASPE. The authors are solely responsible for this document's contents, findings, and conclusions, which do not necessarily represent the views of HHS, ASPE, or NORC. Readers should not interpret any statement in this product as an official position of ASPE or of HHS. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed Nov. 7, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed Nov. 7, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 610   | QA         | 12           | $a: United States. $b: Department of Health and Human Services. $b: Patient-Centered Outcomes Research Trust Fund | True   |
| 610   | PROD       | 12           | $a: United States. $b: Department of Health and Human Services. $b: Patient-Centered Outcomes Research Trust Fund | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Patient Outcome Assessment                                                  | True   |
| 650   | QA         | 22           | $a: Data Collection                                                             | True   |
| 650   | QA         | 22           | $a: Financing, Government                                                       | True   |
| 650   | QA         | 22           | $a: Federal Government                                                          | True   |
| 650   | PROD       | 12           | $a: Patient Outcome Assessment                                                  | True   |
| 650   | PROD       | 22           | $a: Data Collection                                                             | True   |
| 650   | PROD       | 22           | $a: Financing, Government                                                       | True   |
| 650   | PROD       | 22           | $a: Federal Government                                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 651   | QA         |  2           | $a: United States                                                               | True   |
| 651   | PROD       |  2           | $a: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: NORC (Organization), $e: issuing body.                                      | True   |
| 710   | QA         | 1            | $a: United States. $b: Department of Health and Human Services. $b: Office of the Assistant Secretary for Planning and Evaluation, $e: issuing body. | True   |
| 710   | PROD       | 2            | $a: NORC (Organization), $e: issuing body.                                      | True   |
| 710   | PROD       | 1            | $a: United States. $b: Department of Health and Human Services. $b: Office of the Assistant Secretary for Planning and Evaluation, $e: issuing body. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK605135/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK605135/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: IHH $b: 20241107                                                            | True   |
| 993   | PROD       |              | $a: IHH $b: 20241107                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241107                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241107                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241113                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241113                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: HSRREL $b: 20240129                                                         | True   |
| 998   | QA         |              | $a: DREPTEXT $b: 20240412                                                       | True   |
| 998   | QA         |              | $a: DREPHSR $b: 20240412                                                        | True   |
| 998   | QA         |              | $a: BKSHLF $b: 20240802                                                         | True   |
| 998   | PROD       |              | $a: HSRREL $b: 20240129                                                         | True   |
| 998   | PROD       |              | $a: DREPTEXT $b: 20240412                                                       | True   |
| 998   | PROD       |              | $a: DREPHSR $b: 20240412                                                        | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240802                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918879458606676

Leader:
| File       | Leader                   | Equal  |
| QA         | 04238nam a2200445 i 4500 | True   |
| PROD       | 04238nam a2200445 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918879458606676                                                                | True   |
| 001   | PROD       |              | 9918879458606676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241017154847.0                                                                | True   |
| 005   | PROD       |              | 20241017154847.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240802s2024    sz a    ob   i000|0 eng                                          | True   |
| 008   | PROD       |              | 240802s2024    sz a    ob   i000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 020   | QA         |              | $a: 9789240096035 (electronic version)                                          | True   |
| 020   | QA         |              | $z: 9789240096042 (print version)                                               | True   |
| 020   | PROD       |              | $a: 9789240096035 (electronic version)                                          | True   |
| 020   | PROD       |              | $z: 9789240096042 (print version)                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918879458606676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK604893                                                      | True   |
| 035   | QA         |              | $a: (OCoLC)1463504105                                                           | True   |
| 035   | PROD       |              | $9: 9918879458606676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK604893                                                      | True   |
| 035   | PROD       |              | $a: (OCoLC)1463504105                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: Switzerland                                                                 | True   |
| 044   | PROD       |              | $9: Switzerland                                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WC 705                                                                      | True   |
| 060   | PROD       | 00           | $a: WC 705                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 110   | QA         | 2            | $a: World Health Organization. $b: Global Neglected Tropical Diseases Programme, $e: author, $e: issuing body. | True   |
| 110   | PROD       | 2            | $a: World Health Organization. $b: Global Neglected Tropical Diseases Programme, $e: author, $e: issuing body. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Guidelines for the treatment of human African trypanosomiasis.              | True   |
| 245   | PROD       | 10           | $a: Guidelines for the treatment of human African trypanosomiasis.              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Geneva,Switzerland : $b: World Health Organization, $c: June 2024.          | True   |
| 264   | PROD       |  1           | $a: Geneva,Switzerland : $b: World Health Organization, $c: June 2024.          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (xi, 34 pages)) : $b: illustrations           | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (xi, 34 pages)) : $b: illustrations           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: Human African trypanosomiasis (HAT), or sleeping sickness, is a parasitic infection that is endemic in sub-Saharan Africa and is almost invariably fatal unless treated. The infection is transmitted to humans through the bite of an infected tsetse fly. The parasite multiplies in the lymph and blood, causing unspecific symptoms and signs (first-stage or haemo-lymphatic stage) and, over time, crosses the blood-brain barrier to infect the central nervous system (second-stage or meningo-encephalitic stage). Brain involvement causes various neurological disturbances, including sleep disorders (hence the name "sleeping sickness"), progression to coma and, ultimately, death. The disease has two forms: the slowly progressing form (gambiense HAT), caused by infection with Trypanosoma brucei gambiense, found in western and central Africa (92% of cases in 2018-2022); and the more rapidly progressive form (rhodesiense HAT), caused by infection with T. b. rhodesiense, in eastern and southern Africa (responsible for the remainder of cases). All age groups and both sexes are at risk of both forms of HAT, although prevalence is higher in adults than in children. The incidence of the disease has strongly declined in response to intensive surveillance and control interventions in endemic areas. As a result, HAT is among the neglected tropical diseases targeted for elimination by the World Health Organization (WHO). The remarkable progress in the control of gambiense HAT has relied on case-finding and curative treatment, which interrupts transmission by depleting the reservoir of parasites in humans. This has been combined in some areas with vector control activities. In contrast to gambiense HAT, treatment of rhodesiense HAT patients has little impact on disease transmission, but it is certainly life-saving. The WHO interim guidelines for the treatment of gambiense HAT, issued in 2019 added as a therapeutic option the new medicine fexinidazole. Thanks to its recent extension of indication, fexinidazole is now also recommended for treatment of rhodesiense HAT. The present guidelines incorporate all these changes, leading to a substantial reconfiguration of therapeutic choices for both disease forms. HAT is a serious, life-threatening disease and the efficacy of fexinidazole depends on swallowing the medicine after an appropriate intake of food as well as on completing the full 10-day treatment schedule. Therefore, the recommendations regarding fexinidazole administration are considered key elements that must be carefully followed. When the conditions listed in these guidelines are not met for any individual patient, the alternative available treatments should be prescribed. | True   |
| 520   | PROD       | 3            | $a: Human African trypanosomiasis (HAT), or sleeping sickness, is a parasitic infection that is endemic in sub-Saharan Africa and is almost invariably fatal unless treated. The infection is transmitted to humans through the bite of an infected tsetse fly. The parasite multiplies in the lymph and blood, causing unspecific symptoms and signs (first-stage or haemo-lymphatic stage) and, over time, crosses the blood-brain barrier to infect the central nervous system (second-stage or meningo-encephalitic stage). Brain involvement causes various neurological disturbances, including sleep disorders (hence the name "sleeping sickness"), progression to coma and, ultimately, death. The disease has two forms: the slowly progressing form (gambiense HAT), caused by infection with Trypanosoma brucei gambiense, found in western and central Africa (92% of cases in 2018-2022); and the more rapidly progressive form (rhodesiense HAT), caused by infection with T. b. rhodesiense, in eastern and southern Africa (responsible for the remainder of cases). All age groups and both sexes are at risk of both forms of HAT, although prevalence is higher in adults than in children. The incidence of the disease has strongly declined in response to intensive surveillance and control interventions in endemic areas. As a result, HAT is among the neglected tropical diseases targeted for elimination by the World Health Organization (WHO). The remarkable progress in the control of gambiense HAT has relied on case-finding and curative treatment, which interrupts transmission by depleting the reservoir of parasites in humans. This has been combined in some areas with vector control activities. In contrast to gambiense HAT, treatment of rhodesiense HAT patients has little impact on disease transmission, but it is certainly life-saving. The WHO interim guidelines for the treatment of gambiense HAT, issued in 2019 added as a therapeutic option the new medicine fexinidazole. Thanks to its recent extension of indication, fexinidazole is now also recommended for treatment of rhodesiense HAT. The present guidelines incorporate all these changes, leading to a substantial reconfiguration of therapeutic choices for both disease forms. HAT is a serious, life-threatening disease and the efficacy of fexinidazole depends on swallowing the medicine after an appropriate intake of food as well as on completing the full 10-day treatment schedule. Therefore, the recommendations regarding fexinidazole administration are considered key elements that must be carefully followed. When the conditions listed in these guidelines are not met for any individual patient, the alternative available treatments should be prescribed. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed October 17, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed October 17, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Trypanosomiasis, African $x: therapy                                        | True   |
| 650   | QA         | 22           | $a: Neglected Diseases                                                          | True   |
| 650   | PROD       | 12           | $a: Trypanosomiasis, African $x: therapy                                        | True   |
| 650   | PROD       | 22           | $a: Neglected Diseases                                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 655   | QA         |  2           | $a: Practice Guideline                                                          | True   |
| 655   | PROD       |  2           | $a: Practice Guideline                                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604893/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604893/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: CAD $b: 20241017                                                            | True   |
| 993   | PROD       |              | $a: CAD $b: 20241017                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241017                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241017                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241017                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241017                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240802                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240802                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918879461206676

Leader:
| File       | Leader                   | Equal  |
| QA         | 03126nam a2200505 i 4500 | True   |
| PROD       | 03126nam a2200505 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918879461206676                                                                | True   |
| 001   | PROD       |              | 9918879461206676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241101081103.0                                                                | True   |
| 005   | PROD       |              | 20241101081103.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240802s2022    dcua    ob   f000|0 eng                                          | True   |
| 008   | PROD       |              | 240802s2022    dcua    ob   f000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918879461206676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK604788                                                      | True   |
| 035   | PROD       |              | $9: 9918879461206676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK604788                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: QZ 185                                                                      | True   |
| 060   | PROD       | 00           | $a: QZ 185                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Marcial, Laura Haak, $e: author.                                            | True   |
| 100   | PROD       | 1            | $a: Marcial, Laura Haak, $e: author.                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Implementation of an electronic care plan for people with multiple chronic conditions : $b: final report / $c: Laura Haak Marcial, Sara Armson, Keegan Barnes, Eric Puster, Jeanette Renaud, Jacqueline Bagwell, Djibril Camara, Michelle Bobo, MJ Dunne, Matthew Storer, David Dorr ; prepared for Agency for Healthcare Research and Quality. | True   |
| 245   | PROD       | 10           | $a: Implementation of an electronic care plan for people with multiple chronic conditions : $b: final report / $c: Laura Haak Marcial, Sara Armson, Keegan Barnes, Eric Puster, Jeanette Renaud, Jacqueline Bagwell, Djibril Camara, Michelle Bobo, MJ Dunne, Matthew Storer, David Dorr ; prepared for Agency for Healthcare Research and Quality. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Rockville, MD : $b: AHRQ, Agency for Healthcare Research and Quality, $c: November 2022. | True   |
| 264   | PROD       |  1           | $a: Rockville, MD : $b: AHRQ, Agency for Healthcare Research and Quality, $c: November 2022. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (x, 73 pages)) : $b: illustrations.           | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (x, 73 pages)) : $b: illustrations.           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: AHRQ publication ; $v: 23-0010                                              | True   |
| 490   | PROD       | 1            | $a: AHRQ publication ; $v: 23-0010                                              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: The purpose of this project was to develop and test a suite of electronic Care Plan (eCP) tools for adults with multiple chronic conditions (MCC), including an eCP implementation guide specifying data standards and value sets for key use case conditions and two open-source eCP apps (one for patients and one for clinicians). This joint initiative supported the work to develop and test these apps, which are intended to facilitate aggregation and sharing of critical patient-centered data across home-, community-, clinic-, and research-based settings by extracting data from point-of-care health systems and allowing transfer of those data across settings. | True   |
| 520   | PROD       | 3            | $a: The purpose of this project was to develop and test a suite of electronic Care Plan (eCP) tools for adults with multiple chronic conditions (MCC), including an eCP implementation guide specifying data standards and value sets for key use case conditions and two open-source eCP apps (one for patients and one for clinicians). This joint initiative supported the work to develop and test these apps, which are intended to facilitate aggregation and sharing of critical patient-centered data across home-, community-, clinic-, and research-based settings by extracting data from point-of-care health systems and allowing transfer of those data across settings. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: This project was funded under contract number 75P00120F37004 from the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health and Human Services (HHS). This work was supported by the Office of the Secretary Patient Centered Outcomes Research Trust Fund (OS-PCORTF). The opinions expressed in this document are those of the authors and do not reflect the official position of AHRQ or HHS. | True   |
| 536   | PROD       |              | $a: This project was funded under contract number 75P00120F37004 from the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health and Human Services (HHS). This work was supported by the Office of the Secretary Patient Centered Outcomes Research Trust Fund (OS-PCORTF). The opinions expressed in this document are those of the authors and do not reflect the official position of AHRQ or HHS. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed October 31, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed October 31, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Multiple Chronic Conditions $x: therapy                                     | True   |
| 650   | QA         | 22           | $a: Patient Care Planning $x: organization & administration                     | True   |
| 650   | QA         | 22           | $a: Health Plan Implementation $x: methods                                      | True   |
| 650   | QA         | 22           | $a: Electronic Health Records                                                   | True   |
| 650   | QA         | 22           | $a: Medical Informatics Applications                                            | True   |
| 650   | QA         | 22           | $a: Point-of-Care Systems                                                       | True   |
| 650   | PROD       | 12           | $a: Multiple Chronic Conditions $x: therapy                                     | True   |
| 650   | PROD       | 22           | $a: Patient Care Planning $x: organization & administration                     | True   |
| 650   | PROD       | 22           | $a: Health Plan Implementation $x: methods                                      | True   |
| 650   | PROD       | 22           | $a: Electronic Health Records                                                   | True   |
| 650   | PROD       | 22           | $a: Medical Informatics Applications                                            | True   |
| 650   | PROD       | 22           | $a: Point-of-Care Systems                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 651   | QA         |  2           | $a: United States                                                               | True   |
| 651   | PROD       |  2           | $a: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 1            | $a: United States. $b: Agency for Healthcare Research and Quality, $e: issuing body, $e: sponsoring body. | True   |
| 710   | PROD       | 1            | $a: United States. $b: Agency for Healthcare Research and Quality, $e: issuing body, $e: sponsoring body. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: AHRQ publication ; $v: no. 23-0010.                                         | True   |
| 830   | PROD       |  0           | $a: AHRQ publication ; $v: no. 23-0010.                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604788/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604788/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: CAD $b: 20241017                                                            | True   |
| 993   | PROD       |              | $a: CAD $b: 20241017                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241031                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241031                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241101                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241101                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240802                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240802                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918879461506676

Leader:
| File       | Leader                   | Equal  |
| QA         | 04080aam  2200697 i 4500 | True   |
| PROD       | 04080aam  2200697 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918879461506676                                                                | True   |
| 001   | PROD       |              | 9918879461506676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241105115246.0                                                                | True   |
| 005   | PROD       |              | 20241105115246.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240530t20242024dcuab   ob    000 0 eng d                                        | True   |
| 008   | PROD       |              | 240530t20242024dcuab   ob    000 0 eng d                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 020   | QA         |              | $a: 0309713900 $q: (electronic bk.)                                             | True   |
| 020   | QA         |              | $a: 9780309713900 $q: (electronic bk.)                                          | True   |
| 020   | QA         |              | $z: 0309713897                                                                  | True   |
| 020   | QA         |              | $z: 9780309713894                                                               | True   |
| 020   | PROD       |              | $a: 0309713900 $q: (electronic bk.)                                             | True   |
| 020   | PROD       |              | $a: 9780309713900 $q: (electronic bk.)                                          | True   |
| 020   | PROD       |              | $z: 0309713897                                                                  | True   |
| 020   | PROD       |              | $z: 9780309713894                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 024   | QA         | 7            | $a: 10.17226/27425 $2: doi                                                      | True   |
| 024   | PROD       | 7            | $a: 10.17226/27425 $2: doi                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918879461506676                                                            | True   |
| 035   | QA         |              | $a: (OCoLC)1434562153                                                           | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK605474                                                      | True   |
| 035   | PROD       |              | $9: 9918879461506676                                                            | True   |
| 035   | PROD       |              | $a: (OCoLC)1434562153                                                           | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK605474                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: YDX $b: eng $e: rda $c: YDX $d: YDX $d: N$T $d: OCLCO                       | True   |
| 040   | PROD       |              | $a: YDX $b: eng $e: rda $c: YDX $d: YDX $d: N$T $d: OCLCO                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 050   | QA         |  4           | $a: HV6626.2 $b: .N38 2024                                                      | True   |
| 050   | PROD       |  4           | $a: HV6626.2 $b: .N38 2024                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WA 308                                                                      | True   |
| 060   | PROD       | 00           | $a: WA 308                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 072   | QA         |  7           | $a: MED035000 $2: bisacsh                                                       | True   |
| 072   | QA         |  7           | $a: MBP $2: bicssc                                                              | True   |
| 072   | QA         |  7           | $a: MED036000 $2: bisacsh                                                       | True   |
| 072   | QA         |  7           | $a: M $2: bicssc                                                                | True   |
| 072   | PROD       |  7           | $a: MED035000 $2: bisacsh                                                       | True   |
| 072   | PROD       |  7           | $a: MBP $2: bicssc                                                              | True   |
| 072   | PROD       |  7           | $a: MED036000 $2: bisacsh                                                       | True   |
| 072   | PROD       |  7           | $a: M $2: bicssc                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 082   | QA         | 04           | $a: 362.82920973 $2: 23/eng/20240618                                            | True   |
| 082   | PROD       | 04           | $a: 362.82920973 $2: 23/eng/20240618                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 110   | QA         | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Committee on Sustaining Essential Health Care Services Related to Intimate Partner Violence During Public Health Emergencies, $e: author, $e: issuing body. | True   |
| 110   | PROD       | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Committee on Sustaining Essential Health Care Services Related to Intimate Partner Violence During Public Health Emergencies, $e: author, $e: issuing body. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Essential health care services addressing intimate partner violence / $c: Susan J. Curry and Crystal J. Bell, editors ; Committee on Sustaining Essential Health Care Services Related to Intimate Partner Violence During Public Health Emergencies, Board on Health Care Services, Board on Health Sciences Policy, Board on Population Health and Public Health Practice, Health and Medicine Division. | True   |
| 245   | PROD       | 10           | $a: Essential health care services addressing intimate partner violence / $c: Susan J. Curry and Crystal J. Bell, editors ; Committee on Sustaining Essential Health Care Services Related to Intimate Partner Violence During Public Health Emergencies, Board on Health Care Services, Board on Health Sciences Policy, Board on Population Health and Public Health Practice, Health and Medicine Division. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington, D.C. $b: National Academies Press, $c: 2024.                    | True   |
| 264   | QA         |  4           | $c: ©2024                                                                       | True   |
| 264   | PROD       |  1           | $a: Washington, D.C. $b: National Academies Press, $c: 2024.                    | True   |
| 264   | PROD       |  4           | $c: ©2024                                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (xxiv, 294 pages)) : $b: illustrations, maps. | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (xxiv, 294 pages)) : $b: illustrations, maps. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Consensus study report                                                      | True   |
| 490   | PROD       | 1            | $a: Consensus study report                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: A National Academies committee was tasked with identifying essential health care services for women related to intimate partner violence (IPV) during steady state conditions, determining whether the essential health care services related to IPV differ during public health emergencies (PHEs), and identifying strategies to sustain access to those essential health care services during PHEs. This report, Essential Health Care Services Addressing Intimate Partner Violence, presents findings from research and deliberations and lays out recommendations for leaders of health care systems, federal agencies, health care providers, emergency planners, and those involved in IPV research. | True   |
| 520   | PROD       | 3            | $a: A National Academies committee was tasked with identifying essential health care services for women related to intimate partner violence (IPV) during steady state conditions, determining whether the essential health care services related to IPV differ during public health emergencies (PHEs), and identifying strategies to sustain access to those essential health care services during PHEs. This report, Essential Health Care Services Addressing Intimate Partner Violence, presents findings from research and deliberations and lays out recommendations for leaders of health care systems, federal agencies, health care providers, emergency planners, and those involved in IPV research. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 530   | QA         |              | $a: Issued also in print.                                                       | True   |
| 530   | PROD       |              | $a: Issued also in print.                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: This activity was supported by a contract between the National Academy of Sciences and the Health Resources and Services Administration of the U.S. Department of Health and Human Services. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. | True   |
| 536   | PROD       |              | $a: This activity was supported by a contract between the National Academy of Sciences and the Health Resources and Services Administration of the U.S. Department of Health and Human Services. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed November 1, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed November 1, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Intimate Partner Violence $x: prevention & control                          | True   |
| 650   | QA         | 22           | $a: Health Services                                                             | True   |
| 650   | QA         | 22           | $a: Emergencies                                                                 | True   |
| 650   | QA         | 22           | $a: Disaster Planning                                                           | True   |
| 650   | PROD       | 12           | $a: Intimate Partner Violence $x: prevention & control                          | True   |
| 650   | PROD       | 22           | $a: Health Services                                                             | True   |
| 650   | PROD       | 22           | $a: Emergencies                                                                 | True   |
| 650   | PROD       | 22           | $a: Disaster Planning                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 651   | QA         |  2           | $a: United States                                                               | True   |
| 651   | PROD       |  2           | $a: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 700   | QA         | 1            | $a: Bell, Crystal J. $e: editor.                                                | True   |
| 700   | QA         | 1            | $a: Curry, Susan J. $e: editor.                                                 | True   |
| 700   | PROD       | 1            | $a: Bell, Crystal J. $e: editor.                                                | True   |
| 700   | PROD       | 1            | $a: Curry, Susan J. $e: editor.                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Board on Health Care Services, $e: issuing body. | True   |
| 710   | QA         | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Board on Health Sciences Policy, $e: issuing body. | True   |
| 710   | QA         | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Board on Population Health and Public Health Practice, $e: issuing body. | True   |
| 710   | PROD       | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Board on Health Care Services, $e: issuing body. | True   |
| 710   | PROD       | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Board on Health Sciences Policy, $e: issuing body. | True   |
| 710   | PROD       | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Board on Population Health and Public Health Practice, $e: issuing body. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: Consensus study report                                                      | True   |
| 830   | PROD       |  0           | $a: Consensus study report                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK605474/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK605474/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: CAD $b: 20241017                                                            | True   |
| 993   | PROD       |              | $a: CAD $b: 20241017                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241101                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241101                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241105                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241105                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240802                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240802                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918879461606676

Leader:
| File       | Leader                   | Equal  |
| QA         | 06143nam a2200457 i 4500 | True   |
| PROD       | 06143nam a2200457 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918879461606676                                                                | True   |
| 001   | PROD       |              | 9918879461606676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241105112400.0                                                                | True   |
| 005   | PROD       |              | 20241105112400.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240802s2021    dcua    ob    000|0 eng                                          | True   |
| 008   | PROD       |              | 240802s2021    dcua    ob    000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918879461606676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK604777                                                      | True   |
| 035   | PROD       |              | $9: 9918879461606676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK604777                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: QV 771.4                                                                    | True   |
| 060   | PROD       | 00           | $a: QV 771.4                                                                    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Danaei, Goodarz, $e: author.                                                | True   |
| 100   | PROD       | 1            | $a: Danaei, Goodarz, $e: author.                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Developing new methods for comparing treatments in case-control studies / $c: Goodarz Danaei, Bahareh Rasouli, Jessica Chubak, James S. Floyd, Bruce M. Psaty, Matthew Nguyen, Rod Walker, Kerri Wiggins, Roger W. Logan, Barbra A. Dickerman, Miguel A. Hernán. | True   |
| 245   | PROD       | 10           | $a: Developing new methods for comparing treatments in case-control studies / $c: Goodarz Danaei, Bahareh Rasouli, Jessica Chubak, James S. Floyd, Bruce M. Psaty, Matthew Nguyen, Rod Walker, Kerri Wiggins, Roger W. Logan, Barbra A. Dickerman, Miguel A. Hernán. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington (DC) : $b: Patient-Centered Outcomes Research Institute (PCORI), $c: 2021. | True   |
| 264   | PROD       |  1           | $a: Washington (DC) : $b: Patient-Centered Outcomes Research Institute (PCORI), $c: 2021. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (84 pages)) : $b: illustrations.              | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (84 pages)) : $b: illustrations.              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Final research report                                                       | True   |
| 490   | PROD       | 1            | $a: Final research report                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: BACKGROUND: Comparative effectiveness research (CER) and observational analyses of safety and off-target effects of drugs lie at the heart of patient-centered outcomes research. Emulating the design and analysis of a target trial using a cohort design (causal CER methods) reduces potential for several major biases in observational CER. Large cohort studies often use electronic medical record (EMR) data without validating key variables due to feasibility constraints. Using a case-control design provides the opportunity to reduce measurement bias by validating measures of eligibility, exposure, confounders, and outcome using resource-intensive data collection methods such as medical record review within a much smaller population compared with the entire cohort. However, causal CER methods for case-control studies do not yet exist, leaving researchers to choose between using either advanced analytical methods with potentially lower-quality data from a cohort design or a conventional case-control design with higher-quality data. OBJECTIVES: To reduce bias in CER by developing methods to emulate the design and analysis of a target trial using high-quality measurements and a case-control design. METHODS: We developed a guideline and an analytical program to emulate the design and analysis of a target trial using a case-control design. The guideline provides details on how the data should be structured and how to use the accompanying SAS macro to implement the observational analogues of intention-to-treat (ITT) and per-protocol analyses in a case-control design. We conducted 2 sets of interviews with 20 investigators and data analysts and incorporated their comments into the guideline. For our clinical example, we used cohort data from Kaiser Permanente Washington and a case-control study (nested within the same system) that had previously validated case and control status using medical record reviews. We emulated the design and analysis of a target trial of statin therapy among healthy participants. The primary outcome was fatal or nonfatal myocardial infarction (MI). RESULTS: Using a cohort design to emulate a primary prevention statin trial, we selected 76 020 eligible participants into an analytic cohort. During an average follow-up of 73 months, we observed 1318 events. Compared with a pooled hazard ratio (HR) of 0.69 (95% CI, 0.60-0.79) reported in a meta-analysis of randomized controlled trials, the observational analogue of the ITT HR using a cohort design and outcomes based on ICD codes was 1.01 (0.91-1.12), and the ITT odds ratio (OR) using a case-control design and validated case and control status was 0.80 (0.69-0.92). A case-control analysis that measured eligibility, exposures, and confounders at the index date yielded an adjusted OR of 1.12 (0.96-1.31), which suggests a harmful effect of statins on MI. Adherence to assigned treatment in our study population was low, with 70% of initiators discontinuing treatment within 5 years. After adjusting for imperfect adherence by censoring nonadherent person-times and adjusting for time-varying determinants of adherence via inverse probability weighting, the per-protocol HR was 0.80 (0.67-0.94) in the cohort design using ICD codes and the corresponding OR was 0.71 (0.58-0.87) in the case-control design using validated cases and controls. CONCLUSIONS: We were able to replicate the results of statin trials on MI prevention using a causal case-control design and outcome data that were validated using medical record reviews. In contrast, a cohort design that did not use validated outcomes produced null results due to measurement error and lower adherence, and a conventional case-control design with validated events yielded substantially biased results due to a different definition of eligibility and exposure and inappropriate adjustment for confounders. LIMITATIONS: The causal analysis of case-control data requires that the case-control study be nested in a health care system with longitudinal EMR data, which does not apply to many existing studies. Our analyses used only 1 example; further research is needed to examine whether these findings generalize to other drug exposures and health outcomes.Includes bibliographical references. | True   |
| 520   | PROD       | 3            | $a: BACKGROUND: Comparative effectiveness research (CER) and observational analyses of safety and off-target effects of drugs lie at the heart of patient-centered outcomes research. Emulating the design and analysis of a target trial using a cohort design (causal CER methods) reduces potential for several major biases in observational CER. Large cohort studies often use electronic medical record (EMR) data without validating key variables due to feasibility constraints. Using a case-control design provides the opportunity to reduce measurement bias by validating measures of eligibility, exposure, confounders, and outcome using resource-intensive data collection methods such as medical record review within a much smaller population compared with the entire cohort. However, causal CER methods for case-control studies do not yet exist, leaving researchers to choose between using either advanced analytical methods with potentially lower-quality data from a cohort design or a conventional case-control design with higher-quality data. OBJECTIVES: To reduce bias in CER by developing methods to emulate the design and analysis of a target trial using high-quality measurements and a case-control design. METHODS: We developed a guideline and an analytical program to emulate the design and analysis of a target trial using a case-control design. The guideline provides details on how the data should be structured and how to use the accompanying SAS macro to implement the observational analogues of intention-to-treat (ITT) and per-protocol analyses in a case-control design. We conducted 2 sets of interviews with 20 investigators and data analysts and incorporated their comments into the guideline. For our clinical example, we used cohort data from Kaiser Permanente Washington and a case-control study (nested within the same system) that had previously validated case and control status using medical record reviews. We emulated the design and analysis of a target trial of statin therapy among healthy participants. The primary outcome was fatal or nonfatal myocardial infarction (MI). RESULTS: Using a cohort design to emulate a primary prevention statin trial, we selected 76 020 eligible participants into an analytic cohort. During an average follow-up of 73 months, we observed 1318 events. Compared with a pooled hazard ratio (HR) of 0.69 (95% CI, 0.60-0.79) reported in a meta-analysis of randomized controlled trials, the observational analogue of the ITT HR using a cohort design and outcomes based on ICD codes was 1.01 (0.91-1.12), and the ITT odds ratio (OR) using a case-control design and validated case and control status was 0.80 (0.69-0.92). A case-control analysis that measured eligibility, exposures, and confounders at the index date yielded an adjusted OR of 1.12 (0.96-1.31), which suggests a harmful effect of statins on MI. Adherence to assigned treatment in our study population was low, with 70% of initiators discontinuing treatment within 5 years. After adjusting for imperfect adherence by censoring nonadherent person-times and adjusting for time-varying determinants of adherence via inverse probability weighting, the per-protocol HR was 0.80 (0.67-0.94) in the cohort design using ICD codes and the corresponding OR was 0.71 (0.58-0.87) in the case-control design using validated cases and controls. CONCLUSIONS: We were able to replicate the results of statin trials on MI prevention using a causal case-control design and outcome data that were validated using medical record reviews. In contrast, a cohort design that did not use validated outcomes produced null results due to measurement error and lower adherence, and a conventional case-control design with validated events yielded substantially biased results due to a different definition of eligibility and exposure and inappropriate adjustment for confounders. LIMITATIONS: The causal analysis of case-control data requires that the case-control study be nested in a health care system with longitudinal EMR data, which does not apply to many existing studies. Our analyses used only 1 example; further research is needed to examine whether these findings generalize to other drug exposures and health outcomes.Includes bibliographical references. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: Institution Receiving Award: Harvard T.H. Chan School of Public Health PCORI ID: ME-1609-36748 | True   |
| 536   | PROD       |              | $a: Institution Receiving Award: Harvard T.H. Chan School of Public Health PCORI ID: ME-1609-36748 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed Nov. 4, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed Nov. 4, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Clinical Trials as Topic $x: methods                                        | True   |
| 650   | QA         | 22           | $a: Research Design                                                             | True   |
| 650   | QA         | 22           | $a: Comparative Effectiveness Research $x: methods                              | True   |
| 650   | PROD       | 12           | $a: Clinical Trials as Topic $x: methods                                        | True   |
| 650   | PROD       | 22           | $a: Research Design                                                             | True   |
| 650   | PROD       | 22           | $a: Comparative Effectiveness Research $x: methods                              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: Patient-Centered Outcomes Research Institute (U.S.), $e: issuing body.      | True   |
| 710   | PROD       | 2            | $a: Patient-Centered Outcomes Research Institute (U.S.), $e: issuing body.      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: Final research report (Patient-Centered Outcomes Research Institute (U.S.)) | True   |
| 830   | PROD       |  0           | $a: Final research report (Patient-Centered Outcomes Research Institute (U.S.)) | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604777/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604777/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: IHH $b: 20241104                                                            | True   |
| 993   | PROD       |              | $a: IHH $b: 20241104                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241104                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241104                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241105                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241105                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240802                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240802                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918879458406676

Leader:
| File       | Leader                   | Equal  |
| QA         | 03295nam a2200469 i 4500 | True   |
| PROD       | 03295nam a2200469 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918879458406676                                                                | True   |
| 001   | PROD       |              | 9918879458406676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241118114338.0                                                                | True   |
| 005   | PROD       |              | 20241118114338.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240802s2023    dcu     ob   f000|0 eng                                          | True   |
| 008   | PROD       |              | 240802s2023    dcu     ob   f000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918879458406676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK604980                                                      | True   |
| 035   | PROD       |              | $9: 9918879458406676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK604980                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: W 76 AA1                                                                    | True   |
| 060   | PROD       | 00           | $a: W 76 AA1                                                                    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 00           | $a: Call to action : $b: addressing health-related social needs in communities across the nation / $c: U.S. Department of Health and Human Services. | True   |
| 245   | PROD       | 00           | $a: Call to action : $b: addressing health-related social needs in communities across the nation / $c: U.S. Department of Health and Human Services. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 246   | QA         | 1            | $a: Addressing health-related social needs in communities across the nation     | True   |
| 246   | QA         | 1            | $a: HHS call to action                                                          | True   |
| 246   | PROD       | 1            | $a: Addressing health-related social needs in communities across the nation     | True   |
| 246   | PROD       | 1            | $a: HHS call to action                                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington, DC : $b: [Office of the Assistant Secretary for Planning and Evaluation], $c: November 2023. | True   |
| 264   | PROD       |  1           | $a: Washington, DC : $b: [Office of the Assistant Secretary for Planning and Evaluation], $c: November 2023. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (15 pages))                                   | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (15 pages))                                   | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: The U.S. Department of Health and Human Services (HHS) envisions a future in which everyone, regardless of their social circumstances, has access to aligned health and social care systems that achieve equitable outcomes through high-quality, affordable, person-centered care. This Call to Action complements the companion U.S. Playbook to Address Social Determinants of Health, which highlights the critical need to develop well-coordinated systems of health and social care to better address social needs that can impact health and that describes actions the federal government is taking to promote this transformation. This HHS Call to Action is being issued with the intent of catalyzing efforts at the community-level to encourage partnerships across sectors, including health care, social services, public and environmental health, government, and health information technology to address social needs with the goal of improving the health and well-being of every American. It describes key actions that partners in different sectors can take to help build a stronger, more integrated health and social care system, and it provides resources applicable to partners involved in each set of actions. It also discusses the important role that backbone organizations, including community care hubs, can play in managing community-based partnerships across sectors and how they can help develop and sustain the community-based infrastructure needed to improve coordination between health and social care providers. | True   |
| 520   | PROD       | 3            | $a: The U.S. Department of Health and Human Services (HHS) envisions a future in which everyone, regardless of their social circumstances, has access to aligned health and social care systems that achieve equitable outcomes through high-quality, affordable, person-centered care. This Call to Action complements the companion U.S. Playbook to Address Social Determinants of Health, which highlights the critical need to develop well-coordinated systems of health and social care to better address social needs that can impact health and that describes actions the federal government is taking to promote this transformation. This HHS Call to Action is being issued with the intent of catalyzing efforts at the community-level to encourage partnerships across sectors, including health care, social services, public and environmental health, government, and health information technology to address social needs with the goal of improving the health and well-being of every American. It describes key actions that partners in different sectors can take to help build a stronger, more integrated health and social care system, and it provides resources applicable to partners involved in each set of actions. It also discusses the important role that backbone organizations, including community care hubs, can play in managing community-based partnerships across sectors and how they can help develop and sustain the community-based infrastructure needed to improve coordination between health and social care providers. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 530   | QA         |              | $a: Issued also in print.                                                       | True   |
| 530   | PROD       |              | $a: Issued also in print.                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed Nov. 13, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed Nov. 13, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Health Services Needs and Demand                                            | True   |
| 650   | QA         | 22           | $a: Community Networks                                                          | True   |
| 650   | QA         | 22           | $a: Community Support $x: methods                                               | True   |
| 650   | QA         | 22           | $a: Social Determinants of Health                                               | True   |
| 650   | PROD       | 12           | $a: Health Services Needs and Demand                                            | True   |
| 650   | PROD       | 22           | $a: Community Networks                                                          | True   |
| 650   | PROD       | 22           | $a: Community Support $x: methods                                               | True   |
| 650   | PROD       | 22           | $a: Social Determinants of Health                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 651   | QA         |  2           | $a: United States                                                               | True   |
| 651   | PROD       |  2           | $a: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 1            | $a: United States. $b: Department of Health and Human Services. $b: Office of the Assistant Secretary for Planning and Evaluation, $e: issuing body. | True   |
| 710   | PROD       | 1            | $a: United States. $b: Department of Health and Human Services. $b: Office of the Assistant Secretary for Planning and Evaluation, $e: issuing body. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604980/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604980/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: YYC $b: 20241030                                                            | True   |
| 993   | PROD       |              | $a: YYC $b: 20241030                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241113                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241113                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241118                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241118                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240802                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240802                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918879464906676

Leader:
| File       | Leader                   | Equal  |
| QA         | 02253nam a2200505 i 4500 | True   |
| PROD       | 02253nam a2200505 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918879464906676                                                                | True   |
| 001   | PROD       |              | 9918879464906676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241106124545.0                                                                | True   |
| 005   | PROD       |              | 20241106124545.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240802s2023    dcua    obs  f000|0 eng                                          | True   |
| 008   | PROD       |              | 240802s2023    dcua    obs  f000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918879464906676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK605136                                                      | True   |
| 035   | PROD       |              | $9: 9918879464906676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK605136                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WX 215                                                                      | True   |
| 060   | PROD       | 00           | $a: WX 215                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 00           | $a: Factors contributing to reductions in patient wait times at Indian Health Service emergency department facilities : $b: a mixed-methods assessment : research report. | True   |
| 245   | PROD       | 00           | $a: Factors contributing to reductions in patient wait times at Indian Health Service emergency department facilities : $b: a mixed-methods assessment : research report. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington, D.C. : $b: Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, Office of Health Policy, $c: February 2023 . | True   |
| 264   | PROD       |  1           | $a: Washington, D.C. : $b: Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, Office of Health Policy, $c: February 2023 . | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (18 pages)) : $b: illustrations               | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (18 pages)) : $b: illustrations               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Report                                                                      | True   |
| 490   | PROD       | 1            | $a: Report                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: This ASPE Research Report summarizes findings about factors affecting Emergency Department wait times and Primary Care appointment scheduling intervals, and it describes strategies Indian Health Service (IHS) federal facilities have implemented associated with decreased wait times in Emergency Departments. | True   |
| 520   | PROD       | 3            | $a: This ASPE Research Report summarizes findings about factors affecting Emergency Department wait times and Primary Care appointment scheduling intervals, and it describes strategies Indian Health Service (IHS) federal facilities have implemented associated with decreased wait times in Emergency Departments. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 530   | QA         |              | $a: Issued also in print.                                                       | True   |
| 530   | PROD       |              | $a: Issued also in print.                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed Nov. 6, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed Nov. 6, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 610   | QA         | 12           | $a: United States. $b: Indian Health Service                                    | True   |
| 610   | PROD       | 12           | $a: United States. $b: Indian Health Service                                    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Emergency Room Visits                                                       | True   |
| 650   | QA         | 22           | $a: Appointments and Schedules                                                  | True   |
| 650   | QA         | 22           | $a: Primary Health Care                                                         | True   |
| 650   | QA         | 22           | $a: Minority Health                                                             | True   |
| 650   | QA         | 22           | $a: American Indian or Alaska Native                                            | True   |
| 650   | PROD       | 12           | $a: Emergency Room Visits                                                       | True   |
| 650   | PROD       | 22           | $a: Appointments and Schedules                                                  | True   |
| 650   | PROD       | 22           | $a: Primary Health Care                                                         | True   |
| 650   | PROD       | 22           | $a: Minority Health                                                             | True   |
| 650   | PROD       | 22           | $a: American Indian or Alaska Native                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 651   | QA         |  2           | $a: United States                                                               | True   |
| 651   | PROD       |  2           | $a: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 655   | QA         |  2           | $a: Statistics                                                                  | True   |
| 655   | PROD       |  2           | $a: Statistics                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 1            | $a: United States. $b: Department of Health and Human Services. $b: Office of the Assistant Secretary for Planning and Evaluation. $b: Office of Health Policy, $e: issuing body. | True   |
| 710   | PROD       | 1            | $a: United States. $b: Department of Health and Human Services. $b: Office of the Assistant Secretary for Planning and Evaluation. $b: Office of Health Policy, $e: issuing body. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: ASPE report                                                                 | True   |
| 830   | PROD       |  0           | $a: ASPE report                                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK605136/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK605136/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240802                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: IHH $b: 20241106                                                            | True   |
| 993   | PROD       |              | $a: IHH $b: 20241106                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241106                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241106                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241106                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241106                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240802                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240802                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918916893706676

Leader:
| File       | Leader                   | Equal  |
| QA         | 04760nam a2200457 i 4500 | True   |
| PROD       | 04760nam a2200457 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918916893706676                                                                | True   |
| 001   | PROD       |              | 9918916893706676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241101080220.0                                                                | True   |
| 005   | PROD       |              | 20241101080220.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 241002s2019    dcua    ob    000|0 eng                                          | True   |
| 008   | PROD       |              | 241002s2019    dcua    ob    000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918916893706676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK606828                                                      | True   |
| 035   | PROD       |              | $9: 9918916893706676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK606828                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WE 870                                                                      | True   |
| 060   | PROD       | 00           | $a: WE 870                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Allen, Kelli D., $e: author.                                                | True   |
| 100   | PROD       | 1            | $a: Allen, Kelli D., $e: author.                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Comparing physical therapy, internet-based exercise training, and no therapy for knee osteoarthritis / $c: Kelli D. Allen, Liubov Arbeeva, Leigh Callahan, Yvonne Golightly, Adam Goode, Bryan Heiderscheit, Kim Huffman, Herbert Seversen, Todd Schwartz. | True   |
| 245   | PROD       | 10           | $a: Comparing physical therapy, internet-based exercise training, and no therapy for knee osteoarthritis / $c: Kelli D. Allen, Liubov Arbeeva, Leigh Callahan, Yvonne Golightly, Adam Goode, Bryan Heiderscheit, Kim Huffman, Herbert Seversen, Todd Schwartz. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington (DC) : $b: Patient-Centered Outcomes Research Institute (PCORI), $c: [2019] | True   |
| 264   | PROD       |  1           | $a: Washington (DC) : $b: Patient-Centered Outcomes Research Institute (PCORI), $c: [2019] | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (83 pages)) : $b: illustrations               | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (83 pages)) : $b: illustrations               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: BACKGROUND: Most adults with knee osteoarthritis (OA) are inactive, highlighting the need for continued efforts to promote regular engagement in exercise. Few studies have directly compared different strategies, ranging in intensity of resources required, for improving exercise and related outcomes among patients with OA. OBJECTIVE: The objective of this 3-arm study was to compare the effectiveness of physical therapy (PT; with an emphasis on a home exercise program) and internet-based exercise training (IBET), both compared with a wait list (WL) control arm, among individuals with knee OA. METHODS: This study was a randomized controlled trial of 350 participants with symptomatic knee OA, allocated to standard PT, IBET, and WL control group in a 2:2:1 ratio, respectively. The PT group received up to 8 individual visits within 4 months. The IBET program provided tailored exercises, video demonstrations, and guidance on exercise progression. The primary outcome was the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC, range 0-96), assessed at baseline, 4 months (primary time point), and 12 months. General linear mixed effects modeling compared changes in WOMAC among study groups, with superiority hypotheses testing differences between intervention groups and WL and noninferiority hypotheses comparing IBET with PT (noninferiority margin = 5 points on WOMAC). Higher WOMAC scores indicate worse symptoms; therefore, negative scores for comparisons at follow-up indicate more improvement for PT and IBET at groups compared with the WL group. RESULTS: Baseline mean WOMAC scores for PT, IBET, and WL groups were 32.0, 31.3, and 33.6, respectively. At 4 months, improvements in WOMAC score did not differ significantly for either the PT group or IBET group compared with WL (PT: −3.36, 95% CI, −6.84 to 0.12, P = .06; IBET: - 2.70, 95% CI, −6.24 to 0.85, P = .14). Similarly, at 12 months, mean differences compared with WL were not statistically significant for either group (PT: −1.59, 95% CI, −5.26 to 2.08, P = .39; IBET: −2.63, 95% CI, −6.37 to 1.11, P = .17). IBET was noninferior to PT at both time points. CONCLUSIONS: Improvements in WOMAC score following IBET and PT did not differ significantly or clinically from the WL group. This contrasts with prior studies showing that PT improves pain and function for people with knee OA. Additional research is needed regarding strategies to maximize the effects of exercise-based interventions for individuals with knee OA. LIMITATIONS AND SUBPOPULATION CONSIDERATIONS: This study was conducted in 1 geographic region and included only participants who had regular internet access. More than half of participants had a college education. These factors could affect generalizability to other subpopulations. | True   |
| 520   | PROD       | 3            | $a: BACKGROUND: Most adults with knee osteoarthritis (OA) are inactive, highlighting the need for continued efforts to promote regular engagement in exercise. Few studies have directly compared different strategies, ranging in intensity of resources required, for improving exercise and related outcomes among patients with OA. OBJECTIVE: The objective of this 3-arm study was to compare the effectiveness of physical therapy (PT; with an emphasis on a home exercise program) and internet-based exercise training (IBET), both compared with a wait list (WL) control arm, among individuals with knee OA. METHODS: This study was a randomized controlled trial of 350 participants with symptomatic knee OA, allocated to standard PT, IBET, and WL control group in a 2:2:1 ratio, respectively. The PT group received up to 8 individual visits within 4 months. The IBET program provided tailored exercises, video demonstrations, and guidance on exercise progression. The primary outcome was the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC, range 0-96), assessed at baseline, 4 months (primary time point), and 12 months. General linear mixed effects modeling compared changes in WOMAC among study groups, with superiority hypotheses testing differences between intervention groups and WL and noninferiority hypotheses comparing IBET with PT (noninferiority margin = 5 points on WOMAC). Higher WOMAC scores indicate worse symptoms; therefore, negative scores for comparisons at follow-up indicate more improvement for PT and IBET at groups compared with the WL group. RESULTS: Baseline mean WOMAC scores for PT, IBET, and WL groups were 32.0, 31.3, and 33.6, respectively. At 4 months, improvements in WOMAC score did not differ significantly for either the PT group or IBET group compared with WL (PT: −3.36, 95% CI, −6.84 to 0.12, P = .06; IBET: - 2.70, 95% CI, −6.24 to 0.85, P = .14). Similarly, at 12 months, mean differences compared with WL were not statistically significant for either group (PT: −1.59, 95% CI, −5.26 to 2.08, P = .39; IBET: −2.63, 95% CI, −6.37 to 1.11, P = .17). IBET was noninferior to PT at both time points. CONCLUSIONS: Improvements in WOMAC score following IBET and PT did not differ significantly or clinically from the WL group. This contrasts with prior studies showing that PT improves pain and function for people with knee OA. Additional research is needed regarding strategies to maximize the effects of exercise-based interventions for individuals with knee OA. LIMITATIONS AND SUBPOPULATION CONSIDERATIONS: This study was conducted in 1 geographic region and included only participants who had regular internet access. More than half of participants had a college education. These factors could affect generalizability to other subpopulations. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: Original Project Title: Physical Therapy vs. Internet-Based Exercise Training for Patients With Knee Osteoarthritis PCORI ID: CER-1306-02043 ClinicalTrials.gov ID: NCT02312713 | True   |
| 536   | PROD       |              | $a: Original Project Title: Physical Therapy vs. Internet-Based Exercise Training for Patients With Knee Osteoarthritis PCORI ID: CER-1306-02043 ClinicalTrials.gov ID: NCT02312713 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed Oct. 31, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed Oct. 31, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Osteoarthritis, Knee $x: therapy                                            | True   |
| 650   | QA         | 22           | $a: Physical Therapy Modalities                                                 | True   |
| 650   | QA         | 22           | $a: Telerehabilitation                                                          | True   |
| 650   | QA         | 22           | $a: Internet-Based Intervention                                                 | True   |
| 650   | PROD       | 12           | $a: Osteoarthritis, Knee $x: therapy                                            | True   |
| 650   | PROD       | 22           | $a: Physical Therapy Modalities                                                 | True   |
| 650   | PROD       | 22           | $a: Telerehabilitation                                                          | True   |
| 650   | PROD       | 22           | $a: Internet-Based Intervention                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: Patient-Centered Outcomes Research Institute (U.S.), $e: issuing body.      | True   |
| 710   | PROD       | 2            | $a: Patient-Centered Outcomes Research Institute (U.S.), $e: issuing body.      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: Final research report (Patient-Centered Outcomes Research Institute (U.S.)) | True   |
| 830   | PROD       |  0           | $a: Final research report (Patient-Centered Outcomes Research Institute (U.S.)) | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK606828/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK606828/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20241002                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20241002                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: IHH $b: 20241031                                                            | True   |
| 993   | PROD       |              | $a: IHH $b: 20241031                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241031                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241031                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241101                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241101                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20241002                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20241002                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918916893906676

Leader:
| File       | Leader                   | Equal  |
| QA         | 05626nam a2200493 i 4500 | True   |
| PROD       | 05626nam a2200493 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918916893906676                                                                | True   |
| 001   | PROD       |              | 9918916893906676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241101115652.0                                                                | True   |
| 005   | PROD       |              | 20241101115652.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 241002s2019    dcua    ob    000|0 eng                                          | True   |
| 008   | PROD       |              | 241002s2019    dcua    ob    000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918916893906676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK606826                                                      | True   |
| 035   | PROD       |              | $9: 9918916893906676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK606826                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WA 309 AA1                                                                  | True   |
| 060   | PROD       | 00           | $a: WA 309 AA1                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Garcia, Francisco A., $e: author.                                           | True   |
| 100   | PROD       | 1            | $a: Garcia, Francisco A., $e: author.                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Does an offer by phone of community health worker support increase access to primary care for women who are newly enrolled in a health plan? / $c: Francisco A. Garcia, Ada M. Wilkinson-Lee, Patricia M. Herman, Thomas Ball, Alexandra M. Armenta, Rick A. Rehfeld, Gery W. Ryan. | True   |
| 245   | PROD       | 10           | $a: Does an offer by phone of community health worker support increase access to primary care for women who are newly enrolled in a health plan? / $c: Francisco A. Garcia, Ada M. Wilkinson-Lee, Patricia M. Herman, Thomas Ball, Alexandra M. Armenta, Rick A. Rehfeld, Gery W. Ryan. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington (DC) : $b: Patient-Centered Outcomes Research Institute (PCORI), $c: [2019] | True   |
| 264   | PROD       |  1           | $a: Washington (DC) : $b: Patient-Centered Outcomes Research Institute (PCORI), $c: [2019] | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (69 pages)) : $b: illustrations.              | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (69 pages)) : $b: illustrations.              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Final research report                                                       | True   |
| 490   | PROD       | 1            | $a: Final research report                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: BACKGROUND: Women from medically underserved minority and poor communities who historically have limited access to preventive health services may not have the basic information needed to fully benefit from these offerings. Such women may lack the necessary tools to effectively identify personal health care needs, take advantage of health services, or participate equitably in health care decision-making. Our study tests the effectiveness of a Medicaid health plan that offers new members the services of community health workers (CHWs) who use a community-developed curriculum and function as navigation aides. The CHWs assist patients to make informed decisions about the utilization of covered preventive health services and engagement with their health care providers. OBJECTIVES: The following was the overarching question addressed by this study: Does access to a trained CHW improve newly enrolled Medicaid health plan members' engagement in the health care system? METHODS: The study participants consisted of women aged 18 to 39 years who had newly enrolled in a Medicaid health plan serving southern Arizona between March 15, 2015, and March 14, 2016. All eligible health plan members were randomized 2:1 to be offered support from a CHW in addition to the standard services of the health plan or to receive only standard health plan services. We used the health plan's call center to contact those randomized to the intervention. We based the primary and secondary outcomes on analysis of 6 months' health care utilization data captured for all eligible members, and our primary outcome was a visit with a primary care provider (PCP). We also assessed patients' informed choice via a baseline survey completed by all members who worked with a CHW and a 6-month survey fielded to all members. RESULTS: The health plan enrolled 2267 eligible new members during the study; all eligible members were included in the study, and 1521 were randomized to the offer of CHW services. Of those enrolled, 78% were unreachable by the call center to complete the offer and another 5% became unreachable after expressing initial interest and before they could meet with a CHW. Of reached members, 82% said they were interested in working with a CHW and 62% worked with a CHW. Following intent to treat we found no significant difference in our primary outcome (at least 1 PCP visit) between those randomized to the offer (58.2%) and those randomized to control (57.1%). However, although not designed to directly test the effectiveness of CHW services themselves, our results suggest that support provided by the CHW might have a beneficial impact in terms of accessing primary care services. A significantly larger proportion of the group that received the CHW services had 1 or more primary care visits (71.7%) compared with those randomized to the offer who did not work with a CHW (56.6%) or the control group (57.1%). CONCLUSIONS: The study findings do not support the effectiveness of a health plan's offer of CHW services to its members. The direct telephone-based offer of CHW services by a Medicaid health plan to new members is not effective largely due to problems with the reachability of this low-income, highly mobile Medicaid population. The lack of effect may be due not to CHW services, which may themselves have a positive impact, but instead to the way these services were offered. LIMITATIONS AND SUBPOPULATION CONSIDERATIONS: The main limitation of this study was that the health plan call center was unable to consistently connect with its membership using available member contact information. | True   |
| 520   | PROD       | 3            | $a: BACKGROUND: Women from medically underserved minority and poor communities who historically have limited access to preventive health services may not have the basic information needed to fully benefit from these offerings. Such women may lack the necessary tools to effectively identify personal health care needs, take advantage of health services, or participate equitably in health care decision-making. Our study tests the effectiveness of a Medicaid health plan that offers new members the services of community health workers (CHWs) who use a community-developed curriculum and function as navigation aides. The CHWs assist patients to make informed decisions about the utilization of covered preventive health services and engagement with their health care providers. OBJECTIVES: The following was the overarching question addressed by this study: Does access to a trained CHW improve newly enrolled Medicaid health plan members' engagement in the health care system? METHODS: The study participants consisted of women aged 18 to 39 years who had newly enrolled in a Medicaid health plan serving southern Arizona between March 15, 2015, and March 14, 2016. All eligible health plan members were randomized 2:1 to be offered support from a CHW in addition to the standard services of the health plan or to receive only standard health plan services. We used the health plan's call center to contact those randomized to the intervention. We based the primary and secondary outcomes on analysis of 6 months' health care utilization data captured for all eligible members, and our primary outcome was a visit with a primary care provider (PCP). We also assessed patients' informed choice via a baseline survey completed by all members who worked with a CHW and a 6-month survey fielded to all members. RESULTS: The health plan enrolled 2267 eligible new members during the study; all eligible members were included in the study, and 1521 were randomized to the offer of CHW services. Of those enrolled, 78% were unreachable by the call center to complete the offer and another 5% became unreachable after expressing initial interest and before they could meet with a CHW. Of reached members, 82% said they were interested in working with a CHW and 62% worked with a CHW. Following intent to treat we found no significant difference in our primary outcome (at least 1 PCP visit) between those randomized to the offer (58.2%) and those randomized to control (57.1%). However, although not designed to directly test the effectiveness of CHW services themselves, our results suggest that support provided by the CHW might have a beneficial impact in terms of accessing primary care services. A significantly larger proportion of the group that received the CHW services had 1 or more primary care visits (71.7%) compared with those randomized to the offer who did not work with a CHW (56.6%) or the control group (57.1%). CONCLUSIONS: The study findings do not support the effectiveness of a health plan's offer of CHW services to its members. The direct telephone-based offer of CHW services by a Medicaid health plan to new members is not effective largely due to problems with the reachability of this low-income, highly mobile Medicaid population. The lack of effect may be due not to CHW services, which may themselves have a positive impact, but instead to the way these services were offered. LIMITATIONS AND SUBPOPULATION CONSIDERATIONS: The main limitation of this study was that the health plan call center was unable to consistently connect with its membership using available member contact information. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: Original Project Title: Connecting Healthy Women PCORI ID: IHS-1306-04356 ClinicalTrials.gov ID: NCT02157168 | True   |
| 536   | PROD       |              | $a: Original Project Title: Connecting Healthy Women PCORI ID: IHS-1306-04356 ClinicalTrials.gov ID: NCT02157168 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed Oct. 31, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed Oct. 31, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Women's Health Services                                                     | True   |
| 650   | QA         | 22           | $a: Health Services Accessibility                                               | True   |
| 650   | QA         | 22           | $a: Community Health Workers                                                    | True   |
| 650   | QA         | 22           | $a: Medically Underserved Area                                                  | True   |
| 650   | QA         | 22           | $a: Medicaid                                                                    | True   |
| 650   | PROD       | 12           | $a: Women's Health Services                                                     | True   |
| 650   | PROD       | 22           | $a: Health Services Accessibility                                               | True   |
| 650   | PROD       | 22           | $a: Community Health Workers                                                    | True   |
| 650   | PROD       | 22           | $a: Medically Underserved Area                                                  | True   |
| 650   | PROD       | 22           | $a: Medicaid                                                                    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 651   | QA         |  2           | $a: United States                                                               | True   |
| 651   | PROD       |  2           | $a: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: Patient-Centered Outcomes Research Institute (U.S.), $e: issuing body.      | True   |
| 710   | PROD       | 2            | $a: Patient-Centered Outcomes Research Institute (U.S.), $e: issuing body.      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: Final research report (Patient-Centered Outcomes Research Institute (U.S.)) | True   |
| 830   | PROD       |  0           | $a: Final research report (Patient-Centered Outcomes Research Institute (U.S.)) | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK606826/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK606826/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20241002                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20241002                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: IHH $b: 20241031                                                            | True   |
| 993   | PROD       |              | $a: IHH $b: 20241031                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241031                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241031                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241101                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241101                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20241002                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20241002                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918916896006676

Leader:
| File       | Leader                   | Equal  |
| QA         | 02895nam a2200517 i 4500 | True   |
| PROD       | 02895nam a2200517 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918916896006676                                                                | True   |
| 001   | PROD       |              | 9918916896006676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241106134412.0                                                                | True   |
| 005   | PROD       |              | 20241106134412.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 241002s2023    dcua    ob   f000|0 eng                                          | True   |
| 008   | PROD       |              | 241002s2023    dcua    ob   f000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918916896006676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK606574                                                      | True   |
| 035   | PROD       |              | $9: 9918916896006676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK606574                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WM 31.5                                                                     | True   |
| 060   | PROD       | 00           | $a: WM 31.5                                                                     | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Richardson, John, $d: 1984- $e: author.                                     | True   |
| 100   | PROD       | 1            | $a: Richardson, John, $d: 1984- $e: author.                                     | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Implementing and sustaining zero suicide : $b: health care system efforts to prevent suicide / $c: authors: John Richardson, Kiersten Johnson, Dylan DeLisle, Camara Wooten, Adam Miller ; RTI International ; prepared for Office of Behavioral Health, Disability, and Aging Policy, Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services. | True   |
| 245   | PROD       | 10           | $a: Implementing and sustaining zero suicide : $b: health care system efforts to prevent suicide / $c: authors: John Richardson, Kiersten Johnson, Dylan DeLisle, Camara Wooten, Adam Miller ; RTI International ; prepared for Office of Behavioral Health, Disability, and Aging Policy, Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: [Washington, DC] : $b: Department of Health and Human Services, Assistant Secretary for Planning and Evaluation, Office of Behavioral Health, Disability, and Aging Policy, $c: January 2023. | True   |
| 264   | PROD       |  1           | $a: [Washington, DC] : $b: Department of Health and Human Services, Assistant Secretary for Planning and Evaluation, Office of Behavioral Health, Disability, and Aging Policy, $c: January 2023. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (50, A-35 pages)) : $b: illustrations         | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (50, A-35 pages)) : $b: illustrations         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: Zero Suicide is a system-wide approach for health systems to improve the quality and safety of care for those at risk of suicide. Although Zero Suicide is effective in reducing suicide-related outcomes, little is known about how organizations fund and sustain the Zero Suicide initiative. This report provides insight into how organizations choose to implement and sustain a Zero Suicide initiative. | True   |
| 520   | PROD       | 3            | $a: Zero Suicide is a system-wide approach for health systems to improve the quality and safety of care for those at risk of suicide. Although Zero Suicide is effective in reducing suicide-related outcomes, little is known about how organizations fund and sustain the Zero Suicide initiative. This report provides insight into how organizations choose to implement and sustain a Zero Suicide initiative. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: Prepared for Office of Behavioral Health, Disability, and Aging Policy, Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services, Contract #HHSP233201600021I | True   |
| 536   | PROD       |              | $a: Prepared for Office of Behavioral Health, Disability, and Aging Policy, Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services, Contract #HHSP233201600021I | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed November 5, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed November 5, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Suicide Prevention $x: organization & administration                        | True   |
| 650   | QA         | 12           | $a: Suicide Prevention $x: economics                                            | True   |
| 650   | QA         | 22           | $a: Program Evaluation                                                          | True   |
| 650   | QA         | 22           | $a: Delivery of Health Care                                                     | True   |
| 650   | PROD       | 12           | $a: Suicide Prevention $x: organization & administration                        | True   |
| 650   | PROD       | 12           | $a: Suicide Prevention $x: economics                                            | True   |
| 650   | PROD       | 22           | $a: Program Evaluation                                                          | True   |
| 650   | PROD       | 22           | $a: Delivery of Health Care                                                     | True   |
--------------------------------------------------------------------------------------------------------------------------
| 651   | QA         |  2           | $a: United States                                                               | True   |
| 651   | PROD       |  2           | $a: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 700   | QA         | 1            | $a: Johnson, Kiersten, $d: 1989- $e: author.                                    | True   |
| 700   | QA         | 1            | $a: DeLisle, Dylan, $e: author.                                                 | True   |
| 700   | QA         | 1            | $a: Wooten, Camara, $e: author.                                                 | True   |
| 700   | QA         | 1            | $a: Miller, Adam $q: (Adam Bryant), $e: author.                                 | True   |
| 700   | PROD       | 1            | $a: Johnson, Kiersten, $d: 1989- $e: author.                                    | True   |
| 700   | PROD       | 1            | $a: DeLisle, Dylan, $e: author.                                                 | True   |
| 700   | PROD       | 1            | $a: Wooten, Camara, $e: author.                                                 | True   |
| 700   | PROD       | 1            | $a: Miller, Adam $q: (Adam Bryant), $e: author.                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 1            | $a: United States. $b: Department of Health and Human Services. $b: Office of Behavioral Health, Disability, and Aging Policy, $e: issuing body. | True   |
| 710   | QA         | 2            | $a: RTI International, $e: issuing body..                                       | True   |
| 710   | PROD       | 1            | $a: United States. $b: Department of Health and Human Services. $b: Office of Behavioral Health, Disability, and Aging Policy, $e: issuing body. | True   |
| 710   | PROD       | 2            | $a: RTI International, $e: issuing body..                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK606574/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK606574/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20241002                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20241002                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: EJP $b: 20241105                                                            | True   |
| 993   | PROD       |              | $a: EJP $b: 20241105                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241105                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241105                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241106                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241106                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20241002                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20241002                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918916898906676

Leader:
| File       | Leader                   | Equal  |
| QA         | 03327nam a2200577 i 4500 | True   |
| PROD       | 03327nam a2200577 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918916898906676                                                                | True   |
| 001   | PROD       |              | 9918916898906676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241011074009.0                                                                | True   |
| 005   | PROD       |              | 20241011074009.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 241002s2024    dcua    ob    000|0 eng                                          | True   |
| 008   | PROD       |              | 241002s2024    dcua    ob    000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 020   | QA         |              | $z: 9780309718011                                                               | True   |
| 020   | QA         |              | $z: 0309718015                                                                  | True   |
| 020   | PROD       |              | $z: 9780309718011                                                               | True   |
| 020   | PROD       |              | $z: 0309718015                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918916898906676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK604396                                                      | True   |
| 035   | QA         |              | $a: (OCoLC)1456859615                                                           | True   |
| 035   | PROD       |              | $9: 9918916898906676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK604396                                                      | True   |
| 035   | PROD       |              | $a: (OCoLC)1456859615                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WE 552                                                                      | True   |
| 060   | PROD       | 00           | $a: WE 552                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 00           | $a: Living with ALS / $c: Joe Alper, Rebecca A. English, Alan I. Leshner, editors ; Committee on Amyotrophic Lateral Sclerosis: Accelerating Treatments and Improving Quality of Life, Board on Health Care Services, Board on Health Sciences Policy, Health and Medicine Division. | True   |
| 245   | PROD       | 00           | $a: Living with ALS / $c: Joe Alper, Rebecca A. English, Alan I. Leshner, editors ; Committee on Amyotrophic Lateral Sclerosis: Accelerating Treatments and Improving Quality of Life, Board on Health Care Services, Board on Health Sciences Policy, Health and Medicine Division. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 246   | QA         | 1            | $a: Living with amyotrophic lateral sclerosis                                   | True   |
| 246   | PROD       | 1            | $a: Living with amyotrophic lateral sclerosis                                   | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington, DC : $b: National Academies Press, $c: [2024]                   | True   |
| 264   | PROD       |  1           | $a: Washington, DC : $b: National Academies Press, $c: [2024]                   | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (xviii, 207 pages)) : $b: illustrations.      | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (xviii, 207 pages)) : $b: illustrations.      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Consensus study report                                                      | True   |
| 490   | PROD       | 1            | $a: Consensus study report                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: At any one time, at least 30,000 people in the U.S. are living with amyotrophic lateral sclerosis (ALS), a rapidly progressive, fatal neurological disease affecting individuals, caregivers, at-risk genetic carriers, and others. In 2022, Congress directed the National Institutes of Health to commission a National Academies committee of experts to recommend key actions public, private, and nonprofit sectors should take to make ALS a livable disease within the next 10 years. The resulting report, Living with ALS, focuses on an integrated ALS multidisciplinary care and research system to help facilitate earlier diagnosis and connections to specialty care. | True   |
| 520   | PROD       | 3            | $a: At any one time, at least 30,000 people in the U.S. are living with amyotrophic lateral sclerosis (ALS), a rapidly progressive, fatal neurological disease affecting individuals, caregivers, at-risk genetic carriers, and others. In 2022, Congress directed the National Institutes of Health to commission a National Academies committee of experts to recommend key actions public, private, and nonprofit sectors should take to make ALS a livable disease within the next 10 years. The resulting report, Living with ALS, focuses on an integrated ALS multidisciplinary care and research system to help facilitate earlier diagnosis and connections to specialty care. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 530   | QA         |              | $a: Issued also in print.                                                       | True   |
| 530   | PROD       |              | $a: Issued also in print.                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: This activity was supported by a contract between the National Academy of Sciences and the National Institute of Neurological Disorders and Stroke, National Institutes of Health (contract number HHSN263201800029I, task order 75N98022F00011). Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. | True   |
| 536   | PROD       |              | $a: This activity was supported by a contract between the National Academy of Sciences and the National Institute of Neurological Disorders and Stroke, National Institutes of Health (contract number HHSN263201800029I, task order 75N98022F00011). Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed October 8, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed October 8, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Amyotrophic Lateral Sclerosis $x: rehabilitation                            | True   |
| 650   | QA         | 22           | $a: Quality of Life                                                             | True   |
| 650   | QA         | 22           | $a: Long-Term Care $x: methods                                                  | True   |
| 650   | QA         | 22           | $a: Family Support                                                              | True   |
| 650   | QA         | 22           | $a: Health Services Accessibility                                               | True   |
| 650   | QA         | 22           | $a: Self-Help Devices                                                           | True   |
| 650   | PROD       | 12           | $a: Amyotrophic Lateral Sclerosis $x: rehabilitation                            | True   |
| 650   | PROD       | 22           | $a: Quality of Life                                                             | True   |
| 650   | PROD       | 22           | $a: Long-Term Care $x: methods                                                  | True   |
| 650   | PROD       | 22           | $a: Family Support                                                              | True   |
| 650   | PROD       | 22           | $a: Health Services Accessibility                                               | True   |
| 650   | PROD       | 22           | $a: Self-Help Devices                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 700   | QA         | 1            | $a: Alper, Joe, $e: editor.                                                     | True   |
| 700   | QA         | 1            | $a: English, Rebecca A., $e: editor.                                            | True   |
| 700   | QA         | 1            | $a: Leshner, Alan I., $d: 1944- $e: editor.                                     | True   |
| 700   | PROD       | 1            | $a: Alper, Joe, $e: editor.                                                     | True   |
| 700   | PROD       | 1            | $a: English, Rebecca A., $e: editor.                                            | True   |
| 700   | PROD       | 1            | $a: Leshner, Alan I., $d: 1944- $e: editor.                                     | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Committee on Amyotrophic Lateral Sclerosis: Accelerating Treatments and Improving Quality of Life, $e: sponsoring body. | True   |
| 710   | PROD       | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Committee on Amyotrophic Lateral Sclerosis: Accelerating Treatments and Improving Quality of Life, $e: sponsoring body. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: Consensus study report                                                      | True   |
| 830   | PROD       |  0           | $a: Consensus study report                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604396/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604396/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20241002                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20241002                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: CAD $b: 20241008                                                            | True   |
| 993   | PROD       |              | $a: CAD $b: 20241008                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241008                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241008                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241011                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241011                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20241002                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20241002                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918916892606676

Leader:
| File       | Leader                   | Equal  |
| QA         | 09364nam a2200469 i 4500 | True   |
| PROD       | 09364nam a2200469 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918916892606676                                                                | True   |
| 001   | PROD       |              | 9918916892606676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241101115615.0                                                                | True   |
| 005   | PROD       |              | 20241101115615.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 241002s2019    dcua    ob    000|0 eng                                          | True   |
| 008   | PROD       |              | 241002s2019    dcua    ob    000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918916892606676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK607322                                                      | True   |
| 035   | PROD       |              | $9: 9918916892606676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK607322                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: W 85                                                                        | True   |
| 060   | PROD       | 00           | $a: W 85                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Wilkins, Consuelo H., $e: author.                                           | True   |
| 100   | PROD       | 1            | $a: Wilkins, Consuelo H., $e: author.                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Comparing methods to make research more patient centered / $c: Consuelo Wilkins, Sarah C. Stallings, Victoria Villalta-Gil, Mckenzie Houston, Yolanda Vaughn, Alan Richmond, Laurie Novak, Yvonne Joosten, Chris Simpson, Tiffany Israel, Alaina Boyd, Margaret Hargreaves, Velma McBride Murry, Leslie Boone, Kenneth Wallston. | True   |
| 245   | PROD       | 10           | $a: Comparing methods to make research more patient centered / $c: Consuelo Wilkins, Sarah C. Stallings, Victoria Villalta-Gil, Mckenzie Houston, Yolanda Vaughn, Alan Richmond, Laurie Novak, Yvonne Joosten, Chris Simpson, Tiffany Israel, Alaina Boyd, Margaret Hargreaves, Velma McBride Murry, Leslie Boone, Kenneth Wallston. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington (DC) : $b: Patient-Centered Outcomes Research Institute (PCORI), $c: [2019] | True   |
| 264   | PROD       |  1           | $a: Washington (DC) : $b: Patient-Centered Outcomes Research Institute (PCORI), $c: [2019] | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (56 pages)) : $b: illustrations.              | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (56 pages)) : $b: illustrations.              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Final research report                                                       | True   |
| 490   | PROD       | 1            | $a: Final research report                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: BACKGROUND: Engaging patients and communities in research has emerged as a critical element to advancing health research, improving the relevance of research, and enhanced implementation of research findings. While methods of engaging patients exist, variability among methods and limited understanding of how engagement impacts research may limit broader use. OBJECTIVES: The overall purpose of this Methods Award was to develop evidence on the impact of stakeholder engagement on research, which is a critical methodological gap identified by PCORI. Specifically we aimed to demonstrate whether input from patients and communities elicited using the Community Engagement Studio (CE Studio, formerly called Community Review Board)1 was more patient centered than input from a Translation Studio (T2 Studio), which is composed of researchers.2 To evaluate the input from studios, we developed a standard set of terms, Stakeholder Impacts in Research Taxonomy, to describe potential changes in research due to stakeholder input and a quantitative scale, which would be generally applicable to assessment and evaluation stakeholder engagement. METHODS: This methods study randomized 20 researchers to the CE Studio, a structured method of eliciting project-specific input from patients and community stakeholders, or a T2 Studio, which obtains expert advice from researchers. Any faculty member or research trainee at Vanderbilt University or Meharry Medical College was eligible to be randomized. Researchers who requested a CE Studio through StarBRITE, Vanderbilt's online portal for research support services, and agreed to be in the study were randomized to a CE Studio (a panel of community members or patients) or T2 Studio (a panel of researchers). Those who were randomized to the T2 Studio were also offered a CE Studio. Randomization to CE Studio or T2 Studio was done using random number generator software (www.r-project.org). Each studio panel was convened to provide project-specific input. The 153 stakeholders who participated as experts on CE Studios panels were patients, caregivers, or patient advocates identified by health status, health condition, or demographic variables based on the project-based needs of the 20 researchers randomized in this project. Stakeholders include individuals with diabetes, heart failure, Parkinson disease, sickle cell disease, and intensive care unit survivors. All stakeholder experts had experience as a partner or consultant on a research project or through serving on a research advisory board or committee. T2 Studio experts were researchers from Vanderbilt University or Meharry Medical College. All studios were recorded and transcribed, and experienced qualitative researchers analyzed the data. We compared the project-specific input elicited from CE Studios with that elicited from T2 Studios using qualitative analysis. To develop the taxonomy (the Stakeholder Impacts in Research Taxonomy) describing and characterizing wherein the research process stakeholder input has the potential for impact and the types of changes, we used a 3-step approach involving patients in each step: (1) identified stakeholder impacts from existing literature and generated standard terms; (2) evaluated the terms using cognitive interviews and a panel of researchers and stakeholders; and (3) pilot tested the terms using qualitative analysis. Because no such measure existed, we created and validated a quantitative instrument measuring patient (person) centeredness of research. We developed the Person-Centeredness of Research Scale (PCoR Scale) by (1) content and item generation, (2) item evaluation, (3) initial scale testing, (4) scale revision, and (5) revised scale testing. We tested the initial and revised scales by comparing ratings for abstracts from a PCORI conference with those for abstracts from a national translational research meeting. We determined the scale's internal consistency reliability with an exploratory factor analysis and Cronbach α computation. We also examined the interrater reliability of the final rating scale. RESULTS: The CE Studios generated input with more themes consistent with patient centeredness than the T2 Studios and also a striking number of patient experiences that were expressed in storytelling form. The Stakeholder Impacts in Research Taxonomy has 11 domains (representing categories of research activities) and 59 dimensions, flexibly framing the stakeholder engagement impact on translational research for increased understanding and more formal assessment. The domains are (1) preresearch, (2) infrastructure, (3) study design, (4) implementation, (5) analysis, (6) dissemination of research findings, (7) postresearch, (8) ethics, (9) process improvement, (10) engagement, and (11) communication. The PCoR Scale is a 7-item instrument using a 5-point Likert rating scale that successfully classified (based on expert panel assignment) as person centered 71.4% of the conference abstracts tested in discriminant analysis (mean total scores: 7.15 vs −2.08; t = 7.37; P < .001). An exploratory factor analysis showed the PCoR Scale to be unidimensional with an eigenvalue of 5.59 that explained 79.8% of the total variance, and we computed Cronbach α to be .95, showing high internal consistency reliability. CONCLUSIONS: Patients and community members provided project-specific input across a broad range of research areas, and this input was more person centered than input from researchers. The Stakeholder Impacts in Research Taxonomy and the quantitative PCoR Scale can be used by others in the field to help standardize this work and evaluate the patient person centeredness of research products. LIMITATIONS: Although the CE Studio can be used across many studies, it is a consultative method of engagement and may not elicit feedback reflecting the full range of stakeholder engagement. Because the intent of this study was to provide evidence to support the added value of stakeholder engagement, we compared input from stakeholders with input from researchers. We did not compare CE Studios with a different method of stakeholder engagement, which might result in more or less person centeredness. DEFINITIONS: In this report, the term stakeholder includes patients, caregivers, patient advocates, and other community members, but not payers, policy makers, or health care product producers. Researchers are also stakeholders in research, by definition, but for the purposes of this report, the term stakeholder is used to distinguish someone who is a community representative stakeholder from others with interest in the research. We have used community/patient stakeholder where that clarification seemed appropriate. A community representative is a person whose primary affiliation is with a nonacademic, nonresearch community-based organization and/or who represents a defined community.3 NOTE: The term patient centered, well-defined by PCOR, is being replaced by the broader term person centered by researchers in the field.42,43 This terminology shift occurred during the course of our project, and we use both terms, reflecting the terms used during the research and moving toward the newer term during development of the quantitative scale, as noted in the relevant methods section. | True   |
| 520   | PROD       | 3            | $a: BACKGROUND: Engaging patients and communities in research has emerged as a critical element to advancing health research, improving the relevance of research, and enhanced implementation of research findings. While methods of engaging patients exist, variability among methods and limited understanding of how engagement impacts research may limit broader use. OBJECTIVES: The overall purpose of this Methods Award was to develop evidence on the impact of stakeholder engagement on research, which is a critical methodological gap identified by PCORI. Specifically we aimed to demonstrate whether input from patients and communities elicited using the Community Engagement Studio (CE Studio, formerly called Community Review Board)1 was more patient centered than input from a Translation Studio (T2 Studio), which is composed of researchers.2 To evaluate the input from studios, we developed a standard set of terms, Stakeholder Impacts in Research Taxonomy, to describe potential changes in research due to stakeholder input and a quantitative scale, which would be generally applicable to assessment and evaluation stakeholder engagement. METHODS: This methods study randomized 20 researchers to the CE Studio, a structured method of eliciting project-specific input from patients and community stakeholders, or a T2 Studio, which obtains expert advice from researchers. Any faculty member or research trainee at Vanderbilt University or Meharry Medical College was eligible to be randomized. Researchers who requested a CE Studio through StarBRITE, Vanderbilt's online portal for research support services, and agreed to be in the study were randomized to a CE Studio (a panel of community members or patients) or T2 Studio (a panel of researchers). Those who were randomized to the T2 Studio were also offered a CE Studio. Randomization to CE Studio or T2 Studio was done using random number generator software (www.r-project.org). Each studio panel was convened to provide project-specific input. The 153 stakeholders who participated as experts on CE Studios panels were patients, caregivers, or patient advocates identified by health status, health condition, or demographic variables based on the project-based needs of the 20 researchers randomized in this project. Stakeholders include individuals with diabetes, heart failure, Parkinson disease, sickle cell disease, and intensive care unit survivors. All stakeholder experts had experience as a partner or consultant on a research project or through serving on a research advisory board or committee. T2 Studio experts were researchers from Vanderbilt University or Meharry Medical College. All studios were recorded and transcribed, and experienced qualitative researchers analyzed the data. We compared the project-specific input elicited from CE Studios with that elicited from T2 Studios using qualitative analysis. To develop the taxonomy (the Stakeholder Impacts in Research Taxonomy) describing and characterizing wherein the research process stakeholder input has the potential for impact and the types of changes, we used a 3-step approach involving patients in each step: (1) identified stakeholder impacts from existing literature and generated standard terms; (2) evaluated the terms using cognitive interviews and a panel of researchers and stakeholders; and (3) pilot tested the terms using qualitative analysis. Because no such measure existed, we created and validated a quantitative instrument measuring patient (person) centeredness of research. We developed the Person-Centeredness of Research Scale (PCoR Scale) by (1) content and item generation, (2) item evaluation, (3) initial scale testing, (4) scale revision, and (5) revised scale testing. We tested the initial and revised scales by comparing ratings for abstracts from a PCORI conference with those for abstracts from a national translational research meeting. We determined the scale's internal consistency reliability with an exploratory factor analysis and Cronbach α computation. We also examined the interrater reliability of the final rating scale. RESULTS: The CE Studios generated input with more themes consistent with patient centeredness than the T2 Studios and also a striking number of patient experiences that were expressed in storytelling form. The Stakeholder Impacts in Research Taxonomy has 11 domains (representing categories of research activities) and 59 dimensions, flexibly framing the stakeholder engagement impact on translational research for increased understanding and more formal assessment. The domains are (1) preresearch, (2) infrastructure, (3) study design, (4) implementation, (5) analysis, (6) dissemination of research findings, (7) postresearch, (8) ethics, (9) process improvement, (10) engagement, and (11) communication. The PCoR Scale is a 7-item instrument using a 5-point Likert rating scale that successfully classified (based on expert panel assignment) as person centered 71.4% of the conference abstracts tested in discriminant analysis (mean total scores: 7.15 vs −2.08; t = 7.37; P < .001). An exploratory factor analysis showed the PCoR Scale to be unidimensional with an eigenvalue of 5.59 that explained 79.8% of the total variance, and we computed Cronbach α to be .95, showing high internal consistency reliability. CONCLUSIONS: Patients and community members provided project-specific input across a broad range of research areas, and this input was more person centered than input from researchers. The Stakeholder Impacts in Research Taxonomy and the quantitative PCoR Scale can be used by others in the field to help standardize this work and evaluate the patient person centeredness of research products. LIMITATIONS: Although the CE Studio can be used across many studies, it is a consultative method of engagement and may not elicit feedback reflecting the full range of stakeholder engagement. Because the intent of this study was to provide evidence to support the added value of stakeholder engagement, we compared input from stakeholders with input from researchers. We did not compare CE Studios with a different method of stakeholder engagement, which might result in more or less person centeredness. DEFINITIONS: In this report, the term stakeholder includes patients, caregivers, patient advocates, and other community members, but not payers, policy makers, or health care product producers. Researchers are also stakeholders in research, by definition, but for the purposes of this report, the term stakeholder is used to distinguish someone who is a community representative stakeholder from others with interest in the research. We have used community/patient stakeholder where that clarification seemed appropriate. A community representative is a person whose primary affiliation is with a nonacademic, nonresearch community-based organization and/or who represents a defined community.3 NOTE: The term patient centered, well-defined by PCOR, is being replaced by the broader term person centered by researchers in the field.42,43 This terminology shift occurred during the course of our project, and we use both terms, reflecting the terms used during the research and moving toward the newer term during development of the quantitative scale, as noted in the relevant methods section. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: Original Project Title: Improving Patient Engagement and Understanding Its Impact on Research Through Community Review Boards PCORI ID: ME-1306-03342 | True   |
| 536   | PROD       |              | $a: Original Project Title: Improving Patient Engagement and Understanding Its Impact on Research Through Community Review Boards PCORI ID: ME-1306-03342 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed Oct. 31, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed Oct. 31, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Patient Participation                                                       | True   |
| 650   | QA         | 22           | $a: Community Health Services                                                   | True   |
| 650   | QA         | 22           | $a: Health Services Research                                                    | True   |
| 650   | QA         | 22           | $a: Comparative Effectiveness Research                                          | True   |
| 650   | PROD       | 12           | $a: Patient Participation                                                       | True   |
| 650   | PROD       | 22           | $a: Community Health Services                                                   | True   |
| 650   | PROD       | 22           | $a: Health Services Research                                                    | True   |
| 650   | PROD       | 22           | $a: Comparative Effectiveness Research                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: Patient-Centered Outcomes Research Institute (U.S.), $e: issuing body.      | True   |
| 710   | PROD       | 2            | $a: Patient-Centered Outcomes Research Institute (U.S.), $e: issuing body.      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: Final research report (Patient-Centered Outcomes Research Institute (U.S.)) | True   |
| 830   | PROD       |  0           | $a: Final research report (Patient-Centered Outcomes Research Institute (U.S.)) | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK607322/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK607322/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20241002                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20241002                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: IHH $b: 20241031                                                            | True   |
| 993   | PROD       |              | $a: IHH $b: 20241031                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241031                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241031                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241031 $c: REV $d: 20241101                                      | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241031 $c: REV $d: 20241101                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20241002                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20241002                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918916895306676

Leader:
| File       | Leader                   | Equal  |
| QA         | 03812nam a2200493 i 4500 | True   |
| PROD       | 03812nam a2200493 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918916895306676                                                                | True   |
| 001   | PROD       |              | 9918916895306676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241113104200.0                                                                | True   |
| 005   | PROD       |              | 20241113104200.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 241002s2024    dcua    ob    000|0 eng                                          | True   |
| 008   | PROD       |              | 241002s2024    dcua    ob    000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 020   | QA         |              | $z: 9780309717854                                                               | True   |
| 020   | QA         |              | $z: 030971785X                                                                  | True   |
| 020   | PROD       |              | $z: 9780309717854                                                               | True   |
| 020   | PROD       |              | $z: 030971785X                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918916895306676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK607603                                                      | True   |
| 035   | PROD       |              | $9: 9918916895306676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK607603                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WW 320                                                                      | True   |
| 060   | PROD       | 00           | $a: WW 320                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 110   | QA         | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Committee on Focus on Myopia: Pathogenesis and Rising Incidence, $e: author. | True   |
| 110   | PROD       | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Committee on Focus on Myopia: Pathogenesis and Rising Incidence, $e: author. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Myopia : $b: causes, prevention, and treatment of an increasingly common disease / $c: Committee on Focus on Myopia: Pathogenesis and Rising Incidence, Board on Behavioral, Cognitive, and Sensory Sciences, Division of Behavioral and Social Sciences and Education. | True   |
| 245   | PROD       | 10           | $a: Myopia : $b: causes, prevention, and treatment of an increasingly common disease / $c: Committee on Focus on Myopia: Pathogenesis and Rising Incidence, Board on Behavioral, Cognitive, and Sensory Sciences, Division of Behavioral and Social Sciences and Education. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington, DC : $b: National Academies Press, $c: [2024]                   | True   |
| 264   | PROD       |  1           | $a: Washington, DC : $b: National Academies Press, $c: [2024]                   | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (xxiv, 350 pages)) : $b: illustrations.       | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (xxiv, 350 pages)) : $b: illustrations.       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Consensus study report                                                      | True   |
| 490   | PROD       | 1            | $a: Consensus study report                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: Myopia, commonly called nearsightedness, has been increasing globally. If current trends continue, there will be 5 billion near-sighted individuals globally by 2050. The understanding of myopia has been enhanced by advances in genetics, investigations employing animal models, understanding of physiology, ocular imaging, epidemiology, environmental research, and clinical trials of interventional strategies. To further develop the knowledge base related to myopia and to reduce the incidence and negative consequences of the disease, eye care professionals, federal agencies, and funding agencies need to make improvements to standardize care, increase funding to study treatments, encourage outdoor time, and overall facilitate the standardization of assessments and diagnostics. Progress in these areas is imperative to address the current increase in myopia across the country. Myopia: Causes, Prevention, and Treatment of an Increasingly Common Disease identifies and assesses the current mechanistic understanding of myopia pathogenesis and the causes of its increased prevalence. This report also examines knowledge gaps and barriers to progress and develops a research agenda aimed at better understanding the biological and environmental factors that could explain the increasing incidence of myopia. | True   |
| 520   | PROD       | 3            | $a: Myopia, commonly called nearsightedness, has been increasing globally. If current trends continue, there will be 5 billion near-sighted individuals globally by 2050. The understanding of myopia has been enhanced by advances in genetics, investigations employing animal models, understanding of physiology, ocular imaging, epidemiology, environmental research, and clinical trials of interventional strategies. To further develop the knowledge base related to myopia and to reduce the incidence and negative consequences of the disease, eye care professionals, federal agencies, and funding agencies need to make improvements to standardize care, increase funding to study treatments, encourage outdoor time, and overall facilitate the standardization of assessments and diagnostics. Progress in these areas is imperative to address the current increase in myopia across the country. Myopia: Causes, Prevention, and Treatment of an Increasingly Common Disease identifies and assesses the current mechanistic understanding of myopia pathogenesis and the causes of its increased prevalence. This report also examines knowledge gaps and barriers to progress and develops a research agenda aimed at better understanding the biological and environmental factors that could explain the increasing incidence of myopia. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 530   | QA         |              | $a: Issued also in print.                                                       | True   |
| 530   | PROD       |              | $a: Issued also in print.                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: This activity was supported by contracts between the National Academy of Sciences and the American Academy of Optometry; the American Optometric Association; the Health Care Alliance for Patient Safety; the Herbert Wertheim School of Optometry & Vision Science, University of California, Berkeley; Johnson & Johnson Vision; the National Eye Institute (HHSN263201800029I/75N98022F00005); Reality Labs Research; Research to Prevent Blindness; and the Warby Parker Impact Foundation. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. | True   |
| 536   | PROD       |              | $a: This activity was supported by contracts between the National Academy of Sciences and the American Academy of Optometry; the American Optometric Association; the Health Care Alliance for Patient Safety; the Herbert Wertheim School of Optometry & Vision Science, University of California, Berkeley; Johnson & Johnson Vision; the National Eye Institute (HHSN263201800029I/75N98022F00005); Reality Labs Research; Research to Prevent Blindness; and the Warby Parker Impact Foundation. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed November 22, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed November 22, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Myopia                                                                      | True   |
| 650   | QA         | 22           | $a: Biomedical Research                                                         | True   |
| 650   | QA         | 22           | $a: Evidence Gaps                                                               | True   |
| 650   | PROD       | 12           | $a: Myopia                                                                      | True   |
| 650   | PROD       | 22           | $a: Biomedical Research                                                         | True   |
| 650   | PROD       | 22           | $a: Evidence Gaps                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 651   | QA         |  2           | $a: United States                                                               | True   |
| 651   | PROD       |  2           | $a: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: Consensus study report                                                      | True   |
| 830   | PROD       |  0           | $a: Consensus study report                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK607603/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK607603/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20241002                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20241002                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: EJP $b: 20241107                                                            | True   |
| 993   | PROD       |              | $a: EJP $b: 20241107                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241112                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241112                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241113                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241113                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20241002                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20241002                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918916893806676

Leader:
| File       | Leader                   | Equal  |
| QA         | 07533nam a2200469 i 4500 | True   |
| PROD       | 07533nam a2200469 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918916893806676                                                                | True   |
| 001   | PROD       |              | 9918916893806676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241118113231.0                                                                | True   |
| 005   | PROD       |              | 20241118113231.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 241002s2022    dcua    obs   000|0 eng                                          | True   |
| 008   | PROD       |              | 241002s2022    dcua    obs   000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918916893806676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK606827                                                      | True   |
| 035   | PROD       |              | $9: 9918916893806676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK606827                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: QZ 16.1                                                                     | True   |
| 060   | PROD       | 00           | $a: QZ 16.1                                                                     | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Stover, Angela M., $e: author.                                              | True   |
| 100   | PROD       | 1            | $a: Stover, Angela M., $e: author.                                              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Developing patient-reported outcome measures to assess side effects of cancer treatment / $c: Angela M. Stover, Benjamin Y. Urick, Jennifer Jansen, Philip Carr, Allison Deal, Patricia A. Spears, Mary Lou Smith, Cindy Geoghegan, Ethan M. Basch. | True   |
| 245   | PROD       | 10           | $a: Developing patient-reported outcome measures to assess side effects of cancer treatment / $c: Angela M. Stover, Benjamin Y. Urick, Jennifer Jansen, Philip Carr, Allison Deal, Patricia A. Spears, Mary Lou Smith, Cindy Geoghegan, Ethan M. Basch. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington (DC) : $b: Patient-Centered Outcomes Research Institute (PCORI), $c: [2022]. | True   |
| 264   | PROD       |  1           | $a: Washington (DC) : $b: Patient-Centered Outcomes Research Institute (PCORI), $c: [2022]. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (115 pages)) : $b: illustrations.             | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (115 pages)) : $b: illustrations.             | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Final research report                                                       | True   |
| 490   | PROD       | 1            | $a: Final research report                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: BACKGROUND: Although patient questionnaires are commonly used to assess health care experiences (eg, satisfaction with care), patient-reported outcome performance measures (PRO-PMs) assessing symptoms and physical functioning have not been part of quality assessment in oncology. OBJECTIVE: To develop and test PRO-PMs for use during chemotherapy. METHODS: 1. Aim 1: We interviewed 124 stakeholders to identify key symptoms to test as PRO-PMs and potential risk adjustment variables.2. Aim 2: We conducted a structured literature review to identify prevalent symptoms. We combined the results from interviews and the literature review through expert consensus into a final list of symptoms. Then, we evaluated existing PRO-PMs assessing identified symptoms.3. Aim 3: We enrolled patients actively receiving chemotherapy at 6 cancer centers (in California, Connecticut, Florida, Minnesota, North Carolina, and Texas). Each patient completed PRO-PM items at home between 5 and 15 days after initiation of a therapy cycle.Patients chose to complete the questionnaire online, by an automated telephone system, or on paper, and it was available in English, Spanish, and Mandarin. We defined feasibility as at least 75% of patients completing the PRO questionnaire. We developed practice-level PRO-PM specifications for each symptom individually (eg, proportion of patients at a practice with well-controlled symptom [eg, pain]) and for multisymptom summary measures. To account for variation in case mixes across cancer centers, we risk-adjusted every measure using hierarchical logistic regression models predicting the odds of high symptom burden, controlling for cancer type, age, sex, and race. For the multisymptom measures, optimal cutoffs were identified as those that maximized validity (correlation with physical functioning) and reliability (ability to accurately differentiate performance across providers) while remaining clinically actionable. RESULTS: Interviews in aim 1 included patients with cancer in active treatment (n = 56); primary caregivers (n = 21); patient investigators (n = 5); clinicians without clinic administrative responsibilities (n = 11); health care administrators (n = 16, of whom 12 were also clinicians); and national experts, including clinicians (n = 15, of whom 5 were also clinicians). We recruited patients, caregivers, clinicians, and health care administrators from the 6 cancer centers and identified experts nationally. Among patients with cancer, 48% were women, 34% were aged ≥65 years, 14% were Black/African American, 8% were Asian, and 20% had a high school education or less. Common cancer types included genitourinary (32%), gastrointestinal (27%), breast (21%), and lung (20%). Caregiver relationships were typically a spouse, partner, or adult child. In aim 2, we combined a literature review with interview results from aim 1 to refine a final list of symptoms to test, as follows: gastrointestinal symptoms (nausea, vomiting, constipation, diarrhea), sleep issues, depression, anxiety, pain, neuropathy, and shortness of breath. Although fatigue and appetite loss were acknowledged by the stakeholders as being important, we eliminated these symptoms because they are not sufficiently clinically treatable. Stakeholder recommendations for risk adjustment variables to test empirically included insurance status, cancer type, age, sex, and difficulty paying bills. In aim 3, a total of 653 patients enrolled, of whom 607 completed the questionnaire (93%). Specifically, 470 of 607 (77%) completed the PRO questionnaire without a reminder call, and another 14% completed it after a staff member called. Most (>95%) participants found the PRO questions to be easy to understand and complete. When questionnaires were aggregated to the cancer center level, 1 cancer center descriptively appeared to perform better than others across measures, and 1 appeared to perform relatively worse, with the other 4 sites grouped similarly. Adjusting for cancer type and age had a modest effect on site-level scores. Adjustment variables for insurance status, sex, and difficulty paying bills were not significant in models and were thus removed. Empirical testing showed that combining the individual PRO-PM items for pain, nausea, and diarrhea was possible, with an optimal cutoff score of 0 to 4 vs 5 to 12 and with higher scores indicating greater symptom burden. The optimal cutoff scores for the 10-item measure were 0 to 14 vs 15 to 40. Summary PRO-PMs numerically differentiated between cancer centers but did not meet the recommended reliability threshold. CONCLUSIONS: Patients, caregivers, clinicians, national experts, and other stakeholders agree that performance measures based on how patients feel and function would be an important addition for payers to use in evaluating the quality of care provided by health care systems and provider groups. PRO-PMs can be feasibly captured at home during systemic therapy and are acceptable to patients. PRO-PMs may add meaningful information to evaluate quality of care, but more data are needed to establish the reliability and validity of these PRO-PMs before adopting them into performance-based oncology payment models. LIMITATIONS: Testing occurred at 6 sites among more than 600 patients, and further testing would strengthen generalizability. Additional data are also needed to meet recommended reliability thresholds. Such testing is planned. | True   |
| 520   | PROD       | 3            | $a: BACKGROUND: Although patient questionnaires are commonly used to assess health care experiences (eg, satisfaction with care), patient-reported outcome performance measures (PRO-PMs) assessing symptoms and physical functioning have not been part of quality assessment in oncology. OBJECTIVE: To develop and test PRO-PMs for use during chemotherapy. METHODS: 1. Aim 1: We interviewed 124 stakeholders to identify key symptoms to test as PRO-PMs and potential risk adjustment variables.2. Aim 2: We conducted a structured literature review to identify prevalent symptoms. We combined the results from interviews and the literature review through expert consensus into a final list of symptoms. Then, we evaluated existing PRO-PMs assessing identified symptoms.3. Aim 3: We enrolled patients actively receiving chemotherapy at 6 cancer centers (in California, Connecticut, Florida, Minnesota, North Carolina, and Texas). Each patient completed PRO-PM items at home between 5 and 15 days after initiation of a therapy cycle.Patients chose to complete the questionnaire online, by an automated telephone system, or on paper, and it was available in English, Spanish, and Mandarin. We defined feasibility as at least 75% of patients completing the PRO questionnaire. We developed practice-level PRO-PM specifications for each symptom individually (eg, proportion of patients at a practice with well-controlled symptom [eg, pain]) and for multisymptom summary measures. To account for variation in case mixes across cancer centers, we risk-adjusted every measure using hierarchical logistic regression models predicting the odds of high symptom burden, controlling for cancer type, age, sex, and race. For the multisymptom measures, optimal cutoffs were identified as those that maximized validity (correlation with physical functioning) and reliability (ability to accurately differentiate performance across providers) while remaining clinically actionable. RESULTS: Interviews in aim 1 included patients with cancer in active treatment (n = 56); primary caregivers (n = 21); patient investigators (n = 5); clinicians without clinic administrative responsibilities (n = 11); health care administrators (n = 16, of whom 12 were also clinicians); and national experts, including clinicians (n = 15, of whom 5 were also clinicians). We recruited patients, caregivers, clinicians, and health care administrators from the 6 cancer centers and identified experts nationally. Among patients with cancer, 48% were women, 34% were aged ≥65 years, 14% were Black/African American, 8% were Asian, and 20% had a high school education or less. Common cancer types included genitourinary (32%), gastrointestinal (27%), breast (21%), and lung (20%). Caregiver relationships were typically a spouse, partner, or adult child. In aim 2, we combined a literature review with interview results from aim 1 to refine a final list of symptoms to test, as follows: gastrointestinal symptoms (nausea, vomiting, constipation, diarrhea), sleep issues, depression, anxiety, pain, neuropathy, and shortness of breath. Although fatigue and appetite loss were acknowledged by the stakeholders as being important, we eliminated these symptoms because they are not sufficiently clinically treatable. Stakeholder recommendations for risk adjustment variables to test empirically included insurance status, cancer type, age, sex, and difficulty paying bills. In aim 3, a total of 653 patients enrolled, of whom 607 completed the questionnaire (93%). Specifically, 470 of 607 (77%) completed the PRO questionnaire without a reminder call, and another 14% completed it after a staff member called. Most (>95%) participants found the PRO questions to be easy to understand and complete. When questionnaires were aggregated to the cancer center level, 1 cancer center descriptively appeared to perform better than others across measures, and 1 appeared to perform relatively worse, with the other 4 sites grouped similarly. Adjusting for cancer type and age had a modest effect on site-level scores. Adjustment variables for insurance status, sex, and difficulty paying bills were not significant in models and were thus removed. Empirical testing showed that combining the individual PRO-PM items for pain, nausea, and diarrhea was possible, with an optimal cutoff score of 0 to 4 vs 5 to 12 and with higher scores indicating greater symptom burden. The optimal cutoff scores for the 10-item measure were 0 to 14 vs 15 to 40. Summary PRO-PMs numerically differentiated between cancer centers but did not meet the recommended reliability threshold. CONCLUSIONS: Patients, caregivers, clinicians, national experts, and other stakeholders agree that performance measures based on how patients feel and function would be an important addition for payers to use in evaluating the quality of care provided by health care systems and provider groups. PRO-PMs can be feasibly captured at home during systemic therapy and are acceptable to patients. PRO-PMs may add meaningful information to evaluate quality of care, but more data are needed to establish the reliability and validity of these PRO-PMs before adopting them into performance-based oncology payment models. LIMITATIONS: Testing occurred at 6 sites among more than 600 patients, and further testing would strengthen generalizability. Additional data are also needed to meet recommended reliability thresholds. Such testing is planned. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: Institution Receiving Award: University of North Carolina at Chapel Hill Original Project Title: Development and Evaluation of a Patient-Centered Approach to Assess Quality of Care: Patient-Reported Outcomes-based Performance Measures (PRO-PMs) PCORI ID: ME-1507-32079 | True   |
| 536   | PROD       |              | $a: Institution Receiving Award: University of North Carolina at Chapel Hill Original Project Title: Development and Evaluation of a Patient-Centered Approach to Assess Quality of Care: Patient-Reported Outcomes-based Performance Measures (PRO-PMs) PCORI ID: ME-1507-32079 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed November 15, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed November 15, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Neoplasms $x: drug therapy                                                  | True   |
| 650   | QA         | 12           | $a: Antineoplastic Agents $x: adverse effects                                   | True   |
| 650   | QA         | 22           | $a: Patient Reported Outcome Measures                                           | True   |
| 650   | PROD       | 12           | $a: Neoplasms $x: drug therapy                                                  | True   |
| 650   | PROD       | 12           | $a: Antineoplastic Agents $x: adverse effects                                   | True   |
| 650   | PROD       | 22           | $a: Patient Reported Outcome Measures                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 655   | QA         |  2           | $a: Statistics                                                                  | True   |
| 655   | PROD       |  2           | $a: Statistics                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: Patient-Centered Outcomes Research Institute (U.S.), $e: issuing body.      | True   |
| 710   | PROD       | 2            | $a: Patient-Centered Outcomes Research Institute (U.S.), $e: issuing body.      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: Final research report (Patient-Centered Outcomes Research Institute (U.S.)) | True   |
| 830   | PROD       |  0           | $a: Final research report (Patient-Centered Outcomes Research Institute (U.S.)) | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK606827/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK606827/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20241002                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20241002                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: EJP $b: 20241107                                                            | True   |
| 993   | PROD       |              | $a: EJP $b: 20241107                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241115                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241115                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241118                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241118                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20241002                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20241002                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918916898006676

Leader:
| File       | Leader                   | Equal  |
| QA         | 05719nam a2200457 i 4500 | True   |
| PROD       | 05719nam a2200457 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918916898006676                                                                | True   |
| 001   | PROD       |              | 9918916898006676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241101150846.0                                                                | True   |
| 005   | PROD       |              | 20241101150846.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 241002s2020    dcua    ob    000|0 eng                                          | True   |
| 008   | PROD       |              | 241002s2020    dcua    ob    000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918916898006676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK607357                                                      | True   |
| 035   | PROD       |              | $9: 9918916898006676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK607357                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WB 103                                                                      | True   |
| 060   | PROD       | 00           | $a: WB 103                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Alegria, Margarita, $e: author.                                             | True   |
| 100   | PROD       | 1            | $a: Alegria, Margarita, $e: author.                                             | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Shared decision making coaching for behavioral health providers and patients / $c: Margarita Alegria, Ora Nakash. | True   |
| 245   | PROD       | 10           | $a: Shared decision making coaching for behavioral health providers and patients / $c: Margarita Alegria, Ora Nakash. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington (DC) : $b: Patient-Centered Outcomes Research Institute (PCORI), $c: [2020] | True   |
| 264   | PROD       |  1           | $a: Washington (DC) : $b: Patient-Centered Outcomes Research Institute (PCORI), $c: [2020] | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (95 pages)) : $b: illustrations.              | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (95 pages)) : $b: illustrations.              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Final research report                                                       | True   |
| 490   | PROD       | 1            | $a: Final research report                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: BACKGROUND: Shared decision-making (SDM) in health care is a process in which both patients and providers are equal partners collaborating to make health care decisions. SDM improves outcomes and quality of care; yet, few providers actively facilitate SDM. To date, few randomized controlled trials (RCTs) to improve SDM have been conducted with ethnic/racial minorities and none have been tested in behavioral health care. OBJECTIVES: To test the effectiveness of the DECIDE (Decide the problem; Explore the questions; Closed or open-ended questions; Identify the who, why, or how of the problem; Direct questions to your health care professional; and Enjoy a shared solution) patient and DECIDE provider coaching interventions for improving SDM and quality of care among an ethnically/racially diverse population. METHODS: We conducted a cross-level 2×2 RCT including clinicians at level 2 and patients (nested within clinicians) at level 1. We recruited participants (312 patients, 74 providers) starting in September 2013 and collected final data in September 2016 at 13 behavioral health clinics in Massachusetts. The provider intervention focused on promoting patient-centered communication as a pathway to improved SDM. It included a small group workshop and up to 6 individual coaching calls. The patient intervention sought to improve SDM and quality of care for patients in behavioral health care, independent of their clinical profile, and included 3 one-on-one sessions. Main outcome measures included blind coder-assessed SDM based on an audio-recorded clinical encounter, patient and provider SDM ratings, and patients' perception of quality of care (PoC). We conducted intent-to-treat and dosage analyses, followed by mediation and moderation analyses for patients in behavioral health care. RESULTS: The provider intervention significantly increased blind coder-assessed SDM (b = 4.52; SE, 2.17; P = .04); the clinical encounters of providers who received the SDM training intervention were rated 4.52 points higher on the OPTION ("observing patient involvement") scale of SDM, from 0 to 100 (mean, 33.0; SD, 14.43; Cohen d = 0.29). The training dosage analysis corroborated the intent-to-treat analysis, showing that greater provider training dosage significantly increased blind coder SDM (b = 12.01; SE, 3.72; P = .001; Cohen d = 0.78). We found no significant effect of the patient intervention on blind coder SDM or of the patient or provider intervention on patient- or provider-reported SDM. The patient intervention significantly increased PoC (b = 2.27; SE, 1.16; P = .049), such that intervention patients rated their care quality 2.27 points higher on a scale from 0 to 100 (mean, 89.9; SD, 12.0) as compared with the control group. Patient training dosage was significantly positively associated with PoC (b = 3.33; SE, 1.17; P = .01; Cohen d = 0.28). The interaction of patient and provider training dosage was also significantly associated with PoC (b = 7.40; SE, 3.56; P = .04; Cohen d = 0.62), indicating patients rated their quality of care 7 points higher when both obtained the recommended number of training sessions. Patient-centered communication and therapeutic alliance mediated the intervention effect on PoC. Finally, our moderation analyses suggested that the provider intervention had a stronger effect on PoC when patients and providers did not share the same primary language. CONCLUSIONS: The provider intervention improved SDM, with small to moderate effects. We observed the greatest improvement in perception of quality of care when both patients and providers obtained the recommended number of training sessions. LIMITATIONS AND SUBPOPULATION CONSIDERATIONS: We included only providers and patients who voluntarily participated in the study; thus, selection bias might have occurred. The results may not be applicable beyond behavioral health care settings. | True   |
| 520   | PROD       | 3            | $a: BACKGROUND: Shared decision-making (SDM) in health care is a process in which both patients and providers are equal partners collaborating to make health care decisions. SDM improves outcomes and quality of care; yet, few providers actively facilitate SDM. To date, few randomized controlled trials (RCTs) to improve SDM have been conducted with ethnic/racial minorities and none have been tested in behavioral health care. OBJECTIVES: To test the effectiveness of the DECIDE (Decide the problem; Explore the questions; Closed or open-ended questions; Identify the who, why, or how of the problem; Direct questions to your health care professional; and Enjoy a shared solution) patient and DECIDE provider coaching interventions for improving SDM and quality of care among an ethnically/racially diverse population. METHODS: We conducted a cross-level 2×2 RCT including clinicians at level 2 and patients (nested within clinicians) at level 1. We recruited participants (312 patients, 74 providers) starting in September 2013 and collected final data in September 2016 at 13 behavioral health clinics in Massachusetts. The provider intervention focused on promoting patient-centered communication as a pathway to improved SDM. It included a small group workshop and up to 6 individual coaching calls. The patient intervention sought to improve SDM and quality of care for patients in behavioral health care, independent of their clinical profile, and included 3 one-on-one sessions. Main outcome measures included blind coder-assessed SDM based on an audio-recorded clinical encounter, patient and provider SDM ratings, and patients' perception of quality of care (PoC). We conducted intent-to-treat and dosage analyses, followed by mediation and moderation analyses for patients in behavioral health care. RESULTS: The provider intervention significantly increased blind coder-assessed SDM (b = 4.52; SE, 2.17; P = .04); the clinical encounters of providers who received the SDM training intervention were rated 4.52 points higher on the OPTION ("observing patient involvement") scale of SDM, from 0 to 100 (mean, 33.0; SD, 14.43; Cohen d = 0.29). The training dosage analysis corroborated the intent-to-treat analysis, showing that greater provider training dosage significantly increased blind coder SDM (b = 12.01; SE, 3.72; P = .001; Cohen d = 0.78). We found no significant effect of the patient intervention on blind coder SDM or of the patient or provider intervention on patient- or provider-reported SDM. The patient intervention significantly increased PoC (b = 2.27; SE, 1.16; P = .049), such that intervention patients rated their care quality 2.27 points higher on a scale from 0 to 100 (mean, 89.9; SD, 12.0) as compared with the control group. Patient training dosage was significantly positively associated with PoC (b = 3.33; SE, 1.17; P = .01; Cohen d = 0.28). The interaction of patient and provider training dosage was also significantly associated with PoC (b = 7.40; SE, 3.56; P = .04; Cohen d = 0.62), indicating patients rated their quality of care 7 points higher when both obtained the recommended number of training sessions. Patient-centered communication and therapeutic alliance mediated the intervention effect on PoC. Finally, our moderation analyses suggested that the provider intervention had a stronger effect on PoC when patients and providers did not share the same primary language. CONCLUSIONS: The provider intervention improved SDM, with small to moderate effects. We observed the greatest improvement in perception of quality of care when both patients and providers obtained the recommended number of training sessions. LIMITATIONS AND SUBPOPULATION CONSIDERATIONS: We included only providers and patients who voluntarily participated in the study; thus, selection bias might have occurred. The results may not be applicable beyond behavioral health care settings. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: Original Project Title: Effectiveness of DECIDE in Patient-Provider Communication, Therapeutic Alliance & Care Continuation PCORI ID: CD-12-11-4187-IC ClinicalTrials.gov ID: NCT01947283 | True   |
| 536   | PROD       |              | $a: Original Project Title: Effectiveness of DECIDE in Patient-Provider Communication, Therapeutic Alliance & Care Continuation PCORI ID: CD-12-11-4187-IC ClinicalTrials.gov ID: NCT01947283 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed Nov. 1, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed Nov. 1, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Behavioral Medicine                                                         | True   |
| 650   | QA         | 22           | $a: Decision Making, Shared                                                     | True   |
| 650   | PROD       | 12           | $a: Behavioral Medicine                                                         | True   |
| 650   | PROD       | 22           | $a: Decision Making, Shared                                                     | True   |
--------------------------------------------------------------------------------------------------------------------------
| 700   | QA         | 1            | $a: Nakash, Ora, $e: author.                                                    | True   |
| 700   | PROD       | 1            | $a: Nakash, Ora, $e: author.                                                    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: Patient-Centered Outcomes Research Institute (U.S.), $e: issuing body.      | True   |
| 710   | PROD       | 2            | $a: Patient-Centered Outcomes Research Institute (U.S.), $e: issuing body.      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: Final research report (Patient-Centered Outcomes Research Institute (U.S.)) | True   |
| 830   | PROD       |  0           | $a: Final research report (Patient-Centered Outcomes Research Institute (U.S.)) | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK607357/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK607357/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20241002                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20241002                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: IHH $b: 20241101                                                            | True   |
| 993   | PROD       |              | $a: IHH $b: 20241101                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241101                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241101                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241101                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241101                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20241002                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20241002                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918897700906676

Leader:
| File       | Leader                   | Equal  |
| QA         | 05764nam a2200589 i 4500 | True   |
| PROD       | 05764nam a2200589 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918897700906676                                                                | True   |
| 001   | PROD       |              | 9918897700906676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241113085312.0                                                                | True   |
| 005   | PROD       |              | 20241113085312.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240902s2024    dcua    ob    100|0 eng                                          | True   |
| 008   | PROD       |              | 240902s2024    dcua    ob    100|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 020   | QA         |              | $z: 9780309719162                                                               | True   |
| 020   | QA         |              | $z: 030971916X                                                                  | True   |
| 020   | PROD       |              | $z: 9780309719162                                                               | True   |
| 020   | PROD       |              | $z: 030971916X                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918897700906676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK604279                                                      | True   |
| 035   | PROD       |              | $9: 9918897700906676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK604279                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WM 169                                                                      | True   |
| 060   | PROD       | 00           | $a: WM 169                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Babik, Kelsey R., $e: rapporteur.                                           | True   |
| 100   | PROD       | 1            | $a: Babik, Kelsey R., $e: rapporteur.                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Adult attention-deficit/hyperactivity disorder : $b: diagnosis, treatment, and implications for drug development : proceedings of a workshop / $c: Kelsey R. Babik, Noah Ontjes, Carol Berkower, Sheena M. Posey Norris, and Carolyn Shore, rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Health and Medicine Division. | True   |
| 245   | PROD       | 10           | $a: Adult attention-deficit/hyperactivity disorder : $b: diagnosis, treatment, and implications for drug development : proceedings of a workshop / $c: Kelsey R. Babik, Noah Ontjes, Carol Berkower, Sheena M. Posey Norris, and Carolyn Shore, rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Health and Medicine Division. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington, DC : $b: National Academies Press, $c: [2024]                   | True   |
| 264   | PROD       |  1           | $a: Washington, DC : $b: National Academies Press, $c: [2024]                   | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (xx, 149 pages)) : $b: illustration           | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (xx, 149 pages)) : $b: illustration           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: Attention deficit/hyperactivity disorder (ADHD) diagnosis and treatment among adults has increased over the past decade in the U.S. and globally. Evidence suggests adults with ADHD may be more likely to develop a substance use disorder, and there are concerns that nonmedical use of prescription stimulants could lead to misuse, overdose, or toxicity. In December 2023, The National Academies Forum on Drug Discovery, Development, and Translation and Forum on Neuroscience and Nervous System Disorders held a public workshop to examine the diagnosis and treatment of adults with ADHD and explore the challenges and opportunities for the development of new therapeutics. The workshop was supported, in part, through a grant (PAR-23-072) from the Center for Drug Evaluation and Research at the FDA. | True   |
| 520   | PROD       | 3            | $a: Attention deficit/hyperactivity disorder (ADHD) diagnosis and treatment among adults has increased over the past decade in the U.S. and globally. Evidence suggests adults with ADHD may be more likely to develop a substance use disorder, and there are concerns that nonmedical use of prescription stimulants could lead to misuse, overdose, or toxicity. In December 2023, The National Academies Forum on Drug Discovery, Development, and Translation and Forum on Neuroscience and Nervous System Disorders held a public workshop to examine the diagnosis and treatment of adults with ADHD and explore the challenges and opportunities for the development of new therapeutics. The workshop was supported, in part, through a grant (PAR-23-072) from the Center for Drug Evaluation and Research at the FDA. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 530   | QA         |              | $a: Issued also in print.                                                       | True   |
| 530   | PROD       |              | $a: Issued also in print.                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 536   | QA         |              | $a: This activity was supported by contracts between the National Academy of Sciences and Acadia Pharmaceuticals; Alzheimer's Association; American Brain Coalition; American Neurological Association; Amgen Inc.; Association of American Medical Colleges; AstraZeneca; Biogen; Boehringer Ingelheim (Contract No. 755326); BrightFocus Foundation; Burroughs Wellcome Fund (Contract No. 1023129); California Institute for Regenerative Medicine; Cerevel Therapeutics; Cohen Veterans Bioscience; Department of Veteran Affairs (Contract No. 36C24E20C009); Eisai; Eli Lilly and Company; FasterCures, Milken Institute; Foundation for the National Institutes of Health; Friends of Cancer Research; Gatsby Charitable Foundation; Harmony Biosciences; Janssen Research & Development, LLC; Johnson & Johnson; Karuna Therapeutics; Lundbeck Research USA, Inc.; Medable Inc.; Merck & Co., Inc. (Contract No. MRLCPO-23-166623); Michael J. Fox Foundation for Parkinson's Research; National Institutes of Health (Contract No. HHSN263201800029I; Task Order Nos. HHSN26300007 and 75N98024F00001): BRAIN Initiative, National Cancer Institute, National Center for Advancing Translational Sciences, National Center for Complementary and Integrative Health, National Eye Institute, National Institute of Allergy and Infectious Diseases, National Institute of Environmental Health Sciences, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, and National Institute on Drug Abuse, Office of the Director; National Multiple Sclerosis Society; National Science Foundation; New England Journal of Medicine; One Mind; Paul G. Allen Frontiers Group; Sanofi (Contract No. 77646387); Simons Foundation (Contract No. 995152); Takeda (Contract No. A62909); The George & Anne Ryan Institute for Neuroscience at the University of Rhode Island; U.S. Food and Drug Administration (Contract No. 1R13FD007302-01, Contract No. 1R13FD005362-01, and Contract No. 1R13FD008016); Wellcome Trust. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. | True   |
| 536   | PROD       |              | $a: This activity was supported by contracts between the National Academy of Sciences and Acadia Pharmaceuticals; Alzheimer's Association; American Brain Coalition; American Neurological Association; Amgen Inc.; Association of American Medical Colleges; AstraZeneca; Biogen; Boehringer Ingelheim (Contract No. 755326); BrightFocus Foundation; Burroughs Wellcome Fund (Contract No. 1023129); California Institute for Regenerative Medicine; Cerevel Therapeutics; Cohen Veterans Bioscience; Department of Veteran Affairs (Contract No. 36C24E20C009); Eisai; Eli Lilly and Company; FasterCures, Milken Institute; Foundation for the National Institutes of Health; Friends of Cancer Research; Gatsby Charitable Foundation; Harmony Biosciences; Janssen Research & Development, LLC; Johnson & Johnson; Karuna Therapeutics; Lundbeck Research USA, Inc.; Medable Inc.; Merck & Co., Inc. (Contract No. MRLCPO-23-166623); Michael J. Fox Foundation for Parkinson's Research; National Institutes of Health (Contract No. HHSN263201800029I; Task Order Nos. HHSN26300007 and 75N98024F00001): BRAIN Initiative, National Cancer Institute, National Center for Advancing Translational Sciences, National Center for Complementary and Integrative Health, National Eye Institute, National Institute of Allergy and Infectious Diseases, National Institute of Environmental Health Sciences, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, and National Institute on Drug Abuse, Office of the Director; National Multiple Sclerosis Society; National Science Foundation; New England Journal of Medicine; One Mind; Paul G. Allen Frontiers Group; Sanofi (Contract No. 77646387); Simons Foundation (Contract No. 995152); Takeda (Contract No. A62909); The George & Anne Ryan Institute for Neuroscience at the University of Rhode Island; U.S. Food and Drug Administration (Contract No. 1R13FD007302-01, Contract No. 1R13FD005362-01, and Contract No. 1R13FD008016); Wellcome Trust. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed November 12, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed November 12, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Attention Deficit Disorder with Hyperactivity $x: drug therapy              | True   |
| 650   | QA         | 12           | $a: Attention Deficit Disorder with Hyperactivity $x: diagnosis                 | True   |
| 650   | QA         | 22           | $a: Central Nervous System Stimulants $x: therapeutic use                       | True   |
| 650   | QA         | 22           | $a: Central Nervous System Stimulants $x: adverse effects                       | True   |
| 650   | QA         | 22           | $a: Prescription Drug Misuse                                                    | True   |
| 650   | QA         | 22           | $a: Drug Development                                                            | True   |
| 650   | PROD       | 12           | $a: Attention Deficit Disorder with Hyperactivity $x: drug therapy              | True   |
| 650   | PROD       | 12           | $a: Attention Deficit Disorder with Hyperactivity $x: diagnosis                 | True   |
| 650   | PROD       | 22           | $a: Central Nervous System Stimulants $x: therapeutic use                       | True   |
| 650   | PROD       | 22           | $a: Central Nervous System Stimulants $x: adverse effects                       | True   |
| 650   | PROD       | 22           | $a: Prescription Drug Misuse                                                    | True   |
| 650   | PROD       | 22           | $a: Drug Development                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 655   | QA         |  2           | $a: Congress                                                                    | True   |
| 655   | PROD       |  2           | $a: Congress                                                                    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 700   | QA         | 1            | $a: Shore, Carolyn, $e: rapporteur.                                             | True   |
| 700   | QA         | 1            | $a: Norris, Sheena M. Posey, $e: rapporteur.                                    | True   |
| 700   | QA         | 1            | $a: Berkower, Carol, $e: rapporteur.                                            | True   |
| 700   | QA         | 1            | $a: Ontjes, Noah, $e: rapporteur.                                               | True   |
| 700   | PROD       | 1            | $a: Shore, Carolyn, $e: rapporteur.                                             | True   |
| 700   | PROD       | 1            | $a: Norris, Sheena M. Posey, $e: rapporteur.                                    | True   |
| 700   | PROD       | 1            | $a: Berkower, Carol, $e: rapporteur.                                            | True   |
| 700   | PROD       | 1            | $a: Ontjes, Noah, $e: rapporteur.                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Forum on Neuroscience and Nervous System Disorders, $e: issuing body. | True   |
| 710   | QA         | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Forum on Drug Discovery, Development, and Translation, $e: issuing body. | True   |
| 710   | PROD       | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Forum on Neuroscience and Nervous System Disorders, $e: issuing body. | True   |
| 710   | PROD       | 2            | $a: National Academies of Sciences, Engineering, and Medicine (U.S.). $b: Forum on Drug Discovery, Development, and Translation, $e: issuing body. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 711   | QA         | 2            | $a: Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development (Workshop) : $d: (2023 : $c: Washington, DC) | True   |
| 711   | PROD       | 2            | $a: Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development (Workshop) : $d: (2023 : $c: Washington, DC) | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604279/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK604279/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240903                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240903                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: EJP $b: 20241112                                                            | True   |
| 993   | PROD       |              | $a: EJP $b: 20241112                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241112                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241112                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241113                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241113                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240902                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240902                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918897680806676

Leader:
| File       | Leader                   | Equal  |
| QA         | 01991nam a2200421 i 4500 | True   |
| PROD       | 01991nam a2200421 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918897680806676                                                                | True   |
| 001   | PROD       |              | 9918897680806676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241106113316.0                                                                | True   |
| 005   | PROD       |              | 20241106113316.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240902s2022    dcua    ob   f000|0 eng                                          | True   |
| 008   | PROD       |              | 240902s2022    dcua    ob   f000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918897680806676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK605937                                                      | True   |
| 035   | PROD       |              | $9: 9918897680806676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK605937                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WA 310 AA1                                                                  | True   |
| 060   | PROD       | 00           | $a: WA 310 AA1                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 00           | $a: Enhancing data infrastructure to improve women's health outcomes.           | True   |
| 245   | PROD       | 00           | $a: Enhancing data infrastructure to improve women's health outcomes.           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Washington, D.C. : $b: Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, Office of Health Policy, $c: October 2022. | True   |
| 264   | PROD       |  1           | $a: Washington, D.C. : $b: Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, Office of Health Policy, $c: October 2022. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (5 pages)) : $b: illustration                 | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (5 pages)) : $b: illustration                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: This updated 2022 vignette provides examples of how a range of the Office of the Secretary Patient-Centered Outcomes Research (OS-PCORTF) cross-agency projects are working to improve maternal health by 1) Enhancing Women's Health Data for Research 2) Adding Electronic Health Records to the Suite of Maternal Health Data for Research 3) Linking Maternal Survey Data with Other Health Data. | True   |
| 520   | PROD       | 3            | $a: This updated 2022 vignette provides examples of how a range of the Office of the Secretary Patient-Centered Outcomes Research (OS-PCORTF) cross-agency projects are working to improve maternal health by 1) Enhancing Women's Health Data for Research 2) Adding Electronic Health Records to the Suite of Maternal Health Data for Research 3) Linking Maternal Survey Data with Other Health Data. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed Nov. 5, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed Nov. 5, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Maternal Health Services                                                    | True   |
| 650   | QA         | 22           | $a: Outcome Assessment, Health Care                                             | True   |
| 650   | QA         | 22           | $a: Data Collection                                                             | True   |
| 650   | PROD       | 12           | $a: Maternal Health Services                                                    | True   |
| 650   | PROD       | 22           | $a: Outcome Assessment, Health Care                                             | True   |
| 650   | PROD       | 22           | $a: Data Collection                                                             | True   |
--------------------------------------------------------------------------------------------------------------------------
| 651   | QA         |  2           | $a: United States                                                               | True   |
| 651   | PROD       |  2           | $a: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 2            | $a: United States. $b: Department of Health and Human Services. $b: Office of the Assistant Secretary for Planning and Evaluation. $b: Office of Health Policy, $e: issuing body. | True   |
| 710   | PROD       | 2            | $a: United States. $b: Department of Health and Human Services. $b: Office of the Assistant Secretary for Planning and Evaluation. $b: Office of Health Policy, $e: issuing body. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK605937/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK605937/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240904                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240904                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: IHH $b: 20241106                                                            | True   |
| 993   | PROD       |              | $a: IHH $b: 20241106                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241106                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241106                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241106                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241106                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240902                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240902                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918897684606676

Leader:
| File       | Leader                   | Equal  |
| QA         | 02266nam a2200421 i 4500 | True   |
| PROD       | 02266nam a2200421 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918897684606676                                                                | True   |
| 001   | PROD       |              | 9918897684606676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241105100254.0                                                                | True   |
| 005   | PROD       |              | 20241105100254.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240902s2024    sz a    ob   i000|0 eng                                          | True   |
| 008   | PROD       |              | 240902s2024    sz a    ob   i000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 020   | QA         |              | $a: 9789240096394 $q: (electronic version)                                      | True   |
| 020   | QA         |              | $z: 9789240096400 $q: (print version)                                           | True   |
| 020   | PROD       |              | $a: 9789240096394 $q: (electronic version)                                      | True   |
| 020   | PROD       |              | $z: 9789240096400 $q: (print version)                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918897684606676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK605633                                                      | True   |
| 035   | PROD       |              | $9: 9918897684606676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK605633                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: Switzerland                                                                 | True   |
| 044   | PROD       |              | $9: Switzerland                                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WC 503.1                                                                    | True   |
| 060   | PROD       | 00           | $a: WC 503.1                                                                    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 110   | QA         | 2            | $a: World Health Organization, $e: author, $e: issuing body.                    | True   |
| 110   | PROD       | 2            | $a: World Health Organization, $e: author, $e: issuing body.                    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Consolidated guidelines on differentiated HIV testing services.             | True   |
| 245   | PROD       | 10           | $a: Consolidated guidelines on differentiated HIV testing services.             | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: Geneva : $b: World Health Organization, $c: [2024]                          | True   |
| 264   | PROD       |  1           | $a: Geneva : $b: World Health Organization, $c: [2024]                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (xxiii, 164 pages)) : $b: illustrations       | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (xxiii, 164 pages)) : $b: illustrations       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: These guidelines outline a public health approach to strengthening and expanding HIV testing services (HTS). They present and discuss key updates to WHO guidelines on HTS, with a focus on new evidence, new recommendations, good practices and operational considerations that respond to the changing needs of national programmes. New recommendations in this guidance highlight the expanding role of self-testing and network-based testing services, as well as integration with sexually transmitted infections (STIs), including the use of syphilis self-test, dual HIV/syphilis self-tests and STI partner services. This guideline seeks to provide support to Member States, programme managers, health workers and other stakeholders seeking to achieve national and international goals to end the HIV epidemic as a public health threat by 2030 and advance the importance of integrated services delivery. | True   |
| 520   | PROD       | 3            | $a: These guidelines outline a public health approach to strengthening and expanding HIV testing services (HTS). They present and discuss key updates to WHO guidelines on HTS, with a focus on new evidence, new recommendations, good practices and operational considerations that respond to the changing needs of national programmes. New recommendations in this guidance highlight the expanding role of self-testing and network-based testing services, as well as integration with sexually transmitted infections (STIs), including the use of syphilis self-test, dual HIV/syphilis self-tests and STI partner services. This guideline seeks to provide support to Member States, programme managers, health workers and other stakeholders seeking to achieve national and international goals to end the HIV epidemic as a public health threat by 2030 and advance the importance of integrated services delivery. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed November 1, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed November 1, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: HIV Testing                                                                 | True   |
| 650   | QA         | 22           | $a: HIV Infections $x: diagnosis                                                | True   |
| 650   | PROD       | 12           | $a: HIV Testing                                                                 | True   |
| 650   | PROD       | 22           | $a: HIV Infections $x: diagnosis                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 655   | QA         |  2           | $a: Guideline                                                                   | True   |
| 655   | PROD       |  2           | $a: Guideline                                                                   | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK605633/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK605633/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240903                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240903                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: KXP $b: 20241101                                                            | True   |
| 993   | PROD       |              | $a: KXP $b: 20241101                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241101                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241101                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241105                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241105                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240902                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240902                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918897701006676

Leader:
| File       | Leader                   | Equal  |
| QA         | 02731nam a2200469 i 4500 | True   |
| PROD       | 02731nam a2200469 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918897701006676                                                                | True   |
| 001   | PROD       |              | 9918897701006676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241106102723.0                                                                | True   |
| 005   | PROD       |              | 20241106102723.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240902s2023    dcua    on   f000|0 eng                                          | True   |
| 008   | PROD       |              | 240902s2023    dcua    on   f000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918897701006676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK606160                                                      | True   |
| 035   | PROD       |              | $9: 9918897701006676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK606160                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WL 704.6                                                                    | True   |
| 060   | PROD       | 00           | $a: WL 704.6                                                                    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Shekelle, Paul G. $e: author.                                               | True   |
| 100   | PROD       | 1            | $a: Shekelle, Paul G. $e: author.                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Evidence map of massage therapy for painful conditions: update from 2018-2023 / $c: Paul Shekelle, Jennifer Allen, Selene Mak, Meron Begashaw, Isomi Miake-Lye, Jessica Severin, Emily Lawson. | True   |
| 245   | PROD       | 10           | $a: Evidence map of massage therapy for painful conditions: update from 2018-2023 / $c: Paul Shekelle, Jennifer Allen, Selene Mak, Meron Begashaw, Isomi Miake-Lye, Jessica Severin, Emily Lawson. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: [Washington, D.C.] : $b: U.S. Department of Veterans Affairs, Veterans Health Administration, Health Services Research & Development Service, $c: October 2023. | True   |
| 264   | PROD       |  1           | $a: [Washington, D.C.] : $b: U.S. Department of Veterans Affairs, Veterans Health Administration, Health Services Research & Development Service, $c: October 2023. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (vii, 41 pages)) : $b: illustrations.         | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (vii, 41 pages)) : $b: illustrations.         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Evidence synthesis program                                                  | True   |
| 490   | PROD       | 1            | $a: Evidence synthesis program                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 500   | QA         |              | $a: Update of Massage for pain / investigators, principal investigator, Isomi Miake-Lye ; co-investigators, Jason Lee, Tana Lugar, Stephanie Taylor, Paul Shekelle ; research associates, Roberta Shanman, Jessica Beroes. September 2016. | True   |
| 500   | PROD       |              | $a: Update of Massage for pain / investigators, principal investigator, Isomi Miake-Lye ; co-investigators, Jason Lee, Tana Lugar, Stephanie Taylor, Paul Shekelle ; research associates, Roberta Shanman, Jessica Beroes. September 2016. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: This report was prepared by the Evidence Synthesis Program Center located at the VA Greater Los Angeles Healthcare System, responding to a request from the VHA Office of Patient Centered Care & Cultural Transformation, Integrative Health Coordinating Center to provide current evidence regarding use of massage therapy for pain as treatment for conditions of interest to the VA. Findings from this review will be used by VA referring providers, site leadership, and policy makers to improve Veteran access to non-pharmacologic treatment approaches and improve outcomes for Veterans by utilizing evidence-based care pathways. | True   |
| 520   | PROD       | 3            | $a: This report was prepared by the Evidence Synthesis Program Center located at the VA Greater Los Angeles Healthcare System, responding to a request from the VHA Office of Patient Centered Care & Cultural Transformation, Integrative Health Coordinating Center to provide current evidence regarding use of massage therapy for pain as treatment for conditions of interest to the VA. Findings from this review will be used by VA referring providers, site leadership, and policy makers to improve Veteran access to non-pharmacologic treatment approaches and improve outcomes for Veterans by utilizing evidence-based care pathways. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 530   | QA         |              | $a: Issued also in print.                                                       | True   |
| 530   | PROD       |              | $a: Issued also in print.                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed November 6, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed November 6, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Pain Management $x: methods                                                 | True   |
| 650   | QA         | 12           | $a: Massage $x: methods                                                         | True   |
| 650   | PROD       | 12           | $a: Pain Management $x: methods                                                 | True   |
| 650   | PROD       | 12           | $a: Massage $x: methods                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 655   | QA         |  2           | $a: Review                                                                      | True   |
| 655   | PROD       |  2           | $a: Review                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 1            | $a: United States. $b: Department of Veterans Affairs. $b: Health Services Research and Development Service, $e: issuing body. | True   |
| 710   | QA         | 2            | $a: West Los Angeles VA Medical Center. $b: Evidence-Based Synthesis Program Center, $e: issuing body. | True   |
| 710   | PROD       | 1            | $a: United States. $b: Department of Veterans Affairs. $b: Health Services Research and Development Service, $e: issuing body. | True   |
| 710   | PROD       | 2            | $a: West Los Angeles VA Medical Center. $b: Evidence-Based Synthesis Program Center, $e: issuing body. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: Evidence-based synthesis program (Series)                                   | True   |
| 830   | PROD       |  0           | $a: Evidence-based synthesis program (Series)                                   | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK606160/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK606160/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240904                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240904                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: EJP $b: 20241105                                                            | True   |
| 993   | PROD       |              | $a: EJP $b: 20241105                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241106                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241106                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241106                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241106                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240902                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240902                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

Control Number: 9918897700406676

Leader:
| File       | Leader                   | Equal  |
| QA         | 02537nam a2200541 i 4500 | True   |
| PROD       | 02537nam a2200541 i 4500 | True   |

Fields:
| Tag   | File       | Indicators   | Value/Subfields                                                                  | Equal  |
--------------------------------------------------------------------------------------------------------------------------
| 001   | QA         |              | 9918897700406676                                                                | True   |
| 001   | PROD       |              | 9918897700406676                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 005   | QA         |              | 20241107094543.0                                                                | True   |
| 005   | PROD       |              | 20241107094543.0                                                                | True   |
--------------------------------------------------------------------------------------------------------------------------
| 006   | QA         | m            |                                                                                  | True   |
| 006   | PROD       | m            |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 007   | QA         | cr           |                                                                                  | True   |
| 007   | PROD       | cr           |                                                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 008   | QA         |              | 240902s2024    dcua    on   f000|0 eng                                          | True   |
| 008   | PROD       |              | 240902s2024    dcua    on   f000|0 eng                                          | True   |
--------------------------------------------------------------------------------------------------------------------------
| 035   | QA         |              | $9: 9918897700406676                                                            | True   |
| 035   | QA         |              | $a: (DNLM)BKSHLF:NBK606175                                                      | True   |
| 035   | PROD       |              | $9: 9918897700406676                                                            | True   |
| 035   | PROD       |              | $a: (DNLM)BKSHLF:NBK606175                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 040   | QA         |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
| 040   | PROD       |              | $a: DNLM $b: eng $e: rda $c: DNLM                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 041   | QA         | 0            | $a: eng                                                                         | True   |
| 041   | PROD       | 0            | $a: eng                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 042   | QA         |              | $a: pcc                                                                         | True   |
| 042   | PROD       |              | $a: pcc                                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 044   | QA         |              | $9: United States                                                               | True   |
| 044   | PROD       |              | $9: United States                                                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 060   | QA         | 00           | $a: WM 172.5                                                                    | True   |
| 060   | PROD       | 00           | $a: WM 172.5                                                                    | True   |
--------------------------------------------------------------------------------------------------------------------------
| 100   | QA         | 1            | $a: Belsher, Bradley E., $e: author.                                            | True   |
| 100   | PROD       | 1            | $a: Belsher, Bradley E., $e: author.                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 245   | QA         | 10           | $a: Internet and mobile interventions for adults with PTSD and their family members / $c: Bradley E. Belsher, Erin H. Beech, Johanna K. Anderson, Nicholas J. Parr. | True   |
| 245   | PROD       | 10           | $a: Internet and mobile interventions for adults with PTSD and their family members / $c: Bradley E. Belsher, Erin H. Beech, Johanna K. Anderson, Nicholas J. Parr. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 264   | QA         |  1           | $a: [Washington, D.C.] : $b: U.S. Department of Veterans Affairs, Veterans Health Administration, Health Systems Research, $c: April 2024. | True   |
| 264   | PROD       |  1           | $a: [Washington, D.C.] : $b: U.S. Department of Veterans Affairs, Veterans Health Administration, Health Systems Research, $c: April 2024. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 300   | QA         |              | $a: 1 online resource (1 PDF file (vii, 76 pages)) : $b: illustrations.         | True   |
| 300   | PROD       |              | $a: 1 online resource (1 PDF file (vii, 76 pages)) : $b: illustrations.         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 336   | QA         |              | $a: text $b: txt $2: rdacontent                                                 | True   |
| 336   | PROD       |              | $a: text $b: txt $2: rdacontent                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 337   | QA         |              | $a: computer $b: c $2: rdamedia                                                 | True   |
| 337   | PROD       |              | $a: computer $b: c $2: rdamedia                                                 | True   |
--------------------------------------------------------------------------------------------------------------------------
| 338   | QA         |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
| 338   | PROD       |              | $a: online resource $b: cr $2: rdacarrier                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 490   | QA         | 1            | $a: Evidence synthesis program                                                  | True   |
| 490   | PROD       | 1            | $a: Evidence synthesis program                                                  | True   |
--------------------------------------------------------------------------------------------------------------------------
| 504   | QA         |              | $a: Includes bibliographical references.                                        | True   |
| 504   | PROD       |              | $a: Includes bibliographical references.                                        | True   |
--------------------------------------------------------------------------------------------------------------------------
| 520   | QA         | 3            | $a: Military Veterans and service members may experience small to negligible benefits on PTSD and depressive symptoms from internet and mobile interventions for PTSD. Civilians may experience moderate benefits at post-treatment, but these gains do not appear to be sustained. Consequently, the available evidence does not currently support these interventions as an effective treatment for Veterans with PTSD. Based on a small evidence base, internet and mobile interventions do not appear to benefit family members of adults with PTSD. | True   |
| 520   | PROD       | 3            | $a: Military Veterans and service members may experience small to negligible benefits on PTSD and depressive symptoms from internet and mobile interventions for PTSD. Civilians may experience moderate benefits at post-treatment, but these gains do not appear to be sustained. Consequently, the available evidence does not currently support these interventions as an effective treatment for Veterans with PTSD. Based on a small evidence base, internet and mobile interventions do not appear to benefit family members of adults with PTSD. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 530   | QA         |              | $a: Issued also in print.                                                       | True   |
| 530   | PROD       |              | $a: Issued also in print.                                                       | True   |
--------------------------------------------------------------------------------------------------------------------------
| 588   | QA         |              | $a: Description based on online resource; title from PDF title page (viewed November 6, 2024). | True   |
| 588   | PROD       |              | $a: Description based on online resource; title from PDF title page (viewed November 6, 2024). | True   |
--------------------------------------------------------------------------------------------------------------------------
| 650   | QA         | 12           | $a: Stress Disorders, Post-Traumatic $x: therapy                                | True   |
| 650   | QA         | 12           | $a: Telemedicine                                                                | True   |
| 650   | QA         | 22           | $a: Treatment Outcome                                                           | True   |
| 650   | QA         | 22           | $a: Internet-Based Intervention                                                 | True   |
| 650   | QA         | 22           | $a: Veterans                                                                    | True   |
| 650   | QA         | 22           | $a: Family                                                                      | True   |
| 650   | PROD       | 12           | $a: Stress Disorders, Post-Traumatic $x: therapy                                | True   |
| 650   | PROD       | 12           | $a: Telemedicine                                                                | True   |
| 650   | PROD       | 22           | $a: Treatment Outcome                                                           | True   |
| 650   | PROD       | 22           | $a: Internet-Based Intervention                                                 | True   |
| 650   | PROD       | 22           | $a: Veterans                                                                    | True   |
| 650   | PROD       | 22           | $a: Family                                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 655   | QA         |  2           | $a: Systematic Review                                                           | True   |
| 655   | PROD       |  2           | $a: Systematic Review                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 700   | QA         | 1            | $a: Beech, Erin H., $e: author.                                                 | True   |
| 700   | QA         | 1            | $a: Anderson, Johanna, $e: author.                                              | True   |
| 700   | QA         | 1            | $a: Parr, Nicholas J., $e: author.                                              | True   |
| 700   | PROD       | 1            | $a: Beech, Erin H., $e: author.                                                 | True   |
| 700   | PROD       | 1            | $a: Anderson, Johanna, $e: author.                                              | True   |
| 700   | PROD       | 1            | $a: Parr, Nicholas J., $e: author.                                              | True   |
--------------------------------------------------------------------------------------------------------------------------
| 710   | QA         | 1            | $a: United States. $b: Veterans Health Administration. $b: Health Systems Research, $e: issuing body. | True   |
| 710   | PROD       | 1            | $a: United States. $b: Veterans Health Administration. $b: Health Systems Research, $e: issuing body. | True   |
--------------------------------------------------------------------------------------------------------------------------
| 830   | QA         |  0           | $a: Evidence-based synthesis program (Series)                                   | True   |
| 830   | PROD       |  0           | $a: Evidence-based synthesis program (Series)                                   | True   |
--------------------------------------------------------------------------------------------------------------------------
| 856   | QA         | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK606175/                               | True   |
| 856   | PROD       | 40           | $u: https://www.ncbi.nlm.nih.gov/books/NBK606175/                               | True   |
--------------------------------------------------------------------------------------------------------------------------
| 992   | QA         |              | $p: P2 $e: EF $a: 20240904                                                      | True   |
| 992   | PROD       |              | $p: P2 $e: EF $a: 20240904                                                      | True   |
--------------------------------------------------------------------------------------------------------------------------
| 993   | QA         |              | $a: EJP $b: 20241106                                                            | True   |
| 993   | PROD       |              | $a: EJP $b: 20241106                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 994   | QA         |              | $a: CDN $b: 20241106                                                            | True   |
| 994   | PROD       |              | $a: CDN $b: 20241106                                                            | True   |
--------------------------------------------------------------------------------------------------------------------------
| 995   | QA         |              | $a: AUTH $b: 20241107                                                           | True   |
| 995   | PROD       |              | $a: AUTH $b: 20241107                                                           | True   |
--------------------------------------------------------------------------------------------------------------------------
| 998   | QA         |              | $a: BKSHLF $b: 20240902                                                         | True   |
| 998   | PROD       |              | $a: BKSHLF $b: 20240902                                                         | True   |
--------------------------------------------------------------------------------------------------------------------------
| 999   | QA         |              | $a: AUTH                                                                        | True   |
| 999   | PROD       |              | $a: AUTH                                                                        | True   |
--------------------------------------------------------------------------------------------------------------------------

